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ABSTRACT 
Expanding the Toolkit for Metabolic Engineering 
Yao Zong (Andy) Ng 
 
 The essence of metabolic engineering is the modification of microbes for the 
overproduction of useful compounds. These cellular factories are increasingly recognized as an 
environmentally-friendly and cost-effective way to convert inexpensive and renewable 
feedstocks into products, compared to traditional chemical synthesis from petrochemicals. The 
products span the spectrum of specialty, fine or bulk chemicals, with uses such as 
pharmaceuticals, nutraceuticals, flavors and fragrances, agrochemicals, biofuels and building 
blocks for other compounds. However, the process of metabolic engineering can be long and 
expensive, primarily due to technological hurdles, our incomplete understanding of biology, as 
well as redundancies and limitations built into the natural program of living cells. Combinatorial 
or directed evolution approaches can enable us to make progress even without a full 
understanding of the cell, and can also lead to the discovery of new knowledge. This thesis is 
focused on addressing the technological bottlenecks in the directed evolution cycle, specifically 
de novo DNA assembly to generate strain libraries and small molecule product screens and 
selections. 
In Chapter 1, we begin by examining the origins of the field of metabolic engineering. 
We review the classic “design–build–test–analyze” (DBTA) metabolic engineering cycle and the 
different strategies that have been employed to engineer cell metabolism, namely constructive 
and inverse metabolic engineering. This is followed by a discussion of how combinatorial 
methods that draw on both approaches can improve the speed, cost and efficiency of metabolic 
engineering. Next, we discuss how enabling technologies such as DNA assembly methods and 
genome-wide mutagenesis techniques have served as a driver of developments in the field, as 
well as some current limitations in the area of screens and selections for natural products. 
Finally, we offer some perspectives on how the field of metabolic engineering could be advanced 
in the future. 
In order to re-engineer the metabolism of a cell, its genetic program has to be modified, 
either by mutating its DNA or introducing foreign genes and pathways. Furthermore, because 
metabolic engineering is a combinatorial optimization problem, it could be advantageous to 
create a library of strain variants in parallel for testing. However, a key bottleneck is the lack of 
tools to build long multi-gene pathways and libraries, especially in genetically intractable host 
cells. In Chapter 2, we report the de novo assembly of the ~ 100 kb meridamycin Type I 
modular polyketide synthase (mPKS) pathway using Reiterative Recombination. The mPKS 
pathways are difficult to manipulate due to their long, GC-rich and highly repetitive sequences. 
Our strategy was to harness the power of yeast recombination to assemble and engineer the 
pathway in the chromosome of the yeast Saccharomyces cerevisiae, followed by transfer of the 
pathway into a heterologous Streptomyces lividans host for polyketide production. We also 
developed FLIP, which is based on site-specific recombination, for the efficient recovery of the 
pathway/library from the yeast chromosome onto shuttle plasmids. Lastly, we describe the 
construction of a promoter library in yeast using CRISPR in order to optimize the production of 
the polyketide meridamycin, a compound with promising neuroprotective activities. Our 
approach can also be potentially applied for combinatorial biosynthesis to produce novel 
analogs. 
 Although there has been much progress in the development of techniques for the de novo 
assembly of pathways, libraries and even whole genomes, as well as large-scale mutagenesis 
approaches, it is widely held that the current bottleneck to applying combinatorial approaches to 
metabolic engineering is a lack of general and high-throughput screens and selections for the 
product. State-of-the-art methods such as liquid/gas chromatography – mass spectrometry 
(LC/GC-MS) can detect a diverse range of compounds, but are too low-throughput (< 102 
samples/day) to screen libraries of ≥ 103. Other methods that rely on detecting a product’s 
fluorescence, color, bioactivity or reactivity cannot be generally applied to the majority of 
compounds. Thus in Chapter 3, we established a high-throughput screen (104 – 105 samples/day) 
based on the Fluorescence Polarization (FP) assay, which in theory can be adapted as a screen 
for a wide range of small molecules and natural products. The FP assay works by measuring the 
changes in fluorescence polarization values when the target molecule competes with a 
fluorescently-tagged reporter molecule for binding to a common receptor protein. As a proof-of-
principle, we applied the FP assay to screen a UV-mutagenized library of Streptomyces 
tsukubaensis and identified strains that produced higher titers of FK506 (tacrolimus), an 
immunosuppressant drug. We also demonstrate the biosynthesis of FK506 in 96-well, deep well, 
microtiter plates, which is compatible with the throughput of the FP assay performed in 384-well 
microtiter plates. 
In contrast to a screen, genetic selections enable much higher throughput (> 108 
samples/day limited by culture volume), since the population of cells can be assayed together in 
a one pot growth selection. However, this requires that the production of the target compound 
confer a growth advantage on the cell. In Chapter 4, we describe how the yeast three-hybrid 
system (Y3H) can be adapted to detect a product by displacement of one arm of a small molecule 
dimerizer that bridges two receptor protein fusions that reconstitute an active transcription factor, 
thus changing the transcription levels of a reporter gene. We report Y3H systems capable of 
detecting trimethoprim (TMP), meridamycin and FK506, and linking detection to the 
transcription of a selectable marker. This sets the stage to use the Y3H for genetic selections, if 
both the production and detection functions can be performed in the same cell. 
 Although metabolic engineering can potentially be used to biosynthesize a large portfolio 
of compounds, there are limitations to relying completely on this approach. For instance, the 
final products could be toxic to the cell, or the enzymes for a reaction step could be non-existent 
in nature, or more often than not, the biosynthetic process from feedstock to final compound is 
not economically viable or would take too long to develop. Thus, many groups have developed 
semi-synthetic approaches that combine biosynthetic steps with chemical synthesis to generate 
compounds. In Chapter 5, we describe novel semi-synthetic strategies leading to Ambrox, a key 
component of fragrances, and the tocotrienols, key components of Vitamin E that possess anti-
oxidant and anti-cancer properties, as well as their derivatives. Both strategies rely on 
engineering the yeast S. cerevisiae or the bacterium E. coli to produce linear terpenoid 
intermediates followed by modification with synthetic chemistry. To derive Ambrox, E. coli was 
engineered to produce the unnatural polyene intermediate Z,E-farnesol, which was cyclized by 
the halonium-based reagents BDSB (bromodiethylsulfonium bromopentachloroantimonate) and 
IDSI (iododiethylsulfonium iodopentachloroantimonate) to form halo-Ambrox, which could be 
readily converted to 9-epi-Ambrox and its analogs. For the tocotrienols, yeast was engineered 
using a triple enzyme fusion to produce E,E,E-geranylgeraniol, which was converted in one step 
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Strategies and Enabling Technologies 






1.0 Chapter outlook 
Metabolic engineering has the potential to revolutionize how chemicals are made – 
moving from organic synthesis using petrochemical sources or low-yield extraction from natural 
sources to high-yield biosynthesis using engineered microbes. Although fermentation technology 
for the production of chemicals such as ethanol, acetic acid and lactic acid has existed for 
centuries, but the microbes used were either natural strains or derived by artificial selection. In 
contrast, the goal of metabolic engineering is to optimize metabolic flux or improve the fitness of 
microbes via genetic engineering for the overproduction of a target compound. The key advance 
that enabled this was the establishment of recombinant DNA technology in the 1970s. Since the 
inception of metabolic engineering in the 1990s, the field has blossomed into an interdisciplinary 
one encompassing biochemistry, genetic engineering and analytical techniques. In this chapter, 
we trace the origins of metabolic engineering as a discipline within the broader field of industrial 
microbial biotechnology. Next, starting with the classic design-build-test-analyze cycle, we 
review the two key approaches that have been employed in the field, namely constructive 
metabolic engineering and inverse metabolic engineering. We then present a third approach 
using combinatorial libraries or directed evolution to increase the efficiency of strain 
development. This approach has been enabled by advances in technologies for DNA assembly 
and genome-wide mutagenesis to construct gene, pathway, network or whole genome libraries, 
as well as product screens and selections for testing the library. We highlight some prominent 
technologies and discuss their applications and limitations. Finally we offer some perspectives 





1.1 Metabolic engineering – origins 
For centuries, humans have carried out fermentation for the production of beer, wine, 
bread, cheese and soya. However, it was only with the direct observation of microbial cells by 
Leeuwenhoek in the 1680s, and studies by Pasteur from the 1850s–1870s, that the role of 
microbes in fermentation was established, and technologies developed for their isolation, 
characterization and sterile culture1. This led not only to a spurt in the output volume of the 
aforementioned products, but also to a greater diversity of fermentation products, including the 
commodity (bulk) chemicals lactic acid2 and citric acid3. During World War I, to meet war 
needs, acetone and butanol were made by the Weizmann (ABE) fermentation process4 and 
glycerol by the sulfite-steered yeast fermentation process5. However, the rise of the oil industry 
in the early 20th century led to the replacement of these fermentation processes to produce bulk 
chemicals with cheaper petrochemical routes. 
A key turning point in microbial biotechnology was the discovery of penicillin by 
Fleming in 1928, which ushered in the age of antibiotics6. Research on penicillin production 
began in 1941, driven by military needs during World War II. After two years of intensive efforts 
involving screening of natural strains from different environments and random mutagenesis, 
production levels were improved by 140,000 times1. Encouraged by this success, research on 
antibiotics continued and led to compounds such as actinomycin, streptomycin, erythromycin 
and tetracycline7. Because these natural products had more complex structures than bulk 
chemicals, they were difficult to synthesize chemically, and thus the only economically viable 
option to produce them was via fermentation of microbes. 
In the following decades, analogs of the original antibiotics were developed, in order to 





For instance, minocycline and doxycycline have longer half-lives and are active against a wider 
range of bacteria than their parent antibiotic tetracycline8. These analogs were often produced by 
semi-synthesis9: first using microbial fermentation to biosynthesize an intermediate compound, 
which is then chemically modified to create the final compound. This strategy was adopted 
instead of relying solely on biosynthesis as the final compound could be toxic to the producer 
cell, or there could be a lack of natural enzymes to catalyze a chemical reaction or due to the 
overall economics of the process. 
Another prominent branch of industrial biotechnology in the 20th century was the use of 
microbial cells, whole cell extracts or purified enzymes as catalysts for biotransformation10. 
Whereas fermentation involves a multi-step reaction pathway, biotransformation consists of one 
or two steps to produce a compound that is structurally similar to the substrate. Some notable 
examples were the production of vinegar (acetic acid) by oxidation of ethanol using acetic acid 
bacteria11, the conversion of cortisol to prednisolone (an anti-inflammatory drug) using 
Corynebacterium simplex12, and the conversion of acrylonitrile to acrylamide using nitrile 
hydratase13. Since biotransformation relies on enzymes, the reactions occur in mild operating 
conditions and produce compounds with high regioselectivity and stereospecificity. 
In the 1970s, the field of biotechnology was revolutionized with the development of 
recombinant DNA techniques. In 1970, Hamilton Smith discovered restriction enzymes, which 
could cleave dsDNA at specific target sites14. Then in 1972, Paul Berg produced the first 
recombinant DNA by the insertion of viral DNA into bacterial DNA using restriction digest 
followed by ligation15. This was followed in 1973 by Herbert Boyer and Stanley Cohen, who 





an exciting moment as it raised the possibility that rapid-growing microbes could be 
reprogrammed and cultivated in large scale to produce desired genes and their products. 
It was not long before the first drug – human insulin, manufactured using bacteria 
engineered with recombinant DNA, was approved by the FDA in 198217. This obviated the need 
for the purification of insulin from the pancreas of cattle and pigs to treat diabetes. Instead, 
microbes could be fermented in a controlled environment to efficiently and reproducibly produce 
large quantities of the pure drug. This achievement sparked a “gold rush” in biotechnology to 
clone and express heterologous genes in production hosts to produce a variety of compounds, 
including peptide-based drugs (e.g. hormones, growth factors, enzymes and antibodies), vaccines 
(e.g. Hepatitis B), commercial enzymes (e.g. lipases, proteases and carbohydrases), primary 
metabolites (e.g. amino acids, organic acids, vitamins and nucleotides) and secondary 
metabolites with important bioactivities (e.g. anti-bacterial, anti-fungal and anti-parasitic)18. 
In 1991, the term “metabolic engineering” was coined by James Bailey, Gregory 
Stephanopoulos and Joseph Vallino. Metabolic engineering was defined as the improvement of 
cellular activities through the use of recombinant DNA techniques to modify the enzymatic, 
regulatory or transport systems in the cell19. This broad definition recognizes that metabolic 
engineering is not only about manipulating biosynthetic genes or pathways to overproduce a 
compound, but that the same techniques can be applied to optimize relevant physiological 
properties of the cell. Some examples include overcoming product feedback inhibition, 
increasing tolerance to hypoxia or high osmotic pressure, ensuring the delivery of precursors to 
reaction sites, and the channeling of intermediates between enzymes and cellular compartments. 
This definition also sets metabolic engineering apart from traditional microbial biotechnology. 





a cell, the latter relies on natural strains from the environment or strains modified by artificial 
selection. 
 Another early definition of metabolic engineering is “the directed improvement of 
product formation or cellular properties through the modification of specific biochemical 
reaction(s) or the introduction of new one(s) with the use of recombinant DNA technology20.” 
Thus, metabolic engineering is not only about redirecting fluxes in the cell, but also potentially, 
the creation of new ones by the introduction of foreign genes or pathways. These may serve to 
expand the repertoire of chemistry in the cell in order to create non-natural products or to utilize 
non-traditional feedstocks. Other activities that were classified as metabolic engineering include 
heterologous protein production, xenobiotic degradation and the elimination or reduction of 
unwanted side products21. Furthermore, a sense of “direction” is inherent in all metabolic 
engineering efforts and implies making rational changes to the enzymes, regulators, pathways or 
strain background (constructive metabolic engineering, see Section 1.2.2). However, random or 
inverse metabolic engineering (see Section 1.2.3) or combinatorial approaches (see Section 1.3) 
play a critical role to reduce the time and cost of strain development, given a limited knowledge 
of the cell. These approaches can also lead to the discovery of new regulators and interacting 
genes, which can be used in future rational designs. 
 
1.2 Strategies for metabolic engineering 
Nature has imbued cells with robust regulatory networks that maintain homeostasis in the 
face of environmental changes. This is actually an advantage of using live cells as bio-factories, 
since the conditions during fermentation can be extreme (e.g. low pH and high osmotic stress). 





Thus, while it may be possible to create cells that produce many natural chemicals in low 
amounts, it is more difficult to redirect the flux to obtain high yields of a particular metabolite22. 
This problem is compounded by our lack of understanding of all of the interacting enzymatic, 
regulatory or transport networks in the cell. Hence, metabolic engineers typically employ an 
iterative cycle of design, build, test and analysis, which borrows from the engineering design 











1.2.1 The design–build–test–analyze cycle 
The first step in the design-build-test-analyze (DBTA) cycle is “design”24 (Fig. 1-1). This 
process involves selecting a host organism for production, taking into account factors such as 
toxicity of the product or intermediates, availability of metabolic precursors, feedstock 
utilization, and growth characteristics (e.g. optimal temperature and pH). Next, the biosynthetic 
pathway has to be designed to optimize flux towards the product and decrease flux towards 
competing reactions. This involves modeling the enzymes (kcat and Km) in the cell, their 
associated metabolite fluxes, as well as their transcription, translation and regulation, in order to 
identify key nodes for intervention. If the final product is non-natural to the cell, enzymes that 
catalyze the intermediate reactions leading to the product have to be identified and cloned for 
heterologous expression in the host cell. However, if there are no enzymes available, or if 
improvements to the enzymes are desired (e.g. increase kcat, decrease Km or improve substrate 
specificity), directed evolution can be used to evolve novel enzymes. Once a promising design or 
set of designs are made, the next stage is to construct the strains containing the various 
modifications. 
The “build” step involves using genetic engineering techniques to overexpress, 
knockdown, delete or mutate enzymes or their regulators in the desired host cell, and is a key 
step in metabolic engineering25. Indeed, the birth of the field was enabled by the development of 
recombinant DNA techniques (see Section 1.1). Recently, the rise of synthetic biology offers a 
new paradigm and set of tools to construct gene pathways, circuits and networks, by combining 
well-characterized “parts” consisting of promoters, genes, terminators and regulators26. In the 
last few years, technologies for DNA assembly and mutagenesis have blossomed. Coupled with 





that are readily available commercially (~ 5 kb), it is now possible to perform extensive 
mutagenesis of the genome to create large, random or focused libraries (see Section 1.3), or to 
construct long, multigene, designer pathways, circuits and even whole genomes de novo (see 
Chapter 2) (Fig. 1-1). 
The next step after strain construction is the “test” phase27. Broadly, this encompasses all 
attempts to characterize the strain and its performance in culture. This includes sequencing to 
verify the successful incorporation of genes or mutations, gene expression profiling, as well as 
studying protein and metabolite changes in the cell. One can take advantage of various -omics 
technologies such as whole genome sequencing, RNA-seq, high-throughput proteomics and 
metabolomics that can rapidly measure global changes in gene sequences, RNA transcripts, 
proteins and small molecule metabolites respectively28 (Fig. 1-1). Another important tool is 
metabolic flux analysis with 13C or other labelled substrates, which provides a dynamic view of 
changes in the flow of metabolites in the cell29,30. In terms of product output, the Titer (final 
concentration of product in the fermentation medium), Rate (production per unit time), and Yield 
(amount of product made per unit of feedstock consumed), known as “TRY”23, are important 
parameters to be determined by specific product screens or gas/liquid chromatography–mass 
spectrometry (GC/LC-MS) (see Section 1.3.4 and Chapter 3). The strain(s) can be initially 
tested in small-scale microfluidic cells, multi-well plates or test tubes, and later scaled up to 
shake flasks, bench-top fermenters or pilot fermenters31. 
 Finally, the “analyze” or “learn” phase seeks to create new knowledge of how various 
genetic perturbations affect cellular metabolism. This knowledge can be incorporated into future 
designs. There is the potential for synergy with the field of systems biology, which seeks to study 





biology, in order to predict biological function32. Indeed, many of the tools to interpret large data 
sets from –omics approaches are identical. For instance, statistical techniques such as principal 
component analysis (PCA) and machine learning algorithms can be applied to discover obscure 
patterns and trends33. In order for the information to be broadly useful, there needs to be a 
detailed recording of as many parameters as possible, such as a list of genetic perturbations made 
to a strain, cultivation conditions and sampling time. Finally, the “analyze” step can also serve to 
uncover additional interacting enzymes or regulators that were previously unknown, and 
contribute to a more comprehensive understanding of networks in the cell. 
 
1.2.2 Constructive metabolic engineering 
The DBTA cycle is a process that is performed in order to overcome gaps in our 
understanding of cell metabolism. However, the first step “design” implies a certain degree of 
knowledge about the enzymes, regulators or their interacting partners in a biosynthetic pathway. 
This is then used to formulate hypotheses about changes that can be made to increase the titer, 
rate or yield of the product. This approach has been traditionally adopted by metabolic engineers 
and is termed “constructive”, “rational” or “reductionist” metabolic engineering34. This will be 
further described using examples drawn from some notable successes in the field (Fig. 1-2). 
Selection of a production host 
One of the first steps in metabolic engineering is deciding on a production host. 
Typically, model organisms such as E. coli or S. cerevisiae are chosen as their biology is 
relatively well-characterized – there are models and databases of their metabolic networks, 
pathways, enzymes and reactions35, as well as detailed genome36,37, transcriptome37,38, 





engineering, their cultivation and fermentation technology is mature, and they often enjoy 
favorable regulatory status. For instance, DuPont Tate & Lyle have engineered E. coli for the 
commercial production of bio-based 1,3-propanediol (PDO)43, and Genomatica have engineered 
E. coli to produce the commodity chemical 1,4-butanediol (BDO)44, both using renewable 
glucose feedstocks instead of petrochemical sources (Fig. 1-2). However, in the Semi-synthetic 
Artemisinin Project45, which aimed to develop a microbial strain to produce the anti-malarial 
drug precursor artemisinic acid, engineering efforts were switched from the prokaryote E. coli to 
the eukaryote S. cerevisiae, as a late step in the pathway required the expression of an eukaryotic 
cytochrome P450 enzyme derived from the plant Artemisia annua. 
Enzyme identification and pathway design 
Another key step in constructive metabolic engineering is to identify enzymes and design 
pathways that can convert a cellular metabolite to the final compound. If the compound is non-
native to the cell, enzymes have to be identified from foreign sources or evolved by directed 
evolution for heterologous expression in the production host. PDO is naturally produced by 
many bacteria when grown anaerobically on glycerol, but economics strongly favor an aerobic 
process starting from the cheaper feedstock glucose. Thus, a four-step reaction pathway starting 
from the glycolytic pathway intermediate dihydroxyacetone phosphate (DHAP) was designed43 
(Fig. 1-2). For BDO, which is not produced naturally by any organism, 10,000 pathways were 
generated by bioinformatics and ranked by maximum theoretical yield, pathway length, number 
of non-native steps, number of novel steps and thermodynamic feasibility. A five-step reaction 
pathway starting from the tricarboxylic acid (TCA) cycle metabolite succinyl-CoA and 
proceeding through the intermediate 4-hydroxybutyrate (4-HB) was identified for testing44 (Fig. 





catalyzed the conversion of farnesyl pyrophosphate (FPP) to artemisinic acid was codon-
optimized and expressed heterologously expressed in S. cerevisiae46 (Fig. 1-2). 
 





Single enzyme changes 
Another rational change that is made during strain engineering is the identification of 
flux-limiting enzymes in the pathway and attempting to increase their activity. This can be 
achieved by raising gene copy number via expression on high-copy plasmids or multi-copy 
integration into the chromosome, increasing transcription efficiency through the use of stronger 
promoters, performing codon optimization, engineering of ribosome binding sites to improve 
translation efficiency, and less commonly, engineering of the mRNA transcripts25,47. The enzyme 
itself can be engineered via directed evolution to boost its catalytic activity (higher kcat, lower 
km), improve substrate specificity or to eliminate product feedback inhibition. Alternatively, 
homologs of the enzyme possessing more desirable attributes can be discovered via library 
screening approaches48. 
During strain engineering for the production of PDO, BDO and artemisinic acid, non-
native genes had to be cloned and expressed in the production host to channel flux from native 
metabolites in the cell towards the desired product (Fig. 1-2). For PDO, the native E. coli 
oxidoreductase yghD was found to lead to better yields when compared to the original 
heterologous enzyme DhaT49. In the case of BDO, it was observed that production rate decreased 
significantly when BDO titer reached 80-90 g/L, with a concomitant increase in the intermediate 
compound 4-HB. A series of diagnostic experiments revealed that the downstream enzyme Cat2 
was inhibited by high concentrations of BDO. Thus, directed evolution was performed to 
discover Cat2 variants that were insensitive to high levels of BDO. When the best Cat2 variant 
was expressed together with an improved Ald enzyme, the production levels of BDO increased 
by 20 % to > 110 g/L and 4-HB levels decreased by 75 %44. For the biosynthesis of artemisinic 





coenzyme A reductase, was overexpressed by integrating three copies of the gene into the 
chromosome to ensure a steady supply of precursors45. In fact, a truncated version of the enzyme 
was used (tHMGR), which lacked the regulatory domains for feedback control, thus enabling 
higher levels of flux through the pathway50. 
 
Pathway, network or regulatory changes 
Changes can also be made on a broader scale to multiple enzymes in the pathway or other 
interacting networks. For instance, increasing the activity of a flux-limiting enzyme may lead to 
other enzymes becoming rate-limiting, and these can be similarly overexpressed. Enzymes that 
direct flux into competing pathways can be eliminated or knocked down to reduce side products. 
Also to this end, enzyme fusions, scaffold proteins or the co-localization of enzymes in cellular 
compartments can be used to improve substrate channeling and reduce the leakage of metabolites 
into other cellular pathways. In addition, it is important to consider the role of regulatory genes 
on the pathway. Negative regulators or repressors of the enzymes or pathway can be knocked 
down or deleted, while positive regulators can be overexpressed. 
For PDO, the genes encoding glycerol kinase (glpK) and glycerol dehydrogenase (gldA) 
were deleted to prevent glycerol from being channeled back into central carbon metabolism43 
(Fig. 1-2). In the case of BDO, the levels of the side product, acetate, was reduced by 
constitutive expression of the genes encoding acetate kinase and phosphotransacetylase (ackA-
pta), which convert acetate to acetyl-CoA44. For artemisinic acid, all enzymes in the mevalonate 
pathway up to ERG20, which are responsible for the production of terpenoid monomers, were 
overexpressed using the galactose-inducible GAL1/GAL10 divergent promoter51. Furthermore, to 





the regulatory gene GAL80 was deleted to enable constitutive expression of all GAL-regulated 
genes45. Next, the gene encoding squalene synthase (ERG9), which converts FPP to squalene for 
the synthesis of ergosterol (a competing pathway), was knocked down using a CTR3 copper-
repressible promoter. 
 
Strain background changes 
Last but not least, rational changes can be made to the host cell background in order to 
improve strain fitness, genomic stability, tolerance to extreme conditions during fermentation 
(e.g. low pH, osmotic stress, organic solvents), and to mitigate toxicity of the product, 
intermediates or side products34. For example, influx transporters can be expressed to deliver 
feedstocks and nutrients more effectively into the cell, while efflux transporters can help the 
secretion of products or intermediates out of the cell and prevent their accumulation in the 
cytosol52. For commercial BDO production by E. coli, the genes encoding the phage receptors 
tonA and lamB were mutated to impart resistance to common phage53. For artemisinic acid 
production, the gene encoding an artemisinic aldehyde dehydrogenase (ALDH1) from A. annua 
was expressed in yeast, in order to reduce the levels of the toxic intermediate artemisinic 
aldehyde and increase the yield of artemisinic acid45 (Fig. 1-2). In addition, cytosolic catalase 
(CTT1) was overexpressed to mitigate oxidative stress54. Finally, all relevant enzymes were 






1.2.3 Inverse metabolic engineering 
The success of a constructive metabolic engineering approach hinges upon our 
understanding of the enzymes, pathways and regulatory networks in the cell, and our ability to 
model these to predict mutations that can lead to improved titer, rate and yield of a product. 
While there has been much progress on all fronts, especially in our knowledge of cell biology 
and computational modeling, we still do not yet have a complete whole cell metabolic model for 
the basic production hosts E. coli and S. cerevisiae55. Many designs often produce unexpected 
results, which could be due to a number of reasons, such as a failure to model the pathway itself 
accurately, a lack of knowledge of the interactions between the pathway and other networks in 
the cell, the presence of undiscovered regulators, enzymes or regulatory mechanisms, and 
redundancies in enzyme activities. Thus, inverse metabolic engineering offers a way to improve 
strains with only a limited understanding of the cell, and to discover new knowledge. 
The approach was codified by Bailey as “first, identifying, constructing, or calculating a 
desired phenotype; second, determining the genetic or the particular environmental factors 
conferring that phenotype; and third, endowing that phenotype on another strain or organism by 
directed genetic or environmental manipulation56.” Thus, inverse metabolic engineering begins 
with a desired phenotype in mind, followed by random mutagenesis to create a library of mutant 
cells. The library is screened to find clones that exhibit the desired phenotype, which are 
analyzed (e.g. by –omics approaches and sequencing) to find the causative mutations. The 
mutations can be re-created in a targeted manner in a clean strain background to verify the 
phenotype. This approach can reveal potentially novel enzymes, regulators or other cellular 
components that confer a particular phenotype. This knowledge can then be used in future 






Inverse metabolic engineering has been practiced for centuries, albeit on a rudimentary 
level, as part of artificial selection programs for microorganisms with desirable traits. The source 
of genetic diversity was spontaneous mutagenesis arising from errors in DNA replication, which 
occurs rarely (~ 10-10 per base pair per replication in E. coli and S. cerevisiae) if the DNA repair 
machinery of the cell is intact58,59. Thus, the process has to rely on growth selections to cover a 
sufficiently large library of cells (> 108) to increase the chances of uncovering mutants 
possessing the desired phenotype. A screen would be simply too inefficient and impractical to 
perform. For example, ethanol-tolerant mutants of E. coli, which can potentially be advantageous 
for bio-ethanol production, were enriched by serial transfers into broth containing increasing 
concentrations of ethanol60. In order to generate a strain of S. cerevisiae capable of efficiently 
utilizing xylose as a sole carbon source (the second most abundant monosaccharaide after 
glucose), the enzymes xylose reductase, xylitol dehydrogenase and xylulose kinase from Pichia 
stipitis were first expressed heterologously in yeast61. The yeast strain was subjected to serial 
cultivation in minimal media supplemented with xylose to enrich for strains with enhanced 
xylose consumption and growth rates. 
 
Random mutagenesis by chemical mutagens, UV or transposons 
Instead of relying on infrequent spontaneous mutations to generate genetic diversity, one 
can employ chemical mutagens such as N’-nitro-N-nitrosoguanidine (NTG) or 
ethylmethanesulfonate (EMS), or expose the cells to UV, in order to create random mutations 
throughout the genome. Smith et al. treated E. coli with NTG and selected for growth in the 





isobutanol. Subsequently, a strain showing improved flux towards isobutanol production, which 
outcompetes the toxic norvaline, was isolated62. Another way to generate mutations randomly is 
to use transposon mutagenesis. First, a transposon library is created containing random insertions 
of the transposon in the chromosome. The library is then subject to some selective pressure. 
Genomic DNA fragments containing the transposon from the selected libraries can be compared 
with the unselected transposon insertion library using DNA microarrays, in order to identify 
insertions that affect fitness63. 
Compared to spontaneous mutagenesis, these methods of random mutagenesis have a 
sufficiently high mutagenic rate, such that potentially interesting mutants can be found from 
screening a population of cells ~ 104 – 105. This greatly broadens the applicability of the inverse 
metabolic engineering approach to screenable but non-selectable phenotypes (see Section 1.3.4). 
For instance, Alper et al. used transposon mutagenesis to identify gene knockout targets in E. 
coli that led to increased lycopene (a colored compound) production, using a screen for colonies 
that were more orange/red, which indicates more lycopene64. This approach identified two new 
potential gene targets, yjfP and yjiD, which were previously uncharacterized. 
 
1.3 Combinatorial directed evolution strategies and tools for metabolic engineering 
Constructive and inverse metabolic engineering are really two ends of a spectrum of 
possible approaches that can be employed for engineering cellular factories. Hybrid strategies 
that marry the strengths of both approaches can lead to advances in the speed and efficiency of 
metabolic engineering. This approach has been termed “combinatorial metabolic 
engineering”57,65, “evolutionary metabolic engineering”34, “systems metabolic engineering”66 or 





the enzyme, pathway, network or genome level, and second, applying a screen or selection for 
the product molecule to identify variants with improved titer, rate and yield (Fig. 1-3). 
Importantly, although not discussed in this chapter, pathway libraries can also be generated for 
the production of novel analogs of the compound68. 
Thus, the combinatorial directed evolution approach bridges the gap between entirely 
rational and random approaches. The size and degree of “rationality” of the library can be 
designed based on the desired application and the amount of knowledge that is available about 
the enzyme, pathway or cell. The two key technological bottlenecks to this approach are methods 
to generate mutant libraries and screens or selections for the product (Fig. 1-3). While there has 
been much progress addressing the DNA mutagenesis problem, there is still a need for more 
general and high-throughput screens/selections for small molecules. In the next sections, we 
discuss these technologies and provide examples of how they have been harnessed for 
combinatorial metabolic engineering. 
 





1.3.1 Mutagenesis to create single gene libraries 
Protein engineering 
Following the identification of rate-limiting enzymes in a biosynthetic pathway, directed 
evolution can be performed to improve the properties of the enzymes, such as their catalytic 
activity, thermostability and specificity. Various technologies that have been developed for 
single protein engineering can be applied here. For instance, Nair et al. used error-prone PCR to 
improve the specificity of the promiscuous enzyme xylitol reductase for D-xylose over L-
arabinose by 8.7-fold69. This was improved further to 16.5-fold by subsequent rounds of targeted 
site-saturation mutagenesis, using overlap-extension PCR with primers that contained a 
degenerate NNS codon (N: any nucleotide; S: cytosine or guanine). 
Pirakitikulr et al. developed PCRless library mutagenesis via oligonucleotide 
recombination in yeast70. The method relies on mutagenic single-stranded oligonucleotides, 
which can be readily synthesized commercially. The target gene is located on a linearized 
plasmid and co-transformed into the cell with the mutagenic oligonucleotides. The presence of a 
double-stranded DNA break stimulates efficient homologous recombination, which was used to 
mutagenize up to three active site loops simultaneously in a proof-of-principle marker gene 
TRP1. 
A more difficult challenge is to create enzymes with novel catalytic abilities, in order to 
expand the repertoire of chemistry performed by the cell71,72. Arnold and co-workers have 
developed a strategy to accomplish this. First, bioinformatics is used to search for enzymes 
possessing mechanistic similarities to a desired transformation for which no enzymes are known. 





group has successfully evolved cytochrome P450s to catalyze a range of novel chemical 
reactions such as cyclopropanation, carbine and nitrene transfers, and C-H amination71.  
 
Discovery of novel enzymes from metagenomic libraries 
Environmental DNA libraries can also be a valuable resource to search for homologs of 
enzymes with improved properties. For PDO production, metagenomic libraries were screened 
by colony hybridization and enzyme complementation in dehydratase-negative E. coli to find 
homologs of glycerol and diol dehydratases73. Eventually, a diol dehydratase was found, which 
exhibited higher kcat/kM values and retained 40 % of its activity even in the presence of high 
concentrations (2 M) of the product PDO. 
The method of family shuffling or in vitro DNA recombination using PCR can be used to 
mix-and-match different regions of homologous proteins to create a library of hybrids74,75. This 
method was used to shuffle three homologs of the enzyme biphenyl dioxygenase to evolve 
variants that had enhanced activities to degrade polychlorinated biphenyls (PCBs)76. 
 
Tuning single gene expression 
Next, the expression of the enzyme or regulator can be optimized by tuning its level of 
transcription and translation, via the use of promoter libraries and ribosome binding site (RBS) 
variants respectively77. Alper et al. generated a promoter library by error-prone PCR of a 
constitutive promoter, and used it to assess how the levels of the enzymes phosphoenolpyruvate 
carboxylase (ppc) and deoxy-xylulose-P synthase (dxs) impacted growth yield and lycopene 
production respectively in E. coli78. It was found that lycopene yields scaled linearly with dxs 





be tuned by incorporating RNA stabilizing/de-stabilizing elements and protein degradation tags 
respectively79. Babiskin et al. created a library of Rnt1p hairpin substrates, which mediate 
mRNA degradation when placed at the 3’ UTR of mRNAs. They fused the library to the gene 
encoding squalene synthase (ERG9) in S. cerevisiae in order to modulate the flux through the 
ergosterol pathway80. Finally, gene knockout or overexpression libraries such as the Keio 
knockout collection for E. coli81 can be used for the systematic analysis of genes that affect strain 
production57.  
 
1.3.2 Mutagenesis to create pathway libraries 
Since metabolic engineering involves the optimization of multiple interacting genes and 
pathways, combinatorial approaches would benefit from generating libraries of multi-gene 
pathways as well as to optimize their individual expression simultaneously. The two main 
approaches to achieve this are either bottom-up DNA assembly of the pathway library or top-
down mutagenesis of an existing pathway. The advent of synthetic biology has led to the 
development of DNA assembly methods that are capable of efficiently building pathway libraries 
de novo82,83. At the same time, methods for in vivo mutagenesis have continued to expand, 
enabling multiple genomic loci to be targeted simultaneously for systems-level engineering and 
systems biology studies84. These methods will be explored later in the context of genome-wide 
mutagenesis, even though they can also be applied to build pathway libraries. 
 
In vitro DNA assembly methods 
In vitro DNA assembly methods such as restriction enzyme digestion and ligation can be 





restriction digest and ligation schemes to enable re-use of the same restriction sites for multiple 
rounds of assembly. For instance, the BioBrick™ standard involves the creation of DNA 
cassettes flanked at the 5′ region by an EcoRI and XbaI site, while the 3′ region contains a SpeI 
and PstI site85. Ligation of the compatible sticky ends of XbaI and SpeI destroys both sites, 
enabling further rounds of assembly using the same enzymes. Golden Gate employs Type IIS 
restriction enzymes that cleave outside of its recognition sequence to enable scarless DNA 
assembly86. Guo et al. used this method to create a series of standardized biological parts to 
enable the rapid construction of a promoter library (three promoters) for a three-gene carotenoid 
biosynthesis pathway (total of 27 combinations)87. Latimer et al. also used Golden Gate to 
construct promoter libraries for the eight-gene xylose utilization pathway in S. cerevisiae, in 
order to investigate differences in promoter enrichment under various conditions88. 
 
Occasionally, the use of restriction enzyme-based methods may be limited due to the 
occurrence of restriction sites within the sequence of interest. In those cases, other seamless 
assembly methods such as overlap-extension PCR can be used. Jeschek et al. used this method to 
create rationally-reduced RBS libraries (RedLibs) for three genes in order to optimize the flux 
around a branch point in the violacein biosynthesis pathway89. Variants were identified that 
showed increased production of the pigments violacein and deoxyviolacein by 240% and 420% 
respectively. Other useful in vitro methods that enable the rapid and scarless assembly of DNA 
fragments based on homology include sequence and ligation-independent cloning (SLIC)90 and 
Gibson assembly, which has been shown to be capable of assembling several hundred kilobase-





modular fashion to enable the rapid construction of promoter, RBS and origin of replication 
libraries to optimize transcription, translation and plasmid copy number respectively92. 
 
In vivo DNA assembly on plasmids 
Another class of methods for DNA assembly involve harnessing the highly efficient 
homologous recombination machinery in the yeast S. cerevisiae or the bacterium Bacillus 
subtilis for in vivo assembly. For instance, Gibson et al. used gap repair in yeast for the one-step 
assembly of 25 overlapping DNA fragments to form the complete, synthetic, 592 kb 
Mycoplasma genitalium genome93,94 (Fig. 1-4). Larionov et al. developed Transformation 
Associated Recombination (TAR), based on gap repair of a linearized plasmid in yeast, for the 
efficient cloning of genes or genomic regions up to 300 kb in length from co-transformed 
prokaryotic or eukaryotic genomes95. Shao et al. developed DNA Assembler, also based on yeast 
gap repair, and demonstrated the one-step construction of a functional eight-gene, D-xylose 
utilization and zeaxanthin biosynthesis pathway (19 kb)96. Next, the authors used DNA 
Assembler to construct a functional 29 kb aureothin polyketide biosynthesis pathway, and 
modified the pathway gene AurB to produce an analog of aureothin97. However, when the 
assembly of the ~ 45 kb spectinabilin polyketide biosynthesis pathway was attempted, deletions 
were observed in the pathway, which was probably due to recombination between repetitive 
sequences. This necessitated the assembly of the pathway in two steps using yeast followed by in 
vitro assembly. This and our own experience (see Chapter 2) suggest a potential drawback to in 






Figure 1-4. Yeast gap repair for DNA assembly on plasmids. Multiple DNA fragments with 
overlapping homologies can be co-transformed with a linearized plasmid for efficient recombination in 
yeast to form a closed plasmid containing the assembled DNA. 
 
 Mitchell et al. combined in vitro assembly by Golden Gate with in vivo yeast gap repair 
to create a Versatile Genetic Assembly System (VEGAS)98. In that study, Golden Gate was first 
used to construct transcriptional units (promoter – gene – terminator) flanked by orthogonal 
sequences. These were used as homology arms for the one-step assembly of the four gene β-
carotene pathway and the five gene violacein pathway by homologous recombination in yeast. 
Next, the authors used VEGAS to assemble combinatorial promoter and terminator libraries (10 





produced different concentrations of β-carotene and intermediate compounds, which was 
reflected phenotypically in color differences between colonies98. Overall, in vivo DNA assembly 
using yeast gap repair can offer advantages in terms of speed and efficiency over in vitro DNA 
assembly methods, as only a single transformation step is required to create functional pathways 
and libraries on plasmids in yeast (Fig. 1-4). However, for the construction of robust and stable 
production strains, it is preferable to assemble biosynthetic pathways in the chromosome instead 
of plasmids, as plasmids require continuous selection pressure for maintenance, and can exhibit 
variability in their copy number99. 
 
In vivo DNA assembly in the chromosome 
Itaya et al. have developed the B. subtilis genome as a vector (BGM vector) for the 
cloning of the 3.5 Mb genome of the photosynthetic bacterium Synechocystis PCC6803 using a 
homologous recombination-based method named “inchworm”100. However, the method requires 
long (> 100 kb), high quality, continuous DNA as template, which may not be readily available. 
The authors later developed “domino” assembly of overlapping blocks of DNA that can be 
generated by PCR or gene synthesis, and demonstrated the assembly of the 16.3 kb mouse 
mitochondrial genome and the 134.5 kb rice chloroplast genome101. 
Our lab (Wingler et al.) developed Reiterative Recombination as a robust, user-friendly 
and efficient tool for the assembly of multi-gene pathways and libraries in the yeast 
chromosome102,103. Reiterative Recombination relies on inducing an endonuclease to create a 
dsDNA break in the genome, which increases the efficiency of repair by homologous 
recombination by orders of magnitude104,105. A marker recycling scheme (HIS3 and LEU2) that 





rounds of assembly to be performed without running out of markers (Fig. 1-5). We have applied 
this method for the assembly of a challenging ~ 100 kb polyketide biosynthesis pathway for 
meridamycin (Chapter 2). Importantly, the high efficiency allows for the construction of 
pathway libraries of at least 104. Wingler et al. demonstrated this by building a mock library for 
the three gene lycopene biosynthesis pathway (crtE, crtB and crtI) and recovering one active 
clone from a pool of 104 inactive pathways102. 
 
Figure 1-5. Reiterative Recombination cycle. The system relies on cycling between a set of two 
endonucleases and marker genes (HIS3 and LEU2) for indefinite rounds of assembly. In round 1 (top), 
endonuclease 1 is induced by galactose, which creates a dsDNA break at the endonuclease target site in 
the genome. This stimulates efficient homologous recombination using a piece of donor DNA (orange) 
containing the DNA to be assembled. Integration into the chromosome can be selected for using marker 1, 
which is only active on the chromosome and not the plasmid. In round 2 (bottom), endonuclease 2 cuts 
the genome to stimulate homologous recombination with the next piece of donor DNA. The process 





In 2014, Annaluru et al. reported the total synthesis of a ~ 270 kb functional, designer 
yeast chromosome III. The authors used a hierarchical assembly scheme starting from 
oligonucleotides to create ~ 750 bp double-stranded DNA building blocks by overlap-extension 
PCR. These were joined by yeast gap repair to create 2 – 4 kb mini-chunks. Finally, pools of 
overlapping, synthetic mini-chunks, were used to replace native sections of the yeast 
chromosome III by homologous recombination (Fig. 1-6). A total of eleven rounds of 
recombination were performed to replace the entire chromosome with synthetic DNA, using 
alternating marker genes (LEU2 and URA3) to select for mini-chunk integration. 
 
This achievement is part of the S. cerevisiae (Sc2.0) project, which seeks to construct an 
entirely synthetic, designer yeast genome106. Significantly, the refactored genome will have 
destabilizing elements such as transposons removed, and TAG stop codons will be replaced by 
TAA stop codons to free up a codon for future unnatural amino acid incorporation. Finally, all 
non-essential genes and major landmarks such as the centromere and telomere, will be flanked 
by loxPsym sites to enable genome-scale rearrangements, duplications, inversions and deletions 
to occur upon inducible expression of Cre recombinase (SCRaMbLE) (Fig. 1-6). Once the 
synthetic genome is complete, SCRaMbLE can be used to explore genome minimization to 
create a fully-dedicated cell factory107, or to accelerate the directed evolution of the host 







Figure 1-6. Synthetic yeast chromosome and SCRaMbLE. Top: Homologous recombination was 
used to replace all portions of the native yeast chromosome with synthetic constructs. Bottom: Upon 
induction of Cre recombinase, the genes (arrows) can undergo a variety of recombination events between 







Overall, DNA assembly technologies have advanced to the stage where the construction 
of pathway libraries of up to 104 variants are becoming routine. This has largely overcome the 
bottleneck in the mutagenesis step for the directed evolution of biosynthetic pathways. The next 
challenge is to optimize the host strain background by combinatorial approaches. While DNA 
assembly methods are beginning to make inroads into the de novo total synthesis of functional 
bacterial93,94,104 and eukaryotic genomes106,109, these approaches are still developing and remain 
technically challenging to perform. However, in recent years, there has been much progress in 
the development of technologies to perform genome-wide mutagenesis for synthetic and systems 
biology applications. In the next section, we highlight some prominent technologies and 
approaches that are enabling the high-throughput directed evolution of host genomes for 
combinatorial metabolic engineering. 
  
1.3.3 Genome-wide mutagenesis 
Global transcription machinery engineering 
Alper et al. developed global transcription machinery engineering (gTME) for the global 
perturbation of the transcriptome110 (Fig. 1-7). The method relies on using error-prone PCR to 
mutate the E. coli gene rpoD that encodes the main bacterial sigma factor, σ70. In E. coli, sigma 
factors can tune the promoter preferences of RNA polymerase for multiple genes111. Alper et al. 
demonstrated that mutagenizing the global regulator σ70 was more efficient than traditional 
methods targeting multiple genes, to optimize phenotypes such as ethanol tolerance, lycopene 






Figure 1-7. Global transcription machinery engineering. Global regulators such as the sigma factor 
are mutagenized in E. coli. This may result in changes to the gene expression profile of several genes that 
are originally regulated by the sigma factor, or new genes that are now regulated by the mutated factor. 
Various –omics approaches such as transcriptomics can be used to quickly identify target genes that may 
be responsible for an interesting phenotype. 
 
Recombineering in E. coli 
 Recombineering has emerged as an efficient and reliable method to mutagenize the 
genome in E. coli112,113. The method harnesses phage-based recombination machinery such as the 
ET system or λ Red system, for homologous recombination of linear single-stranded DNA 
(ssDNA) or double-stranded DNA (dsDNA) with E. coli plasmids or the genome114-118. The 
efficiency of Red-recombination approaches 25 % of cells surviving electroporation when the E. 
coli mismatch repair system is knocked out119. Importantly, the region of homology required for 





oligonucleotides (ss-oligos) can be synthesized at reasonable cost on a chip for genome-wide 
mutagenesis120. 
 
Figure 1-8. Multiplex automated genome engineering. Low-cost, 90-base single-stranded oligos can 
be used to create large randomized libraries (NNNNN) in specific locations or genes in the genome. 
Using iterative cycles of MAGE, which can be automated, extensive changes can be made to the genome. 
 
 Wang et al. developed Multiplex Automated Genome Engineering (MAGE), based on 
recombineering, for the automated, genome-wide mutagenesis and evolution of E. coli121 (Fig. 1-
8). Each cycle takes ~ 2 – 2.5 h and is capable of mutagenizing > 30 % of the cell population 
using 90-base ss-oligos. The authors applied MAGE to optimize the host background for 
lycopene production. Twenty genes were chosen for the construction of RBS libraries to tune 
their translation, and four genes were targeted for inactivation simultaneously. After 35 cycles of 





lycopene compared to the background strain was isolated. Significantly, the strain exceeded the 
best documented yields at the time, and was evolved in less than a week121. Isaacs et al. applied 
MAGE to refactor all the 314 TAG stop codons in E. coli to TAA, in order to free up a codon for 
potential applications such as unnatural amino acid incorporation. They accomplished this by 
using MAGE to refactor 10 different stop codons at a time using a pool of 10 oligos to generate 
32 strains. The authors then developed hierarchical conjugative assembly genome engineering 
(CAGE) to combine all the refactored genomes in the 32 strains to produce a strain containing all 
314 stop codon replacements122,123. Wang et al. further developed MAGE to enhance the 
efficiency of integrations by co-selection for oligo-mediated reversion of an inactivated genomic 
marker (CoS-MAGE)124. The authors showed that the population of cells containing oligo-
mediated mutations near the co-selection marker was enriched by this co-selection process. They 
further applied CoS-MAGE to combinatorially insert the 20-bp T7 promoter in front of 12 genes 
to optimize the production of indigo. Subsequently, a strain producing four-fold more indigo 
than the background strain was isolated. 
 
While MAGE was applied for the combinatorial tuning of known genes that affect a 
biosynthetic pathway, Warner et al. developed another recombineering-based method, called 
Trackable multiplex recombineering (TRMR), to enable genome-wide searches for unknown 
genes that impact upon a selectable phenotype125 (Fig. 1-9). The authors created a gene 
overexpression library and a gene knockdown library containing unique barcodes for 4,077 
genes in E. coli (95 % of all genes). The libraries were subjected to a selection and screened for 
enriched genes using DNA microarrays to scan for the barcodes. Using TRMR, the authors 





(rich, minimal and cellulosic hydrolysate) and in the presence of growth inhibitors126. To 
showcase how TRMR could be employed for combinatorial metabolic engineering, Sandoval et 
al. used TRMR to identify individual genes that impact upon acetate tolerance, growth at pH 5, 
and cellulosic hydrolysate tolerance. The authors then used recursive recombineering, similar to 
MAGE, to construct combinatorial RBS libraries for the top hits identified from TRMR. 
Superior combinations of mutations were subsequently identified127. The optimization of 
metabolic flux requires more than simple overexpression or knockdown. Thus, Freed et al. 
incorporated inducible promoters by TRMR (T2RMR) to enable a more fine-grained mapping of 
different gene expression levels to specific phenotypes128. 
 
 
Figure 1-9. Trackable multiplex recombineering. Barcoded oligos are used to create a genome-wide 
overexpression or gene knockdown library. After screening or selecting for cells that display a desired 
phenotype, the population can be sequenced using the barcodes to quickly identify target genes that may 






Yeast homologous recombination 
 Compared to E. coli, the yeast S. cerevisiae possesses a highly efficient endogenous 
homologous recombination (HR) machinery, which has enabled efficient genome manipulations 
to be performed for decades129. However, when using dsDNA, high efficiencies of 
recombination (~ 10-3) necessitates either long homology arms (> 500 bp)130 or the generation of 
a dsDNA break near the region of modification102, coupled with the use of selection markers to 
select for integration. When using short ssDNA with homology arms ~ 20 – 30 bp, the efficiency 
drops to ~ 10-6, which can be rescued by using high amounts (~ 1 nmol) of oligonucleotides, 
selecting for reversion of a marker gene131 or creating a dsDNA break near the site of 
modification105. Thus, although it is straightforward to perform the targeted mutagenesis of a few 
genes in the yeast genome, it is challenging to apply libraries of short, synthetic oligos to 
perform genome-wide mutagenesis. 
 
Nevertheless, Di Carlo et al. developed yeast oligo-mediated genome engineering 
(YOGE), for the recombineering of the yeast genome using synthetic oligonucleotides132. After 
knockout of the mismatch repair system, overexpression of DNA recombinase, and optimization 
of conditions such as oligonucleotide length and homology, efficiencies of 0.2 – 2 % were 
achieved across all loci for oligo incorporation without a selectable marker. While an impressive 
achievement, the efficiency of YOGE is still ~ 10 – 100 fold lower than MAGE121. Thus, the 
authors propose that a negative selection against unedited genomes using programmable 
nucleases (see next) can help to eliminate non-mutagenized cells and increase the proportion of 






Programmable sequence-specific DNA-binding proteins 
The development of programmable nucleases that can make targeted dsDNA breaks in 
the genome has opened up new possibilities to perform efficient genome editing in yeast and 
other organisms133 (Fig. 1-10). Zinc finger nucleases (ZFNs) and Transcription activator-like 
effector nucleases (TALENs) have been created by fusing a non-specific DNA-cleaving 
endonuclease to a modular DNA-binding domain (DBD) based on the zinc finger proteins 
(ZFPs) or transcription activator-like effectors (TALEs) respectively134. Due to their modular 
structure, ZFNs or TALENs that target specific DNA sequences can be created by changing the 
amino acid sequence of the DBD. The creation of a dsDNA break can stimulate homologous 
repair with a co-transformed piece of mutagenic ssDNA or dsDNA. Zhang et al. developed 
TALENs-assisted multiplex editing (TAME) in yeast for genome-scale directed evolution135. 
TALENs were designed to recognize the consensus TATA and GC boxes and create a dsDNA 
break in between, in order to produce insertions, deletions and nucleotide substitutions (indels) 
via repair by non-homologous end joining (NHEJ). A total of 66 sites regulating the transcription 
of 98 genes were potentially targeted simultaneously by this approach. The authors then applied 
TAME to evolve yeast strains with improved ethanol tolerance and found that the best 
performing strain contained TALENs-induced indels at 7 sites. The TAME approach is similar to 
gTEM in that a single regulatory system controlling multiple genes is mutagenized. However, 
compared to homologous recombination, NHEJ is inefficient in yeast since repair of dsDNA 
breaks by HR is the dominant pathway136. 
An alternative to editing the DNA sequence of the genome is to apply the programmable 
DNA-binding proteins as artificial transcription factors by fusion of the DBD to an activator or 





effect genome-wide changes in gene expression137. By randomly shuffling DNA segments to 
create three-finger proteins, followed by fusing them individually to either a repression or 
activation domain, the group created a library of artificial transcription factors with varied DNA-
binding specificities. This was used to identify ZFPs that increased the tolerance of yeast cells to 
heat shock, high osmotic pressure and drug resistance. 
 
Figure 1-10. Comparison between the TALENs, ZFNs and CRISPR/Cas9. The DNA-recognition 
modules that enable sequence-specific targeting in these systems are either protein domains (TALENs), 





a nickase/endonuclease, activator or repressor domain to enable the creation of sequence-specific 
ssDNA/dsDNA breaks, gene activation or repression respectively. 
 
CRISPR/Cas9 RNA-programmable DNA targeting proteins 
 Recently, the CRISPR/Cas9 system from Streptococcus pyogenes has been harnessed as 
an RNA-guided DNA-editing tool in various organisms138-141. Compared to the ZFPs and 
TALEs, which are bulky and require multiple changes to the DBD to tune its DNA specificity, 
Cas9 can be easily targeted to a specific DNA sequence by a complementary guide RNA 
(gRNA) (Fig. 1-10). CRISPR/Cas9 has been shown to be highly efficient for the marker-free 
editing of yeast genomes since Cas9 cutting is cell-lethal, which imposes a negative selection 
against non-repaired dsDNA breaks or non-mutated DNA142. Ryan et al. developed CRISPRm 
for the single and multiplex editing of up to three genomic loci in yeast simultaneously by 
driving gRNA expression via a strong tRNA promoter and fusing a HDV ribozyme to the 5’ end 
of the gRNA to improve its stability143. Bao et al. developed HI-CRISPR for the multiplex 
knockout of three genomic loci by using a polycistronic gRNA and repair DNA array, as well as 
an ultra-high copy number plasmid carrying iCas9 to increase efficiency144. The authors used HI-
CRISPR to knockout three genes in a heterologous hydrocortisone biosynthesis pathway with 
100 % efficiency in 6 days. Jakočiūnas et al. demonstrated that CRISPR/Cas9 can be used to 
knockout different combinations of up to 5 genes, and identified strains producing 41-fold higher 
titers of mevalonate compared to the wild-type strain145. 
 
In the same vein as the ZF and TALE-based transcription factors, CRISPR/Cas9 can be 
exploited to target gene transcription. Catalytically inactive Cas9 (dCas9) that retains its DNA 





for RNA-guided DNA targeting (Fig. 1-10). The binding of dCas9 to DNA has been shown to 
inhibit RNA polymerase or transcription factor binding, or transcriptional elongation, resulting in 
the effective silencing of genes (CRISPRi)146,147. This system has been shown to be highly 
specific, reversible and capable of targeting multiple genes at once. In addition, the fusion of 
repressor or activator domains to dCas9 can result in the more effective repression or activation 
of transcription of endogenous genes in eukaryotes respectively148,149. Bikard et al. showed that 
dCas9 can be similarly exploited as an artificial transcriptional repressor in E. coli, and when 
fused to the omega subunit of RNA polymerase, can serve as a transcriptional activator150. 
Farzarhard et al. further showed that the activity of CRISPR-based transcription factors 
(CRISPR-TFs) can be modulated in S. cerevisiae by targeting several CRISPR-TFs to different 
positions in natural promoters, or by creating multiple CRISPR-TF binding sites within synthetic 
promoters151. 
 Examples of using CRISPR-TFs for transcriptional re-programming for metabolic 
engineering are beginning to emerge. Cress et al. constructed a library of T7-lac promoters that 
can be orthogonally repressed by CRISPRi in E. coli152. The authors incorporated these 
promoters into the five-gene, branched violacein biosynthesis pathway, and showed that they 
could use CRISPRi for the selective redirection of flux to produce different compounds. Cleto et 
al. demonstrated the use of CRISPRi to decrease the expression of the genes pgi, pck and pyk in 
Corynebacterium glutamicum and showed that they could achieve increased titers of L-lysine 
and L-glutamate production comparable to levels achieved via gene deletion153. Already, 
genome-wide gRNA libraries that target practically all the genes in fly154 and human155 have 
been constructed. It is anticipated that such gRNA libraries that target all known protein-coding 





metabolic engineering to improve the strain background and to discover new genes and 
regulatory systems that impact production. 
 
1.3.4 Screens or selections for small molecule products 
While there have been major advances in methods for bottom-up DNA assembly and top-
down genome-wide mutagenesis, it is widely held that the current bottleneck to employing 
combinatorial approaches in metabolic engineering is the lack of robust and efficient screens and 
selections for small molecule products156. The current state-of-the-art for small molecule 
detection is gas or liquid chromatography coupled with mass spectrometry (GC/LC-MS), which 
is capable of detecting and quantifying multiple compounds in one sample since 
chromatographic separation is coupled to highly sensitive and specific mass detection157. As 
such, GC/LC-MS has been harnessed to track global changes in carbon networks in the cell by 
13C isotope-based metabolic flux analysis158-160. However, for the purpose of screening a 
combinatorial strain library to detect a single target molecule, the low-throughput and the 
requirement for additional sample preparation steps impose severe limitations on library size – 
assuming sample turnover is on the order of minutes, a modest library of 103 samples will take 
days to screen. This limitation has led groups to develop creative screens/selections or to be 
fastidious in their choice of metabolic engineering targets. 
 
Products with screenable or selectable phenotypes 
Molecules that are intrinsically colored such as lycopene64, indigo161 or violacein162, 
fluorescent such as astaxanthin163, or contain reactive groups that can produce a 





be converted to melanin by tyrosinase164), are excellent targets to develop screens. This is 
because differences in colony color or fluorescence can be easily distinguished on agar plates (up 
to 106 clones) or measured in multi-well plates (~ 104 - 105 samples/day) using a plate reader. 
Also, for fluorescent products, high-throughput fluorescence-activated cell sorting (FACS) (up to 
109 per day) can be used to enrich a population of cells demonstrating increased fluorescence165. 
Even better are target molecules that can confer a growth advantage on the producer cell, 
including primary metabolites such as prephenate166 and pyruvate167, which will enable higher 
producing clones to be enriched in a one-pot growth selection. For growth selections, the library 
size is only limited by culture volume (<1010) and for this reason, selections are indispensable to 
fully cover large random or combinatorial mutant libraries (>108). 
 
Engineering synthetic protein receptor-transducer fusions 
Unfortunately, many metabolic engineering targets of interest, such as fatty acids, short 
chain alcohols and diols, lack obvious properties that will enable the direct application of high-
throughput screening/selection methods168. For such targets, various transduction strategies are 
needed to couple the detection of the molecule to an output amenable to high-throughput assay 
formats. Early work was focused on combining protein-based small molecule receptors with a 
transducer, in order to turn the binding event into a detectable signal. One approach was to 
incorporate a receptor into a transducer such as a fluorescent protein or enzyme169 (Fig. 1-11). 
Some examples include fluorescent protein – receptor fusions that change their fluorescence 
output upon ligand binding170,171, or enzyme (e.g. DHFR) – receptor fusions that exhibit ligand-
dependant activity172-174. These are based on the observation that protein insertions within a 





functional coupling between the two175. However, these methods require cumbersome screening 
of a large pool of circularly permutated fusion proteins for functional variants. 
An alternative approach is to incorporate a transducer into a receptor, for instance, 
labeling the receptor with an environmentally-sensitive fluorophore positioned close to the 
ligand binding site, which can result in changes in fluorescence output upon ligand binding due 
to displacement of the fluorophore from the binding site176 (Fig. 1-11). This has been applied to 
antibodies⁠177-179, cell surface receptors180⁠, bacterial periplasmic binding proteins181 and 
enzymes182-184⁠. However, these methods require the additional step of site-specific protein 
labeling, screening to optimize fluorophore positioning and may result in variable output 
depending on the nature of the fluorophore. 
 
Figure 1-11. Engineering protein receptor – transducer fusions. In one approach (top), receptor 





screened to find a functional variant where the fluorescence output is dependent on the presence of target 
molecule (red star) binding to the receptor.  In another approach (bottom), an environmentally-sensitive 
fluorophore can be placed close to the receptor binding site. Displacement of the fluorophore by ligand 
binding can result in a change in fluorescence, thus producing a detectable signal. 
 
 
Figure 1-12. Engineering RNA aptamers to create aptasensors. A fluorophore and quencher (blue 
circle) are attached to the ends of a RNA aptamer. In the absence of the ligand (blue star), the fluorophore 
is far away from the quencher and thus emits fluorescence. When the ligand is present, the aptamer 
conformation is stabilized, leading to proximity between the quencher and fluorophore, which results in a 
decrease in fluorescence. 
 
Engineering RNA/DNA-based aptamers 
An alternative to protein-based receptors, RNA/DNA-based aptamers that bind to small 
molecules have also generated much interest for use in bio-sensing. This is because there are 
well established methods such as SELEX to develop high-affinity RNA/DNA binders.185,186 
These aptamers have been incorporated into modular RNA/DNA designs that allow for 
switching between different secondary structural states in response to ligand binding to the 
aptamer region, and are known as molecular aptamer beacons or aptasensors187,188 (Fig. 1-12). 
The output is usually a change in fluorescence by having the ligand stabilize a structure that 





beacons have been mostly applied to detect nucleic acids189, which they were originally 
developed for, although progress is being made to detect other molecules such as proteins190,191 
and small molecules192,193. Challenges faced by RNA/DNA-based sensors include biphasic 
switch behavior in response to varying ligand concentrations (absence of a linear dynamic 
range), high background in the cell (tend to enter nucleus and fluoresce) and lack of structural 
stability in different types of conditions194,195. 
 
Engineering natural small molecule regulators 
Drawing inspiration from natural sensing mechanisms in the cell, natural regulators such 
as riboswitches/riboregulators196,197, transcription factors168,198 and nuclear hormone receptors199 
have been harnessed to link small molecule detection to translation or transcription of a reporter 
gene157,195 (Fig. 1-13). These regulators are elegant since they combine the functions of target 
binding and signal transduction in one molecule and can be genetically encoded. When applied 
to metabolic engineering, these regulators can be used to couple small molecule production to 
increased cell growth in selective media in order to enrich for better producers, or to create 
feedback circuits for product-dependent regulation of biosynthetic genes to improve the 
efficiency of production200. For example, Srivatsan et al. used MAGE to create RBS, start codon 
and promoter libraries to tune the expression of genes involved in the production of precursors 
for naringenin production in E. coli201. They then coupled a naringenin sensor, ttgR, to regulate 
the expression of TolC, an outer membrane protein that confers resistance to sodium dodecyl-
sulfate (SDS), and when absent renders the cell tolerant to colicin E1202. Importantly, this 
enabled the authors to perform a positive selection using SDS for high naringenin producers, 





TolC in the absence of induction of naringenin production (toggled selection). After four rounds 
of mutagenesis (15 MAGE cycles each) and toggled selection, a strain producing 36-fold more 
naringenin than the parent strain was isolated. 
 
Figure 1-13. Harnessing natural regulators to create small molecule selections. Riboswitches (top) can 
couple small molecule binding to an RNA aptamer to a change in translational output, for instance by 





in the presence/absence of a small molecule ligand can be used to create ligand-responsive gene circuits. 
Nuclear hormone receptors (bottom) function in a similar manner to transcription factors, except that the 
small molecule ligand promotes the entry of the receptor into the nucleus to affect gene transcription. 
These systems can be used to couple small molecule binding to a change in translation or transcription of 
a selectable marker gene. 
 
However, the repertoire of these small molecule regulators is largely limited by their 
availability in nature. There have been very few reported cases where natural regulators have 
been successfully re-designed or evolved to switch their target specificity, and even then, the 
new target is often similar in structure to the natural target203-207. One possible reason for this is 
that the binding and signal transduction functions are tightly interwoven in these regulators, 
which makes it difficult to rationally design new ligand specificities that still preserve their 
transduction function. The use of directed evolution approaches alone is also limited since this 
will probably require the in vivo exploration of sequence space that is beyond current capabilities 
for routine practice. Further advances in the development of small molecule regulators for 
metabolic engineering can come from using metagenomics to discover new natural regulators 
from the environment, and strategies that combine rational design, computational modelling and 
directed evolution to develop artificial regulators for novel molecules208. 
 
 1.4 Conclusions and future perspectives 
Metabolic engineering for the production of chemicals promises to revolutionize our 
society, leading to cheaper goods and materials, improved access to pharmaceuticals and greener 
production technologies. However, we are only just beginning to realize the potential of living 





engineer, due to our lack of understanding of all the parts and their interactions. While rational 
(constructive) approaches can lead to a strain that produces a low level of compound, inverse or 
directed evolution approaches typically have to be applied to raise production to commercially 
viable levels. These combinatorial strategies depend on technologies for de novo DNA assembly 
or top-down mutagenesis to construct large gene, pathway, network or strain libraries, coupled 
with product screens or selections to identify promising variants. While there has been much 
progress in the “build” technologies, more resources have to be channeled to solve the “test” 
bottleneck. 
Despite our best engineering efforts, a major limitation of using live microbial cells for 
biosynthesis is that they are not fully efficient chemical factories. Ultimately, energy and 
materials are needed for cell growth, maintenance and reproduction209. In addition, there are 
redundant pathways that serve to enhance the robustness of the system, as well as pathways for 
feedback regulation that limit the accumulation of particular metabolites. One potential approach 
to overcome these obstacles is to develop a “chassis organism”, which should contain the 
requisite metabolic precursors, transport systems and also channel most of its resources towards 
production of the desired target compound. A related objective is the development of a “minimal 
cell”, which contains a basic complement of genes and pathways for maintenance and 
reproduction. By chipping away redundant genes and pathways, biosynthetic circuits can be built 
that are orthogonal to unrelated cell functions. Technologies for genome minimization by 
evolution (e.g. SCRaMbLE)107 and de novo genome synthesis94,106 can contribute to future 
advances. 
Another concern of employing cellular factories to perform chemistry is the limited 





enzyme engineering and directed evolution can contribute to the design and evolution of 
enzymes de novo to perform novel reactions. Bio-prospecting or environmental genome mining 
can lead to the discovery of new enzymes and pathways, which can be heterologously cloned and 
tested in the production host. Furthermore, the exploration of non-traditional hosts for production 
can lead to the development of new chassis organisms for producing different classes of 
compounds210. This will require portable technologies such as CRISPR/Cas9138 that are broadly 
applicable to a range of organisms, in order to perform genome engineering. 
 
Finally, advances in our understanding of biology and computational modeling can 
eventually lead to the development of comprehensive whole cell models55. These models would 
include all cellular processes and can be used to predict metabolic responses to environmental 
stimuli or genetic mutations. In this way, the “design-test-build-analyze” cycle can be performed 
at least initially in silico, and multiple cycles can be run to expand the number of permutations 
and combinations of mutations that are tested. De novo DNA assembly or genome-wide 
mutagenesis technologies can then be applied for rapid strain construction and testing. Metabolic 
engineering would then evolve towards a more rational discipline where fewer designs need to 
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2.0 Chapter outlook 
Building and testing combinatorial libraries of biosynthetic pathways is an efficient 
approach to optimize compound production and to produce novel analogs. However, it remains 
technically challenging to assemble and engineer long (10s – 100s kb) and complex multi-gene 
pathways, especially in host cells with a limited toolkit for genetic engineering. One strategy is 
to construct the pathway/library in a genetically tractable host such as yeast, followed by 
shuttling of the constructs into the heterologous production host. In this study, we report the de 
novo assembly of a ~ 100 kb Type I modular polyketide synthase (PKS) pathway for 
meridamycin in the yeast chromosome using Reiterative Recombination. This is one of the 
longest and most complex (highly repetitive and GC-rich) biosynthetic pathways for a small 
molecule natural product. The pathway was assembled in four fragments in parallel to create four 
yeast strains, each containing one fragment. Next, CRISPR/Cas9 was used to build a promoter 
library to drive the expression of each fragment separately, in order to optimize the production of 
meridamycin – a compound with promising neuroprotective properties. Finally, we developed 
FLIP for the efficient recovery of the fragments onto shuttle plasmids for their transfer by 
conjugation into the heterologous host Streptomyces lividans K4-114. We plan to screen the 
library using a high-throughput fluorescence polarization assay (see Chapter 3) to identify 
strains producing higher titres of meridamycin. In future, our approach can potentially be 




Synthetic biology offers a new paradigm for the bottom-up engineering of cells to 
perform user-defined functions, such as bio-sensing or metabolic engineering for the production 
of chemicals and feedstocks1. A key bottleneck is the introduction of multiple non-native genes, 
pathways or even whole genomes to create customized host cells2. De novo gene synthesis can 
provide the ultimate flexibility to build codon-optimized pathways or a library of variants to 
optimize a complex function. However, although the cost of DNA synthesis has dropped 
significantly, the lengths of double-stranded (ds)DNA blocks that are commercially available are 
still quite short (~ 2 – 5 kb). Thus, there is a need for efficient and accessible strategies to 
assemble these dsDNA blocks into multi-gene pathways (10s – 100s kb) and libraries for their 
expression in a host cell3. 
An important class of natural product pathways is the Type I modular polyketide 
synthases (mPKSs), which are large (10s – 100s kb), multi-modular enzyme complexes4. Each 
module consists of enzyme domains that extend the polyketide chain with monomers and modify 
them in assembly line fashion. Many notable drugs are modular polyketides, such as the anti-
bacterial erythromycin5, anti-fungal soraphen and candicidin6, immunosuppressant FK506 and 
rapamycin7, and anti-parasitic avermectin8. Because of their bioactive profile and multi-step, 
low-yield chemical syntheses9-11, there is a strong interest in optimizing the biosynthesis of these 
compounds in native and heterologous hosts. Furthermore, their modular architecture gives rise 
to the opportunity for pathway engineering or combinatorial biosynthesis to obtain novel 
analogs12-14. However, the Type I mPKSs are one of the most challenging pathways to engineer 
due to their length, highly repetitive module sequences, GC content (> 70 %), and lack of tools 
for genetic engineering in their native actinomycetes or myxobacteria hosts15. Although some 
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progress has been made with CRISPR16, the method is still inefficient in Streptomyces spp. and 
may be limited by off-target effects when targeting the repetitive mPKS sequence (see Section 
2.2.2). 
De novo assembly methods can offer the greatest flexibility to create designer 
sequences17. In one report, a combination of in vitro methods such as PCR and restriction 
digest/ligation was used to assemble the DEBS Type I mPKS pathway (32 kb, 6 modules) for 
expression in E. coli3. This approach requires unique restriction sites to be available, which 
would be problematic for longer sequences. In contrast, in vivo methods that rely on homologous 
recombination allow for the scarless assembly of DNA with a simple transformation step. The 
assembly of an iterative Type I PKS (45 kb, 4 modules) was achieved using DNA Assembler, 
based on plasmid gap repair, in the yeast Saccharomyces cerevisiae, followed by expression in 
Streptomyces lividans18. However, the efficiency of the method is low and a two-step assembly 
strategy had to be used to overcome severe gene deletions likely caused by the repetitive PKS 
sequences. Previously, our lab developed Reiterative Recombination as a user friendly, robust 
and efficient tool for assembling multi-gene pathways and libraries in the yeast chromosome19,20. 
The method relies on dsDNA break-induced homologous recombination to increase the 
efficiency of assembly21. Thus, we sought to explore the limits of our method by challenging it 
with building a long and complex mPKS pathway. 
In this chapter, we report the de novo assembly of a ~ 100 kb non-ribosomal peptide 
synthase (NRPS) – Type I mPKS (14 modules) that produces the polyketide meridamycin22. To 
our knowledge, this is the longest Type I mPKS pathway assembled from the bottom-up so 
far3,18. Our strategy was to split the pathway into four fragments according to open reading 
frames (ORFs) for parallel assembly in yeast. Meridamycin is structurally similar to FK506 and 
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rapamycin, but is non-immunosuppressive23, and has shown promise as a neuroprotectant against 
ischemic stroke, Parkinson’s disease and dementia22,24-28. Thus, we sought to optimize the 
production of the compound by using CRISPR in yeast to build a promoter library. Next, we 
developed FLIP, based on Recombinase Mediated Cassette Exchange (RMCE)29, for the 
efficient recovery of the pathway fragments and library from the chromosome onto shuttle 
plasmids. These were amplified in E. coli and cloned in vitro onto expression plasmids for 
transfer into the heterologous host Streptomyces lividans K4-114. Finally, we plan to screen for 
meridamycin production using our previously developed high-throughput fluorescence 
polarization assay (see Chapter 3). Our strategy can potentially be used to study the function of 
the PKS complexes, optimize compound production and for the biosynthesis of novel analogs. 
 
2.2 Results 
2.2.1 ~ 100 kb meridamycin PKS pathway assembly by Reiterative Recombination 
In our design, the ~ 100 kb meridamycin NRPS-PKS pathway was divided into four 
fragments according to open reading frames (ORFs), for parallel assembly in four separate yeast 
strains (Fig. 2-1). The constitutive ermE* promoter (ermEp*)30 from Streptomyces erythraeus 
was placed in front of each fragment to drive their expression separately. Although the Type I 
PKSs are typically transcribed as a single operon, several studies have shown that ORFs cloned 
and expressed in separate loci in the genome can reconstitute a functional PKS for polyketide 
production31-34. This strategy has been harnessed for combinatorial biosynthesis to produce a 
library of analogs. In our study, this “divide and conquer” approach also enabled the faster 
parallel assembly of the pathway by Reiterative Recombination, and in theory, would reduce the 
chances of unwanted recombination events between homologous regions during the assembly 
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process. Various unique restriction sites, recombination sites and bacterial antibiotic resistance 
markers were placed around the fragments to enable their recovery onto shuttle plasmids for 




Figure 2-1. ~ 100 kb meridamycin Type I NRPS – PKS pathway assembly scheme. The fragments 
were split according to open reading frames (ORFs): Fragment 1: merP, merA; Fragment 2: merB; 
Fragment 3: merC; Fragment 4: merE – merT. The core PKS subunits are encoded by merA, merB and 
merC, which are composed of 14 modules (M1 – M14) and a loading module. The rounds of Reiterative 
Recombination performed to assemble each fragment are shown below the horizontal line. Repeated 
numbers indicate that two or three DNA building blocks were assembled in that round. Various enzymatic 
domains in each module are shown schematically below in colored circles. KS: ketosynthase; AT: 




In total, 44 rounds of Reiterative Recombination were performed to assemble all of the 
four PKS pathway fragments (Fig. 2-1). During each round of Reiterative Recombination, we 
assembled one, two or three blocks of dsDNA of length ~ 1.5 – 3 kb each, which were mostly 
PCR amplified from a plasmid (pHLW30) containing the full pathway13 (Tables 2-2 – 2-5). We 
allowed for 100 – 250 bp of overlap between each DNA block in order to reduce the chances of 
off-target recombination, although in theory as little as 30 – 40 bp of homology is sufficient to 
assemble uncomplicated sequences19. After each round of Reiterative Recombination, ~ 104 
colonies/mL were obtained, which is similar to previously reported values20. PCR was used 
initially to screen for the assemblies in the chromosome (Fig. 2-2, Tables 2-6 – 2-9). On 
average, six colonies were screened after each round, of which at least one colony contained the 
correct assembly. When two or more blocks of DNA were assembled at the same time, we 
sometimes had to screen up to 12 colonies to find a correct clone, which was likely due to an 
increased frequency of undesired recombination events happening. 
 
 
Figure 2-2. PCR verification of complete PKS fragment assemblies. Lane 1: NEB 1 kb ladder. From 
left to right: check PCRs that were performed for each fragment to verify its assembly in the genome. 
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Primers and expected product sizes are listed in Table 2-6 (Fragment 1), Table 2-7 (Fragment 2), Table 
2-8 (Fragment 3) and Table 2-9 (Fragment 4). 
 
The four yeast strains containing the pathway fragments in chromosome IV were further 
verified by restriction digest of agarose-embedded DNA, followed by pulsed field gel 
electrophoresis and Southern blotting (Fig. 2-3). 
 
 
Figure 2-3. Pulsed field gel electrophoresis and Southern blotting to verify PKS assemblies. 1 kb 
extend ladder (NEB); 1: LW2591Y undigested, dark band shows position of undigested chromosome IV; 
(2-6: Samples digested with SpeI and expected sizes) 2: LW2591Y (13.9 kb), 3: Fragment 1 (38.5 kb), 4: 
Fragment 2 (37.5 kb), 5: Fragment 3 (50.2 kb), 6: Fragment 4 (33.6 kb). 
 
Also, we checked for fitness defects in the yeast strain containing Fragment 3 (merC), 
which is the longest fragment (~ 36 kb), but did not find any when compared to the Reiterative 




Figure 2-4. Fitness tests for yeast strain containing PKS fragment 3. Comparison of fitness of 
Fragment 3 yeast strain F3-R12 (column 3) with the Reiterative Recombination acceptor strain LW2591Y 
(column 2) and parental strain BY4733 (column 1), when cultured under different conditions. Top row 
from left to right: YPGE, 30 ºC, 6 days; YPD, 30 ºC, pH 4.0, 3 days; YPD + MMS (0.05 %), 30 ºC, 3 
days. Bottom row from left to right: YPD, 25 ºC, 3 days; YPD, 30 ºC, 3 days; YPD, 37 ºC, 3 days. 
 
Furthermore, to determine if the assemblies were stable in the chromosome, the yeast 
strain containing Fragment 3, which has 7 repetitive PKS modules, was sub-cultured for 10 days 
(> 120 generations) in three independent lineages (Fig. 2-5). Due to the presence of repetitive 
sequences, it is possible that portions of the pathway could pop-out by homologous 
recombination35. However, we did not observe any such cases by PCR verification of the 





Figure 2-5. Sub-culture scheme to check the stability of PKS assemblies in the chromosome. 3 
colonies were picked from a streak of strain F3-R12 and sub-cultured independently. Each day, 5 μL of 
culture was transferred into 5 mL of fresh YPD in a 14 mL culture tube. After Day 10 (~ 120 
generations), the culture was plated to obtain single colonies, which were isolated and the genomic DNA 




Figure 2-6. PCR to check the stability of PKS assemblies in the chromosome. Colonies from three 





2.2.2 Sequence editing and promoter library construction using CRISPR 
After the assembly was complete, we sequenced all of the fragments by Sanger 
sequencing of the check PCR products (Fig. 2-2). A total of 12 single base pair differences from 
our reference sequence were found (Table 2-1). Five mutations were found in the PKS genes, 
three of which were missense and two were silent mutations. To demonstrate that we could 
utilize yeast synthetic biology to make sequence edits and to keep the amino acid sequence 
identical to the wild-type (WT), we decided to correct all of the missense mutations in the 
pathway. 
 
Table 2-1. Mutations in yeast assemblies. 
Fragment Position Mutation (sense strand) Locus 
1 15707 G to A (Gly to Glu) merA-M2-AT 
1 21005 T to C (Leu to Pro) merA-M3-AT 
1 23224 Deletion of T tetR promoter 
2 23409 C to T cat (chloramphenicol resistance gene) 
2 23524 Insertion of T cat terminator 
3 1444 G to T ermE* promoter 
3 9058 C to T (silent) 
Linker between merC-M9-AT and merC-
M9-KR 
3 NA Deletion of A 
HO endonuclease cut site in ReRec acceptor 
locus after Round 10) 
3 27250 G to A (silent) 
Linker between merC-M13-DH and merC-
M13-ER 
3 35069 G to A ant3ia promoter 
3 36274 G to T ant3ia terminator 




Recently, the CRISPR/Cas9 method has been developed for the in vivo editing of DNA in 
yeast and other organisms36,37. The method is highly versatile, since the endonuclease Cas9 can 
be directed to make a dsDNA cut at a site that is complementary to a user-designed guide RNA 
(gRNA)38. The dsDNA break stimulates repair by homologous recombination with a block of 
user-supplied repair DNA to allow for sequence editing. We performed CRISPR successfully to 
correct a total of four mutations, including one silent mutation and one single base-pair deletion 
that occurred in the HO endonuclease cut site of the Reiterative Recombination module during 
Round 10 of assembly of Fragment 3 (Table 2-1). However, one missense mutation was 
recalcitrant to our efforts to correct it using CRISPR. This mutation occurred in the 
acyltransferase (AT) domain of PKS module 2, and led to local sequence identity with the 
homologous AT domain in PKS module 1. We hypothesize that this could have led to off-target 
Cas9 cleavage of PKS module 1, since the gRNAs that we designed to target the mutation in 
module 2 differed only by one base-pair from the AT sequence in module 1 (Table 2-10 and 
Table 2-11). We also successfully applied CRISPR to introduce recombination marker genes 
and FRT sites to allow for subsequent fragment recovery onto shuttle plasmids (Table 2-10). 
Next, we decided to apply CRISPR to construct a promoter library in an attempt to 
increase the production yield of meridamycin in a heterologous host. The reported yields of 
meridamycin from native strains is quite low (< 10 mg/L)39,40. Previously, the entire pathway 
was shuttled into the heterologous host S. lividans K4-114, but no production was observed with 
the native promoter13. When the constitutive ermEp* promoter was swapped in to form strain E7, 
a very low yield was observed (~ 240 μg/L)30,41. Thus, promoter libraries could offer a 
combinatorial way to optimize the expression of the major ORFs in the pathway, especially since 




Figure 2-7. Promoter library construction by CRISPR to optimize meridamycin production. 5 
promoters were chosen to build the library in front of each fragment. They are listed in order of increasing 
strength and compared with the ermEp* promoter. Shown on the right are hypothetical combinations of 
different promoters leading to different product yields. 
 
Five constitutive Streptomyces promoters of various strengths were chosen to build the 
library (Fig. 2-7). kasOp*43, SF14p44 and p2145,46 have been shown to be stronger than ermEp*. 
B4p is weaker than ermEp*, while p72 is inactive and serves as a negative control. Compared to 
ermEp*, these promoters have not been fully explored for metabolic engineering in Streptomyces 
spp.45. We performed one round of CRISPR on each fragment and supplied an equimolar mix of 
the five promoters with appropriate homologies to the fragments as repair DNA. Each CRISPR 
attempt yielded hundreds of colonies (data not shown), which is similar to that of other reports36. 
30 colonies were screened by yeast colony PCR and sequenced to verify the identity of the 
promoter. All the screened colonies contained one of the five promoters in place of the original 
ermEp* promoter (Fig. 2-8), making the CRISPR/Cas9 method highly efficient (~ 100 %) at 
producing desired mutations. Assuming all four fragment libraries are transferred into 




Figure 2-8. Proportion of 30 colonies containing each promoter after one round of CRISPR. 
 
2.2.3 Pathway recovery from the chromosome onto a shuttle vector by FLIP 
Development of a FLIP system for pathway recovery 
Next, we sought to recover the NRPS-PKS pathway fragments and library from the yeast 
chromosome onto a shuttle vector for transfer into Streptomyces spp.. For this, we developed 
“FLIP”, which is based on site-specific recombination (SSR). Unlike homologous 
recombination, which can occur between any pair of sequences containing a minimum amount of 
identity, SSR occurs only between a pair of specific target sequences recognized by a 
recombinase enzyme47. In particular, the Cre/Lox system from bacteriophage P1 and Flp/Flp 
Recombinase Target (FRT) site system from yeast have been exploited as efficient tools to 
perform gene insertions, deletions and inversions in a wide variety of organisms48. The original 
FRT site (FRT-WT) has been engineered by the creation of orthogonal 48 base-pair FRT mutant 
sites (FRT-X) differing only in an 8 base-pair spacer, which recombine preferentially with 
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themselves over other variant sites49. This has led to the development of Recombinase Mediated 
Cassette Exchange (RMCE), in which DNA cassettes flanked by the same pair of heterologous 
FRT sites are exchanged in a double SSR event catalyzed by Flp recombinase29. RMCE has been 
harnessed to integrate DNA into the genome of mammalian, plant and insect cells, and can be 




Figure 2-9. Design of the FLIP system based on RMCE. Marker 1 and 2 are fused in frame to the 48 
base pair FRT-WT site. Marker 1 is silent due to the absence of a promoter and start codon. Upon FLIP, 
marker 1 is activated by a strong promoter (pMET25) and start codon on the shuttle vector, whereas 
marker 2 is silenced, enabling positive and negative selection respectively. FRT-X represents a 
heterologous FRT variant site. Flp recombinase was cloned onto the shuttle vector under control of the 




In this study, we engineered RMCE in reverse with a start codon and promoter trap to 
enable in vivo selection for the recovery of DNA from the yeast chromosome onto a shuttle 
plasmid (FLIP) (Fig. 2-9). In the FLIP system, an inactive marker gene (no start codon and no 
promoter) in the chromosome is activated after FLIP onto a plasmid containing a promoter and 
start codon. As a proof-of-principle, we have recovered the URA3 marker gene alone, flanked by 
FRT-WT and FRT-3, from the chromosome onto a pRS series E. coli – S. cerevisiae shuttle 
vector51. High efficiencies of 10-4 were only obtained in the presence of Flp recombinase, 
compared to background homologous recombination rates of ~ 10-6, a 100-fold difference (Fig. 




Figure 2-10. FLIP efficiencies with culture time. The pRS415 shuttle plasmids containing Flp 
recombinase (pAN133, lines C and D) and lacking Flp recombinase (pAN65, lines A and B) were 
transformed into a yeast strain (AN61Y) containing URA3 in the chromosome flanked by FRT-WT and 
FRT-3. Transformants were scraped and cultured in glucose-based media (lines A and C) or galactose-
based media to induce Flp recombinase (lines B and D). After culturing for different time (3 h, 7 h, 12 h, 
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24 h and 48 h), the cells were diluted and plated on selective agar lacking uracil, as well as non-selective 
agar. Efficiencies were calculated as number of colonies on selective / non-selective plates. Error bars 
represent the standard deviation of colony counts from two plates. 
 
Recovery of assembled fragments by FLIP 
In order to recover our large pathway fragments from the yeast chromosome for transfer 
into Streptomyces spp., we modified a pSBAC E. coli – Streptomyces shuttle vector previously 
developed for the cloning of the meridamycin (and other large) pathways13. We incorporated 
yeast replication sequences for its maintenance as a low-copy centromeric plasmid in yeast, the 
LEU2 marker for selection in yeast, the FLIP acceptor module (FRT-WT – TRP1 – FRT-3) 
(pAN98) and the Flp recombinase under control of a galactose-inducible promoter (pAN146). 
Originally, our goal was to recover all four fragments onto a single shuttle plasmid using an 
iterative FLIP scheme (Fig. 2-11). 
 
However, we faced difficulties in the recovery of fragment 3 onto a plasmid that already 
contained fragment 4. Very few/no colonies were obtained, which could have been due to a non-
functional KanMX marker (the FRT-WT site adds an extra 16 amino acids at the N-terminus of 
the protein). The few colonies obtained had plasmids with incomplete pathway fragments, which 
could have been due to unwanted recombination events occurring between the repetitive 




Figure 2-11. Design of FRT sites, yeast and bacterial marker genes for iterative FLIP. 
 
As such, we opted to recover each of the fragments individually by FLIP onto plasmids, 
followed by restriction digest and ligation to clone the fragments onto final shuttle plasmids for 
transfer into Streptomyces spp.. CRISPR was performed on strain F3-R12 to exchange the 
KanMX marker in fragment 3 for the URA3 (cr23-1) or the TRP1 (cr23-2) marker to create 
strain AN501Y and AN503Y respectively (Table 2-10). Various FLIP shuttle plasmids (pAN428 
– pAN432) were created containing different pairs of heterologous FRT sites and markers to 




Figure 2-12. Individual FLIPs to recover all four fragments onto plasmids. Shuttle plasmids for each 
fragment-containing yeast strain are: pAN435 (F1-R10-cr10), pAN437 (F2-R14-cr9), pAN434 (F3-R12-
cr23-1), pAN436 (F3-R12-cr23-2), pAN146 /or pAN433 (F4-R8-cr6-cr7). 
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Next, we carried out FLIP on all four fragments individually and selected for activation 
of the yeast marker genes URA3 (fragment 1, 3 (cr23-1) and 4) or TRP1 (fragment 2 and 3 
(cr23-2)). Efficiencies of > 10-4 were recorded (except for cr23-1), which was similar to flipping 
the URA3 gene alone (Fig. 2-13). Selecting for the TRP1 marker produced about 3-fold higher 
efficiencies than the URA3 marker. However, the efficiencies decreased generally when flipping 
fragment 3, whether selecting for the URA3 (cr23-1) or TRP1 (cr23-2) marker. 
 
 
Figure 2-13. FLIP efficiencies of Fragment 1, 2, 3 and 4. Efficiencies were calculated after incubation 
for one day (T = 24 h) in glucose (GLU) or galactose (GAL) – based media. Galactose was used to induce 
Flp Recombinase. Efficiencies are measured as number of colonies on selective / non-selective plates. 
Error bars represent standard deviation for four plates. 
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Following FLIP, the plasmids were extracted from yeast using a gentle lysis protocol52 
and transformed into E. coli EPI300 by electroporation. Transformants were selected for the 
apramycin resistance marker present in the backbone of pSBAC, as well as for the specific 
antibiotic resistance marker assembled at the end of each fragment (Fig. 2-11). The plasmids 
were amplified and verified by restriction analysis (Fig. 2-14). 
 
 
Figure 2-14. Restriction analysis of plasmids obtained by FLIP. 6 colonies were screened for fragment 
1, 2 and 3 (cr23-1) and (cr23-2). 8 colonies were screened for fragment 4. Successful clones were 
stocked: pAN472 (fragment 1), pAN475 (fragment 5), pAN285 (fragment 4). 
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Flipping fragments 1, 2 and 4 produced plasmids containing the expected fragments, 
except for one colony from F2, which did not contain the fragment. In contrast, the plasmids 
derived from flipping fragment 3 all lacked the expected fragment (Fig. 2-14). We later 
discovered that EPI300 is already resistant to streptomycin, which was used to select for 
fragment 3 in E. coli. 
 
Fragment recovery by transformation associated recombination 
Thus, we explored the use of transformation associated recombination (TAR)53, as an 
alternative method to recover the pathway fragments from the yeast chromosome onto plasmids. 
TAR relies on gap repair of a linearized plasmid containing ~ 60 bp “hook” sequences, which are 
homologous to the ends of the fragment of interest (“bait”)54,55. This approach has been used to 
clone long (up to 250 kb) and repetitive sequences from co-transformed eukaryotic or 
prokaryotic genomes onto yeast plasmids56. In this study, we did not transform any exogenous 
genome into the yeast cell, but rather sought to rely on gap repair of the plasmid using the 
endogenous genome as template. To reduce the background of self-closed plasmids, we removed 
the autonomous replicating sequence (ARS) from our yeast - E. coli - Streptomyces spp. shuttle 
plasmid. Successful replication of the plasmid would then depend on recovery of the 
chromosomal target sequence, which contains an ARS57. TAR has been reported to yield 1-5 % 
of gene-positive clones, which can be raised to 20-30 % by introduction of a dsDNA break near 
the target region58. Since we did not introduce a dsDNA break in the chromosome, hook 
sequences (homology arms) of ~ 1 kb were used to increase the efficiency of recovery. The final 
TAR shuttle plasmid (pAN438) was transformed into a mix of the four fragment-containing 
yeast strains (F1-R10-cr10, F2-R14-cr9, F3-R12, F4-R8-cr6-cr7) and selected on agar plates 
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lacking leucine. After 6 days, colonies containing each of the four fragments on plasmids were 
obtained with an overall efficiency of 50 %, which we verified by yeast colony PCR (Fig. 2-15). 
 
Figure 2-15. Colony PCR to test for the recovery of the pathway onto pAN438 by TAR. Three colony 
PCRs were performed on 48 colonies using the forward primer AN358, which is specific to the pAN438 
backbone, and the reverse primers AN299 / AN681 / AN285, which are specific for fragments 1 and 4 
(top gel) / fragment 3 (middle gel) / fragment 2 (bottom gel) respectively. 
 
 We further extracted the plasmids from the four yeast colonies containing fragment 3, 
and transformed them into E. coli EPI300, followed by amplification and restriction digest to 
verify the integrity of the pathway. Out of the four yeast plasmids, only one (F3-3, also called 
TAR1-C7-c1) contained the full fragment 3 pathway (Fig. 2-16). The other plasmids (F3-1, F3-2 
and F3-4) produced missing or unexpected bands, which may have been due to parts of fragment 





Figure 2-16. Restriction analysis of TAR plasmids containing fragment 3. The top gel is identical to 
the bottom gel, but it has been run for a longer time to increase the resolution of the larger bands. The 
four TAR plasmids from yeast were extracted and transformed separately into E. coli. Three E. coli 
colonies were picked from each transformation for plasmid amplification and restriction analysis using 
the enzymes StuI and XhoI. Expected bands are listed below in kilobases. 
 
Cloning of fragments by restriction digest and ligation 
Finally, we employed an iterative cloning scheme using the unique restriction sites XbaI, 
NheI and MfeI to enable the fragments to be cloned in any combination onto the shuttle plasmid 
pAN84 for transfer into Streptomyces spp. (Fig. 2-17). pAN84 is a derivative of pSBAC, created 
by site-directed mutagenesis to remove existing NheI and MfeI sites in the backbone, followed 
by insertion of a multiple cloning site containing the NheI and MfeI sites to allow for the 
insertion of the pathway fragments. Using the restriction digest and ligation scheme, fragments 1 




Figure 2-17. Restriction digest and ligation scheme to clone pathway fragments. The design of the 
fragment assemblies and restriction sites are shown above. To perform cloning of the fragments, 
FLIP/TAR plasmids containing each of the fragments are digested with XbaI and MfeI. The shuttle 
plasmids (pAN84 or pAN446) are digested with NheI and MfeI. The cut fragment and plasmid are ligated 
together overnight at 16 ºC using T4 ligase (high concentration), followed by transformation into EPI300 
and selection for the apramycin marker on the pSBAC and the antibiotic resistance gene attached to the 
fragment. XbaI and NheI produce complementary sticky ends that when ligated together, destroy both 
sites. Thus, in the second round of cloning, the plasmid containing a single fragment can be digested with 
NheI and MfeI to remove the bacterial selection marker, and allow for the cloning of a second fragment 
digested with XbaI and MfeI. This process can be repeated indefinitely. 
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The pSBAC shuttle plasmid was developed to integrate constructs in the phage φBT1 
attB locus in the genome of Streptomyces spp., using the φBT1 attP/int system encoded on the 
plasmid13. This system has been shown to be compatible with the orthologous φC31 attP/int 
system, which integrates plasmids into a different locus59. Other orthologous systems have been 
developed to enable multiplex integration into four different loci in the Streptomyces spp. 
genome60. Fayed et al. demonstrated this by separately integrating the three DEBS PKS subunits 
and a fourth module containing tailoring enzymes into four different loci. Thus, we replaced the 
φBT1 attP/int system in pAN84 with φC31 attP/int to create pAN446, in order to enable the 
integration of the pathway fragments into different genomic loci to test for locus-specific effects 
on gene expression, which could potentially impact on product yield.  
 
Recovery of the promoter libraries 
 Our next goal was to recover the promoter library from the yeast chromosome onto 
shuttle plasmids. So far, we have recovered the promoter library for fragment 4 on plasmids 
using a single round of FLIP (Fig. 2-18). 
 
Figure 2-18. Restriction analysis of plasmids containing fragment 4 promoter library. All plasmids 
were digested with EcoRV. Expected sizes (kb): 11.7, 9.8, 7.7, 5.3, 2.8, 0.3. 1 kb NEB ladder, 1: 
pAN285, 2: pAN286, 3: pAN340, 4: pAN341, 5: pAN342, 6: pAN343, 7: pAN344, 8: pAN345, 9: 




2.2.4 Transfer of pathway into Streptomyces spp. for meridamycin production and 
library screening 
Pathway transfer into Streptomyces spp. 
Once all the fragments and the promoter library are cloned onto the appropriate shuttle 
plasmids, we plan to transfer the pathway/library into S. lividans K4-114 by conjugation with E. 
coli13. As a proof-of-concept, while awaiting construction of the other shuttle plasmids, we 
transferred a plasmid containing fragment 4 under control of the ermEp* promoter into K4-114. 
We verified the presence of the full fragment 4 in the genome of K4-114 by PCR (A.E. data not 
shown), and detected expression of fragment 4 by RT-PCR (Fig. 2-19). However, we observed a 
very low efficiency for the conjugation process (only two colonies). This will be optimized in 
order to transfer the promoter library. The protoplast transformation method, which is generally 
less efficient than conjugation, can also be tested31. 
 
Figure 2-19. RT-PCR to test for expression of fragment 4 in S. lividans K4-114. Top gel: Total RNA 
extracted from K4-114 (WT) and K4-114-F4, showing the presence of 23S and 16S rRNA. LD: NEB 100 
bp ladder. Bottom gel: Reverse transcription followed by PCR to check for expression. A band that 
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corresponded to the positive control (+ genomic DNA of K4-114-F4) was detected for F4 only when 
reverse transcription was performed (+RT) but not in the absence of reverse transcription (-RT). 
 
Meridamycin production and screening 
We plan to optimize meridamycin production initially in shake flasks using the 
engineered strain E7, which contains the full meridamycin pathway introduced into K4-114 on 
the pSBAC vector13. Since meridamycin production levels reported for that strain are low (~ 240 
μg/L), which may be challenging to detect, we plan on testing several natural strains along with 
media that have been reported to produce higher levels (~ 5 – 10 mg/L) of meridamycin61,62. 
In order to screen our promoter library (theoretical size of 625), we plan to culture the 
streptomyces library in 96-well, deep-well microtiter plates for compound production. In 
Chapter 3, we demonstrate the use of this production platform for culturing Streptomyces 
tsukubaensis for the biosynthesis of FK506 (tacrolimus), a polyketide which is an 
immunosuppressant drug and is structurally similar to meridamycin. Furthermore, we have 
developed a high-throughput fluorescence polarization (FP) assay for the detection and 
quantification of meridamycin (Fig. 2-20) and more generally as a platform for small molecule 
product detection (see Chapter 3). Briefly, a fixed amount of receptor (purified FKBP12) and 
reporter molecules (FK506 linked to the fluorophore fluorescein) are supplied to each sample in 
a 384-well plate. Due to competition between the reporter (FK506-fluorescein) and the target 
compound (meridamycin) for binding to a common receptor (FKBP12), the ratio of bound to 
unbound reporter molecules is inversely correlated with the concentration of meridamycin. This 
results in different fluorescence polarization values, which can be measured using a plate reader. 
A standard curve can be constructed to quantify meridamycin concentrations in the sample (Fig. 
92 
 
2-20). In Chapter 3, as a proof-of-principle, we demonstrate how we can apply the FP assay to 
screen a library of 160 UV-mutagenized S. tsukubaensis colonies for FK506 production. 
 
Figure 2-20. Standard curves to detect meridamycin via the FP assay. Different receptor 
concentrations (50 nM, 500 nM, 1 μM) were used to construct a series of meridamycin standard curves. 
Increasing receptor concentrations shift the detection range to higher levels of meridmaycin. Error bars 
represent standard deviation from 3 wells. 
 
2.3 Discussion 
Type I modular PKS pathway assembly 
In this study, we demonstrate the de novo assembly of the ~ 100 kb meridamycin 
biosynthetic pathway using Reiterative Recombination. To our knowledge, this is the first report 
of the de novo assembly of a modular, Type I hybrid NRPS-PKS pathway of this scale. 
Compared to methods for performing large-scale DNA mutagenesis, bottom-up DNA assembly 
can offer the ultimate flexibility to construct user-defined, heterologous pathways and even 






















organism cannot be cultured in the lab). In addition, substantial refactoring of biosynthetic 
pathways such as codon optimization can be performed by piecing together synthetic DNA 
building blocks. Although we use mostly PCR-amplified products for our pathway assembly, 
Reiterative Recombination is equally compatible with commercially available synthetic DNA 
building blocks (e.g. GeneArt™ Strings or IDT gBlocks®). Importantly, de novo assembly 
allows for unique combinations of genes and regulators to be assembled for the production of 
novel circuits, compounds and analogs. 
There is a strong interest in manipulating the Type I modular PKS pathways to increase 
the naturally low polyketide yields and also for combinatorial biosynthesis for the production of 
novel analogs14,32,33,63. However, the PKS sequences are highly repetitive and GC-rich (~ 70 %), 
which make this class of pathways challenging to engineer. This problem is compounded by a 
lack of genetic engineering tools in their native Streptomyces spp. hosts. Although CRISPR/Cas9 
has been established in Streptomyces spp., but the efficiency of DNA transformation remains 
low, which limits the library sizes that can be built16. Also, long homology arms (~ 1 kb) are 
needed to introduce point mutations by homology-directed repair since homologous 
recombination is not as efficient as in yeast, which prevents the use of low-cost, short (< 90 
bases) oligonucleotides to build large libraries. A potential solution is to perform both pathway 
engineering and compound production in a genetically tractable host, such as E. coli or S. 
cerevisiae. However, due to differences in host cell metabolism, lack of precursor biosynthetic 
pathways, lack of post-translational enzymes, as well as difficulties in heterologous expression of 
the large multi-modular polyketide synthases, these examples have been limited to proof-of-
principle studies using only a few modules of the PKS64,65 or expressing the model Type I DEBS 
PKS for erythromycin in E. coli66,67. Thus, our approach of first harnessing yeast, a genetically 
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tractable organism with developed genetic engineering tools, for pathway assembly and 
engineering, followed by pathway/library transfer into Streptomyces spp. for production, can be a 
potentially general route to engineer the Type I modular PKS pathways. 
Another option is to perform pathway assembly entirely in vitro. Kodumal et al. 
assembled the Type I DEBS PKS pathway de novo using polymerase chain assembly (PCA)68 of 
overlapping synthetic oligonucleotides, followed by hierarchical restriction digest and ligation to 
re-create the pathway3. However, finding unique restriction sites within the long PKS sequences 
may be difficult, and the introduction of sites by mutating the sequence (even silent mutations) 
can interfere with PKS gene expression63. Alternatively, in vitro assembly methods based on end 
homology, such as Gibson assembly, have been developed for the scarless assembly of dsDNA 
building blocks69. Importantly, only a short region of homology (20 – 80 bp) is exposed at both 
ends of each dsDNA block by exonuclease digestion. In theory, this would allow for the one-step 
cloning of multiple building blocks containing highly repetitive sequences, if the junctions are 
carefully placed to maximize the homology at the paired ends of two sequential building blocks, 
and to minimize the amount of homology with the ends of other building blocks. This is an 
advantage over in vivo homologous recombination, which can recombine repetitive sequences 
even if they are in the middle of a building block. However, the efficiency of Gibson assembly 
decreases sharply with increasing numbers of building blocks in a round of assembly70, and in 
vitro handling of long DNA fragments can result in mechanical shearing.  
Itaya and coworkers have explored the use of the Bacillus subtilis genome as a vector for 
DNA assembly71. They have shown that the single, circular chromosome of B. subtilis can 
accommodate large inserts, including the whole 3.5 megabase (Mb) genome of the bacterium 
Synechocystis PCC680372. They have developed assembly methods (“inchworm” and “domino”) 
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both based on homologous recombination for the sequential assembly of DNA in the B. subtilis 
genome73,74. To broaden the scope of their assembly platform, they have also developed a 
method based on homologous recombination (Bacillus recombinational transfer – BReT) to 
recover the assembled DNA onto a plasmid for transfer to other organisms75. Significantly, 
repetitive DNA can be maintained stably in the B. subtilis genome vector76. However, this 
system has yet to be widely adopted by other groups, which may be because the development of 
tools for efficient genome modification in B. subtilis76 still lag behind that of model organisms 
such as E. coli and S. cerevisiae77. 
Our lab developed Reiterative Recombination as an user-friendly and efficient method 
for the in vivo assembly of DNA pathways and libraries in the yeast chromosome19. Despite 
being a sequential assembly method, we can split the PKS pathway by open reading frames for 
faster assembly in parallel. This approach can also be exploited to build libraries to improve 
production or to create analogs31-33. 
Although methods based on yeast gap repair to assemble pathways18 and genomes78 on 
plasmids are quicker, since the plasmids can be directly isolated from yeast cells, but 
chromosomal assembly offers advantages such as a stable, single-copy existence and propagation 
without a selection marker. Compared to the natural chromosome, yeast centromeric plasmids 
(YCps) are present on an average of 1-3 copies per cell, which may increase the chances of 
unwanted recombination events occurring between repetitive sequences. Even yeast artificial 
chromosomes (YACS), which are linear and more similar to natural chromosomes, have an 
elevated rate of recombination resulting in chimeras79. To resolve these issues, recombination 
deficient yeast strains can be used to increase the stability of YACS80, but this results in slower 
growth and lower transformation efficiency81. Thus, assembly in the native yeast chromosome is 
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advantageous, provided there are simple and efficient methods to retrieve the assembly. Indeed, 
our fragment 3 PKS assembly (merC, 35 kb, 7 modules) remained stable in the chromosome for 
at least ~ 120 generations despite the yeast being propagated in non-selective, rich YPD media 
(Fig. 2-6). Furthermore, yeast can be easily freeze-dried or sporulated to form spores, which can 
serve as long-term, stable repositories for DNA assemblies. 
After assembly of the core pathway, we used CRISPR/Cas9 to diversify the pathway to 
create mutations or to build the promoter library. Although Reiterative Recombination can be 
used to build libraries of 104 directly during the assembly process, but this requires prior 
planning. Also, the efficiency of Reiterative Recombination at assembling correct clones 
decreases during later rounds of assembly, which could be due to higher probabilities of 
unwanted recombination events with the previous assemblies in the chromosome. Thus, 
cumbersome screening of clones have to be performed during each round to pick out library 
members without gene deletions to carry forward for subsequent rounds of assembly. If not, the 
population of incorrect clones would quickly overtake the culture over several rounds of 
assembly. Therefore, the most flexible strategy would be to use Reiterative Recombination to 
assemble the core pathway, followed by diversification using CRISPR/Cas9 or other 
programmable nucleases such as the transcription activator-like effector nucleases (TALENs) or 
zinc-finger nucleases (ZFNs)82. These can be used to build promoter/ribosome-binding site 
libraries to optimize expression, or pathway libraries at specific loci to make analogs. In 
addition, other genetic modification techniques that have been developed for yeast, such as 
delitto perfetto83 and YOGE84, can be used for the efficient, precise and scarless modification of 
the pathway to create insertions, deletions and substitutions, and to construct libraries. This 
makes the yeast S. cerevisiae a versatile DNA assembly and engineering factory. 
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Pathway recovery onto shuttle plasmids 
Few approaches are available to clone long DNA fragments from the chromosome onto a 
plasmid. In vitro methods such as restriction digest of genomic DNA, followed by ligation into a 
plasmid, require unique restriction sites to be available that do not cut within the region of 
interest. Also, many clones have to be screened to identify the right constructs (unless a 
selectable marker is available), since restriction enzymes often cut the genome at multiple sites, 
which will produce a high background of unwanted clones. Recently, another in vitro method has 
been developed using a purified CRISPR/Cas9 system to create dsDNA breaks at both ends of 
the fragment of interest, followed by Gibson assembly into a linearized plasmid containing 
homologies to the ends of the fragment. This method greatly reduces the background of 
unwanted clones, due to the high specificities of both CRISPR (target site is complementary to 
gRNA) and Gibson assembly (recombination is based on homology). However, both in vitro 
methods suffer from low efficiencies due to limiting amounts of the genomic target, as well as 
possible shearing of long DNA fragments by mechanical forces during pipetting. 
In vivo methods based on homologous recombination (HR) have been developed for the 
recovery of genomic sequences onto shuttle plasmids in yeast (TAR)53. However, we thought 
that activating the HR machinery near the pathway might result in gene deletions due to 
unwanted recombination events between repetitive elements within the pathway. Thus, we 
developed the FLIP method based on site-specific recombination (SSR), which is catalyzed by a 
specific Flp recombinase enzyme that recognizes defined FRT target sites. The efficiency of 
FLIP in yeast was found to be 10-4 when recovering the URA3 marker (~ 1 kb) (Fig. 2-10), 
which was similar to the values obtained during recovery of fragments 1, 2 and 4 (~ 20 kb each). 
However, the efficiency decreased slightly when recovering fragment 3 (~ 35 kb) (Fig. 2-13). 
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This is to be expected, since Flp recombinase has to search for the short 48 bp FRT sites for 
recombination.  
Next, when FLIP was combined with a bacterial selection marker to select for fragments 
1, 2 and 4, almost all the bacterial colonies obtained from the transformation of FLIP-derived 
plasmids contained correct assemblies (Fig. 2-14). In the case of fragment 3, the streptomycin 
selection was not effective as EPI300 is naturally resistant to the antibiotic. In that case, all the E. 
coli colonies tested contained plasmids identical to the original FLIP acceptor shuttle plasmid 
that was transformed into the yeast cells (verified by sequencing). This background is surprising, 
since we did not observe this when flipping the other fragments. One possibility was human 
error, or that the cells somehow managed to escape the URA3 or TRP1 selection by activating the 
silent marker gene in the chromosome. One approach that we are testing to overcome this is to 
transform the yeast-purified plasmids (after FLIP) into a different strain of E. coli that is 
sensitive to streptomycin. Colonies that appear on streptomycin plates will be scraped and their 
plasmids extracted for transformation into EPI300 for subsequent BAC amplification. 
We also tested TAR for the recovery of our fragments. In yeast, we obtained very high 
efficiencies of 50 %, which is greater than the reported optimized efficiencies of 20 - 30 %58. 
This is probably due to our use of ~ 1 kb homology arms instead of the minimal amount of 
homology required (60 bp)85. However, in the case of fragment 3-containing yeast colonies, only 
one out of four had the complete fragment. This was likely due to unwanted recombination 
occurring during the recovery by HR, resulting in deletions occurring. These results suggest that 
the FLIP approach, when combined with a bacterial selection for the fragment, can potentially 





 In summary, we have shown that the yeast chromosome can be a stable vector for the de 
novo assembly and engineering of long and highly repetitive DNA sequences, such as the Type I 
modular PKS pathways. In addition, we have developed FLIP to enable the efficient recovery of 
the pathway/library from the yeast chromosome onto a shuttle plasmid for transfer and 
expression in a heterologous host. Polyketides are a privileged class of natural products due to 
their interesting bioactivities. Platforms that facilitate the engineering of PKS pathways to 
construct promoter/RBS or pathway libraries can enable combinatorial metabolic engineering 
approaches to be applied to optimize polyketide production or to create novel analogs 
respectively. In the next chapter, we show how the fluorescence polarization assay may be 
harnessed as a high-throughput, general solution to alleviate the screening bottleneck in 
combinatorial metabolic engineering. 
 
2.4 Experimental methods 
General materials and methods. PCR was performed using Phusion High-Fidelity DNA 
Polymerase (NEB, M0530S), using the GC Buffer and adding DMSO unless otherwise stated. 
For E. coli and yeast colony PCRs, GoTaq DNA Polymerase (Promega, M300) was used. For E. 
coli colony PCRs, a tiny quantity of cells were mixed directly into the PCR buffer. For yeast 
colony PCRs, the DNA was first prepared by adding a small quantity of cells (just visible on the 
end of a pipette tip) into 30 μL of 0.02 M NaOH and heating at 98 ºC for 20 minutes. 
Subsequently, 2 μL of the mixture was used as template for the PCR. Oligonucleotides were 
obtained from Integrated DNA Technologies. The dNTPs for PCR were purchased from NEB, 
N0447S. PCR products were purified by agarose gel electrophoresis followed by the QIAquick 
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Gel Extraction Kit, (Qiagen, 28704). DNA ladders were purchased from NEB. All sequencing 
was performed by Genewiz. Restriction enzymes, Gibson Assembly Master Mix (E2611) and T4 
DNA ligase (M0202) were purchased from New England Biolabs. DNA concentrations were 
determined by absorption at 260 nm using a Tecan Infinite M200. Milli-Q water was used for in 
vitro reactions. PCR was carried out using a Bio-Rad T100 thermal cycler. 
 
Standard methods for molecular biology were applied when culturing Saccharomyces 
cerevisiae and E. coli86,87. E. coli strains were grown at 37 ºC in LB media with appropriate 
antibiotics for the selection of plasmids. General cloning was performed using the E. coli strain 
TG1 Electroporation-Competent Cells (Agilent Technologies, #200123). All cloning of pSBAC 
constructs were performed using TransforMax EPI300 Electrocompetent E. coli (Epicentre, 
EC300110). This strain allows for the pSBAC to be maintained at low copy number normally, 
but can be induced to high copy number using the CopyControl Induction Solution (Epicentre, 
CCIS125). S. cerevisiae strains were cultivated at 30°C in YEPD media or SC drop-out media to 
select for auxotrophic marker genes20. SC drop-out media contains 2 % glucose. For galactose 
induction, 2 % galactose supplemented with 2 % raffinose was used instead of glucose. Plasmids 
in E. coli were purified using the QIAprep Spin Miniprep Kit (Qiagen, 27104). Plasmids in yeast 
were purified according to the Silverman et al. protocol52. Yeast genomic DNA for PCR 
verification of the pathway assembly was purified using the YeaStar Genomic DNA Kit (Zymo 
Research, D2002). Transformation of E. coli was performed by electroporation using a Bio-Rad 
E. coli Pulser. Yeast electroporation was carried out using a Bio-Rad Gene Pulser Xcell, 




Pathway assembly by Reiterative Recombination and verification of assemblies in yeast. 
Multiple cycles of Reiterative Recombination were performed to assemble the pathway using 
previously published protocols19,20. Building blocks for fragment assembly were PCR amplified 
using pHLW30 as template13. The list of assembly PCRs, primers, PCR conditions and expected 
lengths can be found in Table 2-2 (Fragment 1), Table 2-3 (Fragment 2), Table 2-4 (Fragment 
3) and Table 2-5 (Fragment 4). The list of check PCRs and primers etc. that were used to verify 
the chromosomal assemblies can be found in Table 2-6 (Fragment 1), Table 2-7 (Fragment 2), 
Table 2-8 (Fragment 3) and Table 2-9 (Fragment 4). 
 pAN68 was created by first PCR amplifying FRT3 with the primers AN264 and AN265, 
using pAN15 as template. The PCR product was used as template for a second round of PCR 
with primers AN266 and AN265. The product was co-transformed into yeast with pLW2593 
digested with SalI and selected on SC(U-) in order for gap repair to clone the FRT3 site into 
pLW2593. Yeast transformants were miniprepped and the plasmids transformed into E. coli for 
verification to create pAN68. 
For pulsed field gel electrophoresis (PFGE), yeast genomic DNA was extracted in 
agarose plugs according to a published method88. In-gel complete restriction digest of the 
genomic DNA was performed at 37 ºC using the enzyme SpeI (NEB R0133S) according to the 
manufacturer’s recommendations. PFGE was performed using the following conditions: Initial 
Switch time: 1.7 seconds; Final Switch time: 2.6 seconds; Total run time: 22 hours; Voltage: 
6V/cm; Buffer: 0.5x commercial grade TBE; Temperature 14 ºC; Gel: 180 ml of 1% BioRad 
Molecular Biology Certified agarose (Amr Al-Zain, Symington lab). For the Southern blot, the 
probe (500 bp of the HIS3 gene) was radiolabeled with the Promega Prime-a-Gene labeling kit, 
but using P-32 dATP instead of dCTP. Following labeling, the probe was hybridized to the blot 
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using the GE Amersham Rapid-hyb buffer. The blot was exposed on a phosphor screen 
overnight and imaged using a phosphor-imager. 
  
CRISPR to correct mutations and build promoter library. Guide RNA (gRNA) plasmids 
were created by PCR of the SNR52 promoter using the gRNA R primer (see Table 2-10) and 
AN318. The SUP4 terminator was amplified by PCR using the gRNA F primer (Table 2-10) and 
AN321. For both PCRs, a gRNA-CAN1 plasmid obtained from the Church lab was used as the 
template36. Fusion PCR was performed using AN318 and AN321 to fuse the pSNR52 and tSUP4 
fragments and create the unique gRNA 20-bp targeting sequence. The fusion PCR product was 
digested with SacI and XhoI, and ligated into gRNA-CAN1 (pRS426)51 that was digested with 
the same pair of enzymes. The ligation product was transformed into E. coli and selected on 
LB/Ampicillin plates. To perform CRISPR, p414-pTEF-Cas9 (a kind gift from the Church lab36) 
containing the Cas9 endonuclease constitutively expressed by the TEF promoter was first 
transformed into yeast and selected on SC(HT-) plates. A few colonies were picked to undergo a 
second round of transformation with 500 ng of gRNA plasmid and 0.05 nmol of repair fragment. 
Transformants were selected on SC(HTU-) plates and verified by colony PCR and sequencing. 
The CRISPR gRNA and Cas9 plasmids were cured from the cells by culturing for one day in 
non-selective media SC(H-), followed by streaking the cells on SC(H-), 0.1 % FOA and 0.05 % 
FAA plates to select against the URA389 and TRP190 marker respectively. The repair fragments 
were generated by PCR using the primers and templates listed in Table 2-11. 
 
For cr16b (promoter libraries), the 5 promoters (SF14p, kasOp*, p21, B4p, p72) were 
PCR amplified using the primers in Table 2-11 and gblocks as templates, to generate each of the 
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promoters flanked by 90 bp of homology on both ends to the respective fragment. An equimolar 
mix of the 5 promoters for each fragment (total 0.05 nmol) and the cr16b gRNA plasmid (1 µg) 
were supplied during the transformation into yeast cells containing the p414-pTEF-Cas9 
plasmid. 30 colonies that appeared on the selective plate SC(HTU-) were picked for colony PCR 
and sequencing to verify the identity of the pathway promoter that was inserted to replace the 
ermEp* promoter. Colony PCR was performed using the following primer pairs: fragment 1 
(LK18, LK23), fragment 2 (AN533, LK19), fragment 3 (LK24, LK26), fragment 4 (AN324, 
LK13). Two colonies / promoter / fragment were cured of the CRISPR/Cas9 plasmids and 
stocked (Table 2-12). These will be used for FLIP to recover the library onto plasmids. 
 
Shuttle plasmid construction. To obtain pAN8, site-directed mutagenesis was performed 
on the pSBAC to remove the NheI restriction site in the int gene. The pSBAC backbone was 
PCR amplified with primers AN3 and AN4, using PfuUltra High-Fidelity DNA Polymerase AD 
(Agilent Technologies, #600385). The PCR product was separated on a gel, purified, digested 
with DpnI overnight, transformed into EPI300 and selected on LB agar plates containing 50 
μg/mL of apramycin to select for the pSBAC backbone. Plasmids were verified by restriction 
digest and sequencing. pAN12 was also created by the same site-directed mutagenesis protocol, 
but using the primers AN21 and AN22 to amplify pAN8, in order to remove the MfeI restriction 
site in the parA gene. To create pAN84, a multiple cloning site containing the NheI and MfeI 
restriction sites was created by PCR extension using primers AN343 and AN344. The product 
was amplified by a second round of PCR using primers AN362 and AN363, followed by 
digestion with EcoRI and HindIII. This was ligated into pAN12 that was digested using the same 
set of enzymes. pAN98 was constructed by Gibson assembly. First, the vector, pAN84, was 
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digested with MfeI and NheI, and gel purified. Next, the inserts containing the yeast CEN/ARS 
replication sequence, LEU2 auxotrophic marker, and the FLIP acceptor module (pMET25 – 
AUG – FRT(WT) – TRP1 – FRT(3)) were amplified from pAN65 in two blocks using the 
primers AN415/AN447 and AN448/AN416. These were Gibson assembled into the cut vector 
(pAN84) to form pAN98. To construct pAN146, pGAL – Flp was amplified from pAN133 using 
the primers AN619 and AN620. tACT was amplified from yeast gDNA using primers 
AN621/AN622. The two inserts were then Gibson assembled into HindIII-digested pAN98 to 
form pAN146. 
To construct the FLIP shuttle plasmids for individually flipping all the fragments, overlap 
extension PCR (no template) was first performed to create the following cassettes using the 
primer pairs in brackets: pAN65-FRT3-MfeI (AN849/AN850), pAN65-FRT13-MfeI 
(AN851/AN852), pAN65-FRT15-MfeI (AN853/AN854), pAN27-FRT13-MfeI (AN851/AN855) 
and pAN27-FRT14-MfeI (AN857/AN856). The first three cassettes were Gibson assembled into 
pAN65 digested with SmaI and NheI, to create pAN428, pAN429 and pAN430 respectively. The 
last two cassettes were Gibson assembled into pAN27 partially digested with KpnI (6.5 kb band) 
to form pAN431 and pAN432 respectively. Next, to create the pSBAC FLIP acceptor plasmids 
pAN433, pAN434, pAN435, pAN436 and pAN437, the FLIP acceptor cassettes were first PCR 
amplified using primers AN416 and AN858 from the templates pAN428, pAN429, pAN430, 
pAN431 and pAN432 respectively. To create the final plasmids, the FLIP acceptor cassettes 
were then Gibson assembled into pAN146 digested with NheI and KfII, together with a fragment 
containing int, TraJ and oriT that was PCR amplified from pAN146 using the primers AN876 
and AN877. The Gibson assembly reaction was transformed into EPI300 and plated on 
LB/apramycin plates to obtain colonies that were verified by plasmid extraction and sequencing. 
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  To construct the TAR acceptor plasmid pAN438, the following cassettes were PCR 
amplified: 1) left homology arm (HO-L) was amplified using primers AN859 and AN884, with 
LW2591Y gDNA as template. 2) right homology arm (HO-R) was amplified using primers 
AN885 and AN862, with LW2591Y gDNA as template. 3) LEU2 gene was amplified using 
primers AN863 and AN890, with pAN146 as template. 4) CEN6 (no ARS) was amplified using 
primers AN891 and AN866, with pAN146 as template. The 4 cassettes were Gibson assembled 
into pAN84 digested with NheI and HindIII, to form pAN438. 
  
To construct the second pSBAC-Streptomyces spp. integrative plasmid pAN446, the 
following cassettes were PCR amplified: 1) Kanamycin resistance marker (aphII) was amplified 
using primers AN892 and AN893, with pGM190 (Addgene, #69614) as template. 2) Fd 
terminator was amplified using primers AN894 and AN895, with gblock-pAN84-tFd as 
template. 3) attP/int from the phage φC31 was PCR amplified using primers AN896 and AN897, 
with pSET152 (kind gift from Alessandra Eustaquio) as template. The cassettes were Gibson 
assembled into pAN84 digested with AvrII, to form pAN446. 
 
Construction of the FLIP system. pAN15 containing the FRT(3) site was created by site-
directed mutagenesis, following the same protocol as above but using primers AN15 and AN16 
to amplify pJ33R. pAN20 containing the N terminal HA-tagged Flp recombinase under control 
of the GALL promoter was constructed by PCR of Flp recombinase from pFL119 using the 
primers AN47 and AN48. The product was amplified by a second round of PCR using the 
primers AN49 and AN48. This insert was digested with BamHI and SalI, and ligated into 
p416GALL digested with the same pair of enzymes, to form pAN20. To construct pAN27, the 
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URA3 gene was first PCR amplified with the primers AN104 and AN106 to remove the start 
codon and create the FRT-WT site. The PCR product was amplified by a second round of PCR 
with the primers AN105 and AN106. This product was digested with BamHI and SalI and 
ligated into p415MET25 digested with the same enzymes, to form pAN27. To construct pAN29, 
the TRP1 gene was first PCR amplified with primers AN107 and AN108 to remove the start 
codon and create the FRT-WT site. The PCR product was amplified by a second round of PCR 
with the primers AN105 and AN108. This product was digested with BamHI and SalI, and 
subsequently ligated into p415MET2591 that was digested with the same set of enzymes, to form 
pAN29. To construct pAN53, the pGAL – HA – Flp – tCYC insert was PCR amplified from 
pAN20 using the primers AN128 and AN138. The product was purified and used as template for 
a second round of PCR using primers AN137 and AN138, followed by digestion with KpnI. This 
was ligated into the vector that was partially digested with KpnI (cut once), to form pAN53. To 
construct pAN65, the insert containing the FRT(3) site was first PCR amplified from pAN15 
using primers AN231 and AN232. The vector pAN29 was partially digested with KpnI (cut 
once), gel purified, and ligated with the FRT(3) insert to form pAN65. To construct pAN133 
(pAN53 but no HA tag on the Flp recombinase), the vector pAN53 was partially digested with 
NdeI (cut once). The insert was created by PCR extension of primers NJ8 and NJ9. This was 
Gibson assembled into the partially digested vector to form pAN133. 
 
FLIP protocol. To perform FLIP, the shuttle plasmid containing the compatible FRT sites 
and FLIP markers were transformed into the yeast strain and selected on SC(L-) plates. FLIP 
shuttle plasmids for the various fragment-containing strains are: pAN435 (F1-R10-cr10), 
pAN437 (F2-R14-cr9), pAN434 (F3-R12-cr23-1), pAN436 (F3-R12-cr23-2), pAN146 /or 
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pAN433 (F4-R8-cr6-cr7). About 40 transformant colonies (1 – 2 plates) were scraped with 
water, pelleted and washed once with sterile water, pelleted again and resuspended in 1 mL of 
sterile water to create the main cell stock. The OD600 was measured by diluting the cell stock 50 
times (20 µL of cells in 980 µL sterile water). The cell stock was diluted to create three 1 mL 
starter cultures of final OD600 = 1. The final media for the three starter cultures were: t0 = sterile 
water, t24-Gal = SC(L-, 2 % galactose, 2 % raffinose), t24-Glu = SC(L-, 2 % glucose). The t0 
culture was diluted and plated on selective (for the FLIP marker in the chromosome) and non-
selective (SC) plates to calculate the efficiency of FLIP at t0. The other two cultures were 
incubated at 30 ºC in a 230 rpm shaker for 24 hours, and plated on selective and non-selective 
plates to calculate FLIP efficiencies in yeast with the induction of Flp recombinase (t24-Gal) and 
without Flp induction (t24-Glu). 
 
Checking gene expression via RT-PCR. RNA was extracted from S. lividans strains K4-114 
and K4-114-F4 using the RNeasy Mini Kit and gDNA eliminator columns (Qiagen, 74104) 
according to the manufacturer’s recommendations. The RNA was treated with DNaseI (NEB, 
M0303) to remove contaminating DNA. Reverse transcription was performed using SuperScript 
II Reverse Transcriptase (Invitrogen, 18064014). PCR was performed to detect merE using 








2.5 Assembly PCR, Check PCR and CRISPR tables 
Table 2-2. Assembly PCRs for Fragment 1. 










Template Strain (AKA) 
1 AN133 31 AN134 1057 1027 58 0:30 pAN38 
F1-R1 
(AN43Y) 
2 (PCR 1) AN217 1022 AN219 1363 342 52.5 0:15 pSE34   
2 (PCR 2)** AN218 1002 AN219 1363 362 53 0:15 2 (PCR 1) F1-R2 
3 EC1 1327 EC2 3424 2098 52 1:00 pHLW30 F1-R3 
4-1*** EC6 3331 KV18 5298 1968 54 1:00 pHLW30 F1-R4 
4-2 KV19 5157 KV20 7159 2003 54 1:00 pHLW30   
5-1 KV21 7024 KV22 9057 2034 54 1:00 pHLW30 F1-R5 
5-2 KV23 8802 KV24 10771 1970 54 1:00 pHLW30   
6-1 KV29 10574 KV30 12378 1805 54.3 1:00 pHLW30 F1-R6 
6-2 KV31 12185 KV32 13874 1690 53 1:00 pHLW30   
7-1 KV56 13497 KV40 15729 2233 54 1:00 pHLW30 F1-R7 
7-2 KV55 15494 KV42 17414 1921 52.5 1:00 pHLW30   
8-1 KV47 17232 KV48 20010 2779 53.9 1:20 pHLW30 F1-R8 
8-2 KV49 19933 KV50 21831 1899 53.6 1:00 pHLW30   
9 KV65 21691 KV66 23205 1515 55 0:45 pHLW30 F1-R9 
10 (PCR 1) KV70 23179 KV71 24643 1465 52.5 0:45 pACYC184   
10 (PCR 2) KV72 23140 KV73 24675 1536 55 0:45 10 (PCR 1)   
10 (PCR 3) KV74 23101 KV73 24675 1575 55 0:45 10 (PCR 2)   
10 (PCR 4)** KV75 23101 KV73 24675 1575 55 0:45 10 (PCR 3) F1-R10 
cr10 see Table 2-11               F1-R10-cr10 
* The first number corresponds to the round of Reiterative Recombination. 
** For Round 2, PCR2 was used for Reiterative Recombination, whereas for Round 10, PCR 4 was used. These blocks were created by multiple rounds of 
PCR, using the previous product as template for the next PCR. 

























Template Strain (AKA) 
1-1* AN100 NA AN101 NA NA 50 0:15 pAN15 F2-R1 (AN23Y) 
1-2* AN102 NA AN103 1353 NA 50 0:15 pSE34   
2 AN109 1324 AN146 3315 1992 54 1:00 pHLW30 F2-R2 (AN41Y) 
3 AN155 3243 AN156 5315 2073 57 1:00 pHLW30 F2-R3 (AN46Y) 
4 AN164 5206 AN165 7197 1992 55 1:00 pHLW30 F2-R4 (AN51Y) 
5 AN168 6942 AN169 9172 2231 55 1:00 pHLW30 F2-R5 (AN57Y) 
6 AN171 8939 AN172 10970 2032 55 1:00 pHLW30 F2-R6 (AN60Y) 
7 AN188 10747 AN189 12752 2006 55 1:00 pHLW30 F2-R7 (AN62Y) 
8 AN215 12482 AN216 14527 2046 55 1:00 pHLW30 F2-R8 (AN63Y) 
9 AN229 14297 AN230 16292 1996 55 1:00 pHLW30 F2-R9 
10 AN241 16061 AN242 18087 2027 56 1:00 pHLW30 F2-R10 
11 AN249 17945 AN250 19916 1972 56 1:00 pHLW30 F2-R11 
12 AN273 19658 AN274 21682 2025 55 1:00 pHLW30 F2-R12 
13-1 AN277 21480 AN345 22705 1226 55 0:40 pHLW30 F2-R13 
13-2** AN346 NA AN347 NA NA 54 0:40 pAN38   
14 (PCR 1) AN485 22668 AN553 23634 967 56 0:30 pACYC184 F2-R14 
14 (PCR 2)** AN487 22648 AN554 23661 1014 55 0:30 14 (PCR 1)   
cr9*** AN531 -33 AN492 1118 1152 57 0:30 
cr9-a (PCR 2), 
cr9-b (PCR 3) 
F2-R14-cr9 
cr9-a (PCR 1) AN133 1 AN532 781 781 55 0:25 pAN39   
cr9-a (PCR 2) AN531 -33 AN532 781 815 55 0:25 cr9-a (PCR 1)   




cr9-b (PCR 2) AN533 730 AN535 1044 315 55 0:15 cr9-b (PCR 1)   
cr9-b (PCR 3) AN533 730 AN524 1078 349 55 0:15 cr9-b (PCR 2)   
* FRT-3 and ermE* promoter were assembled in Round 1, CRISPR (cr9) was performed to replace FRT-3 with FRT-WT, the TRP1 marker and FRT-15. 
** The ampR (ampicillin resistance) gene was originally assembled in Round 13, and replaced by cat (chloramphenicol resistance gene) in Round 14. 

























Template Strain (AKA) 
1* AN133 31 AN134 1057 1027 58 0:30 pAN38 F3-R1 (AN43Y) 
2 (PCR 1)* AN217 NA AN220 1475 NA 52.5 0:15 pSE34   
2 (PCR 2)* AN218 NA AN220 1475 NA 52.5 0:15 2 (PCR 1) F3-R2 
3 KV1 1435 KV2 3462 2028 52 1:00 pHLW30 F3-R3 
4-1 KV4 3296 JK1 5305 2010 54 1:00 pHLW30 F3-R4 
4-2 JK2 5122 JK3 7124 2003 53 1:00 pHLW30   
5-1 JK33 6863 JK34 8879 2017 54 1:00 pHLW30 F3-R5 




              F3-R5-cr4 
6-1 JK40 10364 JK41 12329 1966 54.5 1:00 pHLW30 F3-R6 
6-2 JK42 12211 JK43 14483 2273 54.5 1:00 pHLW30   
7 JK67 14151 JK68 17497 3347 55.5 1:45 pHLW30 F3-R7 
8-1 JK69 17354 JK59 19286 1933 54.5 1:00 pHLW30 F3-R8 
8-2 JK71 19092 JK72 20978 1887 56.5 1:00 pHLW30   
9 JK91 20744 JK76 22986 2243 54 1:00 pHLW30 F3-R9 
10-1 JK92 22790 JK94 25253 2464 54.5 1:10 pHLW30 F3-R10 




              F3-R10-cr12 
cr15 repair*** AN531 -33 AN492 1238 1272 57 0:40 
cr15-a (PCR 3), cr15-
b (PCR 1) 
F3-R10-cr12-cr15 
cr15-a (PCR 1) AN613 43 AN681 644 602 55 0:20 pLW2594   
cr15-a (PCR 2) AN614 36 AN681 644 609 55 0:20 cr15-a (PCR 1)   
cr15-a (PCR 3) AN133 1 AN681 644 644 55 0:20 cr15-a (PCR 2)   
cr15-b (PCR 1) AN682 614 AN492 1238 625 55 0:20 gblock ptKanR   
11-1 JK98 27076 JK100 29742 2667 55 1:15 pHLW30 F3-R11 
11-2 JK130 29612 JK131 31706 2095 56 1:00 pHLW30   
12-1 JK111 31546 JK112 33899 2354 56 1:10 pHLW30 F3-R12 
12-2 JK113 33747 JK114 35050 1304 57 0:40 pHLW30   







12-3a JK115 34912 JK116 35225 314 55.5 0:15 gblock ptKanR   
12-3b JK117 35196 JK118 36206 1011 56 0:30 
Acidophil's plasmid 
with ant3ia gene 
  
12-3c JK119 36178 JK120 36365 188 54 0:15 gblock ptKanR   





cr23-1a AN910 NA AN911 NA 200 55 0:15 F1-R10-cr10 gDNA   
cr23-1b AN913 NA AN914 NA 822 55 0:20 F1-R10-cr10 gDNA   
cr23-1c AN915 NA AN916 NA 226 54 0:15 F3 gDNA   





cr23-2a AN910 NA AN912 NA 208 55 0:15 F2-R14-cr9 gDNA   
cr23-2b AN917 NA AN918 NA 691 55 0:20 F2-R14-cr9 gDNA   
cr23-2c AN919 NA AN916 NA 231 54 0:15 F3 gDNA   
* The URA3 marker was originally assembled in Round 1. CRISPR (cr15) was performed later to convert the URA3 marker to KanMX and add FRT-14. 
** 12-3 was built by PCR fusion of 12-3a, 12-3b and 12-3c. 
*** Repair DNA block for CRISPR (cr15), formed by fusion PCR of cr15-a (PCR 3) and cr15-b (PCR 1). 








Table 2-5. Assembly PCRs for Fragment 4. 














Template Strain (AKA) 
1 AN133 31 AN134 1057 1027 58 0:30 pAN38 F4-R1 (AN43Y) 
2 (PCR 1)* AN217 NA AN221 1407 NA 52.5 0:15 pSE34   
2 (PCR 2)* AN218 NA AN221 1407 NA 52.5 0:15 2 (PCR 1) F4-R2 
3 DD1 1367 DD3 3367 2001 54 1:00 pHLW30 F4-R3 
4 DD5 3198 DD6 5211 2014 56 1:00 pHLW30 F4-R4 
5 DD9 5047 DD10 7292 2246 55 1:00 pHLW30 F4-R5 
6-1 DD18 7105 DD20 9136 2032 54 1:00 pHLW30 F4-R6 
6-2 DD21 9005 DD22 10942 1938 53 1:00 pHLW30   
7-1 DD30 10820 DD31 13093 2274 53.8 1:00 pHLW30 F4-R7 
7-2 DD32 12894 DD33 14972 2079 53.5 1:00 pHLW30   
8** NA 14769 NA 19681 4913 NA NA NA F4-R8 
8a (Gibson) DD51 14769 DD39 16869 2101 55 1:00 pHLW30   
8b (Gibson) DD52 16850 DD41 18667 1818 55 1:00 pHLW30   
8c (Gib-pAN68) DD42 18607 DD54 19681 1075 54 0:30 pAN38   
cr6 see Table 2-11               F4-R8-cr6 
cr7 repair*** AN489 1008 AN492 1170 163 55 0:15 cr7 (PCR 1) F4-R8-cr6-cr7 
cr7 (PCR 1) AN490 1046 AN491 1130 85 55 0:15 Fusion PCR   
* CRISPR (cr7) was performed to insert FRT-13. 
** In Round 8, the 3 building blocks (8a, 8b, 8c) were Gibson assembled into pAN68 digested with SalI. 





















1 AN348 -7 AN219 1367 1375 55 0:40 
2 AN19 1064 KV17 2374 1311 55 0:40 
3 EC8 2276 EC9 4248 1973 56 1:00 
4 KV15 4109 KV16 6125 2017 55 1:00 
5 KV25 5965 KV26 7959 1995 55 1:00 
6 KV27 7881 KV28 9879 1999 55 1:00 
7 KV94 9736 KV95 11667 1932 56 1:00 
8 AN239 11490 KV96 13184 1695 56 0:45 
9 KV51 13002 KV52 15040 2039 56 1:00 
10 KV53 14998 KV54 16755 1758 54.5 1:00 
11 KV60 16525 KV61 18471 1947 56 1:00 
12 KV62 18361 KV63 20794 2434 57 1:00 
13 KV64 20569 KV50 21831 1263 53 0:35 
14 KV65 21691 KV66 23205 1515 56 0:45 

























1 AN348 -7 AN103 1353 1361 55 0:45 
2 AN580 1149 AN146 3315 2167 55 1:00 
3 AN173 2088 AN145 4080 1993 55 1:00 
4 AN144 3969 AN175 5759 1791 55 1:00 
5 AN164 5206 AN187 7707 2502 55 1:00 
6 AN223 7399 AN224 9692 2294 55 1:00 
7 AN245 9380 AN246 11626 2247 55 1:00 
8 AN227 11569 AN228 13570 2002 55 1:00 
9 AN239 13465 AN240 15497 2033 55 1:00 
10 AN247 15389 AN248 17446 2058 55 1:00 
11 AN267 17220 AN268 19232 2013 55 1:00 
12 AN275 18997 AN276 20849 1853 55 1:00 
13 AN364 20614 AN365 22071 1458 55 0:45 
























1 AN348 -7 AN220 1475 1483 55 0:30 
2 AN580 1269 KV3 3084 1816 54.5 1:00 
3 KV6 2924 KV7 4565 1642 55 1:00 
4 KV10 4398 KV11 6418 2021 55 1:00 
5 JK35 5928 JK36 7506 1579 55 0:45 
6 JK4 6954 JK38 9372 2419 55.5 1:10 
7 JK44 9175 JK45 11677 2503 56.4 1:15 
8 JK46 11610 JK47 13648 2039 56 1:00 
9 JK62 13435 JK63 14937 1503 55 0:45 
10 JK64 14814 JK65 16612 1799 55 1:00 
11 JK66 16418 JK53 18197 1780 53.8 1:00 
12 JK73 17848 JK74 19743 1896 56 1:00 
13 JK81 19517 JK82 21845 2329 56 1:00 
14 JK83 21761 JK84 23689 1929 55 1:00 
15 JK85 23555 JK96 25987 2433 55 1:00 
16 JK97 25859 JK107 27762 1904 56 1:00 
17 JK134 27488 JK135 28869 1382 56 0:45 
18 JK104 28747 JK105 30654 1908 55.5 1:00 
19 JK106 30426 JK121 32420 1995 56.5 1:00 
20 JK122 32240 JK123 34372 2133 55.5 1:00 
























1 AN348 -7 AN106 885 893 55 0:30 
2 AN184 463 AN221 1407 945 55 0:30 
3 AN580 1201 DD4 3009 1809 55 1:00 
4 DD7 2900 DD8 4558 1659 54 1:00 
5 DD11 4319 DD12 6343 2025 57 1:00 
6 DD29 5779 DD28 8337 2559 55 1:00 
7 DD26 8103 DD27 10059 1957 56 1:00 
8 DD44 9856 DD45 12026 2171 55.5 1:00 
9 DD36 11746 DD37 13929 2184 56 1:00 
10 DD46 13722 DD47 15724 2003 56.5 1:00 
11 DD48 15535 DD49 17828 2294 55.5 1:00 









Table 2-10. CRISPR details and gRNA primers. 
CRISPR 
no. 





cr14 1 15707 Correct mutation: A to G merA-M2-AT Antisense AN609 AN610 
cr14-2 1 15707 Correct mutation: A to G merA-M2-AT Sense AN693 AN694 
cr10 1 21005 Correct mutation: C to T merA-M3-AT Antisense AN542 AN543 
cr9 2 31 – 1059 
Replace FRT-3 with FRT-WT, 
TRP1 and FRT-15 
ermE* promoter Sense AN525 AN526 
cr4 3 9058 Correct mutation: T to C 
merC-M9-AT and KR 
linker 
Sense AN339 AN340 
cr12-1 3 NA Correct mutation: insert A HO endonuclease cut site Sense AN599 AN600 
cr15 3 79 – 1179 
Replace URA3 with KanMX, FRT-
14 
ermE* promoter Sense AN611 AN612 
cr23-1 3 79 - 885 Replace KanMX with URA3 KANMX Sense AN908 AN909 
cr23-2 3 79 - 885 Replace KanMX with TRP1 KANMX Sense AN908 AN909 




Insert FRT-13 ermE* promoter Sense AN493 AN494 
cr16b-F1 1 NA 
Replace ermE* promoter with 
library 
ermE* promoter Sense EC36 EC37 
cr16b-F2 2 NA 
Replace ermE* promoter with 
library 
ermE* promoter Sense EC36 EC37 
cr16b-F3 3 NA 
Replace ermE* promoter with 
library 
ermE* promoter Sense EC36 EC37 
cr16b-F4 4 NA 
Replace ermE* promoter with 
library 











PCR template for repair 
Repair fragment length 
(bp) 
Comments 
cr14 KV41, KV76 pHLW30 247 
Failed to correct. gRNA sequence is 
identical to merA-M1-AT except for 9th 
base from the PAM sequence 
cr14-2 AN695, AN696 Fusion pcr 97 
Failed to correct. gRNA sequence is 
identical to merA-M1-AT except for 1st 
base from the PAM sequence 
cr10 AN544, AN545 Fusion pcr 90 Corrected 
cr9 see Table 2-3 see Table 2-3 1151 Inserted 
cr4 AN341, AN342 Fusion pcr 98 Corrected 
cr12-1 AN605, AN606 Fusion pcr 91 Corrected 
cr15 see Table 2-4 see Table 2-4 1272 Inserted 
cr23-1 see Table 2-4 see Table 2-4 1189 Inserted 
cr23-2 see Table 2-4 see Table 2-4 1060 Inserted 
cr6 AN374, AN375 Fusion pcr 100 Corrected 
cr7 see Table 2-5 see Table 2-5 163 Inserted 
cr16b-F1 EC46, EC53 gblocks F1-kasOp/SF14p/p21/B4p/p72 Various Inserted 
cr16b-F2 EC46, EC52 gblocks F2-kasOp/SF14p/p21/B4p/p72 Various Inserted 
cr16b-F3 EC46, EC54 gblocks F3-kasOp/SF14p/p21/B4p/p72 Various Inserted 




2.6 Strains and plasmids 
Table 2-12. Strains used in this study. 
Name (AKA) Genotype / Details Source 
LW2591Y Reiterative Recombination parental acceptor 
Wingler and Cornish, 
2011 
AN61Y AN43Y / FRT-3 site (FRT-WT – URA3 – FRT-3) This study 
F1-R1 (AN43Y) 
Fragment 1 (merP, merA) containing strains 
This study 
F1-R2 This study 
F1-R3 This study 
F1-R4 This study 
F1-R5 This study 
F1-R6 This study 
F1-R7 This study 
F1-R8 This study 
F1-R9 This study 
F1-R10 This study 
F1-R10-cr10 This study 
F2-R1 (AN23Y) 
Fragment 2 (merB) containing strains 
This study 
F2-R2 (AN41Y) This study 
F2-R3 (AN46Y) This study 
F2-R4 (AN51Y) This study 
F2-R5 (AN57Y) This study 
F2-R6 (AN60Y) This study 
F2-R7 (AN62Y) This study 
F2-R8 (AN63Y) This study 
F2-R9 This study 
F2-R10 This study 
F2-R11 This study 
F2-R12 This study 
F2-R13 This study 
F2-R14 This study 
F2-R14-cr9 This study 
F3-R1 (AN43Y) 
Fragment 3 (merC) containing strains 
This study 




F3-R3 This study 
F3-R4 This study 
F3-R5 This study 
F3-R5-cr4 This study 
F3-R6 This study 
F3-R7 This study 
F3-R8 This study 
F3-R9 This study 
F3-R10 This study 




F3-R11 This study 








Fragment 4 (merE - merT) containing strains 
This study 
F4-R2 This study 
F4-R3 This study 
F4-R4 This study 
F4-R5 This study 
F4-R6 This study 
F4-R7 This study 
F4-R8 This study 
F4-R8-cr6 This study 
F4-R8-cr6-cr7 This study 
AN367Y F1-cr16b-p72-c5 This study 
AN368Y F1-cr16b-p72-c11 This study 
AN369Y F1-cr16b-kasOp*-c1 This study 
AN370Y F1-cr16b-kasOp*-c3 This study 
AN371Y F1-cr16b-SF14p-c2 This study 
AN372Y F1-cr16b-SF14p-c13 This study 
AN373Y F1-cr16b-B4p-c4 This study 




AN375Y F1-cr16b-p21-c10 This study 
AN376Y F1-cr16b-p21-c14 This study 
AN356Y F2-cr16b-SF14p-c1 This study 
AN357Y F2-cr16b-SF14p-c2 This study 
AN358Y F2-cr16b-kasOp-c1 This study 
AN359Y F2-cr16b-kasOp-c10 This study 
AN360Y F2-cr16b-p21-c5 This study 
AN361Y F2-cr16b-p21-c9 This study 
AN362Y F2-cr16b-p72-c4 This study 
AN363Y F2-cr16b-p72-c8 This study 
AN364Y F2-cr16b-B4p-c3 This study 
AN365Y F2-cr16b-B4p-c6 This study 
AN306Y F3-cr16b-kasOp-c1 This study 
AN307Y F3-cr16b-kasOp-c50 This study 
AN309Y F3-cr16b-SF14p-c7 This study 
AN310Y F3-cr16b-SF14p-c15 This study 
AN350Y F3-cr16b-p72-c17 This study 
AN351Y F3-cr16b-p72-c26 This study 
AN352Y F3-cr16b-B4p-c18 This study 
AN353Y F3-cr16b-B4p-c20 This study 
AN354Y F3-cr16b-p21-c8 This study 
AN355Y F3-cr16b-p21-c13 This study 
AN248Y F4-cr16b-p72-c1 This study 
AN249Y F4-cr16b-p72-c48 This study 
AN250Y F4-cr16b-SF14p-c19 This study 
AN251Y F4-cr16b-SF14p-c27 This study 
AN252Y F4-cr16b-B4p-c24 This study 
AN253Y F4-cr16b-B4p-c38 This study 
AN254Y F4-cr16b-p21-c12 This study 
AN255Y F4-cr16b-p21-c35 This study 
AN256Y F4-cr16b-kasOp-c26 This study 
AN257Y F4-cr16b-kasOp-c37 This study 
K4-114 Streptomyces lividans host strain Liu et al., 2009 / Pfizer 
E7 K4-114 / pHLW30 conjugant (meridamycin producer) Liu et al., 2009 / Pfizer 








Reiterative Recombination   




pLW2593 Reiterative Recombination even round donor plasmid 
pLW2594 Reiterative Recombination Round 1 donor plasmid 
pAN68 
Reiterative Recombination even round donor plasmid containing FRT 
(3) site 
This study 
FLIP system   
p415MET25 E. coli - S. cerevisiae shuttle plasmid 
ATCC 
#87322 
p416GALL E. coli - S. cerevisiae shuttle plasmid 
ATCC 
#87340 
pFL119 Flp recombinase gene G. Struhl 
pJ33R FRT-WT flanking Drosophila DNA G. Struhl 
pAN15 pJ33R / site-directed mutagenesis to create FRT-3 This study 
pAN20 p416GALL with N terminus HA-tagged Flp This study 
pAN27 p415MET25 with AUG-FRT(WT)-URA3 This study 
pAN29 p415MET25 with AUG-FRT(WT)-TRP1 This study 
pAN65 p415MET25 with AUG-FRT(WT)-TRP1-FRT(3) This study 
pAN53 p415MET25 with AUG-FRT(WT)-TRP1-FRT(3) and pGAL-HA-Flp This study 
pAN133 pAN53 / remove HA tag in Flp1 This study 
pAN428 pAN65 / FRT(WT)-TRP1-FRT(3)-MfeI This study 
pAN429 pAN65 / FRT(WT)-TRP1-FRT(13)-MfeI This study 
pAN430 pAN65 / FRT(WT)-TRP1-FRT(15)-MfeI This study 
pAN431 pAN27 / FRT(WT)-URA3-FRT(13)-MfeI This study 
pAN432 pAN27 / FRT(WT)-URA3-FRT(14)-MfeI This study 
pSBAC acceptors   
pSBAC 
E. coli - Streptomyces spp. shuttle Bacterial Artificial Chromosome 
conjugation vector 
Liu et al., 
2009 / 
Pfizer Inc. 
pAN8 pSBAC / Site-directed mutagenesis to remove NheI site in int This study 
pAN12 pAN8 / Site-directed mutagenesis to remove MfeI site in parA This study 





pAN84 / Insert Flp acceptor module FRT(WT)-TRP1-FRT(3), 
CEN/ARS, LEU2 marker 
This study 
pAN146 pAN98 / FRT(WT)-TRP1-FRT(3) / Insert pGAL-Flp1-tACT This study 
pAN433 pAN146 / Replace Flp acceptor with FRT(WT)-TRP1-FRT(3)-MfeI This study 
pAN434 pAN146 / Replace Flp acceptor with FRT(WT)-TRP1-FRT(13)-MfeI This study 
pAN435 pAN146 / Replace Flp acceptor with FRT(WT)-TRP1-FRT(15)-MfeI This study 
pAN436 pAN146 / Replace Flp acceptor with FRT(WT)-URA3-FRT(13)-MfeI This study 
pAN437 pAN146 / Replace Flp acceptor with FRT(WT)-URA3-FRT(14)-MfeI This study 
pAN438 TAR acceptor plasmid with NheI site to linearize This study 
pAN446 
pAN84 / attP-int from phage ɸC31 / kanamycin marker (aphII) / Fd 
phage terminator 
This study 
pSBAC with pathway fragments   
pAN285 pAN146 / Fragment 4 (merE - merT) This study 
pAN340 pAN146 / F4-SF14p-c1 This study 
pAN341 pAN146 / F4-SF14p-c5 This study 
pAN342 pAN146 / F4-B4p-c3 This study 
pAN343 pAN146 / F4-B4p-c12 This study 
pAN344 pAN146 / F4-p72-c4 This study 
pAN345 pAN146 / F4-p72-c8 This study 
pAN346 pAN146 / F4-kasOp-c15 This study 
pAN347 pAN146 / F4-kasOp-c23 This study 
pAN348 pAN146 / F4-p21-c25 This study 
pAN349 pAN146 / F4-p21-c27 This study 
pAN472 pAN435 / Fragment 1 (merP, merA) This study 
pAN475 pAN437 / Fragment 2 (merB) This study 
TAR1-C7-c1 pAN438 / Fragment 3 (merC) This study 
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3.0 Chapter outlook 
Metabolic engineering of microbes is a promising approach to produce compounds of 
pharmaceutical, agricultural and industrial importance in a cheap and green way. However, 
unlike single protein engineering, the combinatorial space is orders of magnitude greater, since 
multiple enzymes and interacting networks have to be optimized. This problem is compounded 
by our incomplete knowledge of enzymatic pathways and networks in the cell. Thus, rational 
(constructive) approaches for the development of high-yielding strains is often a costly and time-
consuming process. On the other hand, inverse metabolic engineering approaches such as 
combinatorial metabolic engineering allow for the generation of improved strains based on 
limited knowledge of their cellular functions. Recent advances in DNA assembly technologies 
and genome-wide mutagenesis techniques have enabled the efficient, multiplex generation of 
large strain libraries. However, a current bottleneck is the lack of general and high-throughput 
screens to detect the small molecule products. We propose that the fluorescence polarization (FP) 
assay can be adapted as a high-throughput and potentially generalizable screen for metabolic 
engineering. The FP assay is quantitative, sensitive, fast and cheap. As a proof of principle, we 
established the FP assay to screen for FK506 (tacrolimus) biosynthesized by Streptomyces 
tsukubaensis in 96-well plates. A UV mutagenized library of 160 colonies was screened to find 
strains showing higher FK506 productivities. The FP assay has the potential to be adapted 





Metabolic engineering has the potential to revolutionize the production of 
pharmaceuticals, chemicals and fuels by lowering its cost and environmental impact, as well as 
providing access to novel chemistry.1-3  However, successful examples such as engineering yeast 
to produce the anti-malarial precursor amorphadiene4,5 and E. coli to produce the bulk chemical 
1,3-propanediol6, all required heroic effort, time and cost to achieve. This is understandable 
given that metabolic engineering is a combinatorial optimization problem involving multi-gene 
pathways and interacting cellular networks.7 As such, platforms that enable the high-throughput 
creation and screening of large populations of mutant strains can transform the speed, cost and 
scale of metabolic engineering. Although many technologies have been established to generate 
large strain libraries8 (> 106), it is widely held that the current bottleneck to applying 
combinatorial approaches to metabolic engineering is the lack of generalizable, high-throughput 
screens for small molecule metabolites.9 
The current state-of-the-art for small molecule detection is gas/liquid chromatography 
(GC/LC-MS), which is an expensive and low-throughput method (~102 samples per day).9 High-
throughput methods such as FACS or growth selections (~107 samples per day) require that the 
target molecule be colored10, fluorescent11, contain reactive groups that allow conversion to a 
colored/fluorescent compound12, or confer a growth advantage on the producer cell13,14, and are 
thus not generalizable to the majority of metabolites. Some assays rely on adapting natural 
regulators such as riboswitches15,16, transcription factors17,18 and nuclear hormone receptors9,19,20, 
but there have been few reports of their successful re-design or evolution to change their target 
specificity21-24, so their generality is still unknown. Likewise, reports of receptors labelled 
directly with reporters (e.g. GFP25,26, enzymes27-29, environmentally-sensitive fluorophores30-38) 
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to detect small molecule binding and RNA/DNA molecular aptamer beacons or aptasensors39-43  
have yet to be widely adopted since their binding and signal transduction functions are tightly 
interwoven, which makes it difficult to alter ligand specificity and still preserve their signaling 
function. 
We propose that the fluorescence polarization (FP) assay, when applied as a competition 
assay, can offer a generalizable and high-throughput screen for small molecule metabolite 
production. Although the FP assay has been used for drug discovery and to study enzyme 
kinetics, antibody–antigen and other biological interactions 44-48, its potential for small molecule 
detection for metabolic engineering remains untapped. In the assay, the target molecules compete 
with a fixed concentration of reporter molecules (labeled with a fluorophore) for binding to a 
common receptor. Thus, the ratio of bound to unbound reporter molecules, which can be 
measured by fluorescence polarization, is inversely correlated with the concentration of target 
molecules. This allows for highly sensitive detection of the target compound and accurate 
quantification without the need for tedious washing steps, unlike other competition assays using 
radioactive ligands.49 The FP assay can be performed using the microtiter plate format (e.g. 
96/384/1536 wells) to screen libraries of 104-105 samples per day 50, making it cheap, 
automatable and high-throughput compared to GC/LC-MS. The dynamic range of the assay is 
tunable to detect a wide range of target concentrations simply by changing the receptor 
concentration. The FP assay requires two components: a receptor, which can either be found in 
nature or evolved using established display technologies such as phage, mRNA or yeast surface 
display51-53, as well as a reporter, which can be the target itself coupled to a fluorophore.54,55 




As a proof-of-concept, we have established the FP assay as a high-throughput screen for 
the polyketide FK506, which is naturally produced by Streptomyces spp.56-62 FK506 
(Tacrolimus) is the major immunosuppressive drug used to prevent the rejection of organ 
transplants (e.g. kidney, liver, heart) and also used topically to treat atopic dermatitis.63 It 
functions by binding to an intracellular receptor FKBP12, which then triggers a signaling 
pathway leading to immunosuppression.64 Due to the off-patent status of tacrolimus as well as a 
need to reduce off-target effects, there is a strong interest in strain and culture process 
development to optimize the production of the drug and analogs.65-69 Previously, FP assays using 
the receptor FKBP12 and various fluoresceinated reporters were developed to identify novel 
FKBP12 ligands and to study other FK506-binding proteins (FKBPs) such as FKBP51 and 
FKBP52.70-72 In this study, we have established a high-throughput production and screening 
platform for FK506, based on culturing Streptomyces tsukubaensis in 96-well, deep-well 
microtiter plates, followed by extraction and detection of FK506 using the FP assay. As a pilot 
experiment, we screened a strain library of 160 colonies created by UV mutagenesis and found 
strains that exhibited higher productivities of FK506. 
 
3.2       Results 
3.2.1 High-throughput FP assay to detect FK506 
The FP assay can be adapted to detect a target small molecule for metabolic engineering 
(Fig. 3-1). To perform the assay, a fixed amount of receptor and reporter molecules (which 
contains a fluorophore and competes with the target molecule for binding to the receptor) are 
added to the sample in a microtiter plate. If the concentration of the target molecules is low, the 
reporter molecules will be mostly bound to the receptor, thus producing higher fluorescence 
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polarization values. However, if the concentration of the target molecules is high, the reporter 







Figure 3-1. FP assay to detect FK506. (a) Principle of applying the FP assay to detect metabolites. 
(b) Competition curves for FK506 standards using 100 nM and 1 µM of FKBP12. Error bars are standard 
deviations of 3 readings each of 2 replicate wells. Concentrations refer to that of the sample. The final 






































As a proof-of-concept, we adapted the FP assay to establish a high-throughput screen for 
FK506 using the receptor FKBP12 and the reporter molecule FK506-fluorescein (Fig. 3-1, b). 
The receptor and reporter were previously used to measure the affinity of FKBP12 receptor 
mutants for FK506.73 We first constructed a standard curve of fluorescence polarization values 
against different concentrations of FK506 that we purchased commercially (Fig. 3-1, b). The 
curve is sigmoidal, and the FP readings approach a maximum and minimum at low and high 
FK506 concentrations in the sample respectively. In order to use the standard curve to determine 
the concentration of FK506 in a sample, the sample reading has to fall within the non-saturating 
region where changes in FP signal occur. We performed the FP assay with two different receptor 
concentrations (100 nM and 1 µM), which shifted the dynamic range from ~0.1–10 mg/L to ~1–
20 mg/L of FK506 respectively (Fig. 3-1, b). This suggests that the dynamic range of the FP 
assay can be readily adjusted to detect different levels of small molecule (FK506) simply by 
tuning the receptor concentration. 
 
3.2.2 Production of FK506 in 96-well microtiter plate format 
In order for the FP assay to be useful as a high-throughput screening platform for 
metabolic engineering, the production platform has to be of similar throughput and also 
compatible with the microtiter plate format used in the FP assay. Thus we attempted to produce 
FK506 by cultivating S. tsukubaensis in 96-well, square, deep-well plates. Microtiter plates are 
cheap, automatable74, standardized and high-throughput compared to shake flasks.75,76 However, 
cultivating Streptomyces spp. in plates is challenging due to its propensity for mycelial growth, 
which tends to limit oxygen transfer. It has been shown that the use of square wells can increase 
oxygen transfer rates by increasing turbulence, and thus improve secondary metabolite 
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production 77-80. While the production of rapamycin has been demonstrated in 96-well plate 
format,81,82 to our knowledge, the production of FK506 in liquid culture in 96-well microtiter 
plates has not yet been reported. 
We cultivated S. tsukubaensis in three different volumes of production media – 500, 750 
and 1000 µL and tested for the production of FK506 over the course of 8 days. Production of 
FK506 was observed after 24 h for all three volumes and increased over the course of 8 days 
(Fig. 3-2, a). Production levels as measured by the FP assay reached ~17 mg/L after 8 days for 
both 750 µL and 1000 µL, which was higher than that for 500 µL (~14 mg/L). Cell growth was 
measured by taking the dry weight of submerged mycelia as well as growth on the walls above 
the liquid level (Fig. 3-2, b). 
We further quantified the amount of FK506 in all our samples by mass spectrometry. The 
values thus obtained correlate with the values measured by the FP assay (R2 = 0.705) (Fig. 3-2, 
c). Compared to the readings obtained by the FP assay, the readings obtained by mass 






























Figure 3-2. Production of FK506 in 96-well plates. (a) FK506 produced (in mg per liter of 
production media) over 8 days using 500, 750 and 1000 µL per well, as measured by the FP assay. All 
error bars represent the standard deviation from 4 wells. (b) Growth curves of cells for 500, 750 and 1000 































































3.2.3 Extraction of FK506 and growth determination in 96-well microtiter plates 
FK506 is insoluble in water and is not secreted from the producer cells. This necessitates 
an additional extraction step before high-throughput screening using the FP assay can be carried 
out. Thus we developed a protocol to extract FK506 from the streptomyces cells using the 
organic solvent ethyl acetate, which can be performed in the same 96-well production plate (see 
Experimental methods). 
We tested our protocol by spiking a series of FK506 standards into production media (no 
cells) and carried out the extraction. We then performed the FP assay with the extracted 
standards, which matched the results obtained from standards that were directly added to the FP 
assay (Fig. 3-3, a). Performing the extraction step in 96-well plates would allow for future 
automation of the extraction step, which should increase the throughput and reproducibility of 
the data obtained. 
Next, we adopted the methylene blue assay to measure the dry weight of S. tsukubaensis 
cells in 96-well plates.83,84 Using a series of samples with different amounts of cells, we 
constructed a standard curve of methylene blue absorbance against dry weight (Fig. 3-3, b). The 
curve shows a linear relationship with the amount of methylene blue left unabsorbed in solution 
decreasing proportionally with an increasing amount of cells. This method is rapid (~30 min) and 
high-throughput compared to traditional methods to determine dry weight, which may require 









Figure 3-3. Extraction of FK506 and growth determination in 96-well plates. (a) Plot of FP values for 
non-extracted FK506 standards versus extracted FK506 standards extracted from media in 96-well plates. 
Error bars are the standard deviation of 3 readings each of 2 replicate wells. (b) Standard curve of 



























FP values for extracted FK506 standards






























3.2.4 Random mutagenesis and screening for improved FK506 production 
As a pilot experiment combining our high-throughput production and screening platform, 
we screened a UV-mutagenized library of 160 S. tsukubaensis mutants for FK506 production 
(Fig. 3-4, a). Overall, one mutagenesis, production and screening cycle took ~12 days, which is 
an improvement over other methods that have been reported that measure rapamycin production 
using the zone of inhibition of sensitive reporter cells.81 
The mutant colonies displayed a range of productivities that range from 47% to 160% of 
the non-mutagenized spores (Fig. 3-4, b). In general, the higher the amount of FK506 produced 
(measured in mg per liter of media), the higher the productivity of the cells (measured as mg of 
FK506 per gram of dry weight), since cell growth (dry weight per mL of media) overall does not 
seem to increase with FK506 production (Fig. 3-4, b). However, in some instances such as 
colony 43, the higher productivity value despite lower FK506 amounts can be explained by 
lower cell growth. Also, colony 119 was not included in the analysis as it had a seemingly high 
productivity value (1.17 mg FK506 / g dry weight) but this was due to the fact that the cells did 
not grow in the production plate. This may be due to experimental error or UV-induced 
mutations that impaired the growth of the cells. 
Thus, when selecting mutants for scaled-up testing or further rounds of mutagenesis, both 
the productivity value and cell growth/density have to be taken into account. Cell growth/density 
is an important parameter in biosynthesis since it relates to the robustness of the cells, rate of 









Figure 3-4. High-throughput mutagenesis and screening platform. (a) Integrated protocol to 
mutagenize and screen a library of spores for improved production. (b) Productivity of mutant colonies 
(bottom black bars, y-axis on the right) arranged in ascending order from left to right. Only half the 
colonies are labelled. The final bar on the right represents the average of 16 wells of non-mutagenized 
(WT) spores. For all other mutant colonies, bars represent the average of 2 wells grown in different plates. 
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dotted bars, y-axis on the left) are also shown. Error bars represent the standard deviation for the 2 
replicates. 
 
3.2.5 Scale-up of top mutants in shake flasks 
 Next, we scaled up production to shake flasks for the top 8 mutants, by order of 
productivity of FK506 (mg of FK506 per gram of dry weight of cells). In our first trial (grey 
bars), all 8 mutants were tested (M41, M1, M71, M94, M95, M79, M83 and M121, listed in 
order of decreasing productivity) and compared to two non-mutagenized colonies (WT2 and 
WT4). In the second trial (yellow bars), only WT2, WT4, M71, M94, M79 and M83 were tested.  
 
 
Figure 3-5. Production titer of FK506 in shake flasks for the top 8 mutants by productivity. Gray bars 
represent the first production trial. Yellow bars represent the second production trial. All error bars 
represent the standard deviation of 3 replicate flasks per colony for each production trial. 
 
The results of the first trial show that the production titer of FK506 (mg/L) for all the 

























































particular, M71, M94 and M83 exhibited ~ 5-fold, 2-fold and 2-fold higher titers of FK506 
compared to WT_ave respectively (Fig. 3-5). In order to validate these results, we repeated the 
production trial. This time, the titers of FK506 obtained were higher generally compared to the 
first trial. The WT colonies produced comparable titers of FK506 with M71, M94 and M83. In 
particular, the variation in titer between replicate flasks for each colony was high. Promisingly, 
the average titer of M71 remained higher than the WT_ave, although the error bars are large, 
thus requiring further validation. 
 
3.2.6 Measuring the performance of the FP assay by Z’ score 
The performance of the FP assay was evaluated by calculating the Z’ score. The Z’ score 
is a statistical parameter that takes into account the assay dynamic range and the variability 
associated with measurements, and thus reports on the suitability of the assay for high-
throughput screening applications.85 
 
We used the FP assay to screen a total of 96 wells of methanol (CH3OH) (maximum FP 
signal) and 96 wells containing a final concentration of 5 µM FK506 (minimum FP signal) that 
were divided across two different 384-well plates (Fig. 3-6). The Z’ score was determined to be 
0.68, which is similar to FP assays used in other contexts, and falls within the classification of an 
excellent assay (An ideal assay has a Z’ score of 1).85-87 The FP assay described here can also be 




Figure 3-6. Z’ score for the FP assay. Faint dots represent FP values for the 96 samples of methanol 
(CH3OH) and 96 FK506 controls. The figure shows the mean of the controls (continuous black line), one 
standard deviation (long dashes) and 3 standard deviations (short dashes) from the mean. 
 
3.3 Discussion 
Tuning the detection range of the FP assay 
The FP assay is versatile in that the dynamic range can be tuned to measure different 
target concentrations by varying the receptor concentration. When screening a library, the 
receptor concentration should be chosen such that the WT (non-mutagenized) or control sample 
falls in the middle or lower part of the dynamic range, which would allow for higher production 
levels to be measured. Alternatively, the samples can be diluted before testing. Thus, the FP 
assay can serve as a high-throughput preliminary screen to identify potentially interesting strains 
for scaled-up production in flask or bioreactors. 
The lower limit (sensitivity) of the assay depends on the Kd of both the target molecule 
and reporter molecule, as well as the fluorophore used. For molecules with Kd in the low nM 



































Z' score = 0.68
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concentrations (e.g. 50 nM), which is possibly approaching the lower limit of the assay since the 
final concentration of reporter used is 2.5 nM. This is the minimum concentration of reporter 
required for a reliable FP signal. The minimum concentration of reporter used can be empirically 
determined by testing various combinations of receptor and reporter concentrations alone in a 
well, until a reliable difference in FP signal between the presence and absence of the receptor is 
observed. 
Potential for the FP assay to be generalized for other target molecules 
We expect that the FP assay can be quickly and easily adopted to screen for a wide range 
of small molecule metabolites. Significantly, the FP assay can be performed by simply adding a 
receptor and competitive reporter molecule to the sample.88 This is unlike other assays based on 
fluorophore quenching in the binding site89 or bioluminescence resonance energy transfer 
(BRET)90, which require receptor modification with a quencher or fluorophore respectively, and 
are highly target-dependent. In order to develop an FP assay for a target molecule, two 
components need to be developed – a receptor and a competitive reporter molecule. 
Receptor design and evolution 
The receptor has to have adequate affinity for both the reporter molecule and target 
molecule, ideally a Kd in the nM – low µM range. This is because weak affinities will require 
very high concentrations of receptor in order to observe a change in FP when the reporter is 
added. This could be problematic as the receptor (if protein), may aggregate or bind non-
selectively to the reporter/fluorophore at high concentrations. 
For the majority of metabolites, we expect that protein-based receptors can be found in 
nature, including its natural target receptor or the inactivated enzyme for which the molecule is 
the substrate or product. A receptor can also be created de novo by computational design, or have 
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its binding affinity increased via established directed evolution technologies (e.g. phage, mRNA, 
yeast surface display).51-53 The receptor can also be an antibody/monobody, RNA-based 
molecule (e.g. aptamers) or other binder.  
The receptor used determines the specificity of the FP assay. In this study, the receptor 
FKBP12 is employed. Since it binds to several ligands with nanomolar affinity including FK506, 
rapamycin and various analogs, the assay can be used to detect any one of these targets (data not 
shown). Similarly, reporter molecules that are based on any one of these molecules (or others 
that bind to FKBP12) can be used interchangeably in the FP assay. Thus, if the FP assay is used 
for screening in metabolic engineering, it is important to verify the identity of the product by an 
alternative method such as mass spectrometry. However, if a higher degree of specificity is 
desired, the receptor can be modified or evolved using directed evolution technologies to 
selectively bind one target molecule over the others. 
Reporter design and synthesis 
The competitive reporter molecule consists of a molecule that is linked to a fluorophore, 
and which competes with the target molecule for binding to the receptor. The reporter can be 
constructed by chemically coupling the target molecule itself to a fluorophore. Analogs of the 
target molecule or inhibitors that bind to the receptor can also be used. However, a major 
concern is that attaching a fluorophore to a target molecule/inhibitor of comparable size would 
be likely to reduce the affinity of the reporter conjugate to the receptor due to steric hindrance 
from the fluorophore. This can be overcome by choosing linker sites on the target/inhibitor that 
are not critical for receptor binding or that point outwards from the binding site. The choice of 
linker sites can be informed by X-ray crystal structures of the target/inhibitor bound to the 
receptor, or structure-activity relationship studies that have been performed on the molecule.54,55 
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Also, the linker length can be increased to reduce steric interaction between the fluorophore and 
receptor. However, the linker length must not be too long since this will increase the flexibility 
of the fluorophore to rotate and result in a lower FP signal when the reporter is bound to the 
receptor (the “propeller effect”).91 
Another important decision lies in the choice of the fluorophore. The fluorophore may 
interact non-specifically with the receptor to produce a false high polarization signal. This can be 
detected by supplying a high concentration of target molecule, which should displace the reporter 
only if it is bound specifically, and decrease the FP signal. Other characteristics of the 
fluorophore such as quantum yield, which affects the signal intensity may also be important 
considerations. Fluorophores with longer excited-state lifetimes are suitable for measuring 
interactions over a larger molecular weight range. Also, red-shifted fluorophores can reduce the 
background from intrinsically fluorescent components in the sample. 
FP assay in a high-throughput setting 
The FP assay provides a measure of the proportion of bound versus unbound reporter 
molecule and is a ratiometric technique. Thus, it is not affected by light absorbance or color 
quenching by other components in the sample. The FP assay is homogeneous – it can be 
performed with all the components added to the same well and there is no need to separate the 
bound and unbound species. This minimizes the number of steps to perform the assay. 
Since the FP assay relies on the detection of changes in polarization of a fluorescence 
signal, the assay is highly sensitive and can be performed easily and cheaply in microtiter plate 
format using a fluorescence plate reader that has a FP module. In this study, we performed the 
FP assay in a 384-well plate format, which would potentially allow screens of up to >104 
samples (~26 plates) per day (30 minutes per plate). The FP assay has also been reported to be 
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achieved in 1536-well plates, which would increase sample throughput to ~105 samples per 
day.92,93 
However, the production platform for culturing the organism can quickly become 
limiting. Here, we demonstrate that FK506 can be produced by cultivation in 96-well plates. In 
general, there have been only a few reports of cultivation of Streptomyces spp. in 96-well plate 
format.76,81,82,94 This is probably due to the requirement of most organisms such as Streptomyces 
spp. for high oxygen transfer rates for growth and secondary metabolite production. This can be 
achieved through the use of high-frequency shakers, smaller culture volumes, tilted rotation and 
larger shaking orbits. Microtiter plates have the added advantage that they can be easily 
automatable. Importantly, cultivation in microtiter plates have been shown to be more 
reproducible than shake flask cultivations.82 However, a key question to be addressed is whether 
the relationship between the productivities of different strains in a microtiter plate will hold when 
scaled up to a shake flask or bioreactor. In the future, novel platforms that use microfluidics to 
cultivate organisms in mini-bioreactor droplets can potentially increase throughput.95 
We have established that the FP assay can be used for small molecule detection for 
metabolic engineering purposes. As a proof-of-concept, we adapted the FP assay for high-
throughput screening of FK506 produced by Streptomyces tsukubaensis in 96-well microtiter 
plates. A FK506 production and extraction protocol in 96-well plates was developed to enable a 
high-throughput production and screening cycle. We applied our platform to screen a UV 
mutagenized library for improved production strains. We further verified that the FP assay is 
robust using the Z’ score. Overall, the platform developed here will be useful not only for 
screening mutagenized strain libraries, but also to screen different culture conditions and media 
compositions to optimize the production process. We expect that the FP assay will be broadly 
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applicable to screen for other targets of interest to the metabolic engineering community, as well 
as for other purposes such as the discovery of natural product pathways in metagenomics. 
 
3.4 Experimental methods 
Strain, sporulation and mutagenesis conditions.  Streptomyces tsukubaensis (NRRL 18488) 
was obtained from the Agricultural Research Service Culture Collection (NRRL), USA. Spores 
were harvested after culturing NRRL 18488 on inorganic salts/starch agar media (ISP4) (BD 
Difco, #277210) at 28 ºC for 4 days. UV mutagenesis was performed using a Stratalinker 2400 
(Agilent). UV dose was calibrated to obtain a 99 % kill rate. 
 
Production conditions.  Production of FK506 was carried out in 2.2 mL, square, 96-well deep 
well microtiter plates (Axygen Scientific) using a two-stage cultivation method.62 First, 500 μL 
of modified BaSa seed medium was inoculated with spores of NRRL 18488 and incubated for 3 
days at 28 ºC and 250 rpm (Innova 44R, 2-inch orbit). The seed culture was used to inoculate 
500 – 1000 μL of ISPz production media 62 per well and incubated for 4 – 8 days at 28 ºC and 
250 rpm. The volume of seed culture added was 10 % of the final volume in the well. The plates 
were sealed with two layers of sterile, breathable rayon seal (AeraSeal) before incubation. 
For flask productions to verify the top 8 mutants by productivity that were found in the 
FP screen, 5 mL of seed culture (4.5 mL of BaSa medium inoculated with 500 μL of spores of 
each mutant) was incubated for 40 h at 28 °C and 230 rpm. The seed cultures were used for the 
inoculation of 5 mL of ISPz production media (to a final OD600 of 1) in 50 mL, unbaffled flasks 




Measurement of cell growth 
Dry weight.  Cell growth was determined by measuring the dry weight of an aliquot of the 
culture. The cells were pelleted in pre-weighed 4 mL glass vials, washed twice with acid to 
remove insoluble CaCO3 in the media, and then dried in an oven for 2 days before measuring the 
mass. For the construction of the standard curve, the cells were transferred onto pre-weighed 
Nalgene filter units (polyether sulfone, membrane diameter 75 mm, pore size 0.45 μm, Thermo 
Scientific), washed twice with acidified water (pH 0.5) to remove insoluble CaCO3 in the media, 
and then dried in an oven at 80 °C until constant weight (1 day) before measuring the mass. 
 
Methylene blue assay.  For the library screening, cell growth was measured using a methylene 
blue absorption assay.83 A standard curve of methylene blue absorption against dry cell weight 
was constructed to convert absorbance values to dry weight (Fig. 3b). The methylene blue assay 
was performed by transferring 100 µL of sample into a Corning Costar polystyrene clear 96-well 
plate. 100 µL of methylene blue solution was added to the sample (final concentration of 1.5 
mM) and the plate was incubated for 15 min at 80 ºC. At 5 min intervals, the plate was agitated 
for 10 s in a high-frequency microplate shaker (800 rpm) to enable mixing. After incubation for 
15 min, the plate was centrifuged for 5 min at 3000 rpm and 10 µL of supernatant was 
transferred into a new 96-well clear plate containing 190 µL of water in each well. The contents 
were mixed and absorbance was determined in a Tecan plate reader at 660 nm. 
 
Extraction of FK506 Initial testing for production.  For the initial testing of production of 
FK506 in microtiter plates and shake flasks, the culture in each well/flask was transferred into a 
2 mL Eppendorf tube. An equal volume of ethyl acetate was added and the tube was vortexed for 
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30 min. After centrifugation for 5 minutes, the top ethyl acetate layer was transferred into a 4 mL 
glass vial and evaporated to dryness by rotary evaporation. An equal volume of methanol was 
added to dissolve any FK506 present for subsequent testing. 
 
Library screening.  For the library screening, FK506 was extracted from cell cultures of S. 
tsukubaensis using the same 96-well deep-well microtiter plate that was used for production 
(Axygen Scientific). Firstly, the cells in the plates were subjected to 3 freeze-thaw cycles. 100 
µL of culture was taken for the methylene blue assay. 500 µL of ethyl acetate was added to the 
remaining culture (~650 µL). The plates were sealed with a silicone mat (ImpermaMat, Axygen 
Scientific), wrapped with parafilm, and incubated for 1 hour at 20 ºC, 800 rpm in a high 
frequency plate shaker. The plates were then centrifuged for 5 minutes at 3000 rpm. 150 µL of 
ethyl acetate was added gently to the top layer, mixed gently, and 100 µL of the top ethyl acetate 
layer was transferred to a 96-well polypropylene plate (Greiner). The plate was evaporated to 
dryness in a chemical hood, and 100 µL of methanol was added to dissolve the extracted FK506. 
The methanol sample was added directly into the assay wells for the FP assay. All procedures 
were performed using 8-channel manual pipettes. 
 
FK506 quantification Fluorescence polarization assay.  The FP assay for FK506 was 
performed using the receptor FKBP12 (purified using the Ni-NTA kit (Qiagen) from a previous 
construct73) and reporter molecule FK506-fluorescein (a gift from Ariad Pharmaceuticals).73,96,97 
The assay was performed in 384-well, round, black-bottomed plates (Corning #3821). A total 
volume of 40 µL per well was used. The final concentrations of reagents in each well were: 2.5 
nM FK506-fluorescein and 1 µM FKBP12 (unless otherwise specified). The order of addition of 
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each reagent into the well was: 32 µL of master mix containing FK506-fluorescein, 2X FP assay 
buffer 73 and water, followed by 4 µL of the sample (in methanol solvent) and finally 4 µL of 10 
µM FKBP12. The plates were left for two hours for equilibrium to be reached. FP readings were 
taken using a Victor X5 plate reader (Perkin Elmer), with excitation filter (485 nm) and emission 
filter (535 nm). FK506 used for the standard curves were purchased from Sigma (#F4679). 
 
Mass spectrometry.  Mass spectrometry was performed using an LC-MS (Agilent 1100 Series 
Capillary LCMSD Trap XCT Spectrometer, NYU). A standard curve was generated by selected 
ion monitoring of ion counts at m/z of 826.4 (FK506 + Na) using different concentrations of 
commercial FK506 (Sigma #F4679). This curve was used to determine the concentration of 
FK506 in the sample. 
 
Random mutagenesis and screening for improved FK506 production.  First, a S. 
tsukubaensis spore suspension was irradiated with UV (killing ratio of 99 %) and plated on ISP4 
agar. Sporulated colonies appeared after 3-4 days. These were picked to create a glycerol spore 
stock in a 96-well plate, which was preserved in a -80 ºC freezer for future testing and further 
rounds of mutagenesis.94 The glycerol stock plate was used to inoculate a seed culture plate. 
After incubation for 3 days, the seed culture plate was used to inoculate two independent 
production plates (replicates). Following incubation for 4 days to allow for production of FK506, 
100 µL of culture in each well was used to determine cell growth by the methylene blue assay. 
The remainder of the culture (650 µL per well) was subject to ethyl acetate extraction in the 




Z’ score.  The Z’ score was calculated using the following equation: Z’ = 1 – (3σn + 3σp) / (µn - 
µp), where σn is the standard deviation of the negative control (methanol), σp is the standard 
deviation of the positive control (final concentration of 5 µM FK506), µn is the mean FP value 
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4.0 Chapter outlook 
In the last chapter, we established the fluorescence polarization (FP) assay as a high-
throughput screen for small molecules, capable of screening ~ 104 – 105 samples per day. 
However, when library sizes approach 108 or more, screening methods becomes impractical and 
growth selections have to be employed in order to sample the full library. Previously, our lab 
developed chemical complementation, based on the small molecule yeast three-hybrid system 
(Y3H), to establish a selection for enzyme catalysis. In this chapter, we propose to adapt the 
Y3H to detect small molecules by displacement of a competitive small molecule dimerizer that 
bridges the two receptor-fusion proteins in the Y3H system. In this way, small molecule 
detection can be coupled to a change in the transcription output of a reporter gene, which can be 
used to create a screen or selection. In preliminary results, we show that the Y3H system can 
detect the small molecule trimethoprim (TMP), as well as the polyketides meridamcyin and 
FK506. At the same time, small molecule detection was coupled to the expression of a selectable 
reporter gene. This sets the stage for the Y3H system to be further developed as a general 




To address the combinatorial complexity of metabolic engineering, directed evolution 
approaches can be applied to optimize the biosynthetic enzymes, pathways, interacting networks 
and the host strain background. However, this will require high-throughput DNA assembly or 
mutagenesis technologies for creating combinatorial libraries, as well as screens and selections 
for the desired product (see Chapter 1). While many technologies have been developed for the 
creation of large DNA libraries1 (> 108), there is a lack of generalizable and high-throughput 
screens or selections for small molecules2. Colorimetric or fluorescence-based screens are 
limited to ~ 104 – 105 samples per day, except for fluorescence activated cell sorting (FACS), 
which can screen up to ~ 108 single cells per day3. However, unless the product is fluorescent 
and accumulates intracellularly, the application of FACS to detect small molecule products for 
metabolic engineering is limited4. In contrast, selections enable large populations of cells ~ 1010 
to be enriched in a one-pot growth selection, and thus remains the method of choice for testing 
really large libraries (> 108)2. 
One strategy to create a small molecule selection is to couple the detection of the 
compound to a change in the expression of a selectable reporter gene. Natural regulators such as 
transcription factors, riboregulators (e.g. riboswitches) and nuclear receptor proteins detect 
natural metabolites and can transduce the binding event into a change in gene transcription or 
translation. Thus, these natural regulators have been harnessed to create product screens or 
growth selections by coupling small molecule detection to the expression of a screenable or 
selectable reporter gene respectively5. In addition, the specificity of some regulators have been 
switched in order to expand the repertoire of compounds that they can detect6. However, this is 
neither trivial nor routine as the binding and signaling functions in these regulators are tightly 
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interwoven. Thus, more modular systems that can interface small molecules with genetics may 
generally be easier to engineer. 
The small molecule three-hybrid (Y3H) system has its roots in the use of natural 
chemical dimerizers such as rapamycin for the control of protein interactions in the cell7. 
Subsequently, the idea of interfacing the two halves of a transcription factor – the DNA binding 
domain (DBD) and activation domain (AD), with a dimeric small molecule, was born as a way to 
modulate gene transcription with small molecules8. The Y3H is highly modular in that different 
receptors can be fused to the DBD and AD. The two receptor-fusion proteins are then bridged by 
a dimeric small molecule (the chemical inducer of dimerization or CID) that can be synthesized 
by joining the ligands of the two receptors together. The Y3H system has since been exploited to 
screen cDNA libraries to discover receptors for small molecules8, to identify FKBP12 or FRAP 
(receptor) mutants that bind specific FK506 or rapamycin analogs9,10, and to evolve receptors to 
bind novel ligands11. 
Cornish et al. developed the idea of “Chemical Complementation”12 to couple enzyme 
activity to a transcriptional output via the Y3H system. By introducing reactive groups in the 
middle of the CID, the three-hybrid system was adapted to select for enzymes that catalyzed 
bond formation (glycosynthases)13 or bond cleavage (cellulases)14 reactions. Here, we envisioned 
that the Y3H system can be applied in a competition format to assay for small molecule 
displacement of one end of the CID from its receptor, which will result in a decrease in reporter 
gene transcription (Fig. 4-1). This is analogous to the Boeke “reverse” yeast one or two-hybrid 
systems, which can be used to screen for mutations or molecules that dissociate DNA-binding 
proteins from DNA or protein-protein interactions respectively15. As a proof-of-concept, we 
established Y3H systems capable of detecting the small molecules trimethoprim (TMP), 
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meridamycin and FK506 (tacrolimus). In addition, we show that the Y3H can be used to 
differentiate varying concentrations of these molecules and to couple detection to the 
transcription of a selectable marker gene. 
 
 
Figure 4-1. Y3H assay for small molecule detection. X and Y are receptor proteins that each bind to 
one half of the small molecule CID, Z. X and Y are fused to the DNA-binding domain (DBD) and 
activation domain (AD) respectively. In the presence of X, Y and Z, an active transcription factor is 
reconstituted, thus activating transcription of the reporter gene. The presence of a small molecule product 
(e.g. biosynthesized by a cell) can compete with one end of the CID for binding to a receptor. The 
displacement of the CID results in inactivation of reporter gene transcription. In this way, the Y3H system 






 4.2.1 Yeast three-hybrid screen for trimethoprim 
First, we tested to see if the Y3H system was capable of detecting small molecules, using 
trimethoprim (TMP) as a proof-of-principle target. Previously, our lab has developed Y3H 
systems based on the two receptor fusion pairs: dihydrofolate reductase (DHFR)–LexA DNA-
binding domain (DBD) and glucocorticoid receptor–B42 activation domain (AD). These are 
brought together by the CID, dexamethasone-methotrexate (Dex-Mtx), to reconstitute a 
transcription factor, resulting in the activation of a downstream reporter gene16. Our lab also 
developed a second generation Y3H system based on the same small molecule-receptor pairs, but 
with the URA3 reporter gene placed under an extra layer of control by the dual tetracycline (Tet)-
inducible regulators, which are in turn regulated by the Y3H system17,18 (Fig. 4-2). This system 
was shown to enable selective enrichment from a mock library of 106.19 The use of URA3 as a 
marker allows for a negative selection to be performed in the presence of 5-fluoroorotic acid 




Figure 4-2. Y3H system to detect TMP. The second generation Y3H system adds an extra layer of 
control mediated by the TetR’-activator and TetR’-repressor. In the absence of TMP, the Y3H is active, 
resulting in transcription of the TetR’-activator. This alleviates the repression of the URA3 reporter by the 
constitutively expressed TetR’-repressor, thus resulting in transcription of URA3, which leads to cell 
death in the presence of 5-FOA (negative selection). When TMP is present, it can displace Mtx-Dex from 
binding to DHFR, resulting in an inactive Y3H system. This prevents the TetR’-activator from being 
expressed. Thus, the TetR’-repressor binds to TetO and inhibits the transcription of URA3, which 
increases cell survival in the presence of 5’-FOA. 
 
Thus, we envisioned that this system could be used to detect TMP, a small molecule 
antibiotic that binds with high affinity to bacterial dihydrofolate reductase (DHFR)21. TMP 
should compete with the methotrexate end of the CID (Dex-Mtx) for binding to DHFR, thus 
reducing transcription of URA3 and promoting cell growth in the presence of FOA (Fig. 4-2). 
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Indeed, when we cultured the cells with different concentrations of TMP (0.5 nM – 50 µM), we 
observed that the cells grew faster in the presence of higher concentrations of TMP (Fig. 4-3).  
 
 
Figure 4-3. TMP detection using the Y3H system. The CID (Dex-Mtx) was either added (+) or not 
added (-) to the wells. CID was added to a final concentration of 5 µM. Dimethyl formamide (DMF) is 
the solvent for the CID. Concentrations of TMP refer to final concentrations in the well. Error bars 



















TMP detection by Y3H
- CID, - DMF - CID, + DMF - CID, + DMF, 50 uM TMP
+ CID, - TMP + CID, 0.5 nM TMP + CID, 5 nM TMP
+ CID, 50 nM TMP + CID, 500 nM TMP + CID, 5 µM TMP
+ CID, 50 µM TMP
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The maximum growth range of the assay is set by the minimum growth curve when the 
CID is added (+ CID), and the maximum growth curve when no CID is added (- CID). Since the 
CID was dissolved in the solvent dimethyl formamide (DMF), we also made sure that its 
presence did not affect growth (- CID, + DMF curve was identical to the - CID, - DMF curve). 
The Y3H system was highly sensitive and we could detect as low as 0.5 nM of TMP, although 
the difference in growth compared to the minimum curve (+ CID, - TMP) was small. Above 5 
µM of TMP, the growth reached the maximum (- CID, - DMF curve). This suggests that the 
Y3H system is capable of differentiating between 0.5 nM and 5 µM of TMP (a dynamic range of 
at least 104) if run as a growth selection, since minor differences in growth can be amplified over 
time. However, when the Y3H is run as a screen based on OD600 measured in microtiter plates, 
the dynamic range may be smaller since minor growth differences can fall within the error of the 
OD600 measurements. In fact, OD600 changes did not scale linearly with TMP concentration. The 
maximum OD600 change occurred between 50 nM and 500 nM of TMP (Fig. 4-3). Thus, when 
applied as a screen, this Y3H system is most useful for detecting product concentrations in that 
range. 
 
 4.2.2 Yeast three-hybrid screen for meridamycin 
Next, we wanted to see if we could construct an Y3H system to detect the polyketide 
meridamycin that we aimed to produce using our engineered Streptomyces spp. strains (see 
Chapter 2). Previously, meridamycin has been shown to bind to the receptor FKBP1222. An 
Y3H system employing the receptor fusions Lex A DBD-glucocorticoid receptor and B42 AD-
FKBP12, bridged by the CID dexamethasone-FK506 has been developed8. Our lab developed an 
Y3H system using the CID methotrexate–SLF (Mtx-SLF)23 to bridge the receptor fusions LexA 
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DBD-DHFR and B42 AD-FKBP12. SLF is a synthetic analog of FK506, and has been used 
successfully as part of a CID in Y3H systems9,23. In that study, various FKBP12 mutants with 
varying affinities for FK506 were generated, in order to test the effect of small molecule-receptor 
affinity on the transcriptional output24. However, it was reported that the Y3H system could only 
activate the screenable marker lacZ but not the auxotrophic markers LEU2 or URA3. Thus, in 
this study, we decided to swap the receptor fusion pairs to B42 AD-DHFR and LexA DBD-
FKBP12, to see if we could couple the Y3H system to a selectable LEU2 reporter gene, which 
would enable growth in the absence of leucine. In this setup, meridamycin would displace the 
SLF moiety of the CID from binding to FKBP12, leading to inactivation of LEU2 transcription 
and decreased cell growth in media lacking leucine (Fig. 4-4). 
 
Figure 4-4. Y3H system to detect meridamycin or FK506. The presence of FK506 or meridamycin 
can displace SLF from binding to the receptor FKBP12. This results in inactivation of the Y3H system, 
which decreases the transcription of the LEU2 gene, leading to lower cell growth in the absence of 
leucine. 
 
To increase our chances of developing a sensitive Y3H system to detect meridamycin, 
various FKBP12 mutants (WT, H87L, Y26F) with varying Kd’s for SLF (15, 7.3, 170 nM 
respectively) were tested. When the CID alone was supplied, only the WT FKBP12 and H87L 
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mutant resulted in LEU2 activation and growth in media lacking leucine, with the higher affinity 




Figure 4-5. LEU2 selection with Y3H systems containing FKBP12 receptor mutants. For each 
receptor mutant (wild-type WT, H87L or Y26F), growth curves were measured in the presence (plus Mtx-
SLF) and absence of the CID. All error bars represent standard deviation across 3 wells. 
 
We selected the H87L Y3H system for use to maximize the dynamic range of the assay, 
and tested the strain with 100 nM and 5 µM of meridamycin. This led to the expected result, 
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Figure 4-6. Detection of 100 nM and 5 µM of meridamycin standards with the H87L Y3H system. 
All error bars represent standard deviation across 3 wells. 
 
  To ensure that the decrease in growth was due to the effect of meridamycin on the Y3H 
output and not the toxicity of the compound itself, we performed a growth assay in the presence 
of different concentrations of meridamycin (0, 50 nM, 100 nM, 1 µM, 5 µM). Although the 
addition of meridamycin led to a ~ 25 % decrease in growth, but all the different concentrations 
tested led to similar levels of growth (Fig. 4-7). This suggests that the differences in growth 
observed between 100 nM and 5 µM of meridamycin, when the CID was added, was likely due 




Figure 4-7. Growth curves with different concentrations of meridamycin. No CID was added. Values 
refer to the final concentrations of meridamycin (0, 50 nM, 100 nM, 1 µM and 5 µM) in the well. 
Standards were dissolved in DMSO. All error bars represent standard deviation across 3 wells. 
 
 4.2.3 Yeast three-hybrid screen for FK506 
 Finally, we sought to optimize the Y3H for detecting biosynthetic meridamycin. 
However, since the high biosynthetic strains for meridamycin were not yet available, we used the 
polyketide FK506 instead as a test bed. In Chapter 3, we demonstrated the production of FK506 
in cultures of Streptomyces tsukubaensis cells.  Here, we tested to see if the Y3H assay could be 
used to detect a real biosynthetic product (as opposed to purified standards). First, we checked 
that the H87L Y3H system could detect FK506. As expected, the addition of 100 nM and 5 µM 
of FK506 standards led to a concentration-dependent decrease in growth (Fig. 4-8), which was 



















Figure 4-8. Detection of 100 nM and 5 µM of FK506 standards with the H87L Y3H system. Chart 
from Marie Harton, thesis. Standards were dissolved in DMSO. Bars represent the average OD600 after 6 
days of culture. All error bars represent standard deviation across 3 wells. 
 
 As biosynthesized FK506 is not secreted from the S. tsukubaensis cells, we first had to 
perform a chemical extraction step using ethyl acetate (see Chapter 3). Previously, to prepare 
the samples for the fluorescence polarization assay, we rotavapped the ethyl acetate extracts and 
resuspended the samples in methanol. In this study, we tested different methods of extraction 
from unfermented Streptomyces spp. ISPz media used for FK506 production25. We tested to see 
if the ethyl acetate extracts could be screened directly by the Y3H assay, and compared that to 
samples that were resuspended in ethanol or extracted with methanol. Our results show that 
adding the unfermented media directly to the Y3H sensor cells inhibited cell growth, whereas the 
ethyl acetate extract produced maximal growth (Fig. 4-9). Replacing the ethyl acetate solvent 
with ethanol led to a decrease in cell growth, while the methanol extracts completely inhibited 
cell growth. One possible explanation for these results is that the ISPz media contained water-
soluble compound(s) that were inhibitory to the growth of yeast. Performing the ethyl acetate 
extraction removed these inhibitory substance(s), leading to the restoration of Y3H growth. 
Furthermore, ethyl acetate did not harm the yeast cells as it was immiscible with the aqueous 
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phase, a small volume (5 µL) was used, and it evaporated quickly in the incubator. Adding either 
ethanol or methanol inhibited yeast growth, and thus these were not tested further. 
 
Figure 4-9. Growth of the Y3H strain in the presence of various extracts of unfermented ISPz media. 
No SM: No small molecule CID. Plus MS: 5 µM of MTX-SLF added. All media were tested in the 
presence of the CID. (1): Unaltered ISPz media. (2A): Ethyl acetate extract. (2B): Ethyl acetate extraction 
followed by rotavap and resuspension in ethanol. (3): Methanol extract of ISPz media. MS_mediaFK506: 
unaltered ISPz media spiked with 5 µM FK506. For the methanol extracts, an equal volume of methanol 
was added to ISPz, vortexed for 1 h and the supernatent tested. Error bars represent one standard 
deviation across three wells. 
 
Finally, we tested an ethyl acetate extract of a sample from a S. tsukubaensis fermentation 















Chapter 3). The expected final concentration of FK506 in the well is 500 nM. Our results show 
a detectable decrease in Y3H growth when the sample was added compared to an ethyl acetate 
extract of unfermented media (Fig. 4-10). These results are promising and in future, further tests 
can be performed with extracts from other time points in the fermentation run, which contain 
different levels of FK506 (Fig. 3-2). 
 
Figure 4-10. Detection of biosynthesized FK506 using the Y3H system. A fermentation sample of S. 
tsukubaensis in ISPz from Day 8 (t192) was extracted with an equal volume of ethyl acetate and 5 µL was 
added to the wells (200 µL) containing the Y3H sensor strain. Thus, the final expected concentration of 

















In this chapter, we show how the Y3H system can be adapted to couple small molecule 
detection to a transcriptional readout for the small molecules TMP, meridamycin and FK506. 
However, these Y3H systems made used of small molecule-receptor pairs that had already been 
previously established. A key question is whether the Y3H is sufficiently modular to be readily 
applied as a general platform to detect small molecules for metabolic engineering. 
Early work on small molecule–protein dimerizer systems26 exploited natural small 
molecule–receptor pairs such as FK506-FKBP12, cyclosporin A-FKBP12, rapamycin-FKBP12 
and rapamycin-FRAP for the control of protein interactions and localization in cells7,9,27-29. Next, 
autonomous systems based on synthetic analogs of FK506/rapamycin that interact only with 
mutant FKBP12 but not the wild-type (WT) receptor were developed to prevent cross-talk with 
endogenous pathways9. Later, Y3H systems based on the small molecule-receptor pairs 
dexamethasone—glucocorticoid receptor (DEX-GR)8,16, FK506-FKBP128,24,30, methotrexate—
dehydrofolate reductase (MTX-DHFR)16,30, DDBO—scytalone dehydratase31, biotin—
streptavidin (SA)32, estradiol—estrogen receptor (ER)32, and O6-benzylguanine—human O6-
alkylguanine-DNA alkyltransferase (hAGT) SNAP tag33 were developed. The Y3H has also 
been applied to screen cDNA libraries to identify the protein targets of small molecules like 
anecortave acetate (AA)34, kinase inhibitors35, erlotinib, atorvastatin and sulfasalazine36, and the 
plant hormones cucurbic acid methylester and 2,6-dihydroxybenzoic acid37. 
As such, there is a rich history of examples where natural and synthetic small molecules 
have been interfaced with receptor proteins to control genetic programs in the cell. In addition, 
most of these studies involving the Y3H system also showed that an excess of the small molecule 
monomer can compete with the CID to inactivate transcription, which suggests that the Y3H can 
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be used as a small molecule sensor16,38. Furthermore, the Y3H has been harnessed for directed 
evolution to switch the specificity of the retinoid X receptor (RXR) from retinoic acid to the 
synthetic ligand LG335 (EC50~40nM)
11, demonstrating that the Y3H can be used to evolve 
receptors for new small molecule targets. 
In terms of the CID, we and others have performed studies on the optimal CID linker 
length38 and type27,35, which can inform future CID designs. Another key concern is the affinity 
(Kd) of the small molecule-receptor pairs needed to create functional Y3H systems. It has been 
estimated for the yeast two-hybrid system that protein-protein interactions with Kd < 1 µM can 
be detected39 and our recent work using the Y3H to fish out the anecortave acetate - PDE6D 
receptor interaction (Kd  = 2.7µM) suggests that this is also true for the Y3H
34. However, this 
may be complicated by other factors such as the uptake of the CID and target molecule into the 
cell, receptor turnover and the influx/efflux of the CID from the nucleus8,30.  Thus for receptors 
with Kd above this range, directed evolution (e.g. using the Y3H system) can be first used to 
evolve a higher affinity binder. 
Finally, in order for the Y3H to be run as a selection and not a screen, the production and 
selection functions for the target molecule have to be combined within the same cell. However, 
there could be a few concerns with this approach. For one, both the production and selection 
functions are naturally antagonistic, which can reduce the power of the selection5. This is 
because optimized production strains are often under heavy metabolic burden and may exhibit 
lowered growth rates as resources are channeled for production. Another potential challenge 
common to all growth selections is that the product, if secreted, can diffuse into other cells 
resulting in cross-talk, which will increase the background noise and reduce the enrichment 
power of the selection. Thus, methods that co-encapsulate the producer and sensor cells, such as 
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in alginate beads, may represent a potential solution to these problems. Microbeads (~100 μm) 
offer an efficient means to compartmentalize cells for biological assays and can be sorted based 
on fluorescence by the large-particle COPAS sorter for libraries of 106 - 107.40-42 In order to 
achieve this, the Y3H system can be coupled to the expression of fluorescent genes such as RFP 
or GFP. Another efficient method to sort the beads is to couple the Y3H output to a gas-
producing enzyme such as peroxidase or carbonic anhydrase. Gas production can cause the beads 
to float in water to allow sorting of the beads easily, cheaply and quickly by density43. 
Alternatively, three-hybrid systems can be constructed in producer hosts such as Streptomyces 
spp. to enable selection for non-secreted compounds such as FK506 or meridamycin. 
In conclusion, we show that the Y3H system can differentiate varying concentrations of 
the small molecules TMP and meridamycin, and couple that to the expression of a selectable 
marker gene. Furthermore, we developed a potential protocol to apply the Y3H to screen real 
biosynthetic FK506 samples. We anticipate that the Y3H system can be a general platform to 
develop small molecule screens/selections for metabolic engineering, and will significantly 
increase the library sizes that can be tested using high-throughput directed evolution approaches. 
 
3.4 Experimental methods 
General methods and molecules. All molecular biology techniques (e.g. PCR, cloning, 
Gibson Assembly, E. coli and S. cerevisiae culture and transformation) were performed 
according to standard methods (see Section 2.4). TMP (#T7883) and FK506 (#F4679) were 
obtained from Sigma. Meridamycin was obtained from Pfizer Inc. Dex-Mtx was synthesized by 




Yeast three-hybrid strains.  The Y3H strain for TMP detection (MH24503_098) was a 
previously constructed strain in the lab19. The Y3H strain for FK506 detection was constructed 
as follows. EGY48 (MATa trp1 his3 ura3 6LexAop-LEU2 GAL+)44 was transformed with the 
plasmid MH423B42-eDHFR and selected for on SC (H-, 2% glucose) plates. Next, colonies 
were transformed with the plasmid MH414LexA-FKBP12* to generate MH-H87L. Successful 
transformants were selected on SC (HT-, 2% glucose) plates. 
 
Plasmid construction. MH414LexA-FKBP12* was constructed as follows. The pGAL1-
LexA fragment was amplified from pKB52112 with primers MH162 (5’- 
AAGCGCGCAATTAACCCTCACTAAAGGGAACAAAAGCTGGCCCCATTATCTTAGCC
TAAA) and MH164 (5’- TCCTGGGGAGATGGTTTCCACCTGCACTCCCAATTCCAG 
CCAGTCGC) that added homology to pRS414GAL1 and the FKBP12*-tADH fragment. The 
FKBP12*-tADH fragment was amplified from 1054E24 with primers MH165 (5’- 
GTTATTCGCAACGGCGACTGGCTGGAATTGGGAGTGCAGGTGGAAAC) and MH163 
(5’- GAGGGCGTGAATGTAAGCGTGACATAACTAATTACATGACGGATCCGTGTGGAA 
GAAC). The fragments pGAL1-LexA and FKBP12*-tADH were Gibson assembled with 
pRS414GAL1 (ATCC 87328) digested with SacI and XhoI according to the manufacturer’s 
protocol (NEB #2611). Plasmid MH423B42-eDHFR was constructed as follows. The pGAL1-
B42-eDHFR fragment was amplified from pBC1034E38 with primers MH162 and MH163. The 
product was Gibson assembled into pRS423 (ATCC 87327) digested with SacI and XhoI. 
Following Gibson assembly, the reaction mix was transformed into E. coli by electroporation 
and selected on LB/ampicillin plates. Plasmids were extracted (Miniprep, Qiagen) and 
characterized by sequencing (Genewiz). The other strains containing WT FKBP12 and the Y26F 
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were constructed in an analogous manner but using templates containing WT FKBP12 or 
Y26F24. 
 
Y3H assays to detect TMP. Three colonies of the Y3H strain were inoculated into SC(HTL-), 
2% glucose media and shaken overnight  at 30°C. Cells were pre-induced for 24 hours in 
SC(HTL-), 2% galactose, 2% raffinose and 2 μg/mL of doxycycline (Dox). The pre-induced cells 
were added to SC(HTL-), 2% galactose, 2% raffinose, 0.2 % FOA, 2 μg/mL Dox, +/- 5 μM Mtx-
SLF to have a starting OD600 of 0.1. 96-well plates were used and the total volume in each well 
was 200 µL. The plates were shaken at 30°C and 230 rpm, and OD600 readings were taken with a 
Tecan plate reader. All growth curves were performed in duplicate with three technical 
replicates. 
 
Y3H assays to detect FK506 or meridamycin. In general, three colonies of the Y3H strain 
were inoculated into SC(HT-), 2% glucose media and shaken overnight  at 30°C. Cells were pre-
induced for 24 hours in SC(HT-), 2% galactose, 2% raffinose media. The pre-induced cells were 
added to SC(HTL-), 2% galactose, 2% raffinose, +/- 5 μM Mtx-SLF to have a starting OD600 of 
0.1. 96-well plates were used and the total volume in each well was 200 µL. The plates were 
shaken at 30°C and 230 rpm, and OD600 readings were taken with a Tecan plate reader. All 
growth curves were performed in duplicate with three technical replicates. 
 
FK506 production. Streptomyces tsukubaensis (NRRL 18488) was obtained from the 
Agricultural Research Service Culture Collection (NRRL), USA. Spores were harvested after 
culturing NRRL 18488 on inorganic salts/starch agar media (ISP4) (BD Difco, #277210) at 28 
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ºC for 4 days. Production of FK506 was carried out in 2.2 mL, square, 96-well deep well 
microtiter plates (Axygen Scientific) using a two-stage cultivation method.25 First, 500 μL of 
modified BaSa seed medium was inoculated with spores of NRRL 18488 and incubated for 3 
days at 28 ºC and 250 rpm (Innova 44R, 2-inch orbit). The seed culture was used to inoculate 
500 – 1000 μL of ISPz production media 25 per well and incubated for 4 – 8 days at 28 ºC and 
250 rpm. The volume of seed culture added was 10 % of the final volume in the well. The plates 
were sealed with two layers of sterile, breathable rayon seal (AeraSeal) before incubation. 
 
Extraction of FK506.  The culture in each well/flask was transferred into a 2 mL Eppendorf 
tube. An equal volume of ethyl acetate was added and the tube was vortexed for 30 min. After 
centrifugation for 5 minutes, the top ethyl acetate layer was used for testing with the Y3H 
system. To obtain the ethanol sample, the ethyl acetate layer was transferred into a 4 mL glass 
vial and evaporated to dryness by rotary evaporation. An equal volume of ethanol was added to 
dissolve any FK506 present for subsequent testing. Methanol extraction was performed by 
adding an equal volume of methanol to the culture. The tube was vortexed for 1 h and 
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5.0 Chapter outlook 
The use of metabolically engineered microbes for the biosynthesis of high-value, 
complex chemicals from cheap, renewable feedstocks represents a potentially environmentally-
friendly and low-cost alternative to chemical synthesis. However, there are several limitations in 
relying entirely on this approach, including toxicity of the final product or intermediates, a lack 
of natural enzymes to catalyze certain chemical steps, as well as the time and cost of developing 
a commercially-ready strain for the conversion of feedstock to end product. Thus, several groups 
have established semi-synthetic schemes, combining biosynthesis with chemical synthesis to 
generate efficient and cost-effective routes to compounds, such as the anti-malarial drug 
artemisinin and anti-cancer drug taxol. In this chapter, we report semi-synthetic strategies to 
produce the terpenoids Ambrox, a key component of fragrances traditionally obtained from the 
rare natural source ambergris (sperm whale excrement), and the tocotrienols, Vitamin E 
components with anti-oxidant and anti-cancer properties, as well as their analogs. To make 
Ambrox, we engineered E. coli to produce the unnatural intermediate Z,E-farnesol, followed by 
cyclization by BDSB (bromodiethylsulfonium bromopentachloroantimonate) and IDSI 
(iododiethylsulfonium iodopentachloroantimonate) to form halo-Ambrox, which could be easily 
converted chemically to 9-epi-Ambrox and its analogs. Attempts to engineer yeast to produce 
Z,E-farnesol were unsuccessful but led to the overproduction of the natural isomer E,E-farnesol 
instead. For the tocotrienols, we engineered yeast to express a novel triple enzyme fusion to 
biosynthesize the intermediate E,E,E-geranylgeraniol, which was converted in one step to the 






Natural products are typically secondary metabolites of plants, fungi and bacteria that 
play important roles in signaling, nutrient acquisition and defense1,2. As such, these compounds 
possess significant bioactivities that have made them an indispensable source of pharmaceutical, 
agricultural, nutraceutical, fragrance and industrial compounds3. Traditionally, natural products 
are extracted from natural sources that produce these molecules in low amounts, which make this 
method expensive and largely unsustainable. It has been estimated that the bark of an entire 
Pacific yew tree is needed to yield one dose of the anti-cancer drug paclitaxel (Taxol)4. On the 
other hand, total chemical synthesis is a powerful tool enabling us to access diverse molecules 
and analogs. However, because natural products are often relatively large and complex 
molecules, their total syntheses require multiple steps and are usually not economically viable for 
commercial production5. 
Metabolic engineering of microbes holds the promise of providing an alternative, 
renewable, high-yield source of natural products from low-cost feedstocks6. Microbes that 
naturally produce the compound can be modified to increase the titer, rate and yield of the 
product. Alternatively, genetically tractable hosts such as E. coli and S. cerevisiae, which are 
easy to cultivate, can be engineered by transplanting entire biosynthetic pathways into them to 
produce non-native natural products7. These approaches have been made possible by advances in 
our ability to manipulate DNA and our understanding of cell biology. 
While there have been numerous landmark successes, the majority of these efforts have 
required a tremendous input of time, labor and resources8-10. There is a long developmental lag-
time between a proof-of-principle strain that can produce the compound in low amounts, and a 





knowledge of all the enzymes and regulatory genes that interact with a given pathway. This 
problem can be compounded when the core biosynthetic pathway is only partially elucidated, 
which limits production to natural hosts4. Even if all the enzymes are known, it may be 
challenging to express them and optimize their activity in a heterologous host. For instance, 
cytochrome P450s are notoriously difficult to express in a heterologous host12. Finally, the 
product or intermediates could be toxic to the host cell. 
Given these challenges, many groups have turned to semi-synthetic strategies, combining 
biosynthesis and organic synthesis steps to derive the compound in the most efficient manner. 
Some prominent examples include the anti-malarial drug artemisinin10 and the anti-cancer drug 
Taxol13. In the former case, yeast was engineered to produce artemisinic acid, which was 
converted to artemisinin chemically in four steps. In the case of Taxol, the intermediate 10-
deacetylbaccatin III was extracted from the needles of the Taxus plants and converted in four 
steps to Taxol13, although currently plant cell culture is the more promising approach for the 
production of Taxol14. Semi-synthesis can offer advantages such as stereo- and regioselective 
catalysis by enzymes and the ability to modify biosynthetic intermediates with synthetic 
chemistry to produce non-natural analogs15. 
The terpenoids form a significant class of natural products because a few key 
intermediates can give rise to an incredibly diverse array of molecules16. Terpenoids offer a 
renewable source of next generation biofuels17-19, materials20, and pharmaceuticals4,10. Our first 
target is the terpenoid 9-epi-Ambrox (Fig. 5-1, (1)) and several related derivatives21,22. Ambrox 
is a valuable tricyclic labdane ether component of fragrances, naturally derived from ambergris 
(sperm whale excrement). Due to the ban on whaling, difficulty in obtaining this compound has 





encumbered by long, multi-step reactions and low yield. Furthermore, the majority of reported 
Ambrox analogs contain modifications to just the tetrahydrofuran ring, leaving the remainder of 
the molecule’s core unexplored23. Thus, we have devised a scheme to engineer E. coli / S. 
cerevisiae for the biosynthesis of the linear, unnatural terpenoid intermediate 2Z, 6E-farnesol 
(Z,E-FOH), which can be chemically modified (Fig. 5-2) and cyclized by the halonium-based 
reagents (bromodiethylsulfonium bromopentachloroantimonate) and IDSI (iododiethylsulfonium 
iodopentachloroantimonate) to form halo-Ambrox (Fig. 5-3). The introduction of a halogen 
handle allows for subsequent functionalization and the preparation of novel labdane analogs. 
 
Our second terpenoid target is the group of molecules known as the tocotrienols. 
Together with the tocopherols, they form the Vitamin E family of compounds, which play 
important roles as anti-oxidants and even cardio-protective agents24. Despite the fact that the 
tocotrienols have shown promise as anti-cancer, neuro-protective25 and hypocholesteromic 
agents26, they have received less attention than the tocopherols, which is probably due to their 
scarcity in nature. While racemic α-tocopherol is produced industrially by a single step 
condensation of isophytol with trimethylhydroquinone (TMHQ)27,28, an analogous direct 
synthesis of α-tocotrienol through the condensation of geranyllinalool (GLOH) with TMHQ has 
not been reported. As such, nearly all of the reported racemic29-31 as well as asymmetric32-34 
tocotrienol preparation methods involve the assembly of the molecule in different stages—first 
the construction of the chroman skeleton, followed by addition of the polyene chain. Our strategy 
was to engineer S. cerevisiae for the production of E,E,E-geranylgeraniol (E,E,E-GGOH), 
followed by a one-pot tandem C-C coupling of the geranylgeranyl chain to TMHQ using a novel 





the catalyst system (type II Adanve acid) was employed to achieve regioselective 




5.2.1 Semi-synthesis approach to Ambrox and derivatives 
 
Figure 5-1. Comparison of natural and semi-synthetic routes to 9-epi Ambrox and analogs. (A) 






Previously, other groups have designed semi-synthetic strategies to produce several key 
drug molecules such as the penicillins35, paclitaxel4 and artemisinin10. In each case, an advanced 
intermediate in the pathway was produced by biosynthesis and subject to organic synthesis steps 
to yield the final product. In contrast to this general strategy, we sought to produce biosynthetic 
intermediates that are amenable to chemical modification and are versatile, in order to enable 
access to a greater number of end products. Importantly, the intermediate need not occur 
naturally in the biosynthetic pathway towards the target molecule. 
 
 
Figure 5-2. Scheme to derive 3-Z,E-homofarnesol from (a) Z,E-FOH and (b) E,E-FOH.  
 
Z,E-FOH is an unnatural terpenoid molecule that is expensive (~$700 per mg, Sigma 





cerevisiae to ensure a cheap and renewable source of Z,E-FOH (Fig. 5-4). As an intermediate, 
Z,E-FOH can be efficiently homologated to 3-Z,E-homofarnesol (Fig. 5-2) and cyclized by 
halonium-donating reagents BDSB and IDSI to form halo-Ambrox (Fig. 5-3). This can be easily 
converted into 9-epi-Ambrox and other analogs. We also explored the use of the natural isomer 
of Z,E-FOH, all-trans-farnesol (E,E-FOH), as a starting material for chemical synthesis37. 
Although only two steps are required to derive homofarnesol, a mixture of E,E-homofarnesol 
and Z,E-homofarnesol (ratio of 2:1) was produced, which required a tedious separation step to 
obtain the desired, pure Z,E-homofarnesol (Fig. 5-2). Thus, it is advantageous to biosynthesize 






Figure 5-3. Scheme for cyclization of homofarnesol to halogenated 9-epi Ambrox and further 
derivatization to novel analogs. 
 
5.2.2 Biosynthesis of Z,E-farnesol in E. coli 
In prokaryotes like E. coli, the building blocks for terpenoid synthesis, isopentenyl 
diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), are generated by the 2-C-methyl-D-
erythritol 4-phosphate (MEP) pathway, whereas in eukaryotes, the mevalonate (MVA) pathway 
is responsible (Fig. 5-4). The condensation of IPP and DMAPP, which is catalyzed by trans-
farnesyl pyrophosphate synthase (trans-FPPS), produces geraniol pyrophosphate (GPP). A 
second condensation of GPP with IPP, which is catalyzed by the same enzyme trans-FPPS, 
produces E,E-farnesyl pyrophosphate (E,E-FPP), which can be dephosphorylated by endogenous 
phosphatases to produce E,E-FOH38. 
 
To engineer E. coli for the production of Z,E-FOH, the enzymes in the MEP pathway 
from Bacillus subtilis (dxs, dxr, ispD, ispF, ispG, ispH and idi) were codon-optimized and 
overexpressed using the IPTG-inducible pLac promoter. It has been shown that B. subtilis dxs 
and dxr possess higher activity than their E. coli homologs39. Next, we heterologously expressed 
cis-farnesyl pyrophosphate synthases (cis-FPPSs) from several bacteria (Mycobacterium 
tuberculosis, Thermobifida fusca, Corynebacterium glutamicum, and Corynebacterium efficiens) 
in our host strain40,41. cis-FPPS catalyzes the same reactions as trans-FPPS but produces the 







Figure 5-4. Biosynthetic pathways for the production of Z,E-FOH and E,E-FOH. (A) E. coli and (B) 
S. cerevisiae. 
 
We tested the strains in shake flasks (small scale production trials) and found that the M. 
tuberculosis cis-FPPS (Rv1086) and C. glutamicum cis-FPPS produced Z,E-FOH, at levels at 
least four-fold higher than the natural isomer E,E-FOH (Fig. 5-5, Fig. 5-11, Fig. 5-13). Rv1086 
resulted in the highest yield of Z,E-FOH (8 mg/L) compared to the C. glutamicum enzyme (~ 1 
mg/L). Finally, we scaled-up production of the Rv1086 strain in a 6 L, bench-top vessel, which 
produced ~ 3 mg/L (Fig. 5-5, Fig. 5-12, Fig. 5-14). During the course of our experiments, an 





containing an exogenous MVA pathway led to production of 7.7 mg/L of Z,E-FOH42. The group 
further fused the E. coli trans-FPPS (IspA) to Rv1086, which led to 115.6 mg/L of Z,E-FOH. 
The authors hypothesized that the enzyme fusion led to higher titers than expressing the enzymes 
separately because the intermediate GPP produced by ispA was channeled more effectively to 
Rv1086. 
 
Figure 5-5. Production yields of Z,E-FOH and E,E-FOH in E. coli expressing different Z,E-FPPSs. 
Production yields are reported as mg/L of media. The production yield for FPP2/A8 (E. coli containing 
the M. tuberculosis Z,E-FPPS Rv1086) is reported for bench-scale production (represented by the jar) and 
flask production. Error bars represent the standard error of four replicates.  
 
 
5.2.3 Biosynthesis of E,E-farnesol in S. cerevisiae 
 We also attempted to engineer the yeast S. cerevisiae for the production of Z,E-FOH, to 





FPPS from T. fusca) for yeast expression as these two enzymes were reported to have the highest 
Kcat/Km values out of the four bacterial trans-FPPSs
40. We constructed high-copy plasmids 
containing Rv1086 or Tfu0456 alone, under control of the strong, constitutive PGK1 promoter, 
or plasmids containing the trans-FPPSs fused to DPP1 (either at the C- or N-terminus) via a 
GGGS linker (Table 5-2). DPP1 is an endogenous phosphatase that is thought to hydrolyze 
FPP/GGPP into FOH/GGOH43. 
 
First, we overexpressed a truncated version of the rate-limiting enzyme in the mevalonate 
pathway, HMG-CoA reductase (tHMG1), in the yeast strain ATCC200589, which has been 
reported to lead to high prenyl alcohol yields44. We tested several colonies and found two 
populations of strains, one that produced ~ 10-fold higher levels of E,E-FOH, nerolidol (NOH), 
GGOH and squalene overall (high-AN-ZE1-T7) than the other (low-AN-ZE1-T7) (Fig. 5-6). 
Next, we transformed the plasmids overexpressing Rv1086 or Tfu0456 alone into the yeast strain 
high-AN-ZE1-T7 to create AN-ZE5-T2 and AN-ZE5-T1 respectively. However, we did not 
manage to detect any Z,E-FOH production in both strains. Instead, both strains produced high 
levels of squalene (2-3 mg/L) and low levels (<0.3 mg/L) of E,E-FOH (Fig. 5-6). When we 
transformed the trans-FPPS-DPP1 fusion constructs into high-AN-ZE1-T7, we found that the 
combination ATCC200589/tHMG1/DPP1-Tfu0456 (CP-51) led to high production of E,E-FOH 







Figure 5-6. Production yields of prenyl alcohols in S. cerevisiae strains engineered for Z,E-FOH 
production. Data is plotted on a log scale. In brackets is the number of independent replicates from which 
the average values and error bars were derived. Error bars represent one standard deviation. 
 
In addition, CP-51 produced comparable levels of NOH and GGOH as the background 
strain high-AN-ZE1-T7, but a ten-fold lower amount of squalene (Fig. 5-6). This effect could be 
due to the overexpressed DPP1 within the fusion construct acting on E,E-FPP to produce E,E-
FOH, which reduces the pool of FPP available for squalene synthase to produce squalene. This 
effect was also observed for the other three trans-FPPS-DPP1 combinations (strains: EA-14, EA-
3 and AN-ZE2-T3). All three produced E,E-FOH (~0.2 mg/L) and GGOH (~0.2 mg/L) at 
comparably low levels as low-AN-ZE1-T7, but did not produce any detectable amounts of 
squalene as compared to low-AN-ZE1-T7 (~0.2 mg/L) (Fig. 5-6). 
 
Finally, in our CP-51 fermentations, we observed a significant side peak at retention time 












our synthetic Z,E-FOH standard (Fig. 5-15). This unidentified side peak was also present in the 
background strain high-AN-ZE1-T7. Furthermore, we occasionally observed this side peak in 
our initial E. coli fermentations performed without decane, which disappeared when we used 20 
% decane as an overlay (Fig. 5-12). This suggested to us that the side peak was due to Z,E-FOH 
and/or E,E-FOH interacting with components in the media or breaking down. Unfortunately, we 
could not test our yeast strains with 20 % decane as their growth was severely impaired when >5 
% decane was added (data not shown). We also tested alternative surfactants such as isopropyl 
myristate for our yeast fermentations to sequester the prenyl alcohol products. However, we and 
our collaborators at Acidophil found that isopropyl myristate stuck to the GC-MS columns, and 
thus could not be used to quantify the products. Our failure to produce Z,E-FOH in yeast could 
also be due to the codon-optimized versions of Rv1086 and Tfu0456 being non-functional in 
yeast. 
 
5.2.4 Semi-synthesis approach to the tocotrienols (Vitamin E) 
 Our semi-synthetic scheme to produce the tocotrienols involves harnessing yeast to 
produce the linear terpenoid E,E,E-geranylgeraniol (E,E,E-GGOH) (Fig. 5-7). E,E,E-GGOH is 
used as a component of fragrances and as a starting material for the production of vitamins and 
other terpenes. Thus there is pharmaceutical and industrial interest in deriving renewable and 
cost-efficient sources of GGOH7. Next, we developed a novel Lewis acid—Phase Transfer 
Catalyst system (type I Adanve acid) to perform the one-pot tandem C-C coupling of the 
geranylgeranyl chain to TMHQ. Furthermore, a Bronsted acid version of the catalyst system 
(type II Adanve acid) was employed to achieve regioselective cycloetherification of 3-






Figure 5-7. Semi-synthesis scheme for the production of the tocotrienols. (A) Engineered yeast for 
the biosynthesis of E,E,E-geranylgeraniol followed by one-step coupling with TMHQ to form the 
tocotrienols. (B) Regioselective cycloetherification of 3-geranylgeranylhydroquinones to the tocotrienols 
catalyzed by type II Adanve acids. (C) Asymmetric chroman synthesis catalyzed by type II Adanve acids. 
 
5.2.5 Biosynthesis of E,E,E-geranylgeraniol in S. cerevisiae 
In yeast, E,E,E-GGOH is derived from the mevalonate pathway. Farnesyl pyrophosphate 
synthase (ERG20) catalyzes the formation of E,E-FPP from IPP and DMAPP. Geranylgeranyl 
pyrophosphate synthase (BTS1) catalyzes the condensation of E,E-FPP and IPP to form 
geranylgeranyl pyrophosphate (GGPP), which can be hydrolyzed by endogenous phosphatases 





in the strain ATCC200589 and AURGG101 (ATCC200589 with mutations in the AUR1C 
gene)44. This was increased to 2.3 mg/L of GGOH in AURGG101 upon overexpression of 
HMG1 or a truncated version of HMG1 (Δ1192–1266). GGOH production has also been 
reported to be achieved by the use of squalene synthase and phytoene synthase inhibitors in the 
carotenoid producing yeast Rhodotorula rubra45. 
 
Figure 5-8. Biosynthetic pathway for the production of E,E,E-geranylgeraniol in S. cerevisiae. 
 
Recently, high-level GGOH production has been reported to be achieved via the use of 





fusions are thought to promote substrate channeling by increasing the proximity between the 
active sites of sequential enzymes, thus reducing diffusive loss of the substrate/product between 
different steps of the pathway48. A diploid prototroph (background YPH499) overexpressing 
HMG1 and the double fusion ERG20-BTS1 was reported to produce 138 mg/L GGOH in a 5 L 
fermenter, but this strain also produced 60 mg/L of squalene46. Later, the group engineered 
YPH499 to overexpress HMG1 and the two double fusion constructs BTS1-DPP1 and BTS1-
ERG20, which they report to produce 3.3 g/L GGOH under optimal conditions in a fermenter47. 
 
In this study, we attempted to express a novel triple fusion construct (DPP1-BTS1-
ERG20) as well as the two double fusions (DPP1-BTS1 and BTS1-ERG20) in the previously 
reported YPH499 strain, and also another background: AN159Y (ATCC200589 engineered with 
the AUR1C mutation using CRISPR). First, we overexpressed a truncated version of the rate-
limiting enzyme in the mevalonate pathway, HMG-CoA reductase (tHMG1), in both 
backgrounds, which led to low level (< 1 mg/L) GGOH production (Fig. 5-9). Next, we found 
that co-expression of the two double fusions (DPP1-BTS1 and BTS1-ERG20) led to the 
production of ~ 5 mg/L GGOH in the background strain YPH499 (strain AN-GG1-T3) but not 
AN159Y (AN-GG2-T5) (Fig. 5-9). This yield was more than doubled to ~ 13 mg/L when we 
overexpressed the triple fusion of DPP1-BTS1-ERG20 in AN159Y/tHMG1 (strain AN-GG2-T3) 






Figure 5-9. Production yield of GGOH in engineered yeast strains. D-B: DPP1-BTS1 double enzyme 
fusion.  B-E: BTS1-ERG20 double enzyme fusion.  D-B-E: DPP1-BTS1-ERG20 triple fusion.  Extracted 
yields are reported in mg/L of growth media.  For each strain, the number in brackets indicates the 
number of independent transformant colonies tested, except for AN159Y/tHMG1/D-B-E (AN-GG2-T3), 
where five independent colonies derived from a streak of one original transformant colony were tested.  
Error bars represent one standard deviation. 
 
Both AN-GG1-T3 (double fusion) and AN-GG2-T3 (triple fusion) produced E,E-FOH at 
approximately ten-fold lower amounts than GGOH, compared to the background strains 





10). This suggests that the enzyme fusion constructs, if properly expressed, can help in substrate 
channeling for GGOH production. 
 
 
Figure 5-10. Production yield of prenyl alcohols in yeast strains engineered for GGOH production. 








Prenyl alcohols such as E,E-FOH, NOH and E,E,E-GGOH are attractive targets for 
metabolic engineering, as they have a variety of uses, such as starting materials for fragrances, 
vitamins and pharmaceuticals49. Our results show that in yeast, overexpression of tHMG1 under 
the strong, constitutive TEF1 promoter (AN-ZE1-T7) can increase the overall production of the 
downstream terpenoids E,E-FOH, NOH, GGOH and squalene (Fig. 5-6). However, out of six 
independent transformants (colonies) of AN-ZE1-T7 screened, two produced a 10-fold higher 
yield of the terpenoids (high-AN-ZE1-T7) compared to the other four (low-AN-ZE1-T7). Also 
for GGOH production, the strains AN-GG1-T4 (triple fusion in YPH499) and AN-GG2-T5 
(double fusions in AN159Y) did not produce any detectable GGOH, which was surprising given 
that the same plasmids, when transformed into the alternate strain background led to production 
(Fig. 5-6). Furthermore, we observed a generally low transformation efficiency with the triple 
fusion plasmids (only four colonies for AN-GG2-T3 and two colonies for AN-GG1-T4). Out of 
the four colonies for AN-GG2-T3, only one led to GGOH production. 
These results suggest that colonies from the same transformation attempt can exhibit large 
differences in production phenotypes, which could be due to reasons such as mutations, 
differences in plasmid copy number and/or imbalance in pathway flux. Therefore, when testing 
various constructs on plasmids, it is important to screen several colonies to account for this 
variability. Alternatively, chromosomal integration of the genes can help to reduce variability 
and increase strain stability. Also, there could be problems with the folding of the enzyme fusion 
constructs or natural selection for spontaneous mutations that prevent the expression of the 
fusion constructs, since these are expressed on high copy plasmids and are likely to impose a 





at a lower temperature (e.g. 28 ºC) to improve folding, using low copy plasmids, and tuning the 
expression levels of the enzyme constructs using promoter libraries. Despite this, the colonies 
that produced GGOH consistently did so across multiple replicate fermentations, which suggests 
that enzyme folding is not an issue. 
E,E-FPP and E,E,E-GGPP are natural intermediates downstream of the MEP pathway in 
E. coli and the MVA pathway in S. cerevisiae (Fig. 5-8). In yeast, two E,E-FPP molecules are 
joined by squalene synthase (ERG9) to form squalene, which is the first committed step in the 
ergosterol biosynthesis pathway. Thus, the majority of engineering efforts in yeast for the 
production of E,E-FOH and other terpenes have traditionally relied on ERG9 repression or 
mutated (non-functional) ERG9 combined with overexpression of specific terpene 
synthases/cyclases to divert flux to the production of terpenoids of interest10,50. However, this 
approach often requires supplementation of the media with ergosterol, an essential component of 
yeast cell membranes, which adds to fermentation costs. Possible ways to circumvent this 
requirement may be to improve substrate channeling through co-localization or fusions of the 
enzymes in the pathway, or introducing a highly active downstream enzyme that can compete 
effectively with ERG9 for the substrate FPP. In our yeast engineering efforts for Z,E-FOH 
production, we observed that expression of enzyme fusions containing the phosphatase DPP1 
resulted in a significant drop in squalene levels (Fig. 5-6). This may be due to substrate 
channeling or DPP1 sequestering FPP and decreasing the pool of FPP for squalene synthesis. 
Next, since Z,E-FPP is a non-natural isomer of E,E-FPP in E. coli and S. cerevisiae, it 
could form a possible orthogonal pathway for the synthesis of unnatural isomers of natural 





biochemistry and cell biology, such as the enantioselectivity of enzymes, and whether unnatural 
metabolite isomers are functional in the cell. 
Finally, the production yields reported in this work are based on mg/L of growth media 
and not of the extract. It has been shown that a significant proportion of FOH and GGOH remain 
stuck within the cell or in the cell membrane even with the addition of soybean oil as a 
surfactant51. Thus, actual production yields are likely to be higher.  Furthermore, during our 
bench-scale production of GGOH using the strain AN-GG2-T3, we noticed that the yield of 
GGOH was lower (about 6 mg/L from one trial, data not shown) than that obtained from small-
scale flask fermentations (~13 mg/L). This was probably due to a lack of proper control of 
aeration, pH, mixing and nutrient availability in our crude setup. Further optimization of these 
factors during scale-up can lead to significant increases in production yield47. 
 
5.4 Experimental methods 
Culture media.  LB media was made from Miller powdered mix (broth:10285, plates:10283), 
TB media was made from BD-Difco powdered mix (243820). 99 % glycerol (G5516), D-(+)-
glucose (G7021), ampicillin sodium salt (A0166) and spectinomycin dihydrochloride 
pentahydrate (S40014) were purchased from Sigma-Aldrich. YPD media (1 L): 10 g BD Bacto 
Yeast Extract (212750), 20 g Bacto Peptone (211677), dH2O to 950 mL, autoclave; when cooled 
to 50 ºC add 50 mL 40 % glucose. For yeast SC selective media, see Table 5-4 and 5-5. 
 
Strain construction for Z,E-FOH production.  BL21 (DE3) cells were made competent using 
CaCl2
52 and transformed with plasmid pA8 (carrying an IPTG-inducible subset of the B. subtillis 





inducible promoter. The four Z,E-FPPSs were derived from various species of bacteria and 
codon-optimized for expression in E. coli: M. tuberculosis/RV1086 (pFPP2), T. fusca/Tfu0456 
(pFPP3), C. efficiens/CE1055 (pFPP4) and C. glutamicum/uppS1 (pFPP5). E. coli transformants 
were selected on LB plates containing 50 mg/L spectinomycin (for pA8) and 100 mg/L 
ampicillin (for pFPPs). The yeast strain ATCC200589 was obtained from the American Type 
Culture Collection, Rookville. The other strains used in this study (see Table 5-1) were 
constructed by transforming various plasmids (see Table 5-2) into the background strain 
ATCC200589. All yeast transformations were performed according to established protocols53. 
 
Strain construction for E,E,E-GGOH production.  The yeast strain YPH499 (ATCC76625) 
was obtained from the American Type Culture Collection, Rookville. AN159Y which contains 
mutations (F158Y and A240C) in the AUR1C gene of ATCC20058944 was constructed by the 
CRISPR method54. In brief, pAN70 (a kind gift from the Church lab) containing yeast codon-
optimized Cas9 under a constitutive TEF1p promoter was transformed into ATCC200589. A 
guide RNA (gRNA) plasmid, pAN151, was constructed to target Cas9 to AUR1C. A repair 
fragment (for homology-directed repair) containing the desired mutations was created by PCR of 
AUR1C in 3 parts using ATCC200589 genomic DNA as template and the following primer 
pairs: AUR1C-a: AN627/AN628; AUR1C-b: AN629/AN630; AUR1C-c: AN631/AN632. The 
three parts were fused by PCR using the external primers AN627/AN632. pAN151 (500 ng) and 
the repair fragment (2 µg) were transformed into the previously obtained ATCC200589/pAN70-
Cas9 colonies and plated on SC agar plates lacking histidine, tryptophan and uracil. Correct 
clones were confirmed by PCR of genomic DNA (YeaStar Genomic DNA Kit, Zymo Research). 





Table 5-1) were constructed by transforming various combinations of plasmids (see Table 5-2) 
into either of the background strains AN159Y or YPH499.  
 
Plasmid construction for Z,E-FOH production.  Four Z,E-FPPSs previously identified in four 
species of bacteria (M. tuberculosis:RV1086, T. fusca:Tfu0456, C. efficiens:CE1055, and C. 
glutamicum:uppS1)40 were codon-optimized for expression in E. coli and synthesized 
commercially by DNA 2.0 Inc. Each of the four Z,E-FPPSs was amplified by PCR to add NcoI 
and XhoI restriction sites on the 5’ and 3’ ends respectively. The resulting amplicons and pTrc2B 
vector were digested with NcoI and XhoI, and the construct inserted via InFusion cloning 
(Clontech), to create the four IPTG-inducible Z,E-FPPS expression plasmids pFPP2, pFPP3, 
pFPP4 and pFPP5. The cloning mix was transformed into electrocompetent E. coli TG1 cells and 
selected on LB/ampicillin agar plates. This cloning was performed by our collaborator Acidophil 
LLC. Plasmid pA8 containing the B. subtilis MEP pathway was also constructed by Acidophil. It 
consists of a pCL1920 backbone55 with a replication origin from pSC1010 and carrying a 
spectinomycin resistance cassette. It contains the B. subtilis MEP genes dxs, dxr, ispD, ispF, 
ispG, ispH and idi, which were codon-optimized for E. coli expression. The genes were cloned 
under the IPTG-inducible pLac promoter. B. subtilis genes were chosen due to the higher flux 
through the MEP pathway in B. subtilis compared to E. coli39. 
 
The general strategy adopted for the construction of yeast expression plasmids was: (1) PCR of 
the individual parts (see Table 5-3 for primers), (2) overlap/fusion PCR (external primers 
AN409 and AN412 for all plasmids except pAN127) to create a transcriptional unit (TU) 





cut plasmid backbone, and (4) transformation of the Gibson mixture into E. coli TG1 cells for 
selection on LB/ampicillin plates and amplification prior to transforming into S. cerevisiae. 
 
pAN96 was constructed by Gibson assembly of the vector pRS41656 digested with SacI and 
KpnI, and PCR products of the promoter and terminator, as well as synthetic double-stranded 
gene fragments (gblock-1 and gblock-2, Integrated DNA Technologies) coding for yeast codon-
optimized Tfu0456 containing an N-terminal His6-tag and TEV cleavage site (Table 5-3). 
pAN99 was constructed via the same strategy but using gblock-3 and gblock-4 coding for yeast 
codon-optimized Rv1086 containing an N-terminal His6-tag and TEV cleavage site. pAN193 and 
pAN194 were constructed by Gibson assembly of the vector pRS426 digested with SacI and 
KpnI and the PCR amplified transcriptional units from pAN96 and pAN99 respectively (primers 
AN409 and AN412). 
 
The plasmids pAN137 and pCP51 containing the enzyme fusions were constructed by Gibson 
assembly of SacI and KpnI-digested pRS426 with a fusion PCR product containing the promoter, 
N-terminal His6-tag and TEV cleavage site, DPP1, GGGS linker, Rv1086 or Tfu0456 and 
terminator amplified from pAN99/pAN96 respectively. For these two plasmids, the N-terminal 
His6-tag and TEV cleavage site were created by primer extension (primers AN466 and AN467) 
followed by a second round of PCR with the primers AN468 and AN469. The plasmids pAN138 
and pAN141 were constructed by Gibson assembly of SacI and KpnI–digested pRS426 with a 
fusion PCR product containing the promoter, Z,E-FPPases amplified from pAN96/pAN99 






Plasmid construction for E,E,E-GGOH production.  The strategy adopted for the construction 
of the yeast expression plasmids pAN117, pAN119, pAN127 and pAN128 (see Table 5-2) was: 
(a) PCR of the individual parts (see Table 5-3 for primers and parts), (b) fusion PCR (external 
primers AN409/AN412 for pAN117/pAN119; AN568/AN569 for pAN127/pAN128) to create a 
transcriptional unit (TU) composed of the promoter, ORF and terminator, (c) Gibson assembly 
(NEB, E2611S) to insert the TU into the cut plasmid backbone (pRS426 digested with SacI and 
KpnI for pAN117/pAN119; pRS424 digested with SacI and KpnI for pAN127/pAN128), (d) 
transformation of the Gibson mixture into electro-competent E. coli TG1 cells followed by 
selection on LB/ampicillin plates, (e) testing of colonies by amplification in LB/ampicillin media 
overnight followed by plasmid extraction (Miniprep kit, Qiagen), sequencing and restriction 
analysis to determine correct constructs. 
 
pAN120 was constructed by Gibson assembly of the vector pAN117 (digested with KpnI) and 
PCR products of PGK1 (AN536/AN540) and BTS1-ERG20 (AN541/AN537) using pAN119 as 
a template. pAN151 was constructed by PCR of SNR52p (AN318/AN625) and SUP4t 
(AN626/AN321) using a CAN1-gRNA plasmid as template (kind gift from the Church lab), 
followed by fusion PCR, restriction digestion (SacI/XhoI) and ligation into SacI/XhoI-digested 
pRS426. 
 
Small scale production trials for E. coli Z,E-FOH production.  E. coli farnesol production 
was performed in sterilized, baffled, 125 mL Erlenmeyer flasks (Corning 4444-125) with culture 
caps (KimKap 73665-25) in an incubator shaker (New Brunswick, Innova 43R). On Day 1, a 





mg/L ampicillin and 50 mg/L spectinomycin. The culture was shaken at 37 C and 230 rpm for 
15 hours. On Day 2, 0.5 mL of the saturated overnight culture was added to 50 mL of LB with 
1% glycerol, 100 mg/L ampicillin and 50 mg/L spectinomycin. The flasks were grown at 30C 
and 230 rpm until they reached an optical density (OD600) of approximately 1.5 (4-6 hrs) as 
determined by a 1:10 dilution of the culture in LB media. OD600 measurements were carried out 
in a SpectraMaxPlus 384 spectrophotometer using 1.5 mL cuvettes (VWR, 97000-586). At this 
point, IPTG was added (0.2 mM) to induce expression of the MEP pathway components and 
Z,E-FPPS. An overlay of 4.5 mL of decane (95 %, Sigma 30570) was added at the time of 
induction. The culture was harvested on Day 3 after 24 hours post-induction. 
 
Small scale production trials for S. cerevisiae Z,E-FOH and E,E,E-GGOH production.  
Yeast prenyl alcohol production was performed in sterilized, 50 ml Erlenmeyer flasks (VWR) in 
an incubator shaker (New Brunswick, Innova 43R) at 30 ºC and 230 rpm for a total of 7 days. On 
Day 1, 0.3 ml of saturated, overnight culture grown in selective SD media was added to 2.7 ml of 
SD or YPD media. On Day 2, 3 ml of YPD and 150 µl of decane (final concentration of 2.5 %) 
were added. On Day 3, 4 ml of YPD and 100 µl of decane were added. Cultures were harvested 
on Day 8 after incubation for 7 days. As a measure of cell growth, the final optical density 
(OD600) was determined by 10-fold dilution of the culture broth with YPD. 
 
Bench scale production for Z,E-FOH production.  Bench scale E. coli production was 
performed in a Bellco 6 L Low Profile Vertical Sidearm Bioreactor vessel. Filtered air was 
supplied via a sidearm sparger, and vented via two exit ports equipped with moisture traps. The 6 





was achieved by the sparged air. There was no control of dissolved oxygen, pH, nutrient 
availability or culture volume. Bench scale production was attempted only with the FPP2/A8 E. 
coli strain. Briefly, on Day 1, a single colony was inoculated into a 14 mL Falcon culture tube 
containing 3 mL LB with 100 mg/L ampicillin and 50 mg/L spectinomycin, and grown at 37 C 
and 230 rpm for 8 hours. The 3 mL culture was then used to inoculate 25 mL of the same media 
and incubated for 15 hours at 37 C and 230 rpm. On Day 2, the 25 mL overnight culture was 
added to 2.5 L of TB broth and 1 % glycerol (autoclaved at 250 F for 45 minutes on Day 1) in a 
6 L vessel, along with 400 µl of Sigma Antifoam-400, 100 mg/L ampicillin and 50 mg/L 
spectinomycin. The culture was grown until it reached an OD600 of approximately 0.3 (4-6 
hours), at which time 0.2 mM IPTG was added to induce expression of the Z,E-FPPS RV1086 
and MEP pathway components. 375 mL of decane was added to the 6 L vessel at the time of 
induction to form an overlay. Pulses of glycerol (25 mL, 1 % of final vol) were added at 8 and 16 
hours post-inoculation. At 24 hours post-inoculation, 1 L of TB media containing the 
aforementioned concentrations of IPTG and antibiotics was added to replace media lost from the 
6 L vessel. A further 250 mL of decane was also added at this time to replenish the overlay. 6 L 
vessels were collected and extracted at 48 hours post-induction. 
 
Bench scale production for E,E,E-GGOH production.  The same setup as for E. coli was 
used. On Day 1, 100 mL of starter culture grown for 2 days was added to 2 L of YPD to start the 
fermentation. On Day 2, 1 L of YPD and 50 mL of decane were added. On Day 3 and Day 6, 







Prenyl alcohol extraction for E. coli.  Small scale flask fermentations were transferred into a 50 
mL falcon tube. The inside of the flask was rinsed with 5 mL of ethyl acetate (99.5 %, Sigma 
437549), and combined with the fermented broth. 1 mL of brine was added to aid separation. 
The tube was vortexed vigorously for 4 x 30 seconds. The tube was then centrifuged at 3200 rpm 
for 10 minutes and the top organic layer was filtered and transferred to a glass GC-MS vial for 
analysis. Bench scale fermentations were transferred into a 2 L separation funnel in batches of 1 
L. 500 mL of ethyl acetate and 20 mL of brine were added to each batch in the funnel, and the 
contents shaken vigorously. Separation was allowed to occur and the aqueous layer was removed 
and re-extracted once more as above. The organic layer was transferred into centrifuge tubes and 
spun at 4000 rpm for 10 minutes to break the emulsion. The top organic layer was recovered, 
combined with organic layers from other batches and rotavapped to remove the ethyl acetate. 
The concentrated product was dissolved in hexane for analysis (99 %, Sigma 32293). 
Prenyl alcohol extraction for S. cerevisiae.  For small-scale fermentation trials, 1 ml of the 
final culture broth was removed for pH and OD600 measurements. The remainder of the culture 
(~8.4 ml) was transferred into a 15 ml falcon tube. 1 ml of brine and 2 ml of hexane were added. 
The tube was placed horizontally in an incubator shaker (230 rpm) for 1 hour to mix. The 
mixture was centrifuged at 3200 rpm for 10 min and the top hexane layer was filtered and 
transferred into a glass GC-MS vial for analysis. For bench-scale production, 8.4 ml of the broth 
was sampled as above and analyzed by GC-MS after 7 days. The remainder of the broth was 
mixed in batches with ethyl acetate and transferred into a 2 L-separating funnel. The organic 
layer was collected, dried (MgSO4) and concentrated under reduced pressure. The resulting 
concentrate was purified on silica gel to yield an oil, which was weighed and its identity further 





Analysis of prenyl alcohols.  Z,E-FOH, E,E-FOH, nerolidol, GGOH and squalene were 
analyzed using a ThermoFinnigan PolarisQ GC-MS (Agilent J&W column, #CP8907, VF-1 ms 
15 m X 0.25 mm x 0.25 µm) at NYU. The instrument was acquired through the support of the 
National Science Foundation under Award number DUE-0126958. GC-MS runs were carried out 
with the following method: MS: ion source 225 ºC, EI/NICI, mass range 50-600. GC: helium 
gas, 1.2 ml/min, inlet temperature 225 ºC, initial column temperature 50 ºC, hold 2.5 minutes, 
raise at 17 ºC/min to 285 ºC, hold 3.5 minutes. 
For quantitative analysis of E. coli fermentations, cis-nerolidol (96 %, Sigma 72180) was 
used as an internal standard. A standard concentration curve was created by graphing the ratio of 
the total ion counts (TIC) area of the E,E-FOH (96 %, Sigma 277541) peak to the TIC area of the 
25 mg/L cis-nerolidol peak for a range of E,E-FOH concentrations. To determine the 
concentration of Z,E-FOH in the biosynthesis extracts, each sample was dosed to achieve a final 
concentration of 25 mg/L cis-nerolidol. The equation of the linear regression of the standard 
curve was used to calculate the concentration of Z,E-FOH42. The production values were back 
calculated and reported as mg/L of culture media. Specifically, the total amount of extracted Z,E-
FOH was calculated by multiplying the determined concentration by the volume of the extract. 
This was then divided by the total volume of culture to determine production yield in mg/L of 
media. 
For quantitative analysis of S. cerevisiae fermentations, undecanol was used as an 
internal standard. The ratio of the selected ion peak area (67 mass fragment) of 25 mg/L 
undecanol to that of 25 mg/L of authentic standards was used as a standard ratio. The amount of 
prenyl alcohol in a sample was determined by comparison of this ratio to the ratio in a sample 





5.5 Strains, plasmids, oligonucleotides and media 
 





FPP2/A8 DH5(DE3)/pA8/pFPP2 This study 
FPP3/A8 DH5(DE3)/pA8/pFPP3 This study 
FPP4/A8 DH5(DE3)/pA8/pFPP4 This study 
FPP5/A8 DH5(DE3)/pA8/pFPP5 This study 
ATCC200589 MATalpha can1 leu2 trp1 ura3 aro7 ATCC 
AN-ZE1-T7 ATCC200589/pAN127-tHMG1 This study 
AN-ZE5-T1 ATCC200589/pAN127-tHMG1/pAN193-Tfu0456 This study 
AN-ZE5-T2 ATCC200589/pAN127-tHMG1/pAN194-Rv1086 This study 
CP-51 ATCC200589/pAN127-tHMG1/pCP51-DPP1-Tfu0456 This study 
EA-3 ATCC200589/pAN127-tHMG1/pAN137-DPP1-Rv1086 This study 
EA-14 ATCC200589/pAN127-tHMG1/pAN138-Tfu0456-DPP1 This study 
AN-ZE2-T3 ATCC200589/pAN127-tHMG1/pAN141-Rv1086-DPP1 This study 
YPH499 
(ATCC76625) 
MATa ura3-52 lys2-801 ade2-101 trp1-Δ63 his3-Δ200 leu2-Δ1 ATCC 




AN-CP4-S1 YPH499/pAN127-tHMG1 This study 
AN-CP2-S4 AN159Y/pAN127-tHMG1 This study 
AN-GG1-T3 YPH499/pAN127-tHMG1/pAN120-DPP1-BTS1/BTS1-ERG20 This study 
AN-GG1-T4 YPH499/pAN127-tHMG1/pAN119-DPP1-BTS1-ERG20 This study 
AN-GG2-T3 AN159Y/pAN127-tHMG1/pAN119-DPP1-BTS1-ERG20 This study 







Table 5-2. Plasmids used in this study. 
 








pLac-(dxs, dxr, ispD,ispF, idi, 
ispH) –T1 
E. coli codon-optimized MEP 





E. coli codon-optimized Z,E-





E. coli codon-optimized Z,E-





E. coli codon-optimized Z,E-





E. coli codon-optimized Z,E-
FPPase from C. glutamicum 








URA3 PGK1p-Rv1086-ADH1t Codon optimized Rv1086 
pAN193 2µ, yeast URA3 PGK1p-Tfu0456-ADH1t Codon optimized Tfu0456 
pAN194 2µ, yeast URA3 PGK1p-Rv1086-ADH1t Codon optimized Rv1086 
pAN137 2µ, yeast URA3 PGK1p-DPP1-Rv1086-ADH1t Fusion of DPP1-Rv1086 
pAN138 2µ, yeast URA3 PGK1p-Tfu0456-DPP1-ADH1t Fusion of Tfu0456-DPP1 
pAN141 2µ, yeast URA3 PGK1p-Rv1086-DPP1-ADH1t Fusion of Rv1086-DPP1 




TRP1 TEF1p-Cas9-CYC1t Gift from Di Carlo, Church lab 
pAN151 2µ, yeast URA3 SNR52p-cr17-gRNA-SUP4t 
CRISPR gRNA plasmid to 
create AUR1C mutation 
pAN127 2µ, yeast TRP1 TEF1p-tHMG1-ACT1t Truncated HMG1 
pAN128 2µ, yeast TRP1 TEF1p-HMG1-ACT1t Wild-type HMG1 










pAN120 2µ, yeast URA3 
PGK1p-DPP1-BTS1-ADH1t / 
PGK1p-BTS1-ERG20-ADH1t-rev 
Two double fusions DPP1-









Table 5-3. Primers and dsDNA gene fragments (gblocks) used in this study. 
 
Name Plasmid Template Sequence (5’ – 3’) 
AN569 pAN127 TEF1p-F 
CACTAAAGGGAACAAAAGCTGGAGCTATAGCTTCAA
AATGTTTCTACTCC 
AN387 pAN127 TEF1p-R 
GTTTTCACCAATTGGTCCATAAACTTAGATTAGATTGC
TATGCT 
AN388 pAN127 tHMG1-F 
TAGCAATCTAATCTAAGTTTATGGACCAATTGGTGAA
AACTGAAG 
AN401 pAN127 tHMG1-R 
TACGCGCACAAAAGCAGAGATTAGGATTTAATGCAG
GTGACGG 
AN402 pAN127 ACT1t-F TCACCTGCATTAAATCCTAATCTCTGCTTTTGTGCGCG 





































































































































AN471 pAN137 DPP1-R 
TAATCTCCATAGAACCACCACCCATACCTTCATCGGA
CAAAGGATG 
AN472 pAN137 Rv1086-F 
AGGTATGGGTGGTGGTTCTATGGAGATTATTCCTCCA
AGATTGAA 
AN473 pAN137 Rv1086-R 
CATAAGAAATTCGCTTATCGACCGTAAGATCTATGAC
G 
AN474 pAN137 ADH1t-F 
CTTACGGTCGATAAGCGAATTTCTTATGATTTATGATT
TTTAT 
AN480 pAN138 PGK1p-R 
GTGATGATGATGGTGCATTTGTTTTATATTTGTTGTAA
AAAGTAGATAATTAC 
AN481 pAN138 Tfu0456-F 
CAACAAATATAAAACAAATGCACCATCATCATCACCA
CG 
AN482 pAN138 Tfu0456-R 
CTGTTCATAGAACCACCACCACAACCAAAACGTCTTT
GTCTGAC 















AN475 pAN141 PGK1p-R 
GTGGTGATGATGATGCATTTGTTTTATATTTGTTGTAA
AAAGTAGATAATTAC 
AN452 pAN141 Rv1086-F 
CAACAAATATAAAACAAATGCATCATCATCACCACCA
TGG 
AN476 pAN141 Rv1086-R 
CTGTTCATAGAACCACCACCTCGACCGTAAGATCTAT
GACGAG 
AN477 pAN141 DPP1-F 
CTTACGGTCGAGGTGGTGGTTCTATGAACAGAGTTTC
GTTTATTAAAACG 



























































































































































AN318 pAN151 SNR52p-F ctaaagggaacaaaagctgGAGCTCTCTTTGAAAAGATAATG 
AN625 pAN151 SNR52p-R 
GCTCTAAAACaaatgaaatagtccgtacggGATCATTTATCTTT
CACTGCGGAGAAG 
AN626 pAN151 SUP4t-F 
ccgtacggactatttcatttGTTTTAGAGCTAGAAATAGCAAGTT
AAAATAAG 
AN321 pAN151 SUP4t-R 
gacataactaattacatgaCTCGAGAGACATAAAAAACAAAAA
AAG 
AN627 NA AUR1a-F ATGGCAAACCCTTTTTCGAGATGG 
AN628 NA AUR1a-R GAAATAGTCCGTACGGTAACCATGC 
AN629 NA AUR1b-F 
cattttagcatggttaccgtacggactatttcattaTGGGGCCCCATTTGTCG
TTG 
AN630 NA AUR1b-R 
gcaccgaaaatgacggaggaatttgaaaaacaTGTAGTATACATATTAA
TACCGAG 
AN631 NA AUR1c-F TTTTTCAAATTCCTCCGTCATTTTCG 




























AN571 pAN128 TEF1p-R cttgaatagcggcggcatAAACTTAGATTAGATTGCTATGCT 
































AN443 pAN117 BTS1-R 
aaatcataaatcataagaaattcgcTCACAATTCGGATAAGTGGTCT
A 










AN445 pAN119 BTS1-R 
taatttctttttctgaagccatagaaccaccaccCAATTCGGATAAGTGGT
CTATTATAT 
AN446 pAN119 ERG20-F 
aatagaccacttatccgaattgggtggtggttctATGGCTTCAGAAAAAG
AAATTAGG 
AN424 pAN119 ERG20-R 
aaatcataaatcataagaaattcgcCTATTTGCTTCTCTTGTAAACTT
TG 



























Table 5-4. Yeast synthetic-dropout media recipe. 
 
Ingredient Amount to 100 mL 
2X (13 g/L) Yeast Nitrogen Base (YNB) from 
BD-Difco (291940) 
50 mL 
40 % Glucose 5 mL 
20X amino acid 5 mL 
1 % Histidine (if required) 0.2 mL 
1 % Leucine (if required) 0.9 mL 
1 % Tryptophan (if required) 0.2 mL 
0.2 % Uracil (if required) 1.0 mL 







Table 5-5. Amino acids used for 20X amino acid mix. 
 
Amino acid To 500 mL Sigma-Aldrich Catalog Code 
Adenine sulfate 0.2 g S/A-8626 
Arginine HCl 0.2 g S/A-5006 
**Aspartic acid 1.0 g S/A-9256 
Glutamic acid 1.0 g S/G-1251 
Isoleucine 0.3 g S/I-2752 
Lysine HCl 0.3 g S/L-5626 
Methionine 0.2 g S/M-9625 
Phenylalanine 0.5 g S/P-2126 
Serine 4.0 g S/S-4500 
**Threonine 2.0 g S/T-8625 
Tyrosine 0.3 g S/T-3754 
Valine 1.5 g S/V-0500 
Autoclave all and add ** when cooled, then sterile filter 
   
Selective amino acids To 200 mL Sigma-Aldrich Catalog Code 
1 % Histidine 2 g S/H-8125 
1 % Leucine 2 g S/L-8000 
1 % Tryptophan 2 g S/T-0254 
0.2 % Uracil 0.4 g S/U-0750 















Figure 5-11. GC-MS traces of E. coli fermentations from FPP2 flask fermentation. Gas 
chromatographs of extract from FPP2 (M. tuberculosis FPPase) flask fermentation in decane (top) and 
synthetic Z,E-FOH standard in decane (below). Corresponding mass spectra at the bottom. Peak (i) 
denotes the Z,E-FOH product of the FPP2 strain. Peak (iii) denotes the synthesized Z,E-FOH, and peak 
(ii) denotes a potential degradation product (side peak) of Z,E-FOH. Retention time (RT) of Z,E-FOH is 
~12.12 min. RT of the Z,E-FOH side peak is ~12.05 min. These runs were performed with a different GC 



















Figure 5-12. GC-MS traces of E. coli fermentations from FPP2 bench-scale production. Gas 
chromatographs of extract from FPP2 bench-scale production in hexane (top) and the synthetic Z,E-FOH 
standard (below) in hexane. Corresponding mass spectra at the bottom. Peak (i) denotes the added cis-
nerolidol standard. Peak (ii) denotes the biosynthesized Z,E-FOH. Peak (iv) denotes the chemically 
synthesized Z,E-FOH, and peak (iii) denotes the side peak as in Fig. 5-11. RT of cis-nerolidol in hexane 









































Figure 5-13. GC-MS traces of E. coli fermentations of the other Z,E-FPPSs. Gas chromatographs of 
extracts from E. coli strains containing the other Z,E-FPPSs: 1) FPP5 (C. glutamicum); 2) FPP4 (C. 
efficiens); 3) FPP3 (T. fusca); 4) Mix of farnesol isomers (Sigma, W247804) in decane; 5) Synthesized 
Z,E-FOH standard in decane. Corresponding mass spectra below.  Peaks (i), (iv), and (vi) denote the 
added cis-nerolidol. Peaks (ii) and (vii) denote biosynthesized Z,E-FOH. Peaks (iii), (v) and (viii) denote 
E,E-FOH. RT of cis-nerolidol in decane is ~8.76 min. RT of standard Z,E-FOH in decane (peaks (ix) and 

































Figure 5-15. GC-MS traces of S. cerevisiae fermentations for Z,E-FOH production. (A) GC 
chromatographs of: 1. Extract from small scale fermentation trial of CP-51. 2. Extract from small scale 
fermentation trial of ATCC200589/tHMG1 (AN-ZE1-T7). 3. Synthetic Z,E-FOH standard. 4. Authentic 
E,E-FOH standard (96 %, Sigma 277541). The undecanol internal standard is present in each trace at 
retention time (RT) ~ 7.68 min. RT of the unidentified side peak is ~ 9.90 min. RT of Z,E-FOH is ~ 9.99 















Figure 5-16. GC-MS analysis of yeast fermentation extracts and authentic GGOH standard. (A) GC 





(ii) AN-GG1-T3, (iii) AN-GG2-T3 and (iv) bench-scale production of AN-GG2-T3.  The undecanol 
internal standard is present in each trace at retention time (RT) ~7.68 min. RT of E,E-FOH is ~10.08 min. 
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A.3 Sequence of Fragment 1 yeast assembly. 
Sequence of Fragment 1 shown schematically in Fig. 2-1. To show the context of the sequence in 
the chromosome, the last 30 bp of the HO(L) region on the 5’ end, and the pPYK promoter of the 
acceptor module on the 3’ end are included. The sequence is in Genbank format: 
LOCUS       mer-fragment-1-031016     27156 bp    DNA     linear   UNA 07-
Apr-2012 
DEFINITION   
FEATURES             Location/Qualifiers 
     Misc._recombina 1..30 
                     /label=HO(L) 
     Misc._recombina 31..78 
                     /label=FRT-WT 
     Primer          72..97 
                     /label=AN913 
     Primer          complement(78..102) 
                     /label=AN911 
     ORF             79..879 
                     /label=URA3 
     Primer_binding_ 463..482 
                     /label=AN184 
     Primer_binding_ complement(688..710) 
                     /label=AN299 
     Primer          complement(857..879) 
                     /label=AN106 
     Terminator      892..1057 
                     /label=tADH 
     Primer          1008..1030 
                     /label=LK18 
     Restriction_sit 1058..1063 
                     /label=XbaI 
     Cleavage_site   1058..1063 
                     /label=assembly1 
     Primer_binding_ 1064..1081 
                     /label=AN19 
     Amplification   1064..1345 
                     /label="from pSE34" 
     Misc._recombina 1073..1164 
                     /label=pAN84-gib1-homology 
     Misc._signal    complement(1077..1096) 
                     /label=cr21-1 
     Misc._signal    1085..1104 
                     /label=cr21-3 
     Primer          1097..1115 
                     /label=EC48 
     Misc._signal    1116..1135 
                     /label=cr21-4 
     Misc._signal    1130..1149 
                     /label=cr21-2 
     Promoter        1167..1343 
                     /label=ermE 
     Primer          complement(1327..1345) 
266 
 
                     /label=AN20 
     Primer          complement(1327..1367) 
                     /label=AN219 
     Primer          1327..1364 
                     /label=EC1 
     RBS             1346..1375 
                     /label=merP 
     Primer          complement(1371..1391) 
                     /label=AN598 
     ORF             1376..6094 
                     /label=merP 
     Primer          complement(1449..1470) 
                     /label=LK23 
     Primer_binding_ 1594..1616 
                     /label=FAN1 
     Primer_binding_ complement(1793..1813) 
                     /label=FAN2 
     Primer          complement(1793..1812) 
                     /label=AN834 
     Primer_binding_ 2276..2296 
                     /label=EC8 
     Primer_binding_ complement(2353..2374) 
                     /label=KV17 
     Primer_binding_ 2944..2963 
                     /label=KV12 
     Primer_binding_ complement(3067..3085) 
                     /label=EC3 
     Primer          3251..3268 
                     /label=EC4 
     Primer          3331..3354 
                     /label=EC6 
     Primer          complement(3407..3424) 
                     /label=EC2 
     Primer_binding_ 3550..3569 
                     /label=FAN3 
     Primer_binding_ complement(3598..3619) 
                     /label=KV13 
     Primer          3989..4009 
                     /label=KV77 
     Primer_binding_ 4109..4131 
                     /label=KV15 
     Primer_binding_ complement(4228..4248) 
                     /label=EC9 
     Primer_binding_ 4760..4780 
                     /label=FAN4 
     Primer_binding_ complement(4760..4780) 
                     /label=KV14 
     Primer          5157..5178 
                     /label=EC10 
     Primer          5157..5177 
                     /label=KV19 
     Primer          complement(5189..5207) 
                     /label=EC5 
     Primer_binding_ complement(5279..5298) 
                     /label=KV18 
     Primer          complement(5279..5298) 
                     /label=EC7 
267 
 
     Primer_binding_ 5368..5391 
                     /label=FAN5 
     Primer          complement(5442..5463) 
                     /label=KV78 
     Primer_binding_ 5965..5984 
                     /label=KV25 
     ORF             6067..23205 
                     /label=merA 
     Primer_binding_ complement(6106..6125) 
                     /label=KV16 
     Active_site     6130..7395 
                     /label=LM-KS 
     Primer_binding_ 6579..6600 
                     /label=FAN6 
     Primer_binding_ complement(6641..6661) 
                     /label=FAN7 
     Primer          7024..7044 
                     /label=KV21 
     Primer          complement(7138..7159) 
                     /label=EC11 
     Primer          complement(7140..7159) 
                     /label=KV20 
     Primer_binding_ 7270..7290 
                     /label=FAN8 
     Primer_binding_ complement(7365..7386) 
                     /label=FAN9 
     Primer          7754..7773 
                     /label=KV33 
     Active_site     7807..8706 
                     /label=LM-AT 
     Primer_binding_ 7881..7901 
                     /label=KV27 
     Primer_binding_ complement(7939..7959) 
                     /label=KV26 
     Primer          8383..8402 
                     /label=KV79 
     Primer_binding_ 8515..8535 
                     /label=FAN10 
     Primer_binding_ complement(8599..8619) 
                     /label=FAN11 
     Primer          8802..8821 
                     /label=KV23 
     Active_site     8977..9189 
                     /label=LM-ACP 
     Primer          complement(9037..9057) 
                     /label=KV22 
     Primer_binding_ complement(9132..9153) 
                     /label=FAN12 
     Primer_binding_ 9221..9240 
                     /label=KV35 
     Active_site     9247..10521 
                     /label=M1-KS 
     Primer          complement(9340..9359) 
                     /label=KV80 
     Primer_binding_ 9693..9713 
                     /label=KV34 
     Primer          9736..9755 
268 
 
                     /label=KV94 
     Primer_binding_ complement(9858..9879) 
                     /label=KV28 
     Primer_binding_ 10360..10379 
                     /label=FAN13 
     Primer_binding_ complement(10414..10433) 
                     /label=FAN14 
     Primer          10574..10592 
                     /label=KV29 
     Primer          complement(10750..10771) 
                     /label=KV24 
     Active_site     10834..11700 
                     /label=M1-AT 
     Primer_binding_ complement(10974..10995) 
                     /label=KV58 
     Primer_binding_ 11005..11025 
                     /label=FAN15 
     Primer          complement(11242..11262) 
                     /label=KV81 
     Primer_binding_ 11482..11502 
                     /label=KV37 
     Primer          11490..11510 
                     /label=AN239 
     Primer          complement(11646..11667) 
                     /label=KV95 
     Primer_binding_ complement(11699..11718) 
                     /label=KV36 
     Primer          11816..11836 
                     /label=KV82 
     Primer_binding_ 12185..12202 
                     /label=KV31 
     Primer_binding_ complement(12361..12378) 
                     /label=KV30 
     Active_site     12508..13035 
                     /label=M1-KR 
     Primer          complement(12511..12530) 
                     /label=KV83 
     Primer          12779..12799 
                     /label=KV84 
     Primer_binding_ 13002..13020 
                     /label=KV51 
     Primer          13055..13073 
                     /label=KV43 
     Primer          complement(13164..13184) 
                     /label=KV96 
     Primer_binding_ complement(13165..13186) 
                     /label=KV38 
     Active_site     13300..13557 
                     /label=M1-ACP 
     Primer          13497..13516 
                     /label=KV56 
     Active_site     13633..14898 
                     /label=M2-KS 
     Primer_binding_ 13668..13685 
                     /label=KV39 
     Primer_binding_ complement(13855..13874) 
                     /label=KV32 
269 
 
     Primer_binding_ 14232..14254 
                     /label=FAN16 
     Primer_binding_ complement(14360..14377) 
                     /label=FAN17 
     Primer          14891..14908 
                     /label=KV45 
     Primer_binding_ 14998..15015 
                     /label=KV53 
     Primer_binding_ complement(15021..15040) 
                     /label=KV52 
     Primer          complement(15075..15094) 
                     /label=KV44 
     Active_site     15190..16059 
                     /label=M2-AT 
     Misc._feature   15272..16021 
                     /label=F1-cr14-repair-gblock 
     Primer          15276..15295 
                     /label=KV85 
     Primer          complement(15313..15334) 
                     /label=KV59 
     Primer          15494..15512 
                     /label=KV55 
     Primer_binding_ 15575..15593 
                     /label=KV41 
     Misc.           15643..15739 
                     /label=cr14-2-repair 
     Primer          15643..15702 
                     /label=AN695 
     Primer          complement(15680..15739) 
                     /label=AN696 
     Misc._signal    complement(15706..15725) 
                     /label=cr14-target 
     Mutation        15707 
                     /label="G to A" 
     Primer_binding_ complement(15711..15729) 
                     /label=KV40 
     Primer          complement(15711..15729) 
                     /label=KV57 
     Primer          complement(15803..15821) 
                     /label=KV76 
     Primer          complement(15997..16015) 
                     /label=KV97 
     Primer          16161..16180 
                     /label=KV86 
     Active_site     16222..16713 
                     /label=M2-DH 
     Primer_binding_ complement(16440..16459) 
                     /label=KV46 
     Primer_binding_ 16525..16546 
                     /label=KV60 
     Primer_binding_ complement(16737..16755) 
                     /label=KV54 
     Primer_binding_ 17232..17250 
                     /label=KV47 
     Primer_binding_ complement(17392..17414) 
                     /label=KV42 
     Active_site     17536..18075 
270 
 
                     /label=M2-KR 
     Primer          17659..17679 
                     /label=KV88 
     Primer          complement(17812..17831) 
                     /label=KV87 
     Primer_binding_ complement(17889..17908) 
                     /label=FAN19 
     Primer_binding_ 17910..17930 
                     /label=FAN18 
     Active_site     18340..18597 
                     /label=M2-ACP 
     Primer_binding_ 18361..18382 
                     /label=KV62 
     Primer_binding_ complement(18450..18471) 
                     /label=KV61 
     Active_site     18652..19932 
                     /label=M3-KS 
     Primer          complement(18660..18680) 
                     /label=KV89 
     Primer_binding_ complement(18900..18918) 
                     /label=FAN20 
     Primer_binding_ 19008..19029 
                     /label=KV67 
     Primer          19440..19459 
                     /label=KV90 
     Primer_binding_ complement(19545..19564) 
                     /label=FAN21 
     Primer_binding_ 19641..19661 
                     /label=KV68 
     Primer          19933..19951 
                     /label=KV49 
     Primer          complement(19993..20010) 
                     /label=KV48 
     Primer_binding_ complement(20158..20179) 
                     /label=FAN23 
     Primer_binding_ 20217..20238 
                     /label=FAN22 
     Active_site     20224..21036 
                     /label=M3-AT 
     Primer_binding_ 20569..20587 
                     /label=KV64 
     Primer_binding_ complement(20772..20794) 
                     /label=KV63 
     Primer          20959..21016 
                     /label=AN544 
     Primer          complement(20992..21048) 
                     /label=AN545 
     Mutation        21005 
                     /label="T to C" 
     Misc._signal    complement(21007..21026) 
                     /label=cr10-target 
     Primer_binding_ 21175..21196 
                     /label=FAN24 
     Primer_binding_ complement(21297..21315) 
                     /label=KV69 
     Primer          complement(21381..21401) 
                     /label=KV91 
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     Primer_binding_ 21691..21711 
                     /label=KV65 
     Primer_binding_ complement(21813..21831) 
                     /label=KV50 
     Active_site     21964..22485 
                     /label=M3-KR 
     Primer_binding_ 22438..22457 
                     /label=FAN25 
     Primer_binding_ complement(22585..22605) 
                     /label=FAN26 
     Primer          complement(22675..22694) 
                     /label=KV92 
     Active_site     22726..22956 
                     /label=M3-ACP 
     Primer_binding_ 23101..23119 
                     /label=KV75 
     Primer          23101..23160 
                     /label=KV74 
     Primer          23140..23199 
                     /label=KV72 
     Primer          23141..23160 
                     /label=AN846 
     Primer          23179..23238 
                     /label=KV70 
     Primer_binding_ complement(23184..23205) 
                     /label=KV66 
     Source          23212..24602 
                     /label=pACYC184 
     Mutation        23224 
                     /label="T deletion" 
     ORF             23312..24502 
                     /label=tet-efflux-classC 
     Primer          23714..23733 
                     /label=KV93 
     Primer_binding_ complement(23938..23959) 
                     /label=FAN28 
     Primer_binding_ 23968..23992 
                     /label=FAN27 
     Primer          complement(24584..24643) 
                     /label=KV71 
     Misc._recombina 24603..24650 
                     /label=FRT-15 
     Primer          complement(24616..24675) 
                     /label=KV73 
     Primer          complement(24752..24767) 
                     /label=AN112 
     ORF             complement(24880..25583) 
                     /label=HIS3 
     Primer          24962..24983 
                     /label=AN835 
     Primer          complement(24962..24983) 
                     /label=AN272 
     ORF             complement(25584..26297) 
                     /label=GFP 
     Primer_binding_ complement(25603..25624) 
                     /label=AN325 
     Misc._recombina 25733..25836 
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                     /label=pAN84-gib1-homology 
     Restriction_sit 25733..25738 
                     /label=MfeI 
     Misc._signal    25736..25755 
                     /label=cr22-1 
     Misc._signal    complement(25780..25799) 
                     /label=cr22-2 
     Misc._signal    complement(25822..25841) 
                     /label=cr22-3 
     Primer          complement(26185..26207) 
                     /label=AN836 
     Promoter        complement(26298..27156) 
                     /label=pPYK 
ORIGIN 
        1 aaaattgtgc ctttggactt aaaatggcgt GAAGTTCCTA TTCCGAAGTT CCTATTCTCT 
       61 AGAAAGTATA GGAACTTCTC GAAAGCTACA TATAAGGAAC GTGCTGCTAC TCATCCTAGT 
      121 CCTGTTGCTG CCAAGCTATT TAATATCATG CACGAAAAGC AAACAAACTT GTGTGCTTCA 
      181 TTGGATGTTC GTACCACCAA GGAATTACTG GAGTTAGTTG AAGCATTAGG TCCCAAAATT 
      241 TGTTTACTAA AAACACATGT GGATATCTTG ACTGATTTTT CCATGGAGGG CACAGTTAAG 
      301 CCGCTAAAGG CATTATCCGC CAAGTACAAT TTTTTACTCT TCGAAGACAG AAAATTTGCT 
      361 GACATTGGTA ATACAGTCAA ATTGCAGTAC TCTGCGGGTG TATACAGAAT AGCAGAATGG 
      421 GCAGACATTA CGAATGCACA CGGTGTGGTG GGCCCAGGTA TTGTTAGCGG TTTGAAGCAG 
      481 GCGGCAGAAG AAGTAACAAA GGAACCTAGA GGCCTTTTGA TGTTAGCAGA ATTGTCATGC 
      541 AAGGGCTCCC TATCTACTGG AGAATATACT AAGGGTACTG TTGACATTGC GAAGAGCGAC 
      601 AAAGATTTTG TTATCGGCTT TATTGCTCAA AGAGACATGG GTGGAAGAGA TGAAGGTTAC 
      661 GATTGGTTGA TTATGACACC CGGTGTGGGT TTAGATGACA AGGGAGACGC ATTGGGTCAA 
      721 CAGTATAGAA CCGTGGATGA TGTGGTCTCT ACAGGATCTG ACATTATTAT TGTTGGAAGA 
      781 GGACTATTTG CAAAGGGAAG GGATGCTAAG GTAGAGGGTG AACGTTACAG AAAAGCAGGC 
      841 TGGGAAGCAT ATTTGAGAAG ATGCGGCCAG CAAAACTAAG TCGACCTCGA Ggcgaatttc 
      901 ttatgattta tgatttttat tattaaataa gttataaaaa aaataagtgt atacaaattt 
      961 taaagtgact cttaggtttt aaaacgaaaa ttcttattct tgagtaactc tttcctgtag 
     1021 gtcaggttgc tttctcaggt atagcatgag gtcgctctct agagagctcg gtaccAGCCC 
     1081 GACCCGAGCA CGCGCCGGCA CGCCTGGTCG ATGTCGGACC GGAGTTCGAG GTACGCGGCT 
     1141 TGCAGGTCCA GGAAGGGGAC GTCCATGCGA GTGTCCGTTC GAGTGGCGGC TTGCGCCCGA 
     1201 TGCTAGTCGC GGTTGATCGG CGATCGCAGG TGCACGCGGT CGATCTTGAC GGCTGGCGAG 
     1261 AGGTGCGGGG AGGATCTGAC CGACGCGGTC CACACGTGGC ACCGCGATGC TGTTGTGGGC 
     1321 ACAATCGTGC CGGTTGGTAg gatccTTTCC ATCAGTCGTC GGGGAAGGCT GTGTTGTGGG 
     1381 GAATTCAGGC GCACCCAAAT CCCGTGGTCT CAGCGCGGCC ATGAGCAATC TCTTCGAGCG 
     1441 GACCAGGAGA AACGAATCCA CCGGCATTGT GCCGGTCGAC CGGGGCCGGG AGCTGAGGGC 
     1501 GTCGTTCGCC CAGCAACGGC TGTGGTTTCT GGACCAGTTG GAACCCGGCA ACGCCTCGTA 
     1561 CAATCTCCCC TTCGCGGTGC GGGTGCGCGG CCGCTTGGAC ATCTCTCATC TCTCCCGGGC 
     1621 CCTCTCGCTC GTGGTCGCCC GGCACGAGGC GCTGCGCACC ACCTTCGGCG AGGCCGGCGG 
     1681 TCAGCCGGTG CAGCGGATCG AGCCCCCCGG CCCCGTCCCG GTGCGCCTTG AAGCGGTGTC 
     1741 CGGCGGCTCG GAGGAGGAGC GGCTGGCCGA GGTCCGGCGG CTGGCCGGAG CCGAGATCAC 
     1801 CGAGCCCTTC GACCTGAGCA CCGGGCCCCT GCTGCGCGCC AAGGCGCTGC GACTGGACGA 
     1861 ACAGGACCAC GTCCTGCTGC TGACGGTGCA CCATGTGGCG ACGGACGCCT GGTCACAAGG 
     1921 CATTGTGGTG CGTGAGCTGT CCGTCGCGTA CGCGTCGCTC GACGCCGGGC GCGAGCCCGT 
     1981 GCTGCCCCCG CTGCCCGTGC AGTACGCGGA CTACGCGGAG TGGGAGCGCG ACTGGCTGTC 
     2041 CGGCCCGACC CTGCGCCGCC AGCTGGACTA CTGGACGAAG CGGCTCGACG GCATGGCGCC 
     2101 CGCGCTGGAG CTGCCCACCG ACCGGCCCAG GCCCTCGGTC GCCAGCCAGG AAGGCGACGC 
     2161 GGTGCGCTGG GAGTTGCCGC CGGAACTGAT CCGGGCGGCC CGCCGGCTGG GCGCCGGTGA 
     2221 GAACGCGACC CTCTACATGA CCCTGCTGGC CGCTTTCCAG CTGGTACTGG GCCGGTACGT 
     2281 GGACAGCGAC GACATCACGG TGGGCACCCC CGTGGCCAAC CGGGGCCGCG CCGAGGTCGA 
     2341 GGGGCTCATC GGGTTCTTCG TCAACACCGT GGTGCTGCGG ACCGACCTGT CCGGCGACCC 
     2401 CACCTTCCGC CAACTGCTGG GCCGGGTCCG CGACACGGCG GCGGGTGCCT TCGCCCATGG 
     2461 CGACCTGCCC TTCGAGTATC TGGTGGAGCA GGTGCACCCC GAGCGGGACT TGTCGCGGAA 
     2521 CCCGCTGGTC CAGGTGCTCT TCCAGATGAT CAACGTACCG GCGGAGCGGC TCGAGCTGCC 
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     2581 CGGCGCGCGG ACCGAGCCCT ACGACCACGG CGGCATCCTC ACGCGAATGG ATCTGGAGGT 
     2641 CCATCTCGTC GAGACCGGGG ACGGGGTTCT GGGGCACATC GTCTTCAGCA AGGCCCTGTT 
     2701 CGACACGAGC ACCATCGAAC GGCTGCTGCA CCACGTCACC GTCGTCCTCC GGGGCGTCCT 
     2761 GGCCGAGCCG GACCGGCGCA TCTCCGAGAT CTCGCTGCTC GACGAGGCGG AGCGGGCGAA 
     2821 GGTCCTGGAG AAGTTCAACA CGACCACGGG CCCCGTACCC GCCGGATCCC TGCCCGCGCT 
     2881 CTTCACCGCC CAGGCCGAGC GCCGCCCCGA TGCGGTGGCC GTGATCAGCG GTGGTGACCG 
     2941 GGTGACCTAC GCCGAGCTGG ATCAGCGGGC GAACCAGCTC GCCCATCTGC TGGAGGGCCG 
     3001 GGGGGTCGGC CCCGAGACCC TGGTCGGGCT CTGCGTCGAT CGCGGCATCG AGATGATCGT 
     3061 GGCGATCCTC GCGATCCTCA AGCTCGGAGC GGCCTATGTG CCGATCGATC CCCACCACCC 
     3121 CCGAGACCGC GTCCAGTTCG TCCTTGCCGA CTCCGGGGTG ACCGTCGCCG TCACCCAGCA 
     3181 GCGCTTCACC GGCCTGCTCG AAACCCCGGA GGCACCCGGG ACGCCCGATG CGTCCGGGAC 
     3241 GTCCGGGATC CGCCTCATCC TGCTCGACGC CGAGCGCGAG CCGCTCGCCG GGCAGCCCCG 
     3301 GACCCCGCCC ACGGCACGGC CCAGCGCCCA GAACCTCGCC TATGTCATTT ACACCTCCGG 
     3361 CTCCACCGGA GTCCCCAAGG GCATCCTCAT GCCCGCCACC TGTGTGCTCA ACCTGGTGGC 
     3421 CTGGCAGAAG CGGGCCCTGC CGATCGGTCC CGACGCCAAG ACGGCACAGT TCGCCACGCT 
     3481 GACCTTCGAT ATCTCGTTGC AGGAGATCTT CTCCGCGCTG CTGTACGGCG AGACGATCGT 
     3541 CGTCCCCGGC GAGGAACTGC GCATGGACCC CGCCGAGTTC GCCACATGGG TCCACGCCAA 
     3601 CGAGATCGAC CAGCTCTTCG TCCCGAATGT GATGCTGCGG GCGATCTCCG AGGAGGTGGA 
     3661 TCCGCACGGC ACCGAGCTGG CCGCACTGCG CCACCTCTCA CAGGCCGGCG AACCCCTCTC 
     3721 CCTCCACCAC GATCTGCGCG AGCTGTGCGC CCGCCGCCCC GAGTTGCGGC TGCACAACCA 
     3781 CTACGGTCCC AGCGAAGCCC ATGTGGTGAC GTCGTACTCG CTCCCCGCCG AGGTGGCCGA 
     3841 GTGGCCGCTC ACCGCACCCA TCGGCCGCCC GATCGGCAAC ACCCGGGTGT ATGTGGTCGA 
     3901 CCGGCGGCTC CGGCCCGTCC CGGTGGGGGT GCCAGGTGAG CTGTGCGTGG CCGGAGAGGG 
     3961 GCTGGCCAGG GGCTATCTCG GCCGCCCGGA TCTGACCGCT TCCCGGTTCG TGGCGGACCC 
     4021 GTTCCGCGGC GACGGATCGC GTATGTACCG CTCCGGCGAC CTGGTGCGCT GGCTGCCCGA 
     4081 CGGCAACCTG GAATTCCTCG GCCGGATCGA TGACCAGGTG AAGATACGTG GCTTCCGGAT 
     4141 CGAACCGGGC GAGATCGAGG CGATCCTCGC CCGGCACCAG GACGTTCTGC ACACGGCCGT 
     4201 GATGGTGCGC GAGGACACCC CCGGCGACAA GAGGCTGGTG GCCTATGTGG TGGCCGATGC 
     4261 CACCGCCGCG GACCGGCACG GCGGGCTGAC CGAGACCCTG CGCCGGCACG TCGAGTCCGC 
     4321 GGTGCCCGAA TACATGGTGC CCTCCGCGTT CGTCCTGCTG GACACCATGC CCCTGACCTC 
     4381 CGGCGGCAAG ATCGACCGGA AGGCGCTGCC CGCCCCCGAT CTGCGCACCG TGCTCGAGGT 
     4441 CGGCTACGTC GCCCCACGCA CCCCCGAGGA AGAGGCCGTC TGCCGGGTTT ACGCGGATCT 
     4501 GCTCGGCGCG GCCAAGGTCG GCATCGACGA CGACTTCTTC GCACTGGGCG GCCATTCCCT 
     4561 CATCGCCACC AGGGTGGTCG CCAGGCTCCG GTCCGCCCTC GGTATCGCCG TACCGCTGAA 
     4621 GACCGTCTTC CAGCAGCGCA CCCCCCGAGA GCTGGCGGCC ACGCTCACCG CCGCGGCCCG 
     4681 CTCCGGTCCC GAACCCGAGC TGCCGCCGCT GGTTCCCACG CGGCGCGACC AGCCCGTCCC 
     4741 CCTCACCTTC GCACAGCAGC AGACGGACCT CTTCTTCGAC GATGTCCTGA ACGCCGGGCA 
     4801 CTGGAACATC CCCATGGCGG TGCGGGTGTC GGGCGAACTG GACCTCGACT GCCTGCGGCG 
     4861 GGCGATGGAC CTGCTGATCG ACCGCCACGA GGCCCTGCGC ACCACCTTCG TCAGGGAAGC 
     4921 CGACGGATAC GTCCAGGTGA TCCGGCCGAG CGCGCCGGTC CAGGTGGAGG TGGCCGAGAC 
     4981 GCACGACGAG ACCGAAGCCT CGGTACTGGC CGGCCAGGAG GCCGCCCGCC CCTTCGACCT 
     5041 CACACGCGGC CCGCTGGCGA GACTGCGCGT GCTGCGGCTG TCCCAGTCCG ACCATGTGCT 
     5101 GGTGCTCACC CTGCACCACC TGGTCACCGA CGGCTGGTCC CAGGGAGTGC TGGTCCGAGA 
     5161 TCTGTCCATC GTGTACGCGG CACTGCTGCA CGGCACCGAA CCCGATCTGC CACCCGCACC 
     5221 CGTCCAGTAC GCCGATGTCG CGAGCTGGGA GCGGAAGTGG TTGCGCGGTC CGCTGCTGCA 
     5281 ACGCCAACTC GAGTTCTGGA AGCGGCATTT CGAGGGCATG ACCCCCGCCG AACTGCCCAC 
     5341 CGACCGGCCC CGCGCCGCGT CGGCCCGCTA CGAGAGTGAC ATCTTCCACT GGCGACTGCC 
     5401 GACGGACGCC GTCGAGACCG CCCGACGGCT GGGCGAATCG TGCAACGCCA CCTTGTACAT 
     5461 GACGCTGCTG ACCGCCCTGA AGGTGGTCAT GTCCGCCCGC TCGGACAACC AGGACGTCCT 
     5521 CGTCGGCGTG CCCACGGCCA ACCGTGGCCG GGACGAACTG GAGAACACGG TGGGCCTCGT 
     5581 CTCCAAGATG CTCGCGCTGC GCACCGAAGT GTCCGGTGCC ACGGACTTCG GCACACTGCT 
     5641 GGCCACGGTG CGCGATGCGA TGTCCGACGC CCATACACAC CAGGACGTGC CCTTCGTGTC 
     5701 CGTTCTCAAG CACATCGGTG ACCACACCGC CGGCCCCGCC GGTGACACCG CCGGCGGCCG 
     5761 GGCCGGGACG CGGCTGTCGG ACGATCCGCC AGTGAAGGTG ATCTTTCAGA TCGTCAACAC 
     5821 CCCGCCGCGG CCACTCCGGC TCACCGGACT GACGGCCGAG CCGTTCCCGA TGACCCACCC 
     5881 GCCGGTCACG GTCAACGTGG ACATGGAGAT CGACCTGTAC GAGAGCGCGG AGGACGGCGG 
     5941 CCTCGCCGGC ACCGTGCTGT TCAGCAAGTC CCTCTTCGAC CGTGCCACGA TCGAGCGGTT 
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     6001 CTGCGACGAC GTGGTGGCGG TCGTCTCCGC GGCCGCCGCG GATCCCGGAC GGCCGGTCTC 
     6061 ACAGGTGTGG CAGGGCCGGG GCCGCGACCA GTGAACGATC CCGCCCCGAG GAAACGCATG 
     6121 GAACCGGATG AGGCCGTCGC CGTTGTCGGA ATGTCCTGCC GCTTTCCGCA GGCACCCGAT 
     6181 CCCGAGGCGT TCTGGCGGCT GCTGAGCGAG GGCATCTCGG CCATCGGTGA GGTGCCCGCG 
     6241 GGGCGGTGGA CCGACGACCA GCCCACGCCG TCCGGGACCG ACGAGCGGTC CACGCCGCCC 
     6301 GCCATCCGCC GCGGCGGCTT CATCGACGAC GTCGACCGCT TCGACCCCGC GTTCTTCGGC 
     6361 ATCTCACCAC GGGAAGCCGC GGCGATGGAC CCCCAGCAGC GGCTGATGCT CGAGCTGGCC 
     6421 TGGGAAGGGC TGGAGGACGC GGGCATCGTG CCCGCCACCC TGCGGGGCGC CACCGTCGGA 
     6481 GCGTTCATCG GCGCCGGGTC CGACGACTAC GCCTCGCTGA TCCGCGCCCG CGGCCGTTCA 
     6541 CACCACACGC TGACCGGCAC CCAGCGGGGC ATGATCGCGA ACCGGCTCTC CCATGTGTTC 
     6601 GGCCTGAGCG GCCCGAGCGT GACCGTGGAC GCGGCCCAGG CATCCTCCCT GGTCGCGGTA 
     6661 CACATGGCCG TGGAGAGCGT GCGCCGCGGC GAGTCACGGC TCGCGCTGGC GGGCGGGGTC 
     6721 AACCTGAACC TCTCCGCGGA GACCGCCGCC GATATCGCGG CGTTCGGCGC ACTGTCCCCG 
     6781 GACGGCCGCT GCTTCACCTT CGACGCACGC GCCAATGGCT ATGTGCGGGG CGAGGGCGGC 
     6841 GGACTCGTCG TCCTGAAACC GCTCTCCGAC GCTCTCGCCG ACGGCGACAC CGTCTACTGC 
     6901 GTGATCGAGG GCAGCGCGGT CAACAACGAC GGCGGCGGTG CATCGCTCAC CGCACCCGAC 
     6961 CCGGACGGCC AGCGACGGGT GCTCCGACTC GCCCAGCGGC GGGCCGCGAT CTCCCCCGAG 
     7021 GCCGTTCAGT ACGTGGAGCT GCACGGCACC GGAACGGCAC TCGGCGACCC GGCGGAAGCG 
     7081 GCGGCCCTGG GCGCCGTCTT CGGCCGGAGC GGAGCGAGGC CGGTGCAGCT GGGGTCGGTG 
     7141 AAGACCAACA TCGGCCACCT CGAAGCCGCC GCCGGTATCG CCGGACTTCT GAAGACCGCA 
     7201 CTGGCCATCC ACCACCGGCA GCTGCCGGCC GGCCTCAATT ACCGCACGCC GAATCCCCGT 
     7261 ATCCCCATGG GCGAACTCAA CCTGGAGATG CGCCTCGCAC CGGGGGAGTG GCCGAAGCCG 
     7321 GACGACCGCC TGGTCGCCGG TGTCAGCTCT TTCGGGATGG GCGGCACCAA CTGCCATGTC 
     7381 CTGCTCGCCG AACCACTCGT CGGCGTCCCC TCCCACGCCT CCGCGCATGC CCCTGAGCCC 
     7441 GACTCCCTCC CCAGCTCGAT CCCGGCCCCG GTCCCGGTCC CGGTCCCGGT CCCGGCCCCG 
     7501 GTCCCGGTCC CGGCCCCGGC CCCGGCCCCG GCCCCGGTCC CGGTCCCCGT CCCGCTTCCG 
     7561 TTGTCCGGGG TGTCCGCTGC CGCGCTTCGC GGCCAGGCGA TGCGGCTACG GCCGTATCTG 
     7621 GAGCGATCGC CGAACCTCAC CGACCTCTCC TTCTCCCTCG CCACCGCACG AACCTCCTTC 
     7681 GACCACCGTG CGGTGCTGAT CACCGGGCAG GCGGCCGACG CGGCACACGG CCTGGACGCG 
     7741 CTCGTCGAAG GCGGCACGGT GGCGGGTTTG GTGACGGGCA CGGCGAGGGC GGCGGGAAAG 
     7801 CTCGCCTTCG CCTTCGCCGG CCAGGGCTCG CAGCGTCTCG GCATGGGACG TGAACTCGGG 
     7861 GCCGTCTTCC CCGTCTTTGC CCAGGCTCTT GACGAAGTGT GCACGGCGCT GGACGCACAC 
     7921 CTGGACCGGC CGCTTCGGGA CGTGATCCAC GGTGACGACG CCGAACCGCT CAACCGGACG 
     7981 GTGTACGCCC AGGCCGGACT CTTCGCGGTG GAGGTGGCGC TGTTCCGGCT GCTGGAGGAC 
     8041 TTCGGCCTCG TACCGGACCT GCTGATCGGC CACTCCCTCG GCGAGGTGAG CGCCGCCCAT 
     8101 GTCGCCGGTG TGCTGTCCTT GGCGGACGCC GCCACCTTCG TCGCCGCCCG TGGGCGGCTG 
     8161 ATGCAGGCCG TGACGGAGCC GGGCGCCATG GTGTCGCTCG AAGCCACCGA GGACGAGGTC 
     8221 ACCCGGACGC TCATGGCGGG CGGGGCATCG GACGACGGTG CCCGGGTGTG CGTGGCGGCG 
     8281 GTCAACGGCC CCACCGCCAC GGTGATCTCG GGGGACGAGC GCGCCGTACT CGACCTGGCG 
     8341 GTGGAGTGGG CCGGTCGCGG ACGCAAGACG AAGCGGCTCC GGACGAGCCA CGCCTTCCAT 
     8401 TCGCCCCATC TGGACCCCGT ACTGGACGAG CTTCGGCACA TCGCCGAGAG CCTCACGTAC 
     8461 CGGGCGCCCC GGATCCCGCT GGTGTCGAAT GTGACCGGCC GACGTGCCAC GGCGGAAGAG 
     8521 CTGTGTTCTC CGGAGTACTG GGTCCGGCAT GTCCGCCGGA CCGTACGGTT CCTGGACGGC 
     8581 GTCCGCTGTC TGGAGGACGA AGGCGTCACC ACCATCCTGG AACTGGGCCC GGACAAGGCG 
     8641 CTCACCACCC TGGCCCGCGA CTGCCTGACC GGGCCCGGGA CGCTGGTGGG CACCCTTCGT 
     8701 CGCGACCGGC CCGAGCCGCA GGCCCTGGTC ACCGCGCTGG CCGAGCTGTA TGTCTCGGGT 
     8761 GTCGAAGTGG CATGGAGCCC GCTGGTGTCC GGTGGGCGGC GGATTCCACT GCCCACGTAC 
     8821 GCCTTCCAGC GGCAGCGGTA CTGGTTCTCC GCTCCCGGGC CCGAGAGCGG AACCACGCCT 
     8881 GGCCATGGGG TCACATCCGG GCGCGAGCGC ACGGACACCG GCCTGAGCGG CGACGAGGCG 
     8941 CCCGACACCG GCCCGAGCGG CGGCGAGACG CTTGGCATGG TCCGGGCGCA CGCGGCCGTC 
     9001 GTGCTCGGAT ACGCGTCGGC AACCGCCATC GGCGCCGAGC ACACCTTCAA GCAACTCGGG 
     9061 TTCGACTCGA TCACCGCCGT CGAACTGTGC GAACGGCTCG GTGCGGCGAC CGCGCTTCCG 
     9121 CTGCCCGGCA CCTTGCTGTT CGACTATCCG ACGCCCGCCG CGCTCGCCGA GCATCTGCAC 
     9181 CGCAGGCTCC ACGGCCGGAC GGATGAGCAG GCCGCGCCCG CGACCGTGCC AACACCTGAC 
     9241 GGCGGCGATC CGGTGGTGAT CGTGGGGATG GGCTGCCGGT TCCCCGGCCG GGCCCACTCG 
     9301 CCGGAGGACC TGTGGCGGAT CGTGGCCGAC GGTGAGGACG CCATCTCCGG CTTTCCGTCC 
     9361 GACCGGGGCT GGGACCTCGC TGGTCTCTAC CACCCCGACC CCGACCACCC CGGCACGTCA 
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     9421 TACGCACGCG ACGGCGGATT CCTCTACGAC GCGGCCGAGT TCGACGCGGG GTTCTTCGGG 
     9481 ATCTCACCGC GTGAGGCCGA GGCGATGGAC CCGCAGCAGC GGCTGCTGCT GGAGACATCG 
     9541 TGGGAGGCGT TGGAACGGGC GGGTATCCCC GCGGAACACA TCAAGGGCAG TAGCACGGGC 
     9601 GTGTTCATCG GCGCCTCGTC GGTCGGCTAC GCGGCGGACG CCGGAGAGGC GGCCGAGGGC 
     9661 TACCAGCTGA CCGGCACTGC CGCGAGCGTG GCCTCGGGCA GGGTGTCCTA CACCCTGGGC 
     9721 CTCGAAGGCC CGGCGGTCAC CGTGGACACG GCATGCTCGT CCTCGCTGGT GGCATTGCAC 
     9781 CTGGCCGTAC AGTCGCTGAG GGCGGGCGAG TGCTCACTGG CATTGGCGGG CGGTGTGACC 
     9841 GTGATGGCCA CACCGGCGAT GTTCGTGGAG TTCTCCCGTC AGCGGGGGCT GGCCATGGAC 
     9901 GGTCGGTGCA AGGCGTTCGC GGCGGCGGCG GACGGCACGG GGTGGGCCGA AGGCGTCGGG 
     9961 GTGCTGGTGG TCGAGCGGTT GTCGGACGCC GAGCGCAATG GGCATCGGGT GTTGGCGGTG 
    10021 GTGCGTGGTT CTGCGGTGAA TCAGGATGGT GCGTCGAATG GTTTGACGGC GCCGAATGGT 
    10081 CCGTCGCAGC AGCGGGTGAT CCGGCAGGCG TTGGCGAGTG CGGGTCTTGT GGCGTCGGAT 
    10141 GTGGATGCGG TGGAGGCGCA TGGTACGGGT ACGACGCTCG GTGATCCGAT TGAGGCGCAG 
    10201 GCGTTGTTGG CCACGTACGG TCAGGGTCGG GATGCGGATC GGCCGTTGTG GTTGGGGTCG 
    10261 GTGAAGTCGA ACATCGGTCA TACGCAGGCG GCCGCGGGTG TGGCTGGTGT GATCAAGATG 
    10321 GTGATGGCCA TGCGGCACGG GGTGCTGCCG CGAACGCTGC ACGTGGATGA GCCGTCGACC 
    10381 CACGTCGACT GGTCCGGCGG CCGGGTAGAG CTGCTCACCG GGACAACGCC ATGGCCCACG 
    10441 ACGGGTGGCC TTCGCCGAGC GGGCGTCTCC TCGTTCGGTG TGAGTGGCAC CAACGCTCAC 
    10501 GTCATCCTGG AGCAGGTCCC GGAGACGGCC CGGCCGACCG GGCCCATCGG GGAAGACGAC 
    10561 GGCGAAGCGG CGCCCGTCGC CTGGGTGTTG TCGGGACAGG GCGAGACTGG GCTGCGGGCC 
    10621 CAGGCCGAGC GGCTGTGCGC CTTCATGGCG GCCGATACCC GCCCCACCCC GGCGGAAGTG 
    10681 GGATGGTCAC TGGCATCGAC ACGTGCGACG TTGTCGCACC GCGCGGTGGT CGTGGGTGCT 
    10741 GGACGCGACG AGTTGTTGCG TGGTGTGAAT GCGGTGGCGA ACGGGACACC CGTGCCGGGA 
    10801 GTGGTACGGG GCACCGGAGC CTCCGGGGAC GTGGTGTTCG TCTTCCCGGG GCAGGGGTCG 
    10861 CAGTGGGTTG GGATGGCGTT GGAGTTGGTG GAGTCGTCGC CGGTGTTCGC GCGGCGGTTG 
    10921 GGTGATTGTG CGGATGCGTT GGCGCCGTTT GTGGAGTGGT CGTTGTTCGA TGTGTTGGGT 
    10981 GATGAGGTGG CGATCGGTCG GGTTGATGTG GTGCAGCCGG TGTTGTGGGC GGTGATGGTG 
    11041 TCGTTGGCGG AGTTGTGGCG TTCGTTTGGT GTGGTGCCGT CGGCGGTGGT GGGGCATTCG 
    11101 CAGGGTGAGA TCGCGGCGGC GTGTGTGGCG GGTGCGTTGA CTTTGGAGGA TGGGGCGCGT 
    11161 GTGGTGGCCT TGCGGAGCAG GGCGTTGCTG GCTCTGTCGG GTCGGGGCGG CATGGTGTCC 
    11221 GTACCGGTGT CCGCCGATCG GCTCCGTGAC CGTGTGGGGT TGTCGGTGGC GGCGGTGAAT 
    11281 GGTCCGGCGT CGACGGTCGT GTCCGGGGCG GTTGAGGTGC TGGAGGCGGT GCTGGCGGAG 
    11341 TTCCCGGAGG CCAAACGGAT TCCGGTGGAT TATGCCTCGC ATTCGGTGCA GGTGGAGGGG 
    11401 ATCCGGGAGG GGCTGGCGGA GGCGTTGGCG CCGGTTCGGC CGCGTACGGG TCAGGTGCCG 
    11461 TTCTATTCGA CGGTGACCGG CCGGCTGATG GACACCATCG AGTTGGACGC GGAGTACTGG 
    11521 TACAGGAACC TGCGCGAGAC GGTGGAGTTC CAGAGCACCG TCGAACACCT CATGCGCCAG 
    11581 GGTCATACGG TGTTTGTCGA GGCCAGCCCG CATCCGGTGC TGACCATCGG CGTCCAGGAC 
    11641 ACCGCCGACA CCACCGACAC TGACATCGTC GTCACCGGAT CGCTGCGCCG CGATGATGGC 
    11701 ACTGTCCAGC GGTTTCTGAC CTCCCTGGCC GAGCTCCACG TGCGCGGTGT CCGGATCGAC 
    11761 TGGGGCCCGC TCTTCGCCGG TGTCTCGCCC GTTGAGCTGC CGACGTACGC CTTCCAACGG 
    11821 GAACGGTTCT GGCTTGGGGC GGACATCGCC GAGTCCGCCG TGGACACGTG GCGATACCAG 
    11881 ATCTCCTGGA AGCCGCTGCC GGACATGGAC CCCCCGGCCC TCTCCGGCAC CTGGCTGGCC 
    11941 GTGGTCCCCG AAGGGGACGA GTGGGCCATG GCGGGCGCAC GGGCGCTGAT CGAGTCGGGC 
    12001 ACGGCCAGCG TCCGTACCCT CCAGGTGACC TGCGACGCGG ACCGCCGGAC CCTGGCCGGG 
    12061 CCGCTGACGG ATGTGGCGGG ATCCGAAGAC ATCGCCGGTG TCGTCTCGTT CCTGGCCGCC 
    12121 GACGAAGTTC CGCATCCGGC CCACCCCGCG CTGTCCCGGG GGATGGCGCA CACGGTCGAG 
    12181 CTGCTGTGCT CGCTCACCAC TGCCGATGTC GAGGCCCCGC TGTGGTGTGT CACCCGGGCG 
    12241 GCCGTCACGG CACTGCCCGC GGACCCGGCG CCGAGCCCCG CCCAGGCGGC GGTATGGGGA 
    12301 TTCGGACGGG TGGCCGGGCT GGAGCGATCC GAGCGGTGGG GCGGCCTGAT CGACCTGCCC 
    12361 GTCCACTGCG ACGCACACGT GCTGCGGCGG TTCGTCGCCG TACTCGCGCA GGCAGCCGGT 
    12421 GAGGACCAGG TGGCGGTGCG GCCATCGGCG GCCCTGGGCC GACGGTTGGA GCCGGCGCCC 
    12481 AGGACCGGAC CGGCCGGCGC ATGGCGCCCG CACGGCACGG TGCTGATCAC CGGTGGCACC 
    12541 GGCGTGCTGG GCGCACATGT GGCACGGTGG CTGGCGCGGT CCGGCGCGGA ACACCTGGTG 
    12601 CTGCTCAGCC GCCGTGGCCC GCAGGCCCCT GGGGCGGCCG TGCTCGACGA CGAACTGACC 
    12661 GCGCTCGGCG TACGAGTGAC CCTGACGGCC TGCGATGTGA CCGACCGGGC CGCTCTCGCC 
    12721 GGGGTGCTGG CATCGGTGCC GGACCTCACC GCCGTGGTCC ATCTCGCGGG GACCGTGCGA 
    12781 TTCGGCAATT CCATCGACGC GGACCTCGAC GAGTACGCCG GCGTCTTCGA CGCCAAGGTC 
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    12841 ACCGGTGCCC TGCATCTGGA CGAGCTCCTC GACCACTCGT CACTGGAGGC GTTCGTCCTC 
    12901 TTCTCCTCGG CAGCGGCCGT CTGGGGCGGT GTCGGCCAGG CCGGTTACGC GGCGGCGAAC 
    12961 GCCCTGCTCG ACGCGGTGGC ACAGCGGCGT CGCGCACGCG GTCTGCCGGC CACTTCGATC 
    13021 GGCTGGGGCA CCTGGGGCGG CAGCCTCGCG CCCGAGGACG AGGAGCGGCT GAGCCGCATC 
    13081 GGCCTGCGCC CGATGCGGCC GGAGGTGGCC GTCACCGAGC TGCGCCACGT CGTCGGATCG 
    13141 GCCGAGCCCT GCCCGGCCAT CGCGGACGTC GACTGGGAGA CCTTCGGCCC GGCCTTCACG 
    13201 GCAGGCCGGC CCAGCCGCCT GCTCAGCGAG TTGCCGCGGC TGCGAAACAC CTCCGGCGCC 
    13261 ATGGCGATGA CCGGCGACCA CGCCGCATTG CGGAGGCGAC TGGCCGGGGT GTCCGCGGCC 
    13321 GACCAGGCCC GGACGCTGGT GGACCTGGTA CGTGAACACG CGGCGGAACT CCTGGGGCAC 
    13381 CGCGGCCCGG CGGCGATCGA CCCCACGGTG CCATTCCGGC AACTGGGCTT CGACTCGCTG 
    13441 ACGGCGGTCG AGCTGCGGAC CCGGCTGAAC GCGGCCACGG GACTGCGCCT CCCGGCCACC 
    13501 TTGCTGTTCG ACCACCCGAG CTGCCGGGCG GTCGCCGATC TGCTGCGCTC GGAACTGCTC 
    13561 GGCGACCGGC CGGGCTCCCT CGCGGCGTCG TCCGCCACGG AGGCTGTGCC CGCCGGCGTG 
    13621 GTGGCCTCCG ACGAGCCGAT CGCCATCGTC GCGATGAGCT GCCGCTTCCC GGGAGGCATC 
    13681 GGAACCCCCG AGGACTTGTG GCGGGTGGTC AGCGAGGGCC GGGACGTGCT CTCCGACTTC 
    13741 CCCGACGACC GCGGCTGGGA CGTGGACGCG CTGTACGACC CGGACCCGGA CCGGCCCGGC 
    13801 ACCAGCTATG TGCGTACCGG TGGATTCCTC CACGACGCCG CGGAGTTCGA CCCGGAACTC 
    13861 TTCGGGATCT CCCCGCGTGA GGCGCTGGCG ATGGATCCCC AGCAGCGGCT GCTGCTGGAG 
    13921 TCGGCGTGGC AGGTCCTGGA GCGCGCCAGG ATGGCGCCGA CCTCCCTGCG ATCCAGCAGG 
    13981 ACCGGTGTCT TCATCGGCGG CTGGGGCCAG GGCTACCCCT CGGCCTCGGA CGAGGGGTAT 
    14041 GCCCTGACCG GCGCCGCGAC CAGCGTGATG TCCGGTCGTA TCGCCTACGC GCTGGGGCTG 
    14101 GAGGGCCCCG CCCTGACCGT GGACACGGCA TGTTCGTCCT CGCTGGTGGC GCTGCATCTG 
    14161 GCGAGCGAGG CGCTACGGCG CGGCGAGTGC TCGCTGGCGC TCGCCGGCGG CGTGACGGTG 
    14221 ATGGCGACGC CCAGTACCTT TGTGGAGTTC TCGCGCCAGC GTGGGCTGGC CCCGGACGGG 
    14281 CGCTGCAAGC CGTTCGCCGG GGCGGCGGAC GGCACGGGGT GGGGCGAGGG CGTGGGCATG 
    14341 CTGCTGGTGG AGCGGTTGTC GGATGCTGAG CGGCTTGGGC ATCCGGTGCT GGCCGTTGTC 
    14401 TCCGGCTCTG CGGTGAATCA AGACGGTGCG TCGAATGGTT TGACGGCGCC GAATGGTCCG 
    14461 TCGCAGCAGC GGGTGATCCG TCAGGCGTTG GCGAGTGCGG GTCTTGTGGC GTCGGATGTG 
    14521 GATGCGGTGG AGGCGCACGG TACGGGTACG ACGCTCGGTG ATCCGATCGA GGCGCAGGCG 
    14581 CTGCTGGCCA CCTACGGTCA GGACCGGGAT GCGGATCGGC CGTTGTGGTT GGGGTCCCTG 
    14641 AAGTCGAACA TCGGTCATAC GCAGGCGGCC GCGGGTGTGG CTGGTGTGAT CAAGATGGTG 
    14701 ATGGCCATGC GGCACGGGGT GCTGCCGCGA ACGCTGCACG TGGATGAGCC GACACCGAAG 
    14761 GTGGATTGGT CCGCCGGCGC GGTGGGACTG CTCACCGAGT CGGCCGAGTG GCGGCAGGAG 
    14821 GGCCGACCGC GCCGAGCCGG GGTGTCGGCT TTCGGGGTGA GCGGCACCAA TGCCCATGTG 
    14881 ATCCTGGAGC AGGCCCCGAA GCACGCACCG GGGGTGGCGG CCGAGGGCAG GAAGGGGCGC 
    14941 GGGGAGCCGC CGACGGTGCC CTGGGTGCTG TCGGGCGCGA GCGAGGCGGG TCTGCGGGCG 
    15001 CAGATCGAAG GCTTGCGGGC CTTCGCTGAC GACAACCCCA CGCTCGATCC GGCGGATGTG 
    15061 GGCTGGTCGT TGGCGTCCAC ACGTGCGCTT CTGCCGTATC GCACTGTCGT CGTGGGCACC 
    15121 GACCTCGACG AGTTGCGGCG TGGGTTGGAC GCGGCGGAGG TGGTGGGCGC GGCCGAGCCG 
    15181 GACCGTGGCG CCGTGTTGGT GTTCCCGGGG CAGGGGTCGC AGTGGGTTGG GATGGCGTTG 
    15241 GAGTTGGTGG AGTCGTCGCC GGTGTTCGCG GGGCGGATGC GTGATTGTGC GGATGCGTTG 
    15301 GCGCCGTTCG CCGAGTGGTC GTTGTTCGGT GTGTTGGGTG ATGAGGTGGC GCTTGGGCGG 
    15361 GTTGATGTGG TGCAGCCGGT GTTGTGGGCG GTGATGGTGT CGTTGGCGGA GTTGTGGCGT 
    15421 TCGTTTGGTG TGGTGCCGTC GGTGGTGGTG GGGCATTCGC AGGGTGAGAT CGCGGCGGCG 
    15481 TGTGTGGCCG GGGGTCTGTC GTTGGAGGAC GGTGCCCGTG TGGTGGCCTT GCGGAGCAGG 
    15541 GCGTTGCTGG CTCTGTCGGG TCGGGGTGGG ATGGTGTCGG TTCCGGTTTC TGCTGACCGG 
    15601 CTGCGGGGTC GTGTGGGGTT GTCGGTGGCG GCGGTGAATG GTCCGGTGTC GACGGTGGTG 
    15661 TCGGGGGCTG TTGAGGTGCT GGAGGGGGTG CTGGCGGAGT TCCCGGGGGC CAAGCGGATT 
    15721 CCGGTGGATT ATGCGTCGCA TTCGGTGCAG GTGGAGGGGA TCCGGGAGGG GTTGGCGGAG 
    15781 GCGTTGGCAC CGGTTCGGCC GCGTACGGGT GAGGTGCCGT TCTATTCGAC GGTGACCGGG 
    15841 CGATTGATGG ACACCGTGGG GCTGGATGGG GAGTACTGGT ATCGGAATCT GCGTGAGACG 
    15901 GTGGAGTTCC AGTCCGCGAT CGAGGGGCTG CTGGAGCTTG GTCATACGGT GTTCGTCGAG 
    15961 GCCAGCCCGC ATCCGGTGCT GACCGTCGGC ATCCAGGACA CCGCCGAGAC CACGGACACC 
    16021 GACATCCTCG TCACCGGCTC GCTGCGCCGT GACGGCGGTG GCCTTGCCTC TTTCCTCACC 
    16081 GCGCTGGCCC GGCTGCATGT CCGGGGTGTC GCGGTGGAGT GGCGGGAGGC GTTCGCCGGG 
    16141 CTGGACGCCC ACGCCGTGGA CCTGCCGACC TACGCCTTTC AGCGTCGGCG CTTCTGGGCG 
    16201 GCCTCCCTGC GGCAGACTCC CGGGACGGCC GAGTTCGACC ATCCCCTCCT GGGCGCGGTG 
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    16261 CTGCCCTTGC CCGATTCCGG CGGCGGTCTG CTCACGGGCG TGCTCACACT GGCCGGACAG 
    16321 CCGTGGCTGG CCGAACACTC GGTGGCCGGT GTGGTGTTGT TCCCGGGGAC GGGGTTTGTG 
    16381 GAGTTGGTGT TGCAGGCGGG GTTGCGGTGG GGGTGTGGGG TGGTTGAGGA GTTGACTTTG 
    16441 GAGGGGCCGT TGGTGCTTCC GGAGCGGGGT GAGGTTGAGG TTCAGGTTTC GGTGGGTGGT 
    16501 GTGGATGGGG CGGGGTGTCG GTCGGTGTCG GTGTTTTCGT GTCGTGGGGG TGAGTGGGTT 
    16561 CGGCATGCGG TGGGTGTGCT TGGGGTGGGG GATGGTGTGG TGCCGGGTGT GGAGGTGTGG 
    16621 CCGCCGGTGG GTGCGGAGCG GGTTGGGGTG GAGGGGGTTT ATGAGGTTTT GGCGGAGCGG 
    16681 GGGTATGTGT ATGGGCCGGT GTTCCAGGGG TTGCGGGACG CCTGGCGCCG GGGCGACGAA 
    16741 ATCTTCGTGG AGGCGGAGGT ACCGGCGGAG GCGCGGGGCG ATGCGGCTCG CTGTGCCATC 
    16801 CATCCCGCGC TGCTCGACGC AGGGCTGCAC GGCGTCGGAT TGGGCGGCCT GATCAGCGAC 
    16861 GACGGCCGGG CGTACCTGCC GTTCTCCTGG AGCGGGGTCA GGCTGCACGC GGTCGGCGCA 
    16921 TCCGCTGTCC GGATGACGCT GACGCCCGCC GGACCGGACG CGGTGTCGCT GAGGGTGACC 
    16981 GATGAGGCGG GCGAGGCGGT GCTGACGGCG GACTCCCTTG TGCTCCGCCC GGTCACCGAG 
    17041 GGACAGCTCG CCGAAGCCGA GATCGGCAAC CGCGATGTGC TTCATCGGGT GGAGTGGGTG 
    17101 GATGCGGGGG CGTGTTCGGT GGGGTCGTTC GTGGAGTGGG GTGAGGTGGC TGCTGGTGGG 
    17161 GTGGTGCCGG ATTGTGTGGT GTTGGCCGGG GCTGATGTGG CGGGTGTGTT GGAGGTTTTG 
    17221 CGGACGTGGG TGGTGGAGGA GCGGTTTGAG GGTTCGCGGT TGGTGGTGGT GACGAGGGGT 
    17281 GCGGTGTCGG TCGGTGGTGA GGGTTTGGAG GATGTGAGTG GTGGTGCGGT GTGGGGGTTG 
    17341 GTGCGGTCGG CGCAGTCGGA GCATCCGGGG CGGTTTGTGC TGGTGGACGC CGATGTAGAT 
    17401 ACGGATGTGG TTCCGGATGT GGTGGGGCTG GGGGAGTGGC AGGTGGCGGT GCGTGCGGGT 
    17461 CGGGTGTGGG TGCCGCGTCT GGTGGATGTG GATGTGAGTG TGGGTGGTGC TGTGGTGCGT 
    17521 GGGGGCTTGG GTTCGGGTGT GGCGTTGGTG ACGGGTGGGA CGGGGTTGCT GGGTGGGTTG 
    17581 GTGGCGCGTC ATCTGGTGTC GGCGTATGGG GTGGGTGAGT TGGTGTTGGT GAGTCGTCGG 
    17641 GGGGTGGCTG CGCCGGGCGT GGAGGAGTTG GTGGGGGAGT TGGAGGGGTT GGGCGCGCGG 
    17701 GTGCGGGTGG TGGCGTGTGA TGTGGCGGAT CGGGGTGCGG TGGCGGAGTT GGTGGGGTCG 
    17761 ATCGAGGGGT TGCGGGTGGT GGTGCACGCG GCGGGTGTCG TGGATGACGG GGTGATCGGT 
    17821 TCGTTGGACG CGGAGCGGTT GTGTGGGGTG ATGGGGCCGA AGGCGTGGGG TGCCTGGCAT 
    17881 CTGCATGAGC TGACGCGTGG GTTGGATCTG TCGGCGTTCG TGTTGTTCTC GTCGGCGGCG 
    17941 GGTGTGTTGG GCAACGCGGG CCAGGGCGGC TACGCGGCCG CGAATGGGTT CCTGGACGCG 
    18001 CTGGCGGTTC ACCGTCGGGG GCGGGGACTC CCCGCGGTGT CGATCGCGTG GGGCTTCTGG 
    18061 GAGGAACGCA GCGAACTGAC CGCCGACCTG GCCGAGGTGC AGCTGTCGAG GATCTCCCGG 
    18121 TCCGTAGGGG CCAGCATCAG CAGCGCACAA GGACTGGATC TGTTCGACGC GGCGCTTGCC 
    18181 GCCGACGAGC CGATGGTGCT GGCCACACCC CTGAACCTGC CCGCGTTGCG GGACCAGGCC 
    18241 GCCGCGGGCA CGTTGCCCTC GATCCTGAGC GGACTGGTCA CCGCTCCCGT CCGCAGGACG 
    18301 GCCGGCACCG GGCGCACTCC GGCCGGACTG CGGCACCAAC TCGCCGGGGT GACAGAGGCC 
    18361 GAAAGGCAGC ACCAGATCAT GCGCCTGGTG CAGGAACATG TGGCCGGCGT TCTGGGACAT 
    18421 GCCTCCGCGG AGTTGGTCGA CGCCTCGCGG ACGTTCCAGG AGATCGGGTT CGACTCGCTG 
    18481 ACCGCCGTGG AACTGCGCAA CCGGATCAGC GCCGCCACCG GCATACGGCT GCCCGCCACC 
    18541 GCGGTCTTCG ACCACCCCAC GCCCAGGCTG CTGGCCGAGC GGGTGCTGGC CGAGGTAGGG 
    18601 GGCTCCTTGC CGACCGCCGC CCCGATCGCG CCGGTGTCGG CCGTCGATGA CGAGCCGATC 
    18661 GTGATCGTGG GCATGAGTTG CCGCTTCCCC GGCGGCGTCG AGTCCCCCGA GGACCTGTGG 
    18721 CGCCTGGTCC ACTCGGCCAC CGACGCGGTC TCCGCGCTGC CCACGGACCG GGGCTGGGAC 
    18781 CTGGCCACCT TGTCCGGTGC CAAGGGCGGC GCCGGTGCCT CGTACGCCCG GGACGGCGGA 
    18841 TTCCTTTACG ACGCGGCTGA GTTCGACGCC GGATTCTTCG GGATCTCGCC GCGCGAGGCG 
    18901 ACCGCGATGG ATCCGCAGCA GCGGCTGCTG CTGGAGGCGG CCTGGGAGGT GTTCGAGCGG 
    18961 GCCGGAATCG CCCCGGACAC GCTCAAAGGC AGCCGGACGG GCGTCTTCAC AGGCGTGATG 
    19021 TACCACGACT ACGGCTCGTG GCTCACCGAT GTCCCGGAGG ACGTCGAGGG CTATCTGGGC 
    19081 ACAGGCATCG CGGGCAGTGT GGCGTCGGGG CGACTCGCCT ATACGTTCGG CCTTGAGGGG 
    19141 CCTGCCCTGA CGGTGGACAC GGCCTGCTCC TCATCACTGG TGGCGCTGCA TCTGGCGGCC 
    19201 GAGTCGCTGC GGCGCGGGGA GTGCTCGCTG GCACTCGCGG GCGGCGTCAC CGTACTGGCG 
    19261 ACTCCGCAGG TCTTCGTGGA GTTCACACGC CAGGGCGGAC TCGCACCGGA TGGCCGGTGC 
    19321 AAGCCCTTCG CCGCTGGTGC GGATGGGACG GGCTGGTCGG AGGGTGTTGG GCTGCTGCTG 
    19381 GTGGAGCGGT TGTCGGATGC CGAGCGGAAC GGGCATCCGG TGCTGGCCGT TGTCTCCGGC 
    19441 TCCGCGGTGA ATCAAGACGG TGCGTCGAAT GGTTTGACGG CGCCGAATGG TCCGTCGCAG 
    19501 CAGCGGGTGA TCCGTCAGGC GTTGGCGAAC GCCGGGCTCG CCGCCAGGGA TGTCGATGCG 
    19561 GTGGAGGCGC ATGGTACGGG GACGACGCTG GGTGATCCGA TCGAGGCGCA GGCGTTGCTG 
    19621 GCCACGTACG GTCAGGGCCG GGATGTGGGT CAGCCGTTGT GGTTGGGGTC GGTGAAGTCG 
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    19681 AACATCGGTC ATACGCAGGC GGCTGCGGGT GTGGCTGGTG TGATCAAGAT GGTGATGGCT 
    19741 ATGCGGCACG GGGTGCTGCC GCGAACGCTG CACGTCGATG AGCCGTCGCC GCATGTGGAT 
    19801 TGGTCTGCTG GGGCGGTGGA GCTCCTGGGG GAGCACATGG GCTGGCCGGA GGTCGGGCGG 
    19861 CCCCGTCGGG CGGGTGTCTC GTCGTTCGGG GCGAGTGGCA CCAACGCCCA TGTGATTCTT 
    19921 GAGCAGGCCC CCGACATGGC GGGTGAACCT GAGCAAAGGC CGGAGCGTAA CGAACTACCG 
    19981 GCGATTCCCT GGGTGTTCTC CGCTGGCGAC GAGGCGGGTT TGCGGGCACA GGCCGTACGG 
    20041 CTACGGGCCT TCGCGGACCG GAATCCGGAT CTGGATCCGG TGGATGTGGG GTGGTCTTTG 
    20101 GCGACTGGTC GTGCGGGGTT GTCGCATCGT GCGGTGGTGG TGGGTGCGGG TCGTGGTGAG 
    20161 TTGTTGGGGG CTTTGGAGGG TGTGCCGGTG GTGGGTGTGC CGGTGGTGGG TGGGTTGGGT 
    20221 GTGTTGTTTG CGGGTCAGGG GTCGCAGCGG TTGGGGATGG GTCGTGGGTT GTATGAGGGG 
    20281 TATCCGGTGT TCGCTGCGGT GTGGGATGAG GTGTGCGCGC AGCTGGACCA GCATTTGGAT 
    20341 AGGCCGGTGG GTGAGGTGGT GTGGGGTGAT GATGCCGGGT TGGTCGGGGA GACGGTGTAT 
    20401 GCGCAGGCGG GGTTGTTCGC GCTTGAGGTG GCGCTGTATC GGCTGATCGC TTCGTGGGGT 
    20461 GTGAGGGGGG ATTATCTGCT GGGTCATTCG ATTGGTGAGT TGGCTGCGGC GTATGTGGCG 
    20521 GGTGTGTGGT CGTTGGAGGA TGCGGGGAGG GTGGTGGTGG CGCGGGGTCG TTTGATGCAG 
    20581 GCGTTGCCGT CGGGTGGTGC GATGGTTGGG GTGGCGGCGT CGGAGGGTGT GGTGCGGCCG 
    20641 CTGCTGGGCG AGGGTGTGGT GGTTGCGGCG GTGAATGGTC CCGAGTCGGT GGTGCTGTCG 
    20701 GGTGATGAGG ATGCGGTTGA GGCGGTTGTG GATGTGTTGG CTGGGCGTGG GGTGCGGACG 
    20761 CGGCGGTTGC GGGTGAGTCA TGCGTTTCAT TCGGCTCGTA TGGACGGGAT GCTGGCGGAG 
    20821 TTCGGTGAGG TGCTTCGGGG GGTGGAGTTC CGTGCCCCGA GCGTGCCCGT GGTGTCGAAC 
    20881 GTGTCCGGTG CGGTGGCGGG TGAGGAGTTG TGTTCGCCGG AGTATTGGGT GCGGCATGTG 
    20941 CGGGAGACGG TCCGGTTCGC CGATGGGCTG GATACTCTCC GTGAGCTGGG TGTGGGTTCG 
    21001 TTCCTGGAGT TGGGGCCGGA CGGGACGTTG ACCGCCTTGG CGGATGGCGA TGGTGTGCCT 
    21061 GTCTTGCGTC GGGATCGTCC GGAGCCTCTG ACCGCTATGG CGGCTTTGGG CGGGCTGTAC 
    21121 GTCCGGGGTG TCCAGATCGA CTGGGATGCG GTGTTCCCGG GTGCTCGGCG GGTTGATTTG 
    21181 CCGACGTATG CCTTCCAGCG TGAGCGGTTC TGGTTGGAGC CGTCCCCTGA GCGGCCCACG 
    21241 ACGAGCGTGG TTGACGCGGC GTTCTGGGAT GCGGTTGAGC GTGGGGATCT CGGTTCGTTC 
    21301 GGCATCGATG CCGAGCAGCC GCTCAGCACC GCCCTGCCCG CCCTCTCGTC CTGGCGGAGG 
    21361 GCGCGGCAGG AGCAGTCGGT GATTGATGGC TGGCGTTACC GGCTCGGTTG GATGCCGATT 
    21421 CCGGCGGTGT CCGGGGAGGT GGGCCTCACC GGTACCTGGC TGGTTGTGGT CGAGCCGGGT 
    21481 GCGGACGGTA CTGATGTGGC TGTCGCGTTG CGGTCGGCCG GGGCCGGTGT CGAGGTTGTG 
    21541 ACGTCGGCGG AGCTGAGCGC TGGTCCGGTT GCGGGTGTGG TGTCGTTGGT GTCGGTCGAG 
    21601 GCGACGGTGT CGTTGCTGCA CGTCCTTGTG GCGGCCGGGG TCGATGCGCC GTTGTGGTGT 
    21661 GTGACTCGTG GTGCGGTCTC GGTGGTCGAC GGTGACTTGG TGGATCCTGG CCAGGCGGGA 
    21721 GTCTGGGGTC TGGGCCGTGT GATCGGTCTG GAGCATCCGG ATCGTTGGGG CGGGCTGATC 
    21781 GACTTGCCTG GCGAACTGGA CGATCGCGCG GGGAATGCGC TGGTAGGCAT CCTTGCCGGG 
    21841 GGCACCGGTG AGGATCAGGT GGCCATCCGT GTCACCGGCA TATGGGGTGC CCGGCTGGTG 
    21901 CGGGCGACGC CGGTCCCGAT CGGTGACGCG GGTGGTGAGG CTGCGGCCGC GTGGCGTGGG 
    21961 CGTGGTACCG CGCTGGTCAC CGGTGGTACG GGGGCGCTGG GGCGCCAGGT GGCGCGCTGG 
    22021 CTGGTGGACA GTGGTCTGGA GCGGGTCGTG CTGACGAGCC GTCGGGGGGG CGAGGCGCCC 
    22081 GGTGCCGTCG AGCTGGTGGC TGAGTTGGGG AGCCGAGTGC GTGTCGTGGC CTGTGATGTC 
    22141 GGCGATCGTG AGGAGCTTGC GGCTCTTTTG GCGATGCTCC CGGATGTGCG GACCATCGTG 
    22201 CATGCGGCGG GTGTCCTCGA CGACGGGGTG CTCGAATCGC TGACGCCCGA GCGGATCCGT 
    22261 GAGGTGATGC GGGCCAAGGC CGACGGCGCG CGGCATCTCC ACGAGTTGAC CCGTGACATC 
    22321 GACCTCGACG CCTTCGTGTT GTTCTCGTCG GCTGCCGGGA CCGTGGGTAA TGCGGGTCAG 
    22381 GGGAGCTATG CGGCGGCCAA CGCCGTCCTG GACGGGCTGG CGTGGCGTCG CCGGGCCGAG 
    22441 GGCTTGGTGG CCACATCGGT GGCCTGGGGA GCCTGGGCCG ACAGCGGCAT GGGGGCTGGG 
    22501 CACGCACGGG CCATGGCACC ACGGCTGGCG CTGGCAGCCC TTCAGCGAGC GTTGGACGAC 
    22561 GACGAGACCG CACTCATGGT CGCGGACGTG GATTGGTCGA GCTTCGGCTC CCGGTTCACC 
    22621 GCCGTACGGC CGAGCCCGCT GCTGAGCGAA CTGCTGCCCC GCTCCAGCGC GCCGGTGGAA 
    22681 CCGGTCGAGG CACTCGCCAC CCGGTTGCGG GGCATGTCGC GGATCGAGCG CGATCGGGCG 
    22741 GTGCTGGAGC TGGTCCGTGC CCAAGTGGCG GCCGTGCTGG GACATGCGAA GCCCGCTTCG 
    22801 GTCGACCCCT CGCGGACCTT CCAGGAAGTC GGCTTCGACT CGCTGACCGC GGTGGAGCTG 
    22861 CGGAACCGGC TGGCCACTGC CACCGGCGTA CCGTTCCCGG GGTCGGTCAT CTTCGACTAT 
    22921 CCGACTCCCA CGGCGCTCGC CGACCATGTC CGGGCCCGGT TCGTTCCGGA CACGGACAAC 
    22981 GACGAGGACG GGGGCGGCGC GACGTCCGTG CTCGACGAGC TGACCAGGCT GGAAGCCGTG 
    23041 CTGTCCGACC TGTCCCCGAG CGACGTGGCC GGTGCCGAGG TCGCCGCGAA GATCAAGAGC 
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    23101 CTGCTGTCCC ACTGGGGAGC GGCCACCAAC AGTGACATCG ACATGGATTC CGCGACGGAC 
    23161 GAGGAGATGT TCGACCTCCT CGGCAAGGAG TTCGGGATCT CGTGAgctag cCGATATAAG 
    23221 TTGTAATTCT CATGTTTGAC AGCTTATCAT CGATAAGCTT TAATGCGGTA GTTTATCACA 
    23281 GTTAAATTGC TAACGCAGTC AGGCACCGTG TATGAAATCT AACAATGCGC TCATCGTCAT 
    23341 CCTCGGCACC GTCACCCTGG ATGCTGTAGG CATAGGCTTG GTTATGCCGG TACTGCCGGG 
    23401 CCTCTTGCGG GATATCGTCC ATTCCGACAG CATCGCCAGT CACTATGGCG TGCTGCTAGC 
    23461 GCTATATGCG TTGATGCAAT TTCTATGCGC ACCCGTTCTC GGAGCACTGT CCGACCGCTT 
    23521 TGGCCGCCGC CCAGTCCTGC TCGCTTCGCT ACTTGGAGCC ACTATCGACT ACGCGATCAT 
    23581 GGCGACCACA CCCGTCCTGT GGATCCTCTA CGCCGGACGC ATCGTGGCCG GCATCACCGG 
    23641 CGCCACAGGT GCGGTTGCTG GCGCCTATAT CGCCGACATC ACCGATGGGG AAGATCGGGC 
    23701 TCGCCACTTC GGGCTCATGA GCGCTTGTTT CGGCGTGGGT ATGGTGGCAG GCCCCGTGGC 
    23761 CGGGGGACTG TTGGGCGCCA TCTCCTTGCA TGCACCATTC CTTGCGGCGG CGGTGCTCAA 
    23821 CGGCCTCAAC CTACTACTGG GCTGCTTCCT AATGCAGGAG TCGCATAAGG GAGAGCGTCG 
    23881 ACCGATGCCC TTGAGAGCCT TCAACCCAGT CAGCTCCTTC CGGTGGGCGC GGGGCATGAC 
    23941 TATCGTCGCC GCACTTATGA CTGTCTTCTT TATCATGCAA CTCGTAGGAC AGGTGCCGGC 
    24001 AGCGCTCTGG GTCATTTTCG GCGAGGACCG CTTTCGCTGG AGCGCGACGA TGATCGGCCT 
    24061 GTCGCTTGCG GTATTCGGAA TCTTGCACGC CCTCGCTCAA GCCTTCGTCA CTGGTCCCGC 
    24121 CACCAAACGT TTCGGCGAGA AGCAGGCCAT TATCGCCGGC ATGGCGGCCG ACGCGCTGGG 
    24181 CTACGTCTTG CTGGCGTTCG CGACGCGAGG CTGGATGGCC TTCCCCATTA TGATTCTTCT 
    24241 CGCTTCCGGC GGCATCGGGA TGCCCGCGTT GCAGGCCATG CTGTCCAGGC AGGTAGATGA 
    24301 CGACCATCAG GGACAGCTTC AAGGATCGCT CGCGGCTCTT ACCAGCCTAA CTTCGATCAT 
    24361 TGGACCGCTG ATCGTCACGG CGATTTATGC CGCCTCGGCG AGCACATGGA ACGGGTTGGC 
    24421 ATGGATTGTA GGCGCCGCCC TATACCTTGT CTGCCTCCCC GCGTTGCGTC GCGGTGCATG 
    24481 GAGCCGGGCC ACCTCGACCT GAATGGAAGC CGGCGGCACC TCGCTAACGG ATTCACCACT 
    24541 CCAAGAATTG GAGCCAATCA ATTCTTGCGG AGAACTGTGA ATGCGCAAAC CAACCCTTGG 
    24601 CAGAAGTTCC TATTCCGAAG TTCCTATTCT TATAGGAGTA TAGGAACTTC TTTCAGCTTT 
    24661 CCGCAACAGT ATAActgtgc ggtatttcac accgcataga tccgtcgagt tcaagagaaa 
    24721 aaaaaagaaa aagcaaaaag aaaaaaggaa agcgcgcctc gttcagaatg acacgtatag 
    24781 aatgatgcat taccttgtca tcttcagtat catactgttc gtatacatac ttactgacat 
    24841 tcataggtat acatatatac acatgtatat atatcgtatg ctgcagcttt aaataatcgg 
    24901 tgtcactaca taagaacacc tttggtggag ggaacatcgt tggtaccatt gggcgaggtg 
    24961 gcttctctta tggcaaccgc aagagccttg aacgcactct cactacggtg atgatcattc 
    25021 ttgcctcgca gacaatcaac gtggagggta attctgctag cctctgcaaa gctttcaaga 
    25081 aaatgcggga tcatctcgca agagagatct cctactttct ccctttgcaa accaagttcg 
    25141 acaactgcgt acggcctgtt cgaaagatct accaccgctc tggaaagtgc ctcatccaaa 
    25201 ggcgcaaatc ctgatccaaa cctttttact ccacgcactg ctcctagggc ctctttaaaa 
    25261 gcttgaccga gagcaatccc gcagtcttca gtggtgtgat ggtcgtctat gtgtaagtca 
    25321 ccaatgcact caacgattag cgaccagccg gaatgcttgg ccagagcatg tatcatatgg 
    25381 tccagaaacc ctatacctgt gtggacgtta atcacttgcg attgtgtggc ctgttctgct 
    25441 actgcttctg cctctttttc tgggaagatc gagtgctcta tcgctagggg accacccttt 
    25501 aaagagatcg caatctgaat cttggtttca tttgtaatac gctttactag ggctttctgc 
    25561 tctgtaccag aaccaccaga accTTTGTAC AATTCATCCA TACCATGGGT AATACCAGCA 
    25621 GCAGTAACAA ATTCTAACAA GACCATGTGG TCTCTCTTTT CGTTTGGATC TTTGGATAAG 
    25681 GCAGATTGAG TGGATAAGTA ATGGTTGTCT GGTAACAAGA CTGGACCATC ACCAATTGGA 
    25741 GTATTTTGTT GATAATGGTC AGCTAATTGA ACAGAACCAT CTTCAATGTT GTGTCTAATT 
    25801 TTGAAGTTAA CTTTGATACC ATTCTTTTGT TTGTCAGCCA TGATGTAAAC ATTGTGAGAG 
    25861 TTATAGTTGT ATTCCAATTT GTGACCTAAA ATGTTACCAT CTTCTTTAAA ATCAATACCT 
    25921 TTTAATTCGA TTCTATTAAC TAAGGTATCA CCTTCAAACT TGACTTCAGC TCTGGTCTTG 
    25981 TAGTTACCGT CATCTTTGAA AAAAATAGTT CTTTCTTGAA CATAACCTTC TGGCATGGCA 
    26041 GACTTGAAAA AGTCATGTTG TTTCATATGA TCTGGGTATC TcGCAAAACA TTGAACACCA 
    26101 TAACCGAAAG TAGTGACTAA GGTTGGCCAT GGAACTGGCA ATTTACCAGT AGTACAAATA 
    26161 AATTTTAAGG TCAATTTACC GTAAGTAGCA TCACCTTCAC CTTCACCGGA GACAGAAAAT 
    26221 TTGTGACCAT TAACATCACC ATCTAATTCA ACCAAAATTG GGACAACACC AGTGAATAAT 
    26281 TCTTCACCTT TAGACATTGT GATGATGTTT TATTTGTTTT GATTGGTGTC TTGTAAATAG 
    26341 AAACAAGAGA GAATAATAAA CAAGTTAAGA ATAAAAAACC AAAGGATGAA AAAGAATGAA 
    26401 TATGAAAAAG AGTAGAGAAT AACTTTGAAA GGGGACCATG ATATAACTGG AAAAAAGAGG 
    26461 TTCTTGGAAA TGAAAAGTTA CCAAAGAGTA TTTATAATTC AGAAAAAAAA GCCAACGAAT 
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    26521 ATCGTTTTGA TGGCGAGCCT TTTTTTTTTT TTAGGAAGAC ACTAAAGGTA CCTAGCATCA 
    26581 TATGGGAAGG AAAGGAAATC ACTTGGAAGA CATCACAAGC ATTCATTTAC CAAGAGAAAA 
    26641 AATATGCATT TTAGCTAAGA TCCATTGAAC AAAGCACTCA CTCAACTCAA CTGAATGAAC 
    26701 GAAAGAAGAA AGAACAGTAG AAAACACTTT GTGACGGTGC GGAACACATT TACGTAGCTA 
    26761 TCATGCTGAA TTCTACTATG AAAATCTCCC AATCTGTCGA TGGCAAAACG ACCCACGTGG 
    26821 CAGAGTTGGG TCAAGTGCCA GTTTCTGGAT TAAGTAACAG ATACAGACAT CACACGCCAT 
    26881 AGAGGAATCC CGCCGTTGCG AGAGATGGAA AACAATAGAG CCGAAATTGT GGAAGCCCGA 
    26941 TGTCTGGGTG TACATTTTTT TTTTTTttCT TTCTTTCTCT TTCAATAATC TTTCCTTTTT 
    27001 CCATTTAGCT TGCCGGAAAA ACTTTCGGGT AGCGAAAATC TTTCTGCCGG AAAAATTAGC 
    27061 TATTTTTTTC TTCCTTATTA TTTTTTTAGT TCTGAAGTTT GACCAGGGCG CTACCCTGAC 







A.4 Sequence of Fragment 2 yeast assembly. 
Sequence of Fragment 2 shown schematically in Fig. 2-1. To show the context of the sequence in 
the chromosome, the last 30 bp of the HO(L) region on the 5’ end, and the pPYK promoter of the 
acceptor module on the 3’ end are included. The sequence is in Genbank format: 
LOCUS       mer-fragment-2-031016     26148 bp    DNA     linear   UNA 07-
Apr-2012 
DEFINITION   
FEATURES             Location/Qualifiers 
     Misc._recombina 1..30 
                     /label=HO-L 
     Misc.           1..1118 
                     /label=cr9-repair-fragment 
     Primer          1..18 
                     /label=AN348 
     Primer          1..60 
                     /label=AN133 
     Primer          1..27 
                     /label=AN531 
     Primer          1..16 
                     /label=AN578 
     Misc._recombina 31..78 
                     /label=FRT-WT 
     ORF             79..750 
                     /label=TRP1 
     Primer          complement(82..110) 
                     /label=AN912 
     Primer          complement(177..199) 
                     /label=AN285 
     Primer          508..529 
                     /label=AN183 
     Primer          complement(722..781) 
                     /label=AN532 
     Primer          730..768 
                     /label=AN533 
     Terminator      751..1005 
                     /label=tACT 
     Primer          complement(974..1026) 
                     /label=AN534 
     Primer          complement(1002..1044) 
                     /label=AN535 
     Restriction_sit 1006..1011 
                     /label=XbaI 
     Misc._recombina 1012..1059 
                     /label=FRT-15 
     Primer          complement(1019..1078) 
                     /label=AN524 
     Cleavage_site   1054..1059 
                     /label=assembly1 
     Primer          complement(1059..1118) 
                     /label=AN492 
     Amplification   1060..1333 
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                     /label="from pSE34" 
     Primer          1149..1168 
                     /label=AN580 
     Promoter        1155..1331 
                     /label=ermE 
     Primer          complement(1307..1327) 
                     /label=AN579 
     Primer          complement(1315..1333) 
                     /label=AN20 
     Primer          complement(1315..1353) 
                     /label=AN103-R9-R1 
     Primer_binding_ complement(1315..1333) 
                     /label=AN20 
     Primer          1324..1353 
                     /label=AN109-R9-R2 
     Amplification   1334..1390 
                     /label="from mer" 
     ORF             1391..22699 
                     /label=merB 
     Primer          complement(1427..1446) 
                     /label=LK19 
     Active_site     1490..2758 
                     /label=M4-KS 
     Primer          complement(1501..1519) 
                     /label=LK20 
     Primer_binding_ 1697..1714 
                     /label=B1 
     Primer_binding_ complement(1894..1913) 
                     /label=B2 
     Primer_binding_ 2088..2107 
                     /label=AN173 
     Primer_binding_ 2449..2467 
                     /label=B3 
     Primer_binding_ complement(2653..2670) 
                     /label=B4 
     Active_site     3059..3964 
                     /label=M4-AT 
     Primer          3243..3263 
                     /label=AN155-R9-R3 
     Primer_binding_ 3273..3291 
                     /label=AN120 
     Primer          complement(3294..3315) 
                     /label=AN119 
     Primer_binding_ complement(3294..3315) 
                     /label=AN146 
     Primer_binding_ 3969..3989 
                     /label=AN144 
     Primer_binding_ complement(4059..4080) 
                     /label=AN145 
     Active_site     4133..4627 
                     /label=M4-DH 
     Primer_binding_ 4472..4490 
                     /label=B5 
     Primer_binding_ complement(4565..4585) 
                     /label=B6 
     Primer          5206..5226 
                     /label=AN164-R9-R4 
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     Primer_binding_ 5206..5226 
                     /label=AN164 
     Primer          complement(5294..5315) 
                     /label=AN156-R9-R3 
     Primer_binding_ complement(5294..5315) 
                     /label=AN156 
     Active_site     5456..6004 
                     /label=M4-KR 
     Primer_binding_ complement(5740..5759) 
                     /label=AN175 
     Primer_binding_ 5779..5797 
                     /label=B7 
     Primer_binding_ complement(5841..5859) 
                     /label=B8 
     Active_site     6260..6517 
                     /label=M4-ACP 
     Primer_binding_ 6382..6400 
                     /label=B9 
     Primer_binding_ complement(6469..6488) 
                     /label=B10 
     Primer          complement(6518..6547) 
                     /label=AN110-r2-pcr1 
     Primer          6518..6547 
                     /label=AN124 
     Active_site     6575..7858 
                     /label=M5-KS 
     Primer          6942..6963 
                     /label=AN168-R9-R5 
     Primer_binding_ 6942..6963 
                     /label=AN168 
     Primer          complement(7179..7197) 
                     /label=AN165-R9-R4 
     Primer_binding_ complement(7179..7197) 
                     /label=AN165 
     Primer_binding_ 7399..7418 
                     /label=AN223 
     Primer_binding_ 7574..7591 
                     /label=B18 
     Primer_binding_ complement(7688..7707) 
                     /label=AN187 
     Primer_binding_ 8146..8164 
                     /label=B11 
     Primer_binding_ complement(8180..8200) 
                     /label=B12 
     Active_site     8189..9058 
                     /label=M5-AT 
     Primer_binding_ 8880..8897 
                     /label=B13 
     Primer_binding_ complement(8891..8909) 
                     /label=B14 
     Primer          complement(8923..8962) 
                     /label=AN125 
     Primer          8923..8962 
                     /label=AN126 
     Primer          8939..8961 
                     /label=AN171-R9-R6 
     Primer          8993..9014 
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                     /label=AN136 
     Primer          complement(9063..9083) 
                     /label=AN135 
     Primer          complement(9153..9172) 
                     /label=AN169-R9-R5 
     Primer          9380..9400 
                     /label=AN245 
     Primer_binding_ 9542..9560 
                     /label=AN225 
     Primer_binding_ complement(9674..9692) 
                     /label=AN224 
     Active_site     10079..10609 
                     /label=M5-KR 
     Primer_binding_ 10157..10176 
                     /label=B15 
     Primer_binding_ complement(10260..10277) 
                     /label=B16 
     Primer          10529..10549 
                     /label=AN400 
     Primer          10747..10765 
                     /label=AN188 
     Active_site     10895..11152 
                     /label=M5-ACP 
     Primer_binding_ 10910..10929 
                     /label=B17 
     Primer          complement(10952..10970) 
                     /label=AN172-R9-R6 
     Primer_binding_ complement(10952..10970) 
                     /label=AN172 
     Primer          complement(11173..11202) 
                     /label=AN127 
     Active_site     11219..12505 
                     /label=M6-KS 
     Primer_binding_ 11569..11586 
                     /label=AN227 
     Primer          complement(11608..11626) 
                     /label=AN246 
     Primer_binding_ complement(11658..11677) 
                     /label=AN226 
     Primer_binding_ 12221..12238 
                     /label=B18 
     Primer_binding_ complement(12335..12354) 
                     /label=AN187 
     Primer          12482..12502 
                     /label=AN215 
     Primer          complement(12734..12752) 
                     /label=AN189 
     Active_site     12809..13675 
                     /label=M6-AT 
     Primer_binding_ 12851..12870 
                     /label=B19 
     Primer_binding_ complement(12940..12961) 
                     /label=B20 
     Primer          13465..13485 
                     /label=AN239 
     Primer_binding_ complement(13550..13570) 
                     /label=AN228 
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     Active_site     13853..14353 
                     /label=M6-DH 
     Primer_binding_ 14096..14116 
                     /label=BAN21 
     Primer_binding_ complement(14099..14120) 
                     /label=BAN22 
     Primer          14297..14316 
                     /label=AN229 
     Primer          complement(14306..14326) 
                     /label=AN286 
     Primer          complement(14508..14527) 
                     /label=AN216 
     Primer_binding_ 14766..14786 
                     /label=BAN23 
     Primer_binding_ complement(14768..14787) 
                     /label=BAN24 
     Active_site     15290..16210 
                     /label=M6-ER 
     Primer          15389..15410 
                     /label=AN247 
     Primer          complement(15478..15497) 
                     /label=AN240 
     Primer          16061..16079 
                     /label=AN241 
     Primer_binding_ complement(16097..16117) 
                     /label=BAN25 
     Active_site     16208..16771 
                     /label=M6-KR 
     Primer          complement(16274..16292) 
                     /label=AN230 
     Primer_binding_ 16753..16770 
                     /label=BAN26 
     Primer_binding_ complement(16781..16801) 
                     /label=BAN27 
     Active_site     17024..17281 
                     /label=M6-ACP 
     Primer          17220..17240 
                     /label=AN267 
     Active_site     17342..18625 
                     /label=M7-KS 
     Primer          complement(17428..17446) 
                     /label=AN248 
     Primer          17945..17965 
                     /label=AN249 
     Primer          complement(18068..18087) 
                     /label=AN242 
     Primer_binding_ 18629..18647 
                     /label=BAN28 
     Primer_binding_ complement(18650..18669) 
                     /label=BAN29 
     Active_site     18914..19780 
                     /label=M7-AT 
     Primer_binding_ 18956..18975 
                     /label=B19 
     Primer          18997..19016 
                     /label=AN275 
     Primer          complement(19212..19232) 
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                     /label=AN268 
     Primer_binding_ complement(19627..19646) 
                     /label=BAN30 
     Primer          19658..19678 
                     /label=AN273 
     Primer          complement(19897..19916) 
                     /label=AN250 
     Active_site     19955..20455 
                     /label=M7-DH 
     Primer_binding_ 20212..20230 
                     /label=BAN31 
     Primer          20614..20634 
                     /label=AN364 
     Primer          complement(20830..20849) 
                     /label=AN276 
     Primer          complement(21343..21361) 
                     /label=AN377 
     Primer          21363..21382 
                     /label=AN376 
     Active_site     21383..21937 
                     /label=M7-KR 
     Primer          21480..21498 
                     /label=AN277 
     Primer          complement(21662..21682) 
                     /label=AN274 
     Primer          21953..21970 
                     /label=AN366 
     Primer          complement(22052..22071) 
                     /label=AN365 
     Active_site     22196..22453 
                     /label=M7-ACP 
     Primer_binding_ 22318..22336 
                     /label=B9 
     Primer          complement(22544..22561) 
                     /label=AN379 
     Primer          22552..22570 
                     /label=AN378 
     Primer          22648..22689 
                     /label=AN487 
     Primer          22668..22727 
                     /label=AN485 
     Primer          complement(22678..22705) 
                     /label=AN345 
     Restriction_sit 22700..22705 
                     /label=NheI 
     Promoter        22706..22824 
                     /label=cat 
     ORF             22825..23484 
                     /label=CAT 
     Primer          complement(23142..23163) 
                     /label=AN298 
     Terminator      23485..23594 
                     /label=cat 
     Primer          complement(23575..23634) 
                     /label=AN553 
     Misc._recombina 23595..23642 
                     /label=FRT14 
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     Primer          complement(23602..23661) 
                     /label=AN554 
     Primer          complement(23643..23672) 
                     /label=LMW375 
     Primer          complement(23744..23759) 
                     /label=AN112 
     Terminator      complement(23745..23802) 
                     /label=tHIS3 
     ORF             complement(23872..24575) 
                     /label=HIS3 
     Primer          complement(23954..23975) 
                     /label=AN272 
     ORF             complement(24576..25289) 
                     /label=GFP 
     Restriction_sit 24725..24730 
                     /label=MfeI 
     Promoter        complement(25290..26148) 
                     /label=pPYK 
ORIGIN 
        1 aaaattgtgc ctttggactt aaaatggcgt GAAGTTCCTA TTCCGAAGTT CCTATTCTCT 
       61 AGAAAGTATA GGAACTTCTC TGTTATTAAT TTCACAGGTA GTTCTGGTCC ATTGGTGAAA 
      121 GTTTGCGGCT TGCAGAGCAC AGAGGCCGCA GAATGTGCAC TAGATTCCGA TGCTGACTTG 
      181 CTGGGTATTA TATGTGTGCC CAATAGAAAG AGAACAATTG ACCCGGTTAT TGCAAGGAAA 
      241 ATTTCAAGTC TTGTAAAAGC ATATAAAAAT AGTTCAGGCA CTCCGAAATA CTTGGTTGGC 
      301 GTGTTTCGTA ATCAACCTAA GGAGGATGTT TTGGCTCTGG TCAATGATTA CGGCATTGAT 
      361 ATCGTCCAAC TGCATGGAGA TGAGTCGTGG CAAGAATACC AAGAGTTCCT CGGTTTGCCA 
      421 GTTATTAAAA GACTCGTATT TCCAAAAGAC TGCAACATAC TACTCAGTGC AGCTTCACAG 
      481 AAACCTCATT CGTTTATTCC CTTGTTTGAT TCAGAAGCAG GTGGGACAGG TGAACTTTTG 
      541 GATTGGAACT CGATTTCTGA CTGGGTTGGA AGGCAAGAGA GCCCCGAGAG CTTACATTTT 
      601 ATGTTAGCTG GTGGACTGAC GCCAGAAAAT GTTGGTGATG CGCTTAGATT AAATGGCGTT 
      661 ATTGGTGTTG ATGTAAGCGG AGGTGTGGAG ACAAATGGTG TAAAAGACTC TAACAAAATA 
      721 GCAAATTTCG TCAAAAATGC TAAGAAATAG TCTCTGCTTT TGTGCGCGTA TGTTTATGTA 
      781 TGTACCTCTC TCTCTATTTC TATTTTTAAA CCACCCTCTC AATAAAATAA AAATAATAAA 
      841 GTATTTTTAA GGAAAAGACG TGTTTAAGCA CTGACTTTAT CTACTTTTTG TACGTTTTCA 
      901 TTGATATAAT GTGTTTTGTC TCTCCCTTTT CTACGAAAAT TTCAAAAATT GACCAAAAAA 
      961 AGGAATATAT ATACGAAAAA CTATTATATT TATATATCAT AGTGTtctag aGAAGTTCCT 
     1021 ATTCCGAAGT TCCTATTCTT ATAGGAGTAT AGGAACTTCt accAGCCCGA CCCGAGCACG 
     1081 CGCCGGCACG CCTGGTCGAT GTCGGACCGG AGTTCGAGGT ACGCGGCTTG CAGGTCCAGG 
     1141 AAGGGGACGT CCATGCGAGT GTCCGTTCGA GTGGCGGCTT GCGCCCGATG CTAGTCGCGG 
     1201 TTGATCGGCG ATCGCAGGTG CACGCGGTCG ATCTTGACGG CTGGCGAGAG GTGCGGGGAG 
     1261 GATCTGACCG ACGCGGTCCA CACGTGGCAC CGCGATGCTG TTGTGGGCAC AATCGTGCCG 
     1321 GTTGGTAgga tccACCTGCC GTCGAGTTCG TCTCCGAGTG AGTCCAGCAC CGCGTTGAGA 
     1381 GGGCCGTCCT GTGGAGAATG AAGAGAAACT TCGTCATTAC CTCAAAGAGG TCACGAAGGA 
     1441 TCTGCGGCAG ACCCGCCAGC GCTTGCAGGA CGTCGAGGCG AAGAGCCGCG AGCCCATCGC 
     1501 GATCGTCGGC ATGAGCTGCC GTTTCCCCGG TGGCATCGCA ACGCCGGAAG CGCTGTGGGA 
     1561 CCTGGTGCGC GAGGGCGGCG ACGCGGTGTC GGAGTTCCCG GCCGACCGCG GATGGGACAC 
     1621 GGAGGGCCTC TACGACCCCG CGGGCGGCTC CGGGAAGTCG GTCACCCGCT ACGGCGGATT 
     1681 CCTGCGCGGC GTCGCCGATT TCGACGCCGC GCTCTTCGGG ATCTCTCCCC GTGAGGCGAT 
     1741 CGCGATGGAC CCGCAGCAGC GGCTGATGCT GGAGACCTCC TGGGAAGCGT TCGAGCGGGC 
     1801 CGGTGTCAAC CGTGACGCGG TGCGGGGCAG CCGGACCGGG GTGTTCATCG GCACCAACGG 
     1861 CCAGGACTAC GCGACACTGC TCAGCGCTGC CCGGGACGAT GTGCAAGGCC ACCTCGGCAC 
     1921 GGGCAGCGCG GCCAGTGTGC TCTCGGGACG GGTCGCCTAC ACCTTCGGTC TCGAAGGGCC 
     1981 GACGGTCACC GTGGACACCG CGTGCTCGTC CTCACTGATC GCCCTGCACC TGGCCGTCCA 
     2041 GGCACTGCGC AACGGCGAGT GCGAGCTGGC GCTGGCGGGC GGCGTCACGG TGATGACGAC 
     2101 GACGAACACC TTCGTCGAGC TGTCCAAGCA GGGCGGGCTG GCGCCGGACG GCCGGTCCAA 
     2161 GGCGTTCGCG GCGGCGGCGG ACGGCACCGG CTGGGGTGAG GGCGCCGGGA TGCTGCTGGT 
     2221 GGAGCGGCTG TCCGACGCCG AACGGCACGG TCACCCCGTG CTGGCGGTGG TGCGTGGCAC 
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     2281 CGCCGCCAAC CAGGACGGCG CGTCGAATGG GCTGACCGCG CCGAACGGGC CCTCCCAGCG 
     2341 CCGGGTCATC CGCGCGGCGC TGTCCAACGC CCAGCTGTCC ACGGGCGATG TCGACGTGGT 
     2401 GGAGGCACAC GGCACCGGCA CCCGGCTCGG CGACCCGATC GAGGCACAGG CCCTGCTCGA 
     2461 CACCTACGGT CAGGACCGGG ACCGGCCGCT GTGGCTCGGA TCGGTCAAGT CGAACCTGGG 
     2521 ACACACCCAG GCCGCCGCGG GTGTCGCCGG GGTCATCAAG ATGGTGCTCG CCATGCGCCA 
     2581 CGGTGTGCTG CCGCGCACCC TGCACGTGGA TGAACCGACC CCGCATGTGG ACTGGTCCGC 
     2641 CGGGGCGGTG CGGCTGCTCA CCGAGCGGAC CCCGTGGCCG GAGGCCGACC GGCCGCGCAG 
     2701 GGCGGGCGTC TCCGCCTTCG GAGTGAGCGG CACCAACGCC CATGTGATCG TGGAGCAGGC 
     2761 ATCGGAGGCC GAGCCCGTCG AGCCGCCCCG GGCCGAACCG GTGACGGTGC CCTGGGTGCT 
     2821 CTCGGGCCAG GGCGAGGCCG GTCTGCGGGC CTTCGCGGCC CGGCTCGCCG ATGTGGCCAC 
     2881 CGAAGCGCAC CCCGGCGACC TCGGATGGAC CCTGGCCACC ACCCGCTCGG CGCTGCCGCA 
     2941 CCGTGCGGTG GTGATCGGAT CCACACCAGA GGAACTGCGG AGCGGCCTCG CGGCGGTGGC 
     3001 CGCCGGAGAG CCGGCCTCGA ACGTGGTGGA GGGAGTGGCC GGCTCCGACA CCGGCGTGGT 
     3061 CTTCGTCTTC CCGGGACAGG GCTCGCAGTG GGCCGGTATG GCCGTGGAAC TGCTGGACTC 
     3121 CTCCCCGGCC TTCGCCCGCC GGTTCGCCGA ATGCGCCCGT GCCCTGGAGA CACACCTCGA 
     3181 CTGGTCCATC GAGGACGTGG TGCGTTCCGC GCCCGGTGCG CCCTCGCTCG ACCTCATCGA 
     3241 GGTCGTCCAG CCGGTCCTGT TCACCATGAT GGTGTCCCTC GCTGAGCTGT GGGCCTCCTA 
     3301 CGGGATCACT CCATCGGCCG TGGTCGGCCA CTCCCAGGGC GAGATCGCGG CGGCCTGTGT 
     3361 GGCCGGGGCG CTGTCGCTGG AGGACGCGGC CAAGGTGGTG GTGTTGCGCA GCCGCCTCTT 
     3421 CGCCGAAACG CTGGTGGGCA ACGGCGCCAT CGCCTCGGTC GCCCTGCCCG CGGAACAACT 
     3481 GGCCACCCGG ATCGAGCCGT GGGGCGAGCG CCTCGTGGTG GCCGGGGTGA ACGGGCCCGC 
     3541 GGCCGCCACG GTGGCCGGCG ATCCCCAGAG CCTCGAGGAG TTCGTCGCCG CATGCGCGGC 
     3601 GGACGGCGTA CGCGCCCGCG TCGTGCCCGC CACCGTGGCC TCCCACGGCC CGCAGGTGGA 
     3661 ACCGCTGCGG GAACGGCTGC TCGCCCTGCT GGCCGACGTG GCGCCACGCC AGTCCACCGT 
     3721 TCCGTTCTAC TCCACGGTGA CCGGCGGACT CCTGGACACC ACCGAACTCG ACGCGGACTA 
     3781 CTGGTTCTGG AACGCCCGTA AGCCGATCGA CTTCCTCGGC GCGCTCCGGG CGCTGTTCGC 
     3841 CGACGGCCAC CGCGTCTTCG TGGAGTCGAG CACCCACCCC GCCCTGACCA TGGGGGTCCA 
     3901 GGACACCGCG GATGCCTCCG GCGAGTCCGT GGAGGTCACC GGCTCGTTGC GGCGTGGCGA 
     3961 GGGCGGGCTC GACCAGTTCC ACTCGGCCGT GGCGCGGCTG CATGTGCACG GCGTACGGGT 
     4021 GGACTGGTCC GCGGCCTTCG GGGCGGCGCG GCGGGTGGAG CTGCCGACCT ACCCCTTCCA 
     4081 GCGGGAGCGT TACTGGCTGA CGCCCCGGCC CGGCCAGGGT GACGCCTCCG CCCTGGGGCT 
     4141 GGGTGCGCTC GACCACCCCC TGCTGGGGGC CACGGTCGTG CTGCCCGAGT CCGGCGGTTG 
     4201 CCTGCTCACC GGTCGGCTGT CCCTGGCCGG ACAGCCGTGG CTGGCCGATC ACGCCCTCTC 
     4261 CGGTGTGGTG TTGCTGCCGG GGACGGGGTT TGTGGAGTTG GTGTTGCAGG CGGGGTTGCG 
     4321 GTGGGGGTGT GGGGTGGTTG AGGAGTTGAC TTTGGAGGGG CCGTTGGTTC TTCCGGAGCG 
     4381 GGGTGAGGTT GAGGTTCAGG TTTCGGTGGG TGGTGTGGAT GGGGCCGGGT GTCGGTCGGT 
     4441 GTCGGTGTTT TCGTGTCGTG GGGGTGAGTG GGTTCGGCAT GCGGTGGGTG TGCTTGGGGT 
     4501 GGGGGATGGT GCGGTGCCGG TGGCGGAGGT GTGGCCGCCG GTGGGTGCGG AGCGGGTTGG 
     4561 GGTGGAGGGG GTTTATGAGG CGTTGGCGGA GCGGGGGTAT GCGTACGGCC CGGTGTTCCA 
     4621 GGGGCTGCGG GACGCCTGGC GCCGGGGAGA CGAAATCTTC GTCGAGGTGG CGGTGGCCCA 
     4681 GGAGGCACGG GCGGACGCGG CGCGGTGCGC GATCCATCCC GCGCTGCTCG ACGCCGCGCT 
     4741 CCACGGGGTG CGATTCGGTG ACTTCGTATC CGACGACGAC CAGGCTTATG TGCCGTTCTC 
     4801 CTGGACCGGC GTCACGCTGC ACGCGGTCGG TGCGACGGTC CTGCGCGTCA CACTGTCCCC 
     4861 GGCAGGACGC GACGCGATCG CCCTCCGGGC CACGGACACC ACCGGTGCGC CGGTCCTGTC 
     4921 GGCACGCTCA CTGGCCCTGC GACCGGTCTC CGCCCAGCAG TTGAACGACA CGCGGGGGAG 
     4981 CAGGACTGAC GCCCTCCATC GGGTGGAGTG GGTGGACGCG TCCGGAACCG TGGCGGTGGG 
     5041 GGGTGAGGTG GCGCCGCGGA CTGAGGTGGT GCGGGTCGTC TCCGAGGGTC CGGATGTGGT 
     5101 GGGTGAGGCG TACGGGCATG TGCTTGAGGT TCTGGAGCGG GTGCAGGCGT GGGTGGCGGA 
     5161 TGAGGACCTG GCGGGTGAGC GGTTGGTGGT GGTGACGCGG GGCGCTGTCG ACACGGGTGA 
     5221 TGGTGTGGCG GACGTGGCTG GGGCCGCGGT GTGGGGCCTG GTGCGGTCCG CGCAGTCGGA 
     5281 GAACCCGGGG CGTCTGGTGC TGGTGGACAC CGATGACCTG GACGGCGTCG ACAGTCTGCT 
     5341 TCCCGGGATG CTGGCTCTGG ATGAGGAGCA GGTGCTGGTG CGGTCGGGTG CGGTGCGGGT 
     5401 GCCGCGTCTG GCTCGGGTGC CGGCGCCGGG TGAGGTATCG GGAGGGTTTG GTTCCGGTGC 
     5461 GGTGTTGGTG ACGGGTGGCA CTGGTGTGCT GGGCGGTCTG GTGTCACGGC ATCTGGTGGC 
     5521 GCGGCATGGG GTGAGCAGGC TGGTGCTGCT GTCGCGTCGC GGTGCGGAGG CCGAAGGTGC 
     5581 GGCGGAGTTG CGGGAGGAGC TGGAGGCCGC GGGCGCCGAG GTGGTGATCG CGGCGTGTGA 
     5641 TGCCGCGGAT CGTGAGGCTC TGGCCGGGGT GTTGTCGGGG TTGTCGGCGG ACTTCGCCTT 
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     5701 GAGCGGTGTG GTGCATGCGG CGGGTGTGCT GGACGACGGG TTGCTCACGT CGTTGACGCG 
     5761 TGAGCGGGTC GAGCCGGTGT TGCGGGCGAA GGTGGACGCG GCGTGGAACC TGCATGAGCT 
     5821 GACCACGGGC ATGGATCTGT CGGCGTTTGT GCTGTTCTCA TCGGCGGCGG GTATTCTGGG 
     5881 CAACGCGGGC CAGGGCAGTT ATGCGGCGGC GAACGGGTTC CTGGACGCGC TGGCGGCTCA 
     5941 TCGGCGGGCG CGGGGACTGC CCGCGGTGTC GATCGCGTGG GGCTTCTGGG AAGCACGCAG 
     6001 CGAGCTGACC CAGCACCTGT CGGCCGACGA TCTGGCGCGT GCCCACGCGG TGCCGATGCC 
     6061 CACCTCCCAG GCACTGGATC TGTTCGACGC GACGCTCGCC GCCGACGAGC CGATGGTGCT 
     6121 GGCCGCACCC CTGAACCCGC AGGCATGGTC GGACGCCGGC CACCTGCCTC CCGTCCTGCG 
     6181 CGATCTGGTC CGGCCGCGGA TCCGGCGCGC GGCGGAGACA ACCGGCGCCC CCGAATCGGC 
     6241 CTCCGCGCTC GGACACCGGC TGGCCGCCGT CGACCGCTCC GAGTGGGACC AGGTCGTACG 
     6301 CGAACTCGTG CGCAATCACA TCGCGGCGGT GCTGCGCCAT GCCTCCGGGG AGTCGGTGGA 
     6361 CACCTCGCGG ACGTTCCAGG AGATCGGCTT CGACTCGCTG ACCGCCGTGG AACTGCGCAA 
     6421 CCGGATCAGC GCCGCCACCG GCGTACGGCT GCCCGCCACC GCCGTGTTCG ACTACCCGAC 
     6481 ACCGCAAGCG CTGGCCGAGT ACCTGCTCGC CGAAGTCCTC GGGAAGGACA GCGCCGCCGC 
     6541 CGCGACACCC GTCGGAACCG CCCTCGTCGC CGACGATCCC ATCGTCATCG TCGGAATGAG 
     6601 CTGCCGCTAC CCCGGCGGGA TCACCTCGCC GGAAGCGCTG TGGGACCTGG TGCGCTCGGA 
     6661 CGGCGATGCC ATATCCGTCC TGCCGGCCGA CAGAGGATGG GACCTGGACG GCCTCTACGA 
     6721 CCCGGATCCG GACCGCACCG GTACGTCGTA CGCCCGCAGC GGTGGATTCG TCTACGACGC 
     6781 GGCCGAGTTC GACGCCGCCT TCTTCGGGAT CTCGCCGCGC GAGGCCGCCG CCATGGACCC 
     6841 GCAGCAGCGG CTGCTACTGG AAACCTCATG GGAGGCGTTC GAACGCGCGG GCATCCCCGC 
     6901 CACCTCCGTC AAGGGTGAGC GGATCGGCGT GTTCACCGGG GTGATGCACC ACGACTACCT 
     6961 CACCCGCCTG TCGACCACAC CGGACGCCGT TGAGGGCTAT CTGGGCACGG GCGCGGCAGC 
     7021 GGGCGTCGCC TCGGGCCGCG TGGCCTACAC CTTCGGACTC GAGGGCCCGG CGGTCACCGT 
     7081 GGACACCGCC TGCTCGTCGT CGCTGGTGGC CCTGCACCTC GCCGTACAGG CGCTGCGCCT 
     7141 CGGCGAGTGC TCGCTCGCGC TGGCCGGTGG TGTGACGGTG ATGTCCACGC CCACCGTCTT 
     7201 CGTCGAGTTC TCCCGCCAGC GCGGGCTCGC GCCGGACGGC AGGTGTAAGG CGTTCGCGGG 
     7261 AGCGGCGGAC GGCACCGGCT TCGCCGAAGG CATCGGCATG CTGCTGGTCG AACGGCTCTC 
     7321 GGACGCACGG CGCAACGGAC ACCCCGTCCT GGCCGTGGTG CGGGGCAGTG CGGTGAATCA 
     7381 GGATGGTGCG TCGAATGGGT TGACGGCCCC GAATGGTCCG TCGCAGCAGC GGGTGATCCG 
     7441 GCAGGCGCTG GCGAGCGCGG GGCTGTCCAC GGTGGATGTG GACGCGGTGG AGGCGCACGG 
     7501 TACGGGTACG ACGCTGGGTG ATCCGATCGA GGCGCAGGCG TTGCTGGCCA CGTACGGTCA 
     7561 GGGCCGGGAT TCGGACCGGC CGTTGCTGCT GGGGTCGATC AAGTCGAACA TCGGTCACAC 
     7621 TCAGGCGGCC GCCGGTGTGG CTGGTGTGAT CAAGATGGTG ATGGCGATGC GCCACGGCGT 
     7681 GCTGCCGCAG AGCCTGCACA TCGATGAGCC CACTCCCCAC GTCGACTGGT CCACCGGCGC 
     7741 GGTGGAGCTC CTGAGCGAAC AGACGGCATG GCCGGAGGCC GGGCGGCCCC GCCGGGCCGG 
     7801 GGTGTCGTCG TTCGGCATCA GCGGGACGAA CGCGCACCTG ATCCTTGAGC AGGCTCCGCT 
     7861 GCCGACGGCA GCGGAGCGGC CCGGTGACGC CGAGCCCGTT CCGGTCGAGC CTGCCGCGGT 
     7921 GGTCCCGTGG ATCGTCTCGG GGCGCGACCG GCATGCCGTG CGCGCGCAGG CGGAACGACT 
     7981 GCGCGCACAC GTGGTGAGCC ACCCTGACCG GAGGGTGGCG GACATCGGTT TCTCGCTGCT 
     8041 GACCAGCCGC GCCGTGCTGG AGCACCGAGC GGTGGTACTC GGCGGTGACC ATGCCGAACT 
     8101 GCTGGCCGGG CTGACGGCCC TGGCACGGGA CGAACCCGCA CCGGGCGTGG TGGAGGCCCT 
     8161 GGACGCGGCC GAGCCGGGGC GCAAGGTGGT GTTCGTCTTC CCCGGTCAGG GGTCGCAGTG 
     8221 GGCCGGGATG GCGCTGGAAC TGATGGAGTC CTCGCCCGTG TTCGCACGGC GGATGGGCGA 
     8281 GTGCGCCGAT GCGCTGGCTC CGCTGGTGGA GTGGTCGCTG CCGGACGTGC TGGCGGATGA 
     8341 GCGAGCGCTG GCCCGTGTCG ATGTGGTGCA GCCGGTGCTG TGGGCGGTGA TGGTGTCGCT 
     8401 GGCCGAGCTG TGGCGTTCGT ACGGTGTGGT GCCGTCGGCG GTGGTGGGTC ACTCGCAGGG 
     8461 TGAGATCGCG GCGGCGTGTG TCGCGGGTGG CCTGTCCCTG GCGGACGGGG CAAGGGTGGT 
     8521 CGTGCTGCGC GGCAAGGCGC TGCTCGCCTT GTCGGGCCGG GGCGGAATGG TGTCCGTTCC 
     8581 GGTGCCCGCC GACCGGCTGC GGGACCGGCC CGGGGTCTCC ATCGCGGCGG TGAACGGCCC 
     8641 ATCCTCGACA GTGGTGTCCG GCGGCGACGA GGTGCTGGAC GCGGTGCTGG CGGAGTTCCC 
     8701 GGCCGCCAAG CGCATCCCGG TGGACTACGC CTCCCACTCG CCCCAGATCG ACGACATCCG 
     8761 GGACGAACTG CTGAAGGCCC TGGCGCCGAT CGAGCCGCGC ACCGCGGCGA TCCCCTTCCA 
     8821 CTCCACGGTG ACCGGACGGC CCATCGACAC CGCCGACCTG GACGCGGACT ACTGGTATCG 
     8881 CAATCTGCGC GAGACCGTGG AGCTCGAGCG GGTCATCCGT ACGGCGGTCG AGGACGGCCA 
     8941 CCACACCTTC ATCGAGATCA GCCCCCACCC GGTGCTGACC ACGGGCCTGC GCGAAACACT 
     9001 CGACGACGCG GACGCGCACG GCGGCCTCGT ACTGGCCTCA CTGCGCCGGG ACGACGGTGG 
     9061 CCCTACCCGC TTCCTCACCG CCTTGGCCGA GGCGTACGCA CACGGCGTCG AGGTCGACTG 
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     9121 GCTGCCGCTG TTCCCGGGCG CCCGCCGGGT GGATCTGCCG ACGTACGCCT TCCAGCGCGA 
     9181 GCGCTACTGG CTGGACGCGC CCACCGCCGA GGCCCCCACC AGCGCGATCG ACGCGGAATT 
     9241 CTGGGCCGCC GTCGAGCGCG AGGACCTCGA GTCGCTCGCC GCGACGCTGC GCGTCGACGG 
     9301 GCAGCCGCTG CGCGAAGTGC TGCCCGCCCT GTCCCAGTGG CGGCGCGAAC GCCGTGACGT 
     9361 CTCCACCATC GACTCATGGC GTTACACGAT CCGGTGGAAG CCGCTCACCC CGCCCGCCAC 
     9421 TTCACCGACC GGCACCTGGC TGGTCGTGGT CTGCCATGCC GAGGCCGGGC ACGAGTGGGT 
     9481 CGCGGGGGTG ACCGACGCGC TGACCCGTCA CGGTGCCGAG CCGCTCGTGG TCGTTCTCGG 
     9541 CGAGCCCGAA CTGGACCGTG CCGCGCTGGC CGCCCGGCTG GGCGGCGTAC TGGCCGACAC 
     9601 CCCCAGGATC AGCGGTGTGG TGTCGCTGAC CGCGCTGGAC GAGAGCCCGC ACCCGGCGTA 
     9661 CCCCTCGGTC CCCCAGGGAT ACGCGATGAC GCTGCTGCTC TCGCAGGCGC TCGGGGACGC 
     9721 CAGGGTGGAA GCTCCGCTGT GGTGCCTCAC CCAGCGCGGC GTCTCGCTCG GCGATGCCGG 
     9781 AGGCAGTGGC AGTGGCAGTG GCACTGGCGA CGGCAGGGGC AAGGGCAAGG GTGATGTGGC 
     9841 CGTCAGCCGG AAGCAGGCCC TGACCTGGGG TCTCGGCAAG GTGATCGCTC TGGAACAGCC 
     9901 CCTGCGCTGG GGCGGTTTGA TCGACCTGCC GGAGGGCGTG GCCCCGCATA CCCAGGACTA 
     9961 CCTTGCCGGT GTGCTGTCCG GCACCTCGGA CGAGGACCAG GTGGCGATCC GCCCGACGGG 
    10021 GCTCTTCGGC CGTAGGCTGG CCCACGCGCC GGCCCGCGAG CGCGGCGGGG GCTGGCAACC 
    10081 CCGCGGCACC GTACTGGTCA CCGGTGGCAC CGGAGCGCTG GGCGGCCATG TCGCCCGGTG 
    10141 GCTGGCCGGC CAGGGGGCTG AACACGTGGT GCTGACCAGT CGCCGGGGCA TGGCCGCGCC 
    10201 CGGCGCCGAG CGGCTGGCCG GGGAGCTGGA GGCGCTCGGC GCCCGGGTGA CGGTGGCGGC 
    10261 GTGCGACGTC GGTGACCGGG ACGCCCTGGC CGGGTTGCTG GCCGAGGTCG GCCCGCTGAC 
    10321 CGCTGTGGTG CACACCGCGG CGGTGCTCGA CGACGGCACG CTGAACTCGC TCACCACCGA 
    10381 CCAGCTGCAA CGCGTGCTGC GCGTCAAGAC CGACGGCGCG GTGCATCTGC ACGAACTGAC 
    10441 GCGGGACATG GAGCTGTCCG CGTTCGTGCT CTTCTCCTCG CTGTCCGGCA CTCTGGGCGC 
    10501 ACCCGGTCAG GGCAACTACG CACCCGGCCA TGTCTTCGTG GACACGCTGG CCGAGCAGCG 
    10561 GCGGGCCGAG GGCCTGGTGG CCACCTCCAT CGCCTGGGGG CTGTGGGCCG GTGACGGCAT 
    10621 GGGCGAGGGC GGTGTGGGCG ACGTGGCCCG CCGCCATGGC GTACCGGAGA TGGCGCCGGA 
    10681 GATGGCGGTC GCCGCCATGG CACGCGCCGT CGAGCAGGAC GACACCGTCG TCACGGTGGC 
    10741 CGAGATCGAC TGGGACCGGC ACTACGTCGC GTTCACCGCG ACCCGCCCCA GCCCGCTGCT 
    10801 GTCCGACCTC CCCGAGGTGC GTGCGCTGGT CGACGCCGGA GTCGGCCAGG AGAGCGCCGA 
    10861 GCCGGGCCAC GAGCGCTCGG AATTCGCGGA GCGGCTCGCC GGGATGGCCG AGACCGACCG 
    10921 GAACCACGCG TTGCTGGACC TGGTCCGGCG CCATGTCGCC GTCGTACTCG GACACACCGG 
    10981 TCCGGACGCG ATCGACCCCG GCCGGGCCTT CCACGAGATC GGCTTCGACT CGGTCACCGC 
    11041 GGTCGAACTG CGCAACCGGC TCAACCGGGC CACCGGCCTA CGGCTGCCCG CCACCGTGAC 
    11101 GTTCGACCAG CCCACCCCGC TGGCGATGGC GCAGTACCTC CGCGGCGAAC TGCTGCACGA 
    11161 CGGCCAAGGC CGATCGGCCC CCGCCCTCCC GGTCCGCGCG ACCGGCGCGG TGGACGACGA 
    11221 GCCTATCGCG ATCGTGGGGA TGAGCTGCCG CTTCCCCGGG GACGTCGCGT CCCCCGAGGA 
    11281 CCTGTGGCGG CTGCTCGCCG ACGGTTCCGA CGCCATCGGC GAGTTCCCCG AGAACCGGGG 
    11341 CTGGGACACC GCGCACCTCT TCCACCCGGA CCCCGACCAC CGAGGCACCT CCTCCACCCG 
    11401 AGCGGCCGCG TTCGTCTCCG GGGCCGGTGA GTTCGACGCC GGATTCTTCG GGATCTCCCC 
    11461 GCGGGAAGCG GTGGCGATGG ACCCGCAACA GCGGCTGCTG CTCGAAGTGT CATGGGAGGC 
    11521 GCTGGAGCGG GCCGGGATCG ACCCCACGAC CCTGCGGGGC AGCGAGACCG GCGTGTTCAC 
    11581 GGGGACGAAC GGTCAGGACT ACGCGTCGTT GCTGAAGGCG GACGAGACGG GTGACTTCGA 
    11641 GGGCCGGGTG GGCACCGGCA ACTCGGCATC GGTCATGTCC GGCCGGATCT CCTACGTCCT 
    11701 CGGTCTCGAA GGCCCCGCGC TGACCGTGGA TACGGCGTGC TCGTCGTCGC TGGTGGCATT 
    11761 GCACCTGGCG GTGCGGGCCC TGCGGTCGGG CGAGTGCTCA CTGGCCCTGG CGGGAGGCGC 
    11821 GAGTGTCATG ACGACCGCCG GCATCTTCGT GGAGTTCTCC CGTCAGCGCG CGTTGGCGGC 
    11881 CGATGGACGC TGCAAGGCGT TCGCGGCGGC GGCGGACGGT ACCGGCTGGG GTGAGGGTGC 
    11941 CGGAATGCTG GTGGTGGAGC GGTTGTCGGA TGCTGAGCGG CTTGGGCATC GGGTGTTGGC 
    12001 GGTGGTGCGT GGTTCTGCGG TGAATCAGGA TGGTGCGTCG AATGGTTTGA CGGCGCCGAA 
    12061 TGGTCCGTCG CAGCAGCGGG TGATCCGGCA GGCGCTGGCG AGCGCGGGGC TGTCCACGGT 
    12121 GGATGTGGAC GCGGTGGAGG CGCACGGTAC GGGTACGACG CTGGGTGATC CGATCGAGGC 
    12181 GCAGGCGTTG CTGGCCACGT ACGGTCAGGG CCGGGATTCG GACCGGCCGT TGCTGCTGGG 
    12241 GTCGATCAAG TCGAACATCG GTCACACTCA GGCGGCCGCC GGTGTGGCTG GTGTGATCAA 
    12301 GATGGTGATG GCGATGCGCC ACGGTGTGCT GCCGCAGAGC CTGCACATCG ATGAGCCCAC 
    12361 TCCCCACGTC GACTGGTCCA CCGGCGCGGT GGAGCTCCTG AGCGAACAGA CGGCATGGCC 
    12421 GGAGAACACA CGGCCCCGCC GCGCCGGGGT GTCCGCCTTC GGAGTGAGCG GCACCAACGC 
    12481 GCATGTGATT CTGGAGCAGG CCCCCGAGCC GACCGCCGCC CAGCCCGAAC TCTCGCCGGA 
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    12541 ACGCGACGAA ATGAGGGCCG TGCCGTGGGT GGTGACGGGT GCGAGCGAGG CCGGAGTCCG 
    12601 CGCACAGGCC GCGCGCCTCA TGGCCTTTGT CGACGACCGG CCGGAACTCC GCCCGGTGAA 
    12661 CATCGGCTGG TCGCTGGCCT CGACCCGCGC GGCCCTGTCA CACCGTGCCG TGGTCGTAGG 
    12721 TGCTGAACGT ACGGAACTGC TGCGTGAGCT GGAGGCCGTG GCCAGTGGCA GCGTCACGGT 
    12781 CGGCGAGGCC CGCACGCATT CCGGGGTGGT GTTCGTCTTC CCGGGGCAGG GGTCGCAGTG 
    12841 GGTTGGGATG GCGTTGGAGT TGGTGGAGTC GTCGCCGGTG TTCGCGGGGC GGATGCGTGA 
    12901 TTGTGCGGAT GCGTTGGCCC CGTTTGTGGA GTGGTCGTTG TTCGATGTGT TGGGTGATGA 
    12961 GGTGGCGCTT GGGCGGGTTG ATGTGGTGCA GCCGGTGTTG TGGGCGGTGA TGGTGTCGTT 
    13021 GGCGGAGTTG TGGCGTTCGT TTGGTGTGGT GCCGTCGGTG GTGGTGGGGC ATTCGCAGGG 
    13081 TGAGATCGCG GCGGCGTGTG TGGCCGGGGG TCTGTCGTTG GAGGACGGTG CCCGTGTGGT 
    13141 GGCCTTGCGG AGCAGGGCGT TGCTGGCTCT GTCGGGTCGG GGCGGCATGG TGTCGGTTCC 
    13201 GGTTTCTGCT GACCGGCTGC GGGGTCGTGT GGGGTTGTCG GTGGCGGCGG TGAATGGTCC 
    13261 GGTGTCGACG GTGGTGTCGG GGGCTGTTGA GGTGCTGGAT GGGGTGCTGG CGGAGTTCCC 
    13321 GGAGGCGAGG CGGATTCCGG TGGATTATGC GTCGCATTCG GTGCAGGTGG AGGGGATCCG 
    13381 GGAGGGTTTG GCGGAGGCGT TGGCGCCGGT TCGGCCGCGT ACGGGTGAGG TGCCGTTCTA 
    13441 TTCGACGGTG ACCGGCCGGC TGATGGACAC CATCGAGTTG GACGCGGAGT ACTGGTACCG 
    13501 GAACCTGCGC GAGACGGTGG AGTTCCAGAG CGCGATCGAG GGGCTGCTGG AGCTTGGCCA 
    13561 TACGGTGTTC GTCGAGGCCA GCCCGCATCC GGTGCTGACC ATTGGCATCC AGGACACCGC 
    13621 CGACACCACC GACACCGACA TCGTCGTAAG CGGGTCACTG CGCCGCGACG ACGGCGGTCC 
    13681 TGTCCGCTTC CTCAGCACCG TCGGGCGACT GTTCACCGAG GGCGTGCCGG TGGAGTGGCA 
    13741 GCCGCTGTTC GCCGCGGCCG GGGCGCGAAA GGTCGATCTC CCGACCTATG CGTTCCAGCA 
    13801 TGAGTGGTTC TGGCTGGATC CGGTGCGCGG CGCGAGTGAT GTGGGCGGCG CGGGCCTTGC 
    13861 CGGTCTCGCT CACCCCTTGG TGAGCGCGGT GTTGCCGCTG CCCGAATCCG ATGGCTGTGT 
    13921 GCTGACCGGC TCGCTCTCCT CGGCCACCCA TCCTTGGCTG CGTGACCACG CCGTGCTGGA 
    13981 CAAGGTGTTG CTGCCGGGCA CCGGGTTCGT GGAACTGGCC CTTCAGGCCG GGCTGCACCT 
    14041 GGGCTGCCGG ACGCTGGATG AGCTGACCCT GCAGGCGCCG CTCATGCTGC CCGCGCACGG 
    14101 AGACGTACAG ATCCAGGTGG CGGTCGGCGG ACCGGACGAC AGCGGCCGCC GGCCGGTCAC 
    14161 GGTGTACTCC AGGCCGGGCA AGGACCGGAC CTGGATGCGG CACGCCACCG GCAGCATCAG 
    14221 CCCCGTCGGT GAAACGGCCA CCGTGGACCG GGCGGTGTGG CCCCCGGTCG GCGCCACACC 
    14281 GGTCGAGCTC ACCGATGTCT ACGCCGAGAT GAGCACGCAC GGTTACGCGT ATGGGCCCGT 
    14341 CTTCCAGGGG CTGCGCGCCG CATGGCGACG TGGCGACGAG GTGTTCGCCG AGGTGGTCCT 
    14401 GCCCGAGACG GCCGAGAGCG ACGCGGGTCG TTGCGCCATC CACCCCGCCC TCCTCGACGC 
    14461 CGCCCTGCAC GGTGCCGGAC TGGGCACGTT CGTGACCGAA CCAGGCCGAC CGCACCTTCC 
    14521 GTTCACCTGG ACCGGTGTCA CCCTGCACGC CGTCGGTGCC ACCACCTTGC GGGTCGTCCT 
    14581 GTCGCCCGCC GGGCCGGACG CCATCTCGCT CCTGGCCATG GACGGCACGG GAGCGCCGGT 
    14641 GCTGACGGCG GACTCTCTGG CCCTGCGCCC GGTGTCCGAG GGCGGGCTCG GCGGCTCCCA 
    14701 CGACGACTCG CTGTTCCGCG TGGACTGGAC CGAGCTCACC CTGGACGCCT CGGACGCCTC 
    14761 GGACGCACCG GAGGTGTCGG ATGAAGCGGC CTTCCCGGTC GTCGAGTCCG TGGCCCAGCT 
    14821 GGCCGGGGTG GCGGCGGCCC GGAGCGGGCG CGGGGCCGTG GTGTTCAGGC TTTCCACCAC 
    14881 GGAGACCACA GGAGGCGCCG CCGAGGAGAG CCCGGAGGAC GTCTACGCGC TCACCAGCCG 
    14941 TGTCCTCAAG GTCGCGCAGG CGTGGTTGGC GGACGACCGG TTCGGGGACG CCCGCCTCGT 
    15001 CGTGGTGACG CGGGGCGCGG TCGCGACCAC GCCCGGAGAG AACCCGGAGA GCCTTGCCGC 
    15061 CGCCGCGGTC TGGGGCCTCA TCCGCACCGC GCAGACCGAG AACCCCGGCC GTTTCGTCCT 
    15121 CGTGGACACG GTGGACGAGG ATCCGTCGGC GTTGCCGGGG GTGCTCGCCA CCGATGAGCC 
    15181 ACAGGTGGCG ATCCGGGCGG GGAAGGCGCT GGTGCCCAGG CTGGTACGGG CCACCTCGTC 
    15241 GGCGTTGCCG GTACCAGCTG AGACGGACAC CTGGCGGCTG GAGACCGACG GTCAGGGCAC 
    15301 TCTGGAGAAC CTGGTCCTCT CGCCCCGCGC CGAGGCGTCC AGGCCACTTG CCGCACATGA 
    15361 GATCCGGGTG GCCGTGCACG CGGCCGGGGT CAACTTCCGC GATGTACTGC TCGCTTTGGG 
    15421 GATGTACCCG GACAAGGCCG GTCTGCTGGG CAGCGAAGCC GCCGGGACGG TGCTGGAGAT 
    15481 CGGCTCCGGA GTAGTGGGAG TGGCACCGGG AGACCGGGTG ATGGGTCTGT TCTCCGGTGC 
    15541 CTTCGCGCCG GTGGCGATCA CCGATCACCG ACTGGTGGCA CCGATCCCGG AGGGGTGGTC 
    15601 CTTCCCGCAG GCCGCCGCCA CCCCGATCGC CTTCCTCACG GCGATGTACG CCTTGATCGA 
    15661 CCTGGCCGAA GTGCGGAGCG GCGAGTCGGT GCTGGTGCAC GCGGCGGCCG GTGGCGTCGG 
    15721 GATGGCGGCA GTGCAGGTGG CGCGCTGGCT GGGCGCCGAG GTGTTCGCCA CCGCGAGCCC 
    15781 GGCCAAGTGG GATGCGGTGC GCGCATGCGG GGTCGCCCCG CGGCGGATCG CTTCCTCCCG 
    15841 CTCGCCGGAG TTCGCGGACC GCTTCCGCTC GGACGCACCG GACGGTGTGG ATGTCGTACT 
    15901 CAACTCGCTG ACCGGTGAAC TCCTCAACGC GTCGCTCGGA CTGCTGCGTC CCGGTGGACG 
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    15961 GCTGATCGAG ATGGGCAGGA CCGAACTCCG GGACGCACAG GAGGTGATGG CGCGCCACGG 
    16021 TGTGTCGTAC CGGGCCTTCG AACTGCTCGA CGCCGGTCCC GACCGTATCG GCCGACTGCT 
    16081 CACCGAGCTG CTCGCCCTGT TCCACCAGGG CGTGTTCACC CCGCTGCCAC TGCGCGTCCA 
    16141 GGACGTACGG CAGGCGAGTG ACGCTTTCCG CCACCTCTCC CAGGCGCGCC ACATCGGCAA 
    16201 GCTGGCCCTC ACCATCCCGC GACCGTTGTC CGGCGGCACC GCACTGATCA CCGGGGGCAC 
    16261 CGGGACACTG GGCGGTCTGG TGGCTCGCCA ACTGGTGCGG GAGCACGGCG TGACGGAGCT 
    16321 GGTGCTGGCC AGCCGTCGTG GTGACACCGC TCCGCAGGCG GCGGAGCTGC TCACCGAGCT 
    16381 GGAGGCCGCC GGGGCGCGGG TGCGGGTGGC CGCATGCGAT GTGTCGGACC GGGACGCCAT 
    16441 CGCCGCACTC GTCGCCTCGC TGCCGAACCT GCGGAGCGTG GTGCACACGG CCGGTGTCCT 
    16501 CGACGACGCC GTGATCGGGT CGCTCACCCC GGAGCGGCTG CGGACGGTAC TGCGTCCCAA 
    16561 GGCGGACGCC GCATGGCATC TGCATGAACT GACCCGGGAC CGGGACCTTG CCGAGTTCGT 
    16621 GTTGTTCTCC TCGGCGGCCG GAGTACTCGG TGGCCCAGGG CAGGGCAATT ACGCGGCGGC 
    16681 CAACGCCTTC CTGGACGCGC TGGCCGCGCG CCGCCGGGCA CAGGGACTGC CCGCGACCTC 
    16741 GCTGGCCTGG GGCTTCTGGG AGCAGCGCAG CGGACTGACC GAACACCTGA CCACCGATCG 
    16801 GCTCGCCCGG GCCGGCGTCC TGCCGCTGTC CACCGACGAG GGGCTGGTCC TCTTCGACGA 
    16861 CGCCCGCGCG ACCGGCGACA CCCTGCTGGT GCCGATGCGT TACGAACCGT CCTCGCCGGG 
    16921 CCCTGAGCCG GTACCCGCCC TGCTGCGTGG CCTCGTACGC GCTCCGCTCG CCCGCGCCCT 
    16981 TCCGGGCCCG GCCGATGGTG TGGGCAGCGG TGTGGCGGAG GGCCTCACAG GGCTGGCGGC 
    17041 GGACGAACGC CTCGGCGCAC TGCTCGACCT GGTCCGCCGG GAGGCGGCGG CCGTGCTCGG 
    17101 CCACGGCGGT CCGGAATCGG TGACACCCCA GCGTCCGTTC AAGGAACTCG GCTTCGACTC 
    17161 GCTCTCCGCC GTGGAACTGC GCAACCGGCT GCGCGCGGCG ACCGGCCGAC GGCTGGAGGC 
    17221 CACCCTTGTC TTCGACCACC CCACTCCGGC CGTGCTCGCA CGCCACCTCG ACGCCGAGCT 
    17281 GTTCGGCGCC ACCGACGTGG CGGCGCCCGT ACCAGCACCG GCGGTCGCGC ACCCGGCCGA 
    17341 CGAGCCGATC GCCATCGTCG GCATGAGCTG TCGGCTCCCG GCCGGGGTGG ACTCCCCGGA 
    17401 GGCGCTGTGG AAGCTGCTGG TGAGCGGCAC GGACGCGATA TCGGAGCTGC CCCCCGACCG 
    17461 CGGCTGGGAC CTTGACAGGC TCTACGACCA GGATCCGAGC CGGCCCGGTA CGACATACGC 
    17521 CAAGACCGGT GGCTTCCTGA AGAACGCGGC GGACTTCGAC GCGGGATTCT TCACGATCTC 
    17581 CCCCCGAGAG GCGCTGGCCG CGGATCCCCA GCAACGGCTG TGGCTCGAGG CGTGCTGGGA 
    17641 AGCCTTCGAA CGCGCCGGTA TCGATCCGCT CGCCCTGAAG GGCACCCGAA CCGGGGTGTT 
    17701 CGCGGGTGCC GTTTCGACGA CGTACGGCGC GGGTCAGGCC GCCACTCCGG ACGGCTCCGA 
    17761 GGGGTACCTG CTCACCGGCA ACTCCACCTC CGTGATCTCC GGCCGCGTGG CCTACACCCT 
    17821 CGGCCTCGAA GGCCCCGCCG TCACCGTGGA CACCGCGTGC TCGTCCTCGC TGGTCAGCGT 
    17881 GCACTGGGCG TGTGAGTCCC TGCGCCGGGG CGAAAGCACA CTGGCGCTGG CGGGCGGTGT 
    17941 GGCGGTGATG ACGACACCGG ACCTGCTGGT CGAATTCTCC CGCCAGCGCG GACTCGCACC 
    18001 GGACGGGCGG TGCAAGTCGT TCGCCGCCGC CGCTGACGGC ACAGGGTTCG CCGAAGGCGT 
    18061 CGGGGTGCTC GTCCTGGAAC GGCTGTCCGA CGCCACGCGG AACGGCCACC AGGTGCTGGC 
    18121 GGTGATCCGC GGCTCCGCCG TCAACCAGGA CGGCGCGTCC AACGGTCTGA CCGCGCCGAA 
    18181 CGGCCCCTCG CAGCAGCGGG TGATCCGGCA GGCGCTGGTG AACGCCGGAC TCGCCTCCCA 
    18241 GGATGTCGAC GTGGTGGAGG CGCACGGTAC GGGTACGACG CTGGGCGACC CCATCGAGGC 
    18301 GCAGGCTCTG CTGGCCACCT ACGGCCAGGA CCGGGATCCG GATCGGCCGC TGCTGCTGGG 
    18361 CTCCGTGAAG TCCAACATCG GGCACACCCA GGCGGCCGCA GGTGCCGCCG GACTCATCAA 
    18421 GATGGTTCTG GCGCTGCGCA ACGGCGTACT GCCGCGCACC CTGCACGTCG ACGAGCCCTC 
    18481 CCCGCACGTC GACTGGTCCG CCGGGGCCAT GGAGCTGCTG ACCGAGCAGA CCGCGTGGCC 
    18541 CGACCGGGAC CACCTGCGCC GGGCCGGGGT GTCCGCGTTC GGAGTGAGCG GCACCAACGC 
    18601 CCATGTGATC CTCGAACAGG CCCCGGAGCC GGATGAGAAC GGCGAACCGG ACACCGTCCG 
    18661 GTCGTGGTTG CCCGCGGTGC CCTGGGTGCT GTCGGGCGCG GGAGCGGCCG GGCTTCGGGC 
    18721 CCAGGCCCAG CGGTTGGCGT CCTTCGTGCG GGAGAACCCC GGGCTCGACC CCGTGGACGT 
    18781 GGGCTGGTCC CTGGTCGCGA CCCGCGCCGC CCTGTCGCAC CGAGCCGTCG TCGTGGGCGC 
    18841 GGACCGCACG GAACTGCTGC GCGAGCTGGC CGCGGTGGAA TCCGTGGGCG CCGCCGAGGC 
    18901 GGAGCGCGAC GTGGTGTTCG TCTTCCCGGG GCAGGGGTCG CAGTGGGTTG GGATGGCGTT 
    18961 GGAGTTGGTG GAGTCGTCGC CGGTGTTCGC GGGGCGGATG CGTGAATGTG CCGATGCGCT 
    19021 CGCCCCGTTT GTGGAGTGGT CGTTGTTCGG TGTGTTGGGT GATGAGGTGG CGCTCGGTCG 
    19081 GGTTGATGTG GTGCAGCCGG TGTTGTGGGC GGTGATGGTG TCGCTGGCGG AGTTGTGGCG 
    19141 TTCGTTTGGT GTGGTGCCGT CGGTGGTGGT GGGGCATTCG CAGGGTGAGA TTGCGGCGGC 
    19201 GTGTGTGGCG GGTGCGTTGA CTTTGGAGGA TGGGGCGCGT GTGGTGGCCT TGCGGAGCAG 
    19261 GGCGTTGCTG GCTCTGTCGG GTCGGGGCGG CATGGTGTCG GTTCCGGTGT CCGCTGATCG 
    19321 GCTGCGGGGT CGTGTGGGGT TGTCGGTGGC GGCGGTGAAT GGTCCGGTGT CGACGGTGGT 
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    19381 GTCGGGGGCT GTTGAGGTGC TGGATGGGGT GCTGGCGGAG TTCCCGGAGG CGAGGCGGAT 
    19441 TCCGGTGGAT TATGCGTCGC ATTCGGTGCA GGTGGAGGGG ATCCGGGAGG GTTTGGCGGA 
    19501 GGCGTTGGCG CCGGTTCGGC CGCGTACGGG TGAGGTGCCG TTCTATTCGA CGGTGACCGG 
    19561 TCGGTTGATG GACACCGTGG GGCTGGACGG GGAGTACTGG TATCGGAATC TGCGTGAGAC 
    19621 GGTGGAGTTC CAGAGCACCG TCGAAGCTCT GATCGGCCAG GGCCACACGG TGTTCGTCGA 
    19681 GGCCAGCCCG CATCCGGTGC TGACCGTCGG CGTCCAGGAC ACCGCCGACG CGATGGAGAC 
    19741 CCCCATAGTG GCCACCGGTT CGCTTCGCCG GGACGAGGGA GGCGTACGAC GGTTCCTGAC 
    19801 GTCACTGGCT GAGGTATCCG TCCATGGCAT CGAGGTCAAC TGGCAGACGG TCTTCGACGG 
    19861 CACCGGCGCT CGGCGAGTCG ACTTGCCCAC CTACGCGTTC CAGCGTGAGC GGTTCTGGCT 
    19921 GGTGCCATCG ACGGGCACGG GCGACGCGTC CGGGCTGGGC CTGGGCGCCG TTGACCATCC 
    19981 GCTGCTGGGC GCGGCGGTGC CGCTTCCGGA CGCGGACGGC TGTGTGCTGA CCGGTGCGCT 
    20041 GTCGCTGGCC GGGCAGCCAT GGCTGGCCGA CCACTCCGTC CTCGGCATGG TCCTTCTGCC 
    20101 GGGCACCGCG TTCGTGGAGC TCGCGTTGCA GGCGGGGGCG CGGTTCGGCT GCGGCACTCT 
    20161 GGAAGAGCTG ACGTTGCATG AGCCGCTCGT CCTGCCCGAG CGGGAGACCG TGCAGCTCCA 
    20221 GGTGTCGGTC GGAGGCTCGG ACGACTTCGG AGGCCGCCCC TTCACGGTGT TCTCCCGCTG 
    20281 TGAGGGTGAG TGGATACGCC ACGCCGGGGG CACCCTGCGT GTGGGCGAGC GTGGCGATCC 
    20341 GCCCGCGAAC CCGTCGGTCT GGCCACCGGC CGATGCCCGG CCGGTCGATG TCGCCGAGTT 
    20401 GCACACGACG ATGGCCGAGC GGGGCTATCA GTACGGGCCC GCCTTCCAGG GCCTGCGGAA 
    20461 GGCATGGATC CGTGACAGCG AAGTGTTTCT CGACGTCGCG TTGCCCGAGC AGGTGAGGGG 
    20521 CGACGCGGCC CGCTGCGGAG TGCATCCCGC GTTGCTGGAC GCGGCCCTGC AAGGCATCGG 
    20581 CCTCGGCGCC TTCGTCAACG AACCGGGCCA GGCCCATCTC CCCTTCTCCT GGAGCGGGGT 
    20641 GACCCTGCAC GCGGTGGGCG CCACTGCCGT GCGGGTGACA CTCAGCCCGG CCGGACCGGA 
    20701 CACGGTGGCC ATCCGGATGG CGGACACCAT CGGGGCGCCC GTGCTGTCCA TCGACGCGCT 
    20761 GGCGATGCGT CCGCTCGCGG AGCAGCGGCT GCTCGAGGCG GGTGGCAGCC GCGGCGATGC 
    20821 GCTGTTCCGG CTGGAGTGGA AGGAGCTTCC CGTCCCCACG GGGGCCACCG GCCCACGGGC 
    20881 GCAGTCCTGG GGCCTGCTGG GCGGCCACGA CGAGCCTCGA CTGACCGCGG CGCTGACCGC 
    20941 GGCCGGTGTG TCGCCACAAC GCCATCGGGA CCTCGCCTCC ATCGACCAGG TGCCGGATGT 
    21001 GCTGGTCCTG TCGTGTCCGC CCGAGGCGGA TGGCGGCCCG GCCCCGGAAG CCACCTCGTC 
    21061 CGCCCTCCGC CGAGTGCTGG AAGTGGTGCG GGAGTGGCTC GGGGACGCGC GGTACACCGA 
    21121 TGCCCGACTG ATGGTGCTCA CCCGCCGCGC GGTGGCCACA TCCACCGGTG ACGACGTGGA 
    21181 GGATCTGGCG GCGGCCGCTG TACGGGGACT CCTGCGCACC GCACAACAGG AGAACCCCGA 
    21241 CCGGCTCGTC GTGATCGACC ATGACGACTC GGACCTTGAG GTGCTCCCCG TGGTGCTCGG 
    21301 GACAGGGGAG CCCGAAGCGG CCATCCGGGC CGGTAAGGTG CTGGTGCCCA GGCTGGTCAA 
    21361 GGCGGCCGTA TCGGAAGGGA AGGCCCCTGC CTGGGACGCC GGCACCGTGC TGATCACCGG 
    21421 CGGGACGGGG ACACTCGGCG GCCTGGTCGC CCGCCATCTG GTGACCACCC ATGGCGCGCG 
    21481 TGACCTGGTG CTGGCCAGTC GCGGAGGTGA CACCGCGCCC GGCGCCGTGG AACTGGCCAC 
    21541 CGAACTGGAG GCGCTCGGTG CCCGCATCCG CGTCGCCGCC TGCGATGTGG CCGATCGTGC 
    21601 CCAGCTGACC GCGCTGCTCG ACACCATTCC GGCGCTGCGT GCTGTCGTCC ACACCGCAGG 
    21661 TGTGGTGGAC GACGGTGTCA TCGGCTCGAT GACCGCCGAA CGCGTGGAGA CCGTCCTACG 
    21721 GCCGAAGGCG AACGCGGCGT GGCACCTGCA CGCGCTGACC CGCCACCTGG ACCTGGACGC 
    21781 GTTCGTACTG TTCTCCTCCG CCACCGGAGT GCTGGGCAGC GCGGGACAGG GCAACTACGC 
    21841 CGCGGCCAAC GCCTTCCTCG ACGCGCTGGC CGTGCACCGG CGCGCCCAGG GGCTCCCCGC 
    21901 GGTGTCGGTG GCATGGGGCC TGTGGGAGCG GCGCAGTGGC CTGACCGCAC ATCTGTCGGA 
    21961 GCAGGACGTG GCCCGTATGA CCAGCACGGG CGCCGTTCCC CTCTCCGACG AACGCGGTCT 
    22021 CGAGCTGTTC GACGCCGCGT GCCGGAGTGG CGAACCCACA CTCGTGGCCA CCCCGTTGCA 
    22081 CCTTCGTGCG GTGGCGGCCA CCGGTACGGT GCCCCACGTG CTCAGCGCGC TGGCACCGAC 
    22141 CCCGCCACGC CGGGCCGCCG AGGCCGGTGA CGGTGGAGTG GCTCTACGGC AGAGCCTTGC 
    22201 CGAGATGTCG GGCGCGGAAC AGAGCCAGAC CGTCCTGGGG CTGGTACGCG GGCAGGTCGC 
    22261 CGCCGTGCTG CGGCACCCGG ACCCGTCGGC GATCGACACG GCGCGGACGT TCCAGGAGAT 
    22321 CGGCTTCGAC TCGCTGACCG CGGTGGAGCT GCGCAACCGG CTGGGCGCCA CCACCGGGAT 
    22381 CAGGCTGGCC GCGACCGCGA TCTTCGACTA TCCGACACCT GCCACGCTGG CACAGCACCT 
    22441 GCTCGCCGAG ATCGTGCCGG AGACCGCCGA CCCGGTCGCG GCCCGGCTCG GCGAGCTGGA 
    22501 CAAGGTGGCC GCCATGATTT CGGCGATGGC CGAGGACGAC ACCCTGCGCG AGCAGTTGTC 
    22561 CTCGCGGATG GAGACCATCG TCGCGATGTG GGCCGACCTG CACCGTCCGG AGCGGCCGGG 
    22621 CACGGTTGAG CGGGACCTCG AATCCGCCTC GCTCGACGAC ATGTTCGGAA TCATCGACCA 
    22681 GGAACTCGAT GGGTCATGAg ctagcGGCGA AAATGAGACG TTGATCGGCA CGTAAGAGGT 
    22741 TCCAACTTTC ACCATAATGA AATAAGATCA CTACCGGGCG TATTTTTTGA GTTATCGAGA 
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    22801 TTTTCAGGAG CTAAGGAAGC TAAAATGGAG AAAAAAATCA CTGGATATAC CACCGTTGAT 
    22861 ATATCCCAAT GGCATCGTAA AGAACATTTT GAGGCATTTC AGTCAGTTGC TCAATGTACC 
    22921 TATAACCAGA CCGTTCAGCT GGATATTACG GCCTTTTTAA AGACCGTAAA GAAAAATAAG 
    22981 CACAAGTTTT ATCCGGCCTT TATTCACATT CTTGCCCGCC TGATGAATGC TCATCCGGAA 
    23041 TTCCGTATGG CAATGAAAGA CGGTGAGCTG GTGATATGGG ATAGTGTTCA CCCTTGTTAC 
    23101 ACCGTTTTCC ATGAGCAAAC TGAAACGTTT TCATCGCTCT GGAGTGAATA CCACGACGAT 
    23161 TTCCGGCAGT TTCTACACAT ATATTCGCAA GATGTGGCGT GTTACGGTGA AAACCTGGCC 
    23221 TATTTCCCTA AAGGGTTTAT TGAGAATATG TTTTTCGTCT CAGCCAATCC CTGGGTGAGT 
    23281 TTCACCAGTT TTGATTTAAA CGTGGCCAAT ATGGACAACT TCTTCGCCCC CGTTTTCACC 
    23341 ATGGGCAAAT ATTATACGCA AGGCGACAAG GTGCTGATGC CGCTGGCGAT TCAGGTTCAT 
    23401 CATGCCGTCT GTGATGGCTT CCATGTCGGC AGAATGCTTA ATGAATTACA ACAGTACTGC 
    23461 GATGAGTGGC AGGGCGGGGC GTAATTTTTT TAAGGCAGTT ATTGGTGCCC TTAAACGCCT 
    23521 GGTGCTACGC CTGAATAAGT GATAATAAGC GGATGAATGG CAGAAATTCG AAAGCAAATT 
    23581 CGACCCGGTC GTCGGAAGTT CCTATTCCGA AGTTCCTATT CTATCAGAAG TATAGGAACT 
    23641 TCTTTCAGCT TTCCGCAACA GTATAActgt gcggtatttc acaccgcata gatccgtcga 
    23701 gttcaagaga aaaaaaaaga aaaagcaaaa agaaaaaagg aaagcgcgcc tcgttcagaa 
    23761 tgacacgtat agaatgatgc attaccttgt catcttcagt atcatactgt tcgtatacat 
    23821 acttactgac attcataggt atacatatat acacatgtat atatatcgta tgctgcagct 
    23881 ttaaataatc ggtgtcacta cataagaaca cctttggtgg agggaacatc gttggtacca 
    23941 ttgggcgagg tggcttctct tatggcaacc gcaagagcct tgaacgcact ctcactacgg 
    24001 tgatgatcat tcttgcctcg cagacaatca acgtggaggg taattctgct agcctctgca 
    24061 aagctttcaa gaaaatgcgg gatcatctcg caagagagat ctcctacttt ctccctttgc 
    24121 aaaccaagtt cgacaactgc gtacggcctg ttcgaaagat ctaccaccgc tctggaaagt 
    24181 gcctcatcca aaggcgcaaa tcctgatcca aaccttttta ctccacgcac tgctcctagg 
    24241 gcctctttaa aagcttgacc gagagcaatc ccgcagtctt cagtggtgtg atggtcgtct 
    24301 atgtgtaagt caccaatgca ctcaacgatt agcgaccagc cggaatgctt ggccagagca 
    24361 tgtatcatat ggtccagaaa ccctatacct gtgtggacgt taatcacttg cgattgtgtg 
    24421 gcctgttctg ctactgcttc tgcctctttt tctgggaaga tcgagtgctc tatcgctagg 
    24481 ggaccaccct ttaaagagat cgcaatctga atcttggttt catttgtaat acgctttact 
    24541 agggctttct gctctgtacc agaaccacca gaaccTTTGT ACAATTCATC CATACCATGG 
    24601 GTAATACCAG CAGCAGTAAC AAATTCTAAC AAGACCATGT GGTCTCTCTT TTCGTTTGGA 
    24661 TCTTTGGATA AGGCAGATTG AGTGGATAAG TAATGGTTGT CTGGTAACAA GACTGGACCA 
    24721 TCACCAATTG GAGTATTTTG TTGATAATGG TCAGCTAATT GAACAGAACC ATCTTCAATG 
    24781 TTGTGTCTAA TTTTGAAGTT AACTTTGATA CCATTCTTTT GTTTGTCAGC CATGATGTAA 
    24841 ACATTGTGAG AGTTATAGTT GTATTCCAAT TTGTGACCTA AAATGTTACC ATCTTCTTTA 
    24901 AAATCAATAC CTTTTAATTC GATTCTATTA ACTAAGGTAT CACCTTCAAA CTTGACTTCA 
    24961 GCTCTGGTCT TGTAGTTACC GTCATCTTTG AAAAAAATAG TTCTTTCTTG AACATAACCT 
    25021 TCTGGCATGG CAGACTTGAA AAAGTCATGT TGTTTCATAT GATCTGGGTA TCTcGCAAAA 
    25081 CATTGAACAC CATAACCGAA AGTAGTGACT AAGGTTGGCC ATGGAACTGG CAATTTACCA 
    25141 GTAGTACAAA TAAATTTTAA GGTCAATTTA CCGTAAGTAG CATCACCTTC ACCTTCACCG 
    25201 GAGACAGAAA ATTTGTGACC ATTAACATCA CCATCTAATT CAACCAAAAT TGGGACAACA 
    25261 CCAGTGAATA ATTCTTCACC TTTAGACATT GTGATGATGT TTTATTTGTT TTGATTGGTG 
    25321 TCTTGTAAAT AGAAACAAGA GAGAATAATA AACAAGTTAA GAATAAAAAA CCAAAGGATG 
    25381 AAAAAGAATG AATATGAAAA AGAGTAGAGA ATAACTTTGA AAGGGGACCA TGATATAACT 
    25441 GGAAAAAAGA GGTTCTTGGA AATGAAAAGT TACCAAAGAG TATTTATAAT TCAGAAAAAA 
    25501 AAGCCAACGA ATATCGTTTT GATGGCGAGC CTTTTTTTTT TTTTAGGAAG ACACTAAAGG 
    25561 TACCTAGCAT CATATGGGAA GGAAAGGAAA TCACTTGGAA GACATCACAA GCATTCATTT 
    25621 ACCAAGAGAA AAAATATGCA TTTTAGCTAA GATCCATTGA ACAAAGCACT CACTCAACTC 
    25681 AACTGAATGA ACGAAAGAAG AAAGAACAGT AGAAAACACT TTGTGACGGT GCGGAACACA 
    25741 TTTACGTAGC TATCATGCTG AATTCTACTA TGAAAATCTC CCAATCTGTC GATGGCAAAA 
    25801 CGACCCACGT GGCAGAGTTG GGTCAAGTGC CAGTTTCTGG ATTAAGTAAC AGATACAGAC 
    25861 ATCACACGCC ATAGAGGAAT CCCGCCGTTG CGAGAGATGG AAAACAATAG AGCCGAAATT 
    25921 GTGGAAGCCC GATGTCTGGG TGTACATTTT TTTTTTTTtt CTTTCTTTCT CTTTCAATAA 
    25981 TCTTTCCTTT TTCCATTTAG CTTGCCGGAA AAACTTTCGG GTAGCGAAAA TCTTTCTGCC 
    26041 GGAAAAATTA GCTATTTTTT TCTTCCTTAT TATTTTTTTA GTTCTGAAGT TTGACCAGGG 




A.5 Sequence of Fragment 3 yeast assembly. 
Sequence of Fragment 2 shown schematically in Fig. 2-1. To show the context of the sequence in 
the chromosome, the last 30 bp of the HO(L) region on the 5’ end, and the pPYK promoter of the 
acceptor module on the 3’ end are included. The sequence is in Genbank format: 
LOCUS       mer-fragment-3-031016     38831 bp    DNA     linear   UNA 07-
Apr-2012 
DEFINITION   
FEATURES             Location/Qualifiers 
     Misc._recombina 1..30 
                     /label=HO-L 
     Primer          1..27 
                     /label=AN531 
     Primer          1..60 
                     /label=AN133 
     Primer          1..18 
                     /label=AN348 
     Misc._recombina 31..78 
                     /label=FRT-WT 
     Primer          36..66 
                     /label=AN614 
     Primer          43..102 
                     /label=AN613 
     ORF             79..885 
                     /label=KanMX 
     Misc.           610..1288 
                     /label=AN-cr15-gblock 
     Primer          614..637 
                     /label=AN682 
     Primer          complement(622..644) 
                     /label=AN681 
     Misc._signal    685..704 
                     /label=cr23-target 
     Terminator      886..1125 
                     /label=tKanMX 
     Misc._differenc 1043 
                     /label="different from R1-donor" 
     Primer          1055..1077 
                     /label=LK24 
     Primer          complement(1108..1140) 
                     /label=AN615 
     Primer          complement(1117..1176) 
                     /label=AN616 
     Restriction_sit 1126..1131 
                     /label=XbaI 
     Cleavage_site   1126..1131 
                     /label=assembly1 
     Misc._recombina 1132..1179 
                     /label=FRT-14 
     Primer          complement(1146..1196) 
                     /label=AN617 
     Primer          complement(1179..1238) 
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                     /label=AN492 
     Amplification   1180..1453 
                     /label="from pSE34" 
     Primer          complement(1268..1288) 
                     /label=DD77 
     Primer          1269..1288 
                     /label=AN580 
     Promoter        1275..1451 
                     /label=ermE 
     Misc._recombina 1385..1444 
                     /label=CRISPR-repair 
     Misc._recombina complement(1423..1488) 
                     /label=CRISPR-repair-delete-bamHI 
     Misc._recombina 1427..1446 
                     /label=CRISPR-target 
     Primer          complement(1427..1447) 
                     /label=AN579 
     Primer_binding_ complement(1434..1453) 
                     /label=AN697 
     Primer          complement(1435..1453) 
                     /label=AN20 
     Primer          complement(1435..1475) 
                     /label=AN220 
     Primer          1435..1473 
                     /label=KV1 
     Mutation        1444 
                     /label="G to T" 
     RBS             1454..1483 
                     /label=merC-RBS 
     ORF             1484..35050 
                     /label=merC 
     Primer          1489..1506 
                     /label=JK22 
     Active_site     1631..2914 
                     /label=M8-KS 
     Primer          complement(1650..1669) 
                     /label=LK26 
     Primer_binding_ complement(1831..1850) 
                     /label=GAN1 
     Primer          1856..1875 
                     /label=JK9 
     Primer_binding_ complement(2503..2522) 
                     /label=GAN2 
     Primer          2504..2523 
                     /label=JK33 
     Primer          2913..2932 
                     /label=JK139 
     Primer          2924..2944 
                     /label=KV6 
     Primer          2931..2950 
                     /label=JK52 
     Primer          complement(3064..3084) 
                     /label=KV3 
     Active_site     3197..4009 
                     /label=M8-AT 
     Primer          3293..3315 
                     /label=JK10 
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     Primer          3296..3318 
                     /label=KV4 
     Primer_binding_ 3440..3462 
                     /label=GAN3 
     Primer          complement(3441..3462) 
                     /label=KV2 
     Primer_binding_ 3535..3553 
                     /label=GAN10 
     Primer_binding_ 3634..3653 
                     /label=GAN62 
     Primer_binding_ complement(3656..3674) 
                     /label=GAN25 
     Primer_binding_ 3969..3990 
                     /label=GAN4 
     Primer_binding_ complement(3969..3990) 
                     /label=GAN5 
     Primer          complement(4393..4409) 
                     /label=JK32 
     Primer          4398..4417 
                     /label=KV10 
     Primer          complement(4544..4565) 
                     /label=KV7 
     Primer          complement(4565..4585) 
                     /label=JK140 
     Primer_binding_ 4786..4805 
                     /label=GAN59 
     Primer_binding_ 4820..4839 
                     /label=GAN63 
     Active_site     4907..5437 
                     /label=M8-KR 
     Primer_binding_ complement(5057..5076) 
                     /label=GAN7 
     Primer          5057..5076 
                     /label=KV8 
     Primer          5122..5141 
                     /label=JK2 
     Primer          complement(5255..5273) 
                     /label=KV5 
     Primer          complement(5284..5305) 
                     /label=JK1 
     Primer_binding_ 5687..5708 
                     /label=GAN6 
     Active_site     5711..5947 
                     /label=M8-ACP 
     Primer_binding_ complement(5729..5748) 
                     /label=GAN8 
     Primer          5928..5950 
                     /label=JK35 
     Primer          complement(5963..5980) 
                     /label=JK23 
     Active_site     6005..7273 
                     /label=M9-KS 
     Primer_binding_ 6236..6253 
                     /label=GAN9 
     Primer_binding_ complement(6236..6253) 
                     /label=GAN60 
     Primer          complement(6398..6418) 
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                     /label=KV11 
     Primer_binding_ complement(6862..6881) 
                     /label=GAN2 
     Primer          6863..6882 
                     /label=JK33 
     Primer          6954..6974 
                     /label=JK4 
     Primer          complement(7103..7124) 
                     /label=KV9 
     Primer          complement(7104..7124) 
                     /label=JK3 
     Primer          7275..7293 
                     /label=JK37 
     Primer          complement(7487..7506) 
                     /label=JK36 
     Active_site     7556..8368 
                     /label=M9-AT 
     Primer_binding_ complement(7871..7889) 
                     /label=GAN12 
     Primer_binding_ 7894..7912 
                     /label=GAN10 
     Primer_binding_ 8544..8563 
                     /label=GAN11 
     Primer_binding_ complement(8592..8611) 
                     /label=GAN13 
     Primer          8704..8722 
                     /label=JK7 
     Primer          complement(8861..8879) 
                     /label=JK34 
     Primer          complement(8926..8944) 
                     /label=JK6 
     Primer          complement(8926..8945) 
                     /label=JK5 
     Primer          9008..9067 
                     /label=AN341-cr4-repair 
     Misc._RNA       9039..9058 
                     /label="Target mutated sequence" 
     Primer          complement(9046..9105) 
                     /label=AN342-cr4-repair 
     Mutation        9058 
                     /label="C to T" 
     Primer          9175..9194 
                     /label=JK44 
     Active_site     9278..9820 
                     /label=M9-KR 
     Primer          complement(9353..9372) 
                     /label=JK38 
     Primer_binding_ 9690..9713 
                     /label=GAN14 
     Primer          complement(9962..9982) 
                     /label=JK39 
     Active_site     10028..10285 
                     /label=M9-ACP 
     Active_site     10343..11599 
                     /label=M10-KS 
     Primer          10364..10382 
                     /label=JK40 
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     Primer_binding_ complement(10451..10469) 
                     /label=GAN16 
     Primer          complement(10686..10705) 
                     /label=JK8 
     Primer_binding_ complement(10982..10999) 
                     /label=GAN17 
     Primer_binding_ 11039..11060 
 
                     /label=GAN15 
     Primer          11610..11629 
                     /label=JK46 
     Primer          complement(11658..11677) 
                     /label=JK45 
     Active_site     11909..12781 
                     /label=M10-AT 
     Primer          12211..12230 
                     /label=JK42 
     Primer          complement(12301..12319) 
                     /label=JK41 
     Primer_binding_ 12813..12832 
                     /label=GAN18 
     Primer_binding_ complement(12919..12937) 
                     /label=GAN19 
     Primer          13435..13454 
                     /label=JK62 
     Primer          complement(13629..13648) 
                     /label=JK47 
     Active_site     13796..14326 
                     /label=M10-KR 
     Primer          14151..14173 
                     /label=JK67 
     Primer_binding_ complement(14164..14183) 
                     /label=GAN20 
     Primer          14270..14288 
                     /label=JK48 
     Primer          14271..14288 
                     /label=JK60 
     Primer          complement(14464..14483) 
                     /label=JK43 
     Active_site     14612..14869 
                     /label=M10-ACP 
     Primer          14814..14834 
                     /label=JK64 
     Primer          complement(14918..14937) 
                     /label=JK63 
     Active_site     14927..16213 
                     /label=M11-KS 
     Primer_binding_ complement(15491..15509) 
                     /label=GAN22 
     Primer_binding_ 15533..15551 
                     /label=GAN21 
     Primer_binding_ complement(16065..16084) 
                     /label=GAN23 
     Primer          16212..16231 
                     /label=JK50 
     Primer          16230..16249 
                     /label=JK52 
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     Primer          complement(16363..16383) 
                     /label=KV3 
     Primer          complement(16418..16437) 
                     /label=JK49 
     Primer          16418..16438 
                     /label=JK66 
     Active_site     16496..17308 
                     /label=M11-AT 
     Primer          complement(16592..16612) 
                     /label=JK65 
     Primer_binding_ 16839..16858 
                     /label=GAN24 
     Primer_binding_ complement(16955..16973) 
                     /label=GAN25 
     Primer          17354..17372 
                     /label=JK55 
     Primer          complement(17376..17393) 
                     /label=JK58 
     Primer          complement(17477..17496) 
                     /label=JK54 
     Primer          complement(17477..17497) 
                     /label=JK68 
     Primer          17848..17870 
                     /label=JK73 
     Primer          complement(18088..18107) 
                     /label=JK51 
     Primer          complement(18180..18197) 
                     /label=JK53 
     Active_site     18218..18739 
                     /label=M11-KR 
     Primer_binding_ 18424..18443 
                     /label=GAN26 
     Primer_binding_ complement(18512..18530) 
                     /label=GAN27 
     Active_site     18995..19240 
                     /label=M11-ACP 
     Primer          19092..19111 
                     /label=JK71 
     Primer_binding_ complement(19121..19139) 
                     /label=GAN28 
     Primer          complement(19265..19285) 
                     /label=JK56 
     Primer          complement(19265..19286) 
                     /label=JK59 
     Primer          complement(19265..19284) 
                     /label=JK61 
     Primer          complement(19265..19286) 
                     /label=JK70 
     Active_site     19307..20590 
                     /label=M12-KS 
     Primer          19517..19537 
                     /label=JK81 
     Primer          complement(19722..19743) 
                     /label=JK74 
     Primer          19776..19797 
                     /label=JK80 
     Primer_binding_ 20093..20111 
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                     /label=GAN29 
     Primer_binding_ complement(20193..20213) 
                     /label=GAN31 
     Primer          20267..20287 
                     /label=JK127 
     Primer          20589..20608 
                     /label=JK50 
     Primer          20607..20626 
                     /label=JK52 
     Primer_binding_ complement(20743..20762) 
                     /label=GAN32 
     Primer          20744..20763 
                     /label=JK91 
     Primer          20804..20824 
                     /label=JK75 
     Active_site     20858..21670 
                     /label=M12-AT 
     Primer          complement(20957..20978) 
                     /label=JK72 
     Primer_binding_ complement(21303..21321) 
                     /label=GAN33 
     Primer_binding_ 21317..21336 
                     /label=GAN30 
     Primer          21761..21781 
                     /label=JK83 
     Primer          complement(21826..21845) 
                     /label=JK82 
     Primer          complement(22382..22401) 
                     /label=JK126 
     Primer_binding_ 22411..22430 
                     /label=GAN34 
     Active_site     22598..23119 
                     /label=M12-KR 
     Primer          22790..22809 
                     /label=JK78 
     Primer          22790..22809 
                     /label=JK92 
     Primer          22906..22965 
                     /label=AN607 
     Primer          complement(22942..23001) 
                     /label=AN608 
     Primer          complement(22966..22986) 
                     /label=JK76 
     Primer          complement(22966..22986) 
                     /label=JK77 
     Primer_binding_ 22991..23010 
                     /label=GAN35 
     Primer_binding_ complement(23009..23027) 
                     /label=GAN36 
     Active_site     23360..23614 
                     /label=M12-ACP 
     Primer          23555..23576 
                     /label=JK85 
     Primer          complement(23669..23689) 
                     /label=JK84 
     Active_site     23672..24955 
                     /label=M13-KS 
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     Primer_binding_ 24138..24157 
                     /label=GAN37 
     Primer_binding_ complement(24142..24161) 
                     /label=GAN40 
     Primer_binding_ 24748..24768 
                     /label=GAN38 
     Primer_binding_ complement(24762..24781) 
                     /label=GAN41 
     Primer          25066..25085 
                     /label=JK86 
     Primer          25066..25085 
                     /label=JK95 
     Primer          25131..25149 
                     /label=JK128 
     Primer          complement(25233..25253) 
                     /label=JK79 
     Primer          complement(25233..25253) 
                     /label=JK93 
     Primer          complement(25233..25253) 
                     /label=JK94 
     Active_site     25241..26056 
                     /label=M13-AT 
     Primer_binding_ 25295..25315 
                     /label=GAN39 
     Primer_binding_ complement(25360..25379) 
                     /label=GAN42 
     Primer          25859..25878 
                     /label=JK97 
     Primer          complement(25967..25987) 
                     /label=JK96 
     Primer          26318..26338 
                     /label=JK133 
     Active_site     26393..26917 
                     /label=M13-DH 
     Primer_binding_ 26460..26479 
                     /label=GAN43 
     Primer_binding_ complement(26512..26531) 
                     /label=GAN44 
     Primer_binding_ complement(27076..27096) 
                     /label=GAN45 
     Primer          27076..27096 
                     /label=JK98 
     Mutation        27250 
                     /label="G to A" 
     Primer          27269..27289 
                     /label=JK89 
     Primer          complement(27367..27386) 
                     /label=JK87 
     Primer          complement(27367..27386) 
                     /label=JK88 
     Primer          complement(27398..27417) 
                     /label=JK129 
     Primer          27488..27508 
                     /label=JK134 
     Primer          complement(27743..27762) 
                     /label=JK107 
     Active_site     27950..28858 
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                     /label=M13-ER 
     Primer          28220..28241 
                     /label=JK108 
     Primer          complement(28292..28313) 
                     /label=JK132 
     Primer          28747..28767 
                     /label=JK104 
     Primer          complement(28846..28866) 
                     /label=JK103 
     Primer          complement(28850..28869) 
                     /label=JK135 
     Active_site     28856..29422 
                     /label=M13-KR 
     Primer_binding_ complement(29435..29455) 
                     /label=GAN47 
     Primer          29435..29455 
                     /label=JK101 
     Primer          29612..29630 
                     /label=JK130 
     Active_site     29696..29953 
                     /label=M13-ACP 
     Primer          complement(29723..29742) 
                     /label=JK90 
     Primer          complement(29723..29742) 
                     /label=JK99 
     Primer          complement(29723..29742) 
                     /label=JK100 
     Primer_binding_ 30007..30025 
                     /label=GAN46 
     Active_site     30014..31291 
                     /label=M14-KS 
     Primer_binding_ complement(30032..30051) 
                     /label=GAN48 
     Primer          30426..30447 
                     /label=JK106 
     Primer_binding_ 30464..30481 
                     /label=JK136 
     Primer          complement(30634..30654) 
                     /label=JK105 
     Primer_binding_ 31030..31051 
                     /label=GAN49 
     Primer_binding_ complement(31030..31051) 
                     /label=GAN51 
     Primer          31546..31565 
                     /label=JK111 
     Active_site     31637..32506 
                     /label=M14-AT 
     Primer_binding_ 31665..31684 
                     /label=GAN50 
     Primer          complement(31679..31700) 
                     /label=JK102 
     Primer          complement(31684..31706) 
                     /label=JK131 
     Primer_binding_ 32230..32250 
                     /label=JK137 
     Primer          32240..32261 
                     /label=JK122 
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     Primer_binding_ complement(32246..32265) 
                     /label=GAN61 
     Primer          complement(32401..32420) 
                     /label=JK121 
     Active_site     32684..33103 
                     /label=M14-DH 
     Primer_binding_ complement(32891..32914) 
                     /label=GAN53 
     Primer          32891..32914 
                     /label=JK125 
     Primer_binding_ 33599..33618 
                     /label=GAN52 
     Primer_binding_ complement(33616..33635) 
                     /label=GAN54 
     Primer          33747..33765 
                     /label=JK113 
     Primer          complement(33878..33899) 
                     /label=JK112 
     Primer          33997 
                     /label="C to A mutation" 
     Active_site     34001..34477 
                     /label=M14-KR 
     Primer          34270..34289 
                     /label=JK124 
     Primer          complement(34352..34372) 
                     /label=JK123 
     Primer_binding_ complement(34364..34384) 
                     /label=JK138 
     Active_site     34631..34888 
                     /label=M14-ACP 
     Primer_binding_ complement(34843..34862) 
                     /label=GAN56 
     Source          34912..35225 
                     /label=gblock-AN-ptKanR 
     Primer          34912..34931 
                     /label=JK115 
     Primer          complement(35032..35050) 
                     /label=JK114 
     Promoter        35057..35195 
                     /label="from pSPL" 
     Mutation        35069 
                     /label="G to A" 
     Primer          35196..35213 
                     /label=JK117 
     ORF             35196..36206 
                     /label=ant3ia-specm-strpm 
     Primer          complement(35205..35225) 
                     /label=JK116 
     Primer_binding_ complement(35451..35474) 
                     /label=GAN57 
     Primer_binding_ 35537..35559 
                     /label=GAN55 
     Primer_binding_ complement(36006..36025) 
                     /label=GAN58 
     Source          36178..36363 
                     /label=ptKanR 
     Primer          36178..36198 
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                     /label=JK119 
     Primer          complement(36182..36206) 
                     /label=JK118 
     Terminator      36207..36277 
                     /label="kanR terminator" 
     Mutation        36274 
                     /label="G to T" 
     Misc._recombina 36278..36325 
                     /label=FRT-13 
     Primer          complement(36326..36355) 
                     /label=LW375 
     Primer          complement(36339..36365) 
                     /label=JK120 
     Primer          complement(36427..36442) 
                     /label=AN112 
     ORF             complement(36555..37258) 
                     /label=HIS3 
     Primer          complement(36637..36658) 
                     /label=AN272 
     ORF             complement(37259..37972) 
                     /label=GFP 
     Promoter        complement(37973..38831) 
                     /label=pPYK 
ORIGIN 
        1 aaaattgtgc ctttggactt aaaatggcgt GAAGTTCCTA TTCCGAAGTT CCTATTCTCT 
       61 AGAAAGTATA GGAACTTCgg taaggaaaag actcacgttt cgaggccgcg attaaattcc 
      121 aacatggatg ctgatttata tgggtataaa tgggctcgcg ataatgtcgg gcaatcaggt 
      181 gcgacaatct atcgattgta tgggaagccc gatgcgccag agttgtttct gaaacatggc 
      241 aaaggtagcg ttgccaatga tgttacagat gagatggtca gactaaactg gctgacggaa 
      301 tttatgcctc ttccgaccat caagcatttt atccgtactc ctgatgatgc atggttactc 
      361 accactgcga tccccggcaa aacagcattc caggtattag aagaatatcc tgattcaggt 
      421 gaaaatattg ttgatgcgct ggcagtgttc ctgcgccggt tgcattcgat tcctgtttgt 
      481 aattgtcctt ttaacagcga tcgcgtattt cgtctcgctc aggcgcaatc acgaatgaat 
      541 aacggtttgg ttgatgcgag tgattttgat gacgagcgta atggctggcc tgttgaacaa 
      601 gtctggaaag aaatgcataa gcttttgcca ttctcaccgg attcagtcgt cactcatggt 
      661 gatttctcac ttgataacct tatttttgac gaggggaaat taataggttg tattgatgtt 
      721 ggacgagtcg gaatcgcaga ccgataccag gatcttgcca tcctatggaa ctgcctcggt 
      781 gagttttctc cttcattaca gaaacggctt tttcaaaaat atggtattga taatcctgat 
      841 atgaataaat tgcagtttca tttgatgctc gatgagtttt tctaatcagt actgacaata 
      901 aaaagattct tgttttcaag aacttgtcat ttgtatagtt tttttatatt gtagttgttc 
      961 tattttaatc aaatgttagc gtgatttata ttttttttcg cctcgacatc atctgcccag 
     1021 atgcgaagtt aagtgcgcag aaagtaatat catgcgtcaa tcgtatgtga atgctggtcg 
     1081 ctatactgct gtcgattcga tactaacgcc gccatccagt gtcgatctag aGAAGTTCCT 
     1141 ATTCCGAAGT TCCTATTCTA TCAGAAGTAT AGGAACTTCt accAGCCCGA CCCGAGCACG 
     1201 CGCCGGCACG CCTGGTCGAT GTCGGACCGG AGTTCGAGGT ACGCGGCTTG CAGGTCCAGG 
     1261 AAGGGGACGT CCATGCGAGT GTCCGTTCGA GTGGCGGCTT GCGCCCGATG CTAGTCGCGG 
     1321 TTGATCGGCG ATCGCAGGTG CACGCGGTCG ATCTTGACGG CTGGCGAGAG GTGCGGGGAG 
     1381 GATCTGACCG ACGCGGTCCA CACGTGGCAC CGCGATGCTG TTGTGGGCAC AATCGTGCCG 
     1441 GTTGGTAgga tccCGGAATC ATCGACCAGG AACTCGATGG GTCATGAGCA GCGAGAACGT 
     1501 CCGACCGGAA ATCGAGGGGA CTGGCACGCG GATGTCGAAC GACGAAAAGG TACTCGAGTA 
     1561 CCTCAAGAAG CTCACCGCCG ATCTGCGCCA GACGCGTCAG CGTCTCCAGG ACGTCGAGGC 
     1621 CAAGAGCCGC GAGCCGATCG CGATCGTCGG TATGAGCTGC CGTTTCCCGG GTGGGGTGAG 
     1681 CTCCCCGGAA GACCTGTGGC GGCTGACGGA GTCTGCGGTG GACGCGGTCT CCGGTTTCCC 
     1741 CACGGACCGA GGCTGGGACC TGGACGGTCT GTACGACCCC GACCCGGATC GCGCGGGCCG 
     1801 GTCGTACGCC CGAGAGGGCG CGTTCATCCC CGATGCAGGC CACTTCGACC CCGGCCTCTT 
     1861 CGGGATCTCG CCACGTGAGG CGCTGGCGAT GGATCCGCAG CAGCGGCTGC TGCTGGAGGC 
     1921 ATCGTGGGAG GCCCTGGAGC GGGCGGGTAT TCCCACCGAT TCCCTGAAGG GCAGCCGGAC 
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     1981 CGGGGTGTTC GCCGGACTGA TGTCTTCCGA CTATGTCTCG CGGCTGTCCG CGGTCCCGGA 
     2041 CGAACTCGAG GGGTACGTCG GAATCGGAAG CGCGGCGAGC GTCGCCTCCG GCCGCGTGTC 
     2101 GTACACCCTG GGGCTTGAGG GCCCGGCGGT CACCGTGGAC ACGGCGTGTT CGTCGTCGTT 
     2161 GGTGGCGTTG CATCTGGCGG TGCAGGCATT GCGGTCGGGT GAGTGCTCGC TGGCGCTCGC 
     2221 GGGCGGTGTC ACGGTGATGG CGACACCCGG CACCTTCGTC CAGTTCTCCC GCCAGCGCGG 
     2281 CCTGGCCGCC GACGGCCGGT GCAAGGCGTT CGCGGCGGGG GCCGACGGTA CCGGCTGGGG 
     2341 CGAAGGCGTC GGCATGCTGG TGGTGGAGCG GTTGTCGGAT GCTGAGCGGC TTGGGCATCG 
     2401 GGTGTTGGCG GTGGTGCGTG GTTCTGCGGT GAATCAGGAT GGTGCGTCGA ATGGTTTGAC 
     2461 GGCGCCGAAT GGTCCGTCGC AGCAGCGGGT GATCCGTCAG GCGTTGGCGA ATGCCCGTTT 
     2521 GTCGGCGGTG GATGTGGATG CGGTGGAGGC GCATGGTACG GGTACGGCGT TGGGTGATCC 
     2581 GATTGAGGCG CAGGCGTTGT TGGCCACGTA TGGTCAGGGT CGGGATGTGG GTCGGCCGTT 
     2641 GTGGTTGGGG TCGGTGAAGT CGAACATCGG TCATACGCAG GCGGCTGCGG GTGTGGCTGG 
     2701 TGTGATCAAG ATGGTGATGG CGATGCGGCA TGGGGTGTTG CCGCGGACGT TGCATGTGGA 
     2761 TGAGCCGTCG CCGCATGTGG ATTGGTCTGC TGGTGCGGTT GAGTTGTTGA CGGGGCAGGT 
     2821 GGCGTGGCCG GAGGTGGATC GGCCGCGTCG GGCGGGTGTG TCGGCGTTCG GGGTGAGTGG 
     2881 GACGAATGCG CATGTGATTG TGGAGCAGGC GCCTGAAGTG GCGGAGTCTG AGGCTGAAGG 
     2941 TGTGGTGTTG CCTGCTGTGC CGTGGGTGGT GTCGGGTGTG GGTGAGGTGG CGGTGCGGGC 
     3001 GCAGGTGGAG CGGTTGCGGG CCTTTGCGGA CCGGAATCCG GGTCTGGATC CGGTGGATGT 
     3061 GGGGTGGTCT TTGGCGACTG GTCGTGCGGG GTTGTCGCAT CGTGCGGTGG TGGTGGGTGC 
     3121 GGGTCGTGGT GAGTTGTTGG GGGCTTTGGA GGGTGTGCCG GTGGTGGGTG TTCCGGTGGT 
     3181 GGGTGGGTTG GGTGTGTTGT TTGCGGGTCA GGGGTCGCAG CGGTTGGGGA TGGGGCGTGG 
     3241 GTTGTATGAG GGGTATCCGG TGTTCGCTGC GGTGTGGGAT GAGGTGTGCG CGCAGCTGGA 
     3301 TCGGTATTTG GATAGGCCGG TGGGTGAGGT GGTGTGGGGT GATGATGCCG GGTTGGTCGG 
     3361 GGAGACGGTG TATGCGCAGG CGGGGTTGTT CGCGCTTGAG GTGGCGTTGT ATCGGCTGAT 
     3421 CGCTTCGTGG GGTGTGAGGG CGGATTATCT GCTGGGTCAT TCGATTGGTG AGTTGGCTGC 
     3481 GGCGTATGTG GCGGGTGTGT GGTCGTTGGA GGATGCGGTG AGGGTGGTGG TGGCGCGGGG 
     3541 GCGTTTGATG CAGGCGTTGC CGTCGGGTGG TGCGATGGTT GCGGTGGGGG CGTCGGAGGG 
     3601 TGTGGTGCGG CCGCTGCTGG GCGAGGGTGT GGTGGTTGCG GCGGTGAATG GTCCCGAGTC 
     3661 GGTGGTGCTG TCGGGTGATG AGGATGCGGT TCAGGTTGTG GTGGATGTGT TGGCTGGGCG 
     3721 TGGGGTGCGG ACGCGGCGGT TGCGGGTGAG TCATGCGTTT CATTCGGCTC GTATGGACGG 
     3781 CATGCTGGCG GAGTTCGGTG AGGTGCTTCG GGGCGTGGAG TTCCGTGCCC CGAGCGTGCC 
     3841 CGTGGTGTCG AACGTGTCCG GTGTGGTGGC GGGCGAGGAG TTGTGTTCGC CGGAGTATTG 
     3901 GGTGCGGCAT GTGCGGGAGA CGGTCCGGTT CGCCGATGGG CTGGAGACGC TGCGCGAGCT 
     3961 GGGTGTGGGT TCGTTCCTGG AGTTGGGACC GGACGGGACA TTGACCGCGC TGGCCGACGG 
     4021 CGATGGTGTG TCGGCGCTGC GCCGGGACCG TCCGGAACCG ACTGCGGTAA TGGCTGCTTT 
     4081 GGGTGGGTTG TATGTCCGGG GTGTGGAGGT CGACTGGGAC GCGGTGTTCC CGGGTGCTCG 
     4141 GCGGGTCGAT TTGCCGACGT ATGCCTTCCA GCGTGAGCGG TTCTGGCTGG AACCGGCCGC 
     4201 TGAGCAGCCT GCGACGAGCG CGGTGGACGC GGCGTTCTGG GACGCGGTCG AGCGGGGCGA 
     4261 TGCGGAGATT CTCGGGGTTG ACGTTGAGCA GCCGTTGAGT GCCGCGTTGC CCGCATTGGC 
     4321 GTCGTGGCGA CGGGCGCGGC AGGAAGAGTC GGTCATCGAC GCATGGCGGT ATCGGCTGAC 
     4381 CTGGACCCCG GTCGCGGGTC TCTCTTCGCA GCTCTCCGGC GTGTGGTTGG TGGTGGTCGA 
     4441 GCCGGACGAG GCGGAGCCGG ACGTCGTCGC CGCGCTGCGG GGCGCCGGCG CCGAGGTGCG 
     4501 TGTCGTAACG ATCGATGAGC TGGACGCGGG CCCGGTCGCG GGCGTGGTGT CTTTGTTGTC 
     4561 GGTCGAGACG ACGGTGTCAT TGCTCCAGGC CCTTGTGGCA GAGGGGGGCG ATGCGCCGTT 
     4621 GTGGTGTGTC ACTCGGGGTG CGGTCTCCGT GGTGGACGGG GATGTGGTGG ATCCGCATGC 
     4681 GTCGGCCGTC TGGGGTTTGG GCCGTGTGAT CGGTCTGGAG CATCCGGACC GTTGGGGCGG 
     4741 GCTGATCGAT CTGCCCACCG CATGGGGTGA GCGAACCTCC GGCATGTTGT GCTCGGTGCT 
     4801 TTCGGGCGCC ACGGGTGAGG ACCACACAGC GATCCGTGGC GACGAGGTGT TGGGTTGTCG 
     4861 TCTGAGCCGT GCGACGACGT CGGCACCGGG GCCGTCCACT GCCTGGGAAG CGTCGGGGAC 
     4921 CGCGCTGATC ACCGGTGGAA CGGGTGCCTT GGGGAGCCAT GTCGCCCGAT GGCTCGCGGA 
     4981 TACCGGCGTC GAAGAGATCG TGCTGACGAG CCGACGAGGC GCGGACGCTC CCGGAGCACG 
     5041 GGAACTGGTC GCCGAACTGT CGGCCATGGG CGTATCGGCC CGCGTCGTGG CGTGTGATGT 
     5101 GGCCGATCGG GACGCGGTTG CGGAGCTGAT CGAGACCATT CCGGACCTCC GCGTGGTCGT 
     5161 CCACGCCGCG GGAGTACCGA GCTGGGGTGC GTTGAGCACA CTTACCGCAC AGGGCCTTCA 
     5221 GGATGGGATG CGGGCGAAGG TCGCGGGAGC CATCCACCTG GATGAGCTGA CGCGCGATAT 
     5281 GCGCTTGGAC GCCTTTGTGT TGTTCTCGTC GGTGGCGGGG GTGTGGGGGA GCGGTAGTCA 
     5341 GTCGGCGTAT GCGGCGGCGA ACGCGTTTCT GGATGGGTTG GCGTGGCGGC GTCGTGGTGT 
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     5401 TGGGTTGGTG GCGACGTCGG TGGCGTGGGG GATGTGGGGT GGCGGTGGTA TGGCGGTTGG 
     5461 GGGTGAGGAG TTTCTGGTTG AGCGTGGTGT GTCGGGGATG GCTCCGGGGT CGGCGGTGGC 
     5521 TGCGTTGCGG CGGGCGCTGT GTGATGGTGA GACGGCGCTT GTGGTGGCGG ATGTGGATTG 
     5581 GGAGCGGTTC GGGCCGAGGT TCACCGCGTT GCGTCCGAGC CCACTGCTGA GCGAGCTGAT 
     5641 CCCCGACACC GTCGGCTCGG GGGTTCCGCT GGGTGAATTC GCGGCCCGTT TCCAGACCAT 
     5701 GTCCGAGGGC GAGCGCATGC GCGCGGCCGT CGAGCTGGTG CGTGTTTCGG CCGCGGCCGT 
     5761 GCTGGGGCAC CAGGGCCCGG AGGCCATCGA TCCCGTCAGG ACGTTCCAGG AGATCGGCTT 
     5821 CGACTCGCTG ACCGCGGTGG AACTGCGCAA CCGGATCGCC ACGGCTACCG GTATCCGCCC 
     5881 GCCGGCCACG ATGGTCTTCG ACTATCCGAC TCCTGTGGCC CTCGCCGAAT ATCTGAGCGT 
     5941 GGAATTGCTC GGTTCGCCGC AGGACAGTGT GCCGCCGTTG CAGGTGGCCG CGCCGGACGA 
     6001 CGGTGATCCC ATTGTCATCG TCGGCATGAG CTGCCGCTTC CCCGGGGACG TCGAGTCTCC 
     6061 CGAGGATCTG TGGCGGTTGA TCGACTCCGA CGGCGATGCC ATAACGGCCT TTCCGACGGA 
     6121 CCGTGGATGG GACCTGACCG GCCTCTTCGA CACGGCTGTG GGGGAGTCGG GGACGTCGTA 
     6181 TGCGCGTGTT GGTGGCTTCG TCCACGACGC GGGTGAGTTC GATCCGGCCT TCTTCGGTAT 
     6241 CTCGCCGCGT GAGGCGACCG CGATGGATCC GCAGCAGCGG CTGCTGCTGC ACGCGGCATG 
     6301 GGAGGCGTTC GAGCGGGCCG GTATCCCGGC CGCCTCGGTC AGGGGCAGCA GGACTGGAGT 
     6361 GTTCGTCGGA GCCTCGCCGC AGGGCTATGG CGCCGCCGAA GCGTCGGAAG GCTATTTCCT 
     6421 CACCGGTAGT TCGGGCAGTG TCATTTCGGG TCGCGTGTCG TACACGCTGG GTCTTGAGGG 
     6481 CCCGGCGGTC ACGGTGGATA CGGCGTGTTC GTCGTCGTTG GTGGCGTTGC ATCTGGCGGT 
     6541 GCAGGCGTTG CGGTCGGGCG AGTGTTCGCT GGCGCTCGCG GGCGGTGTCA CGGTGATGGC 
     6601 GACACCCACT GCTTTCGTGG AGTTCTCGCG TCAGCGTGGG CTGGCCGCCG ATGGCCGCTG 
     6661 CAAGTCCTTT GCCGCTGGTG CGGATGGGAC AGGTTGGTCG GAGGGTGTTG GGCTGCTGCT 
     6721 GGTGGAGCGG TTGTCGGATG CGGAGCGGCT TGGGCATCGG GTGCTGGCGG TGGTGCGTGG 
     6781 TTCTGCGGTG AATCAGGATG GTGCGTCGAA TGGTTTGACG GCGCCGAATG GTCCGTCGCA 
     6841 GCAGCGGGTG ATCCGTCAGG CGTTGGCGAA TGCCCGTTTG TCGGCGGTGG ATGTGGATGC 
     6901 GGTGGAGGCG CATGGTACGG GTACGGCGTT GGGTGATCCG ATCGAGGCGC AGGCCCTGTT 
     6961 GGCCACGTAT GGTCAGGGTC GGGATGTGGG TCGGCCGTTG TGGTTGGGGT CGGTGAAGTC 
     7021 GAATATTGGT CATACGCAGG CGGCTGCGGG TGTGGCTGGT GTGATCAAGA TGGTGATGGC 
     7081 GCTGCGGCAT GGGGTGCTGC CGCGAACGTT GCACGTCGAT GAACCCTCCC CGCATGTGGA 
     7141 CTGGTCGTCC GGGGCGGTCG AGTTGTTGAG CGAGAGGGCT GCTTGGCCGG AGATGGGCCG 
     7201 ACCGCGTCGG GCGGGCGTGT CGTCGTTCGG GGTGAGCGGG ACGAACGCGC ATGTGGTGTT 
     7261 GGAGCAGGCT CCTGGGGCGG TGGAGGAGTC TCGGGGCGAG GGTGTTGCGT TGCCTGCTGT 
     7321 GCCGTGGGTG GTGTCGGGTG CGGGTGAGGT GGCGGTGCGG GCGCAGGTGG AGCGGTTGCG 
     7381 GGCCTTCGCG GACCGGAATC CGGGTCTGGA TCCGGTGGAT GTGGGGTGGT CTTTGGTGGC 
     7441 CACTCGTTCT GGGTTGTCGC ATCGTGCGGT GGTGGTGGGT GCGGATCGTG AGGAGTTGCT 
     7501 GGGTGGGTTG GGTTCGGTGG TGGTGGGTGT TCCGGTTGCG GGTGGGTTGG GTGTGTTGTT 
     7561 TGCGGGTCAG GGGTCGCAGC GGTTGGGGAT GGGTCGTGGG TTGTATGAGG GGTATCCGGT 
     7621 GTTCGCTGCG GTGTGGGATG AGGTGTGCGG GGAGCTGGAT CGGTATCTGG ATAGGCCGGT 
     7681 GGGTGAGGTG GTGTGGGGTG ATGATGCCGG GTTGGTCGGG GAGACGGTGT ATGCGCAGGC 
     7741 GGGGTTGTTC GCGCTGGAGG TGTCGCTGTA TCGGCTGATC GCTTCGTGGG GTGTGAGGGG 
     7801 GGATTATCTG CTGGGTCATT CGATTGGTGA GTTGGCTGCG GCGTATGTGG CGGGTGTGTG 
     7861 GTCGTTGGAG GATGCGGGGA GGGTGGTGGT GGCGCGGGGG CGTTTGATGC AGGCGTTGCC 
     7921 GTCGGGTGGT GCGATGGTTG CGGTGGCGGC GTCGGAGGGT GAGGTGCGGC CGCTGCTGGG 
     7981 CGAGGGTGTG GTGGTTGCGG CGGTGAATGG TCCCGAGTCG GTGGTGGTCT CGGGGGATGA 
     8041 GGATGCGGTT GAGGCGGTTG TGGATGTGTT GGCTGGGCGT GGGGTGCGGA CGCGGCGGTT 
     8101 GCGGGTGAGT CATGCGTTTC ATTCGGCTCG TATGGACGGG ATGCTCGCGG AGTTCGGTGA 
     8161 GGTGCTTCGG GGCGTGGAGT TCCGTGCCCC GAGCGTGCCC GTGGTGTCGA ACGTGTCCGG 
     8221 TGCGGTGGCC GGTGAAGAGC TCTGCTCGCC GGAGTATTGG GTGCGTCATG TGCGGGAGAC 
     8281 GGTCCGATTC GCGGATGGGC TGGAGACGCT CCGTGAGCTG GGTGTTGGTT CGTTCCTGGA 
     8341 GTTGGGGCCT GACGGGACGT TGACCGCCTT GGCGGATGGC GATGGTGTGC CTGTCTTGCG 
     8401 TCGGGATCGT CCGGAGCCTC TGACCGTTAT GGCGGCTTTG GGTGGGCTGT ACGTCCGGGG 
     8461 TGTCCAGATC GACTGGGATG CGGTGTTCCC GGGTGCTCGG CGGGTTGATT TGCCGACGTA 
     8521 TGCCTTCCAG CGTGAGCGGT TCTGGTTGGA GCCGTCCCCT GAGCAGCCCA CGACGAGCGC 
     8581 GGCGGACGCG GCGTTCTGGG ATGCGGTTGA GCGTGGGGAT CTCGGTTCTT TCGGTATCGA 
     8641 TGCCGAACAG CCGCTCAGCG CCGCACTGCC CGCCCTCTCG TCCTGGCGCC GCCGTCACCA 
     8701 GGAGAGGTCA CTCGTCGAGT CCTGGCGGTA CCGCCTCGAC TGGTCCCCGA TCGGCACCGC 
     8761 TTCCGAGCAG CCGAGTCTGC GCGGCACGTG GCTGGTGGTG GGCGAGGGCG GAGACGACGT 
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     8821 GGTCGCCGTG CTGCGGGCTG CGGGGGCCGA TGCGCGAGTT GTGACAATGG CGGAGCTGGG 
     8881 CGAGGTCGCG GCTGCGGGTG TGGTGTCGTT GTTGCCGGTC GAGGCGACGG TGTCACTGGT 
     8941 GCAGGCACTG GGGACGGCCG GGGCCGATGC GCCGTTGTGG TGTGTGACTC GGGGTGCGGT 
     9001 GTCGGTGGTC GATGGTGATG TGGTGGATCC GGGGCAGTCG GGGGTGTGGG GTCTTGGCCG 
     9061 GGTGATCCGT TTGGAGCATC CGGATCGTTG GGGTGGTCTG ATCGATGTGC CGGTGGTGGT 
     9121 GGATGAGGAG GCCGGGGCTT GGTTGTGCCG GGTGTTGGGT GGGGGTACGG GGGAGGACCA 
     9181 GGTTGCGGTT CGTGGTGGTG GGGCGTGGGG TGCTCGGCTG GTGCGGGTGT CGGGCTCGGG 
     9241 TTCGGGATCG GGTGGGGCGG TTGTGTGGCG GGGTCGAGGG GCGGCGTTGG TGACGGGCGG 
     9301 TACGGGTGCG TTGGGTGGTC ATGTGGCGCG GTGGTTGGCC GGTGCTGGTG TGGAGACTGT 
     9361 TGTGCTGGCG AGTCGTCGGG GGATGGCTGC GCCGGATGCG GAGCAGCTGG TCGCGGAGTT 
     9421 GGAGGGGTTG GGTGTTGCGG TGCGGGTGGT GGCGTGTGAT GTGGCGGATC GGGGTGCGGT 
     9481 GGCGGAGTTG TTGGAGGGGA TTGGGGATTT GCGTGTGGTG GTGCATGCGG CGGGTGTGCT 
     9541 GGATGACGGT GTGTTGGAGT CGCTGACGTC TGAGCGGGTT CGTGAGGTGA TGCGGGTCAA 
     9601 GGCGGAGGGT GCGCGGTATC TGGATGAGTT GACGCGGGGT TGGGATCTGG ATGCGTTTGT 
     9661 GTTGTTTTCT TCGGCTGCGG GGACTGTGGG TAATGCGGGT CAGGGGAGTT ATGCGGCGGC 
     9721 GAATGCGGTG TTGGACGGGT TGGCTTGGCG GCGTCGGGCG GAGGGGTTGG TGGCCACGTC 
     9781 GGTGGCTTGG GGAGCCTGGG CCGACAGCGG CATGGGGGCT GGGCACGCAC GGGCCATGGC 
     9841 ACCACGGCTG GCGTTGGCAG CCCTTCAGCG AGCGTTGGAC GACGACGAGA CCGCACTGAT 
     9901 GATCGCGGAC GTGGATTGGT CGAGCTTCGG CTCCCGGTTC ACCGCCGTGC GGCCCAGCCC 
     9961 GCTGCTCGGT GAATTGCTGG GTGGCGCCGC TCATCCCGCG CCCGCGGTGG GCGGGTTCGT 
    10021 CGACCGGCTA CGGGACCTCC CCCCGGCCGA GCGGGAACGG ACGGTCCTTG AGCTCGTACG 
    10081 TGGCCAGGTG GCCGTCGTTC TGGGACATGC CACCCCGGGG GCGATCGACA CCGCAGCGAC 
    10141 ATTCCAGTCA GCCGGTTTCG ACTCCCTGAC CGCGATCGAA CTCCGCAATC GGCTCATGGC 
    10201 GGCCACCGGA GTGCAGACAC CTGCCTCGGT CGTCTTCGAC TACCCCACTC CGGAACTTCT 
    10261 CGCCGGCCAC CTGCGGGAGC AACTGCTCGG GGCAGGGTCG GCAGCACTCT CGACGACGGT 
    10321 CGCCACGGCT CCGGTCGATG ACGACCCGAT TGCGATCATC GGCATGAGCT GCCGATTCCC 
    10381 TGGTGGTGTC GACTCGCCCG AAGAGCTGTG GCGGCTCCTG GAGTCGGGGA CGGATGCCAT 
    10441 TTCCGCCTTT CCACAAGACC GCGGCTGGGA CCTCGTGGGC GGAGTCGATG GCGCGTCGGT 
    10501 CCGGGCGGGT GGCTTCCTCT ACACGGCGGC CGAGTTCGAC CCCGCGTTCT TCGGGATCTC 
    10561 GCCGCGCGAG GCGATCGCGA TGGATCCGCA GCAGCGGCTG CTGCTCGAGG CCTCGTGGGA 
    10621 GGTCTTCGAG CGGGCCGGGA TCGCCGCGGA CGCGTTGCGG GACAGCCCCA CCGGAGTGTT 
    10681 CGTCGGCACC AACGGCCAGG ATTACGCCGC CCTCGTCGGT AACGCGCCAC AGCGTGCGGA 
    10741 CGGCCATCTG GCCACCGGCA GCGCGGCGAG CGTGGCATCC GGCCGACTGT CCTACACCTT 
    10801 CGGGCTCGAG GGCCCGGCCA TCACCGTGGA CACCGCGTGT TCGTCGTCGC TGGTGGCCAT 
    10861 GCACCTGGCC GCGCAGGCGC TGCGCTCGGG CGAATGCCGT ATGGCCCTTG CGGGCGGCGC 
    10921 CACGGTAATG GCCACGCCCA CCGCGTTCGC CGAGTTCTCC CGGCAAGGCG CGTTGGCCGC 
    10981 TGATGGCCGG TGCAAGGCGT TCGCGGCGGG CGCGGACGGC ACCGGCTGGG GCGAAGGCGT 
    11041 AGGCATTCTG CTGTTGGAGC GGCTGTCCGA CGCCGAGCGG AACGGCCACC GGGTGCTGGC 
    11101 GGTGATGCGT GGCTCCGCCG TCAACCAGGA TGGTGCGTCG AATGGTTTGA CGGCGCCGAA 
    11161 TGGTCCGTCG CAGCAGCGGG TGATCCGGCA GGCGCTGGCG AACGCACGTC TGTCCACAGT 
    11221 AGACGTGGAC GCGGTGGAGG CGCACGGTAC GGGTACGACG CTGGGCGACC CCATCGAGGC 
    11281 GCAGGCTCTG CTGGCCACCT ACGGCCAGGA CCGGGATCCG GATCGGCCGC TGCTGCTGGG 
    11341 CTCCGTGAAG TCCAACATCG GCCATACGCA GGCCGCGGCC GGTGTGGCTG GTGTGATCAA 
    11401 GATGGTGATG GCGATGCGCC ACGGCGTGCT GCCGCGGAGC CTACACATCG ACGAGCCCAC 
    11461 TCCCCACGTG GACTGGACGG CCGGACGGAT CGCACTGCTC ACCGAACCGT CCCCCTGGCC 
    11521 TCTGACGGGA GCGCCGCGAC GCGCCGCCGT CTCCTCGTTC GGTGTGAGTG GCACCAACGC 
    11581 GCATGTGATC CTCGAACAGG CATCTGCGGT GGCCGAACCC GAGGAAACCG ACACGGCGCG 
    11641 AACACCCGAA CCGCCAGCTG TTCCGTGGGT GCTCTCGGCA CGGAGCGAGG CGGGGCTACG 
    11701 GGCGCATGCC CTCAGGCTTC GGTCCTTCGT GAACGCCGAT GCTGATCTGC GTCCAGTCGA 
    11761 TGTCGGCTGG TCGCTGGCGT CGGCTCGCTC GGTGTTGTCA CACCGTGCGG TGGTCGTGGG 
    11821 CGCGGACCGC GATGAACTCC TCCGTGAACT GGAGGCCGTG GCCAGTGGCA GCGTCACGGT 
    11881 CGGCGAGGCC CGCACGCATT CCGGGGTGGT GTTTGTCTTC CCGGGGCAGG GGTCGCAGTG 
    11941 GGTTGGGATG GCGTTGGAGC TCCTGGAGCA TTCGCCGGTG TTCGCGGGGC GGATGCGTGA 
    12001 TTGTGCGGAT GCGTTGGCGC CGTTTGTGGA GTGGTCGTTG TTCGATGTGT TGGGTGATGA 
    12061 GGTGGCGCTC GGTCGGGTTG ATGTGGTGCA GCCGGTGTTG TGGGCGGTGA TGGTGTCGCT 
    12121 GGCCGAGTTG TGGCGTTCGT TTGGTGTGGT GCCGTCGGCG GTGGTGGGGC ATTCGCAGGG 
    12181 TGAGATCGCG GCGGCGTGTG TGGCCGGGGG TCTGTCGTTG GAGGACGGTG CCCGTGTGGT 
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    12241 GGCCTTGCGG AGCAGGGCGT TGCTGGCTCT GTCGGGTAGG GGCGGCATGG TGTCGGTTCC 
    12301 GGTTTCTGCT GACCGGCTGC GGGGTCGTGT GGGGTTGTCG GTTGCGGCGG TGAATGGTCC 
    12361 GGTGTCGACG GTGGTGTCGG GGGCGGTTGA GGTGCTGGAG GGGGTGCTGG CGGAGTTCCC 
    12421 GGAGGCCAAG CGGATTCCGG TGGATTATGC GTCGCATTCG GTGCAGGTGG AGGGGATCCG 
    12481 GGAGGGTTTG GCGGAGGCGT TGGCGCCGGT TCGGCCGCGT ACGGGTGAGG TGCCGTTCTA 
    12541 TTCGACGGTG ACCGGCCGGC TGATGGACAC CATCGAGTTG GACGGGGAGT ACTGGTACCG 
    12601 GAATCTGCGT GAGACGGTGG AGTTCCAGAG CACCGTCGAA GCTCTGATCG GCCAGGGTCA 
    12661 TACGGTGTTC GTCGAGGCCA GCCCGCATCC GGTGCTGACC GTCGGCGTCC AGGACACCGC 
    12721 CGACACCACC GACACCGCCA CCGACATCGT CGTCACCGGA TCGCTGCGCC GCGACGACGG 
    12781 CGGTCCGGCG CGCTTCCTCA CCGCGCTGGC CGAGCTGTCC GTACGAGGGG TGGCGACGGA 
    12841 CTGGCGGCAG GCGTTCGAAG GGACCGGCGC CCGACATGTC GACTTGCCGA CCTACCCCTT 
    12901 CCAGCGGCAG CGCTTTTGGA TCGAACCCAC TGCCCCGGAC GTGGCCCGGG AGGACGCTCG 
    12961 CGTCACCACT GCGGACGGCG AGTTCTGGGC GGCCGTCGAG CGCGAAGACG CCGCATCCCT 
    13021 GGCAACAGCC CTGGAGGTCG ACGACGCCTC ACTGGGCAAC CTGCTGCCCG CCTTGTCGGC 
    13081 CTGGCGCCGC CGGCGGCACG AGTGGTCCGC ATTGGAGGCC GTCCGGTACC AGGTCAACTG 
    13141 GAAGCGGCTC GTCGATGACC GACCCGCGAT GTTGTCAGGT GCCTGGCTGG TCGTGGTTTC 
    13201 CCAGGCCGAC GCCGACCATG AGTGGGTCTC CGGCGTAAGC GAGACGCTCG CCGAGTACGG 
    13261 GGCCGAGCCA GTGGTGTGCC CGGTGGACGA GCGACACCTG GATCGTGCCG TGCTGGCCGA 
    13321 CCGGCTGGCG AGCATGACCG GTACGAGCAG CACGACGAGC ACGGCGAGTA TCAGCGGCGT 
    13381 GGTGTCGCTG GTCGCCCTGG ACCAGCGCCC GCACCCGGAC TTCGCCTCCG TGCCCATTGG 
    13441 TTTCGCGATG ACGGTGCTGC TGACTCAGGC GTTGGGCGAC ACGGGGGTGG AGGCCCCGCT 
    13501 GTGGAGTCTG ACCCAACACG CCGTGTCCAC CGGGCCCGCT GACACCCTCC TCGCGTCCGC 
    13561 ATCGGCGCAG GCACTGGTGT GGGGCGTCGG CCGAGTGATC GCACTCGAGC AGCCCCTGCG 
    13621 CTGGGGTGGT CTCATCGACC TGCCGACCGA GGTGAACGCG AGGGCGCGGG AACGGCTGGC 
    13681 AAGGGTCCTG TCAGGCGTTT CGGGCGAGGA CCAGGTCGCG ATCCGGACGG TGGGGGCCTT 
    13741 CGGACGCAGG CTCGTCCATG CACCCGCGTT GCGGACCGAC CTGCCGTCCT GGCAGCCGAG 
    13801 CGGGACCGTA CTGGTCACCG GAGGCACTGG AGCGCTGGGC GGTCATATCG CGCGGTGGCT 
    13861 GGCGCATCAG GGCGCGGAGC ACCTCGTGCT GACCAGCCGA CGCGGTATGG CCGCGCCCGG 
    13921 GGCGTCCGCA CTCGTGGCGG ACCTGGAAGC GGCCGGAGCG GCGGTGACGG TGGCCGTGTG 
    13981 CGACGTGGCC GAGCGTGCCC AACTGGCCGA CCTGGTGGCG GATGTCGGCC CGCTGACGGC 
    14041 TGTTGTGCAC ACGGCCGCCC TGCTGGACGA CGCGACGGTC GAGTCCCTGA CCACCGAGCA 
    14101 ACTGCACCGG GTGCTCCGCG TCAAGGTCGA CGGTGCGACG CATCTGCACG AGTTGACCCG 
    14161 TGACATGGAA CTCTCCGCGT TCGTGCTCTT CTCCTCCTTG TCCGGGACGG TCGGCACACC 
    14221 GGGGCAGGGC AACTACGCAC CGGGCAACGC CTTCCTCGAC GCGCTGGCCG AGTACCGCAG 
    14281 GACCCAAGGC CTGGTGGCGA CATCGGTGGC CTGGGGCCTG TGGGCCGGTG ACGGGATGGG 
    14341 AGAGGGCGAA GCCGGCGAGG TGGCCCGGCG GCATGGTGTT CCCGCGCTGT CGCCGGAGCT 
    14401 GGCGGTGGCC GCTCTGCGTG CGGCCGTCGA ACAGGGCGAC GCGGTGGTCA CGGTTGCCGA 
    14461 CATCGAATGG GAACGCCATT ACGCCGCCTT CACCGCGACG CGCCCCAGCC CCTTGCTCGC 
    14521 CGACCTTCCA GAGGTACGGC GACTCATCGA CGCGGGCGCC GCTTCGGCCG TCGAGGAGAC 
    14581 GGACCGGGAC CGATCCGGAC TCAGCGGGCG CTTGGCAGGG CTCGACGGGG CCGAACAGCG 
    14641 GCGACTGCTG CTCGATTTGG TACGCCGCAA TGTCGCGGTG GTGCTCGGGC ACACCGACCC 
    14701 AGAAGCCGTG TCGTCCCACC GCGCCTTCCA GGAGCTCGGC TTCGACTCCG TGACGGCGGT 
    14761 CGAGTTCCGC AACCGGCTGG GTGCCGCGAC CGGTCTGCGG CTCCCGGCCA CTGCCGTATT 
    14821 CGACTACCCG ACCCCGCTGG CCCTGGCGGA GTACGCGCTG TCGGAACTGC TGGGGACGGT 
    14881 CGGGGAGCCC CTTCGCGTCG AGTCGAGCGG CTCCCCCGTG GACGACGATC CGATCGTGAT 
    14941 CGTGGGAATG AGCTGCCGCT TCCCCGGCGG GGTGAGCTCG CCGGAGGACC TGTGGGACCT 
    15001 CCTCACCGAG GGCGGGGACG CGATGTCGGC GTTCCCCGGG GACCGTGGCT GGGACCTGGC 
    15061 CGGGCTCTTC CACAGCGACC CCGGCCACCC GGGTACCTCG TACACCCGGA CAGGTGGTTT 
    15121 CCTCCATGAC GCGACCGCGT TCGACGCCGA CTTCTTCGGC ATCTCGCCAC GTGAAGCGCT 
    15181 GGCGATGGAC CCGCAGCAGC GGCTGCTGCT GGAGGCGTCA TGGGAGGCGT TCGAGCGGGC 
    15241 GGGGATCGAT CCTCGGTCGC TGCGGGGCAG CGAGACCGGG GTGTTCGCCG GCACCAATGG 
    15301 TCAGGACTAC GTCAGCCTTT TGGGCGGAGA TCAGCCGCAG GAGTTCGAGG GCTATGTCGG 
    15361 AACGGGCAAT TCGGCATCGG TGATGTCCGG CCGGATCGCC TACGTCCTGG GCCTTGAGGG 
    15421 CCCGGCGCTG ACGGTGGATA CGGCGTGTTC GTCGTCGTTG GTGGCGTTGC ATCTGGCGGT 
    15481 GCAGGCGTTG CGGTCGGGTG AGTGTTCGCT GGCGCTCGCG GGCGGTGTCA CGGTGATGGC 
    15541 GACACCGGGT CTGTTCGTGG AGTTCTCCCG TCAGCGTGGC CTGGCCGCCG ATGGTCGGTG 
    15601 CAAGGCGTTC GCGGGGGCGG CTGATGGCAC CGGTTTCTCC GAGGGTGTGG GGATGCTGGT 
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    15661 GGTGGAGCGG TTGTCGGATG CTGAGCGGCT TGGGCATCGG GTGTTGGCGG TGGTGCGGGG 
    15721 CAGTGCGGTG AATCAGGATG GTGCGTCGAA TGGTTTGACG GCGCCGAATG GTCCGTCGCA 
    15781 GCAGCGGGTG ATCCGTCAGG CGTTGGCGAG CGCGGGTCTT GTGGCGGTGG ATGTGGATGC 
    15841 GGTGGAGGCG CATGGTACGG GTACGGCGTT GGGTGATCCG ATTGAGGCGC AGGCGTTGTT 
    15901 GGCCACGTAT GGTCAGGGTC GGGATGTGGG TCGGCCGTTG TGGTTGGGTT CGGTGAAGTC 
    15961 GAATATTGGT CATACGCAGG CGGCCGCGGG TGTGGCTGGT GTGATCAAGA TGGTGATGGC 
    16021 GCTGCGGCAT GGGGTGTTGC CGCAGAGTCT GCACATCGAT GAGCCGACAC CGCATGTGGA 
    16081 CTGGTCCACC GGCGCGGTGG AGCTCCTGGG GGAGCACACG GGCTGGCCGG AGGTGGATCG 
    16141 GCCGCGTCGG GCGGGTGTGT CGGCGTTCGG GGTGAGTGGG ACGAATGCGC ATGTGATTGT 
    16201 GGAGCAGGCG CCTGAAGTGG TGGAGCCTGA GGCTGAAGGT GTGGTGTTGC CTGCTGTGCC 
    16261 GTGGGTGGTG TCGGGTGTGG GTGAGGTGGC GGTGCGGGCG CAGGTGGAGC GGTTGCGGGC 
    16321 CTTTGCGGAC CGGAATCCGG GTCTGGATCC GGTGGATGTG GGGTGGTCTT TGGCGACTGG 
    16381 TCGTGCGGGG TTGTCGCATC GTGCGGTGGT GGTGGGTGCG GATCGTGGTG AGTTGTTGGG 
    16441 GGCTTTGGAG GGTGTGCCGG TGGTGGGTGT TCCGGTGGTG GGTGGGTTGG GTGTGTTGTT 
    16501 TGCGGGGCAG GGGTCGCAGC GGTTGGGGAT GGGTCGTGGG TTGTATGAGG GGTATCCGGT 
    16561 GTTCGCTGCG GTGTGGGATG AGGTGTGCGC GCAGCTGGAC CAGCATTTGG ATAGGCCGGT 
    16621 GGGTGAGGTG GTGTGGGGTG ATGATGCCGA GCTAATTGGC GAGACGGTGT ATGCGCAGGC 
    16681 GGGGTTGTTC GCGCTTGAGG TGGCGCTGTA TCGGCTGATC GCTTCGTGGG GTGTGAGGGG 
    16741 GGATTATCTG CTGGGTCATT CGATTGGTGA GTTGGCTGCG GCGTATGTGG CGGGTGTGTG 
    16801 GTCGTTGGAG GATGCGGCGA GGGTGGTGGT GGCGCGGGGT CGTTTGATGC AGGCGTTGCC 
    16861 GTCGGGTGGT GCGATGGTTG CGGTGGCCGT TTCGGAGGGT GTGGTGCGGC CGCTGCTGGG 
    16921 CGAGGGTGTG GTGGTTGCGG CGGTGAATGG TCCCGAGTCG GTGGTGCTGT CGGGTGATGA 
    16981 GGATGCGGTT CAGGTTGTGG TGGATGTGTT GGCTGGGCGT GGGGTGCGGA CGCGGCGGTT 
    17041 GCGGGTGAGT CATGCGTTCC ATTCGGCTCG TATGGACGGG ATGCTGGCGG AGTTCGGTGA 
    17101 GGTGCTTGGG GGCGTGGAGT TCCGTGCCCC GAGCGTGCCC GTGGTGTCGA ACGTGTCCGG 
    17161 TGCGGTGGCG GGTGAGGAGT TGTGTTCGCC GGAGTATTGG GTGCGGCATG TGCGGGAGAC 
    17221 GGTCCGGTTC GCCGATGGGC TGGAGACGCT GCGCGAGCTG GGTGTGGGTT CGTTCCTGGA 
    17281 GTTGGGGCCT GACGGGACGT TGACTGCCTT GGCGGATGGC GATGGTGTGC CTGTCTTGCG 
    17341 TCGGGATCGT CCGGAGCCTC TGACCGCTAT GGCGGCTTTG GGCGGGCTGT ACGTCCGGGG 
    17401 TGTCCAGATC GACTGGGGGG CGGTGTTCCC GGGTGCTCGG CGGGTCGATT TGCCGACGTA 
    17461 TGCCTTCCAG CGTGAGCGGT TCTGGTTGGA GCCATCCGCT GAGCAGCCTG CGACGAGCGT 
    17521 GGTGGACGCG GCGTTCTGGG ACGCGGTCGA GCGGGGCGAT GCGGAGGCTC TTGGGGGCGA 
    17581 TGCCGAGCAG TCGTTGAGTG CCGCGTTGCC TGCTTTGGCG TCGTGGCGGC GGGCGCAGCA 
    17641 GGAAGAGTCG GTTATCGACG GGTGGCGTTA CCGGCTCGGC TGGACGCCGA TCCCGGTGGT 
    17701 GCTGGGGGAG CCATGCCTCA CTGGCACTTG GCGGGTTGTG GTCGAACCGG GTGCGGACGG 
    17761 TACCGATGTG GCTGCCGCGC TGCGGTCGGC CGGGGCTGAT GCCGAGGTCG TGACGTCGGC 
    17821 GGAACTGAGC GCGGGGCCGG TCGCGGGTGT GGTGTCATTG TTGTCGGTCG AGGCGACGGT 
    17881 GGCGCTGGTG CAGGCTCTCG GGACGGTCGG GATCGATGCG CCGTTGTGGT GTGTGACGCG 
    17941 GGGTGCGGTC TCCGTGGTGG ACGGGGATGT GGTGGAACCG TACGCGTCGG CCGTCTGGGG 
    18001 TCTGGGCCGT GTGATCGGTC TGGAGCATCC GGACCGTTGG GGCGGGCTGA TCGACCTGCC 
    18061 CACGGAGGCG GACGCACGTG TGGGTGCGTT GTTGGCCGGG GTTCTCGCCG GGCGCACCGG 
    18121 GGAGGATCAG GTGGCAATCC GGGCCGCCGG GGCGTGGGGT GCCCGGCTGA GCCGGGCGAC 
    18181 ACCGATTGCG GACACGTCTG GCGGGTGGCG TGGTCGGGGA GCTGCCTTGA TCACCGGGGG 
    18241 TACGGGTGCG CTGGGCGGCC ATGTGGCGCG CTGGCTGGCG GGGACCGGGG TGGAGCGCAT 
    18301 CGTGCTGACG AGCCGCCGGG GGATCGAGAC CCCGGGTGCG GCCGAGCTGG TGACCGAGTT 
    18361 GGAGGAGTTC GGAGTCCAGG TGACGGTGGT CGCGTGCGAT GTCGCCGATC GGGAGGCGGT 
    18421 CGCGACGCTG CTGGTCACCA TCCCCGATCT CCGGGTCGTC GTACACGCCG CAGGGGTGCC 
    18481 GAGCTGGAGT GCGGTGGACA GCCTGACACC CGAGGAGTTC GAGGAGAGCG CGCGGTCGAA 
    18541 GGTTGCCGGG GCGGCGAACC TGGACGCGCT CCTGGCGGAC GCTGAGCTGG ACGCCTTTGT 
    18601 GTTGTTCTCG TCGGTGGCGG GGGTGTGGGG GAGCGGTAGT CAGTCGGCGT ATGCGGCGGC 
    18661 GAACGCGTTT CTGGATGGGT TGGCGTGGCG GCGTCGTGGT GTTGGGTTGG TGGCGACGTC 
    18721 GGTGGCGTGG GGGATGTGGG GTGGCGGTGG TATGGCGGTT GGGGGTGAGG AGTTTCTGGT 
    18781 TGAGCGTGGT GTGTCGGGGA TGGCTCCGGG GTTGGCGGTG GCTGCGTTGC GGCGGGCGCT 
    18841 GTGTGATGGT GAGACGGCGC TTGTGGTGGC GGATGTGGAT TGGGAGCGGT TCGGGCCGAG 
    18901 GTTCACCGCG TTGCGTCCGA GCCCACTGCT GAGCGAGCTG ATCCCCGATA CGTCCGAACC 
    18961 ACTCGCGTCG ACGGTGGGTG AGTTCGCGGT CGAGCTGCGC GGATTGTCGC GCGAGGACCG 
    19021 GGACCGTGCC GTCGTGGAGC TCGTACGGAC ACATGCCGCC GAGGTGTTGG GCCACCAGAA 
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    19081 CCCGAGCGCG ATCGACCTGG ACCGGACGTT CCAGGAGCTG GGCTTTGACT CGCTGACCGC 
    19141 CGTGGAATTG CGGGACCGGC TCGGCACGGC TACTCAGCTG CGATTCCCAG CGTCCGTGAT 
    19201 CTTCGACTAC CCGACTCCGG CGGCACTCGC CGAGCATGTG TGCGGGGCGG CCCTCGGACT 
    19261 GGCCGAAGAG ATACAGGTAG CGCACACGCC CAGCGCGGTG GCCGACGATC CGATCGTGAT 
    19321 CATCGGCATG AGCTGCCGAT TCCCGGGCGG TGTGGACTCT CCGGAGGCGC TGTGGCGGCT 
    19381 GGTCAGCGCC GGTGGCGACG CCGTATCGTC CTTCCCGTCC GACCGTGGCT GGGACCTGGC 
    19441 CGGTGTGTAC GACGCCGACG CCACTCGCTC GGGCCGGTCG TACGTCCGCA CGGGTGGATT 
    19501 CCTCCATGAC GCGGCTGAGT TCGACGCCGG ATTCTTCGGG ATCTCGCCGC GCGAGGCGAC 
    19561 CGCGATGGAT CCGCAGCAGC GGCTGCTGCT GGAGGCGTCC TGGGAGGCGT TCGAGCGGGC 
    19621 CGGAATCCCG GCCTCGACGC TCAAGGGCAG CCAGACCGGC GTCTTCGTGG GCGCGTCCGC 
    19681 ACAGGGCTAT GGCGGCGGGG ACGGGCAGGC GCCGGAAGGA TCCGAAGGAT ACCTTCTGAC 
    19741 CGGCAACGCG GGCAGCGTGG TGTCCGGTCG GGTGGCCTAT ACGTTTGGGC TGGAGGGCCC 
    19801 GGCGGTCACC GTGGACACGG CGTGCTCGTC CTCGTTGGTG GCGCTGCACT GGGCGGTGCG 
    19861 GGCCCTTCGG TCGGGCGAGT GCTCCCTCGC GCTGGCCGGC GGAGTGACGG TGATGGCGAC 
    19921 ACCCGCCACC TTTGTGGAGT TCTCACGTCA GCGTGGGCTG GCCGCCGATG GCCGCTGCAA 
    19981 GTCCTTCGCC GCCGGTGCGG ATGGGACGGG CTGGTCGGAG GGTGTTGGGC TGTTGCTGGT 
    20041 GGAGCGGTTG TCGGATGCCG AGCGGAACGG GCATCCGGTG CTGGCCGTTG TCTCCGGCTC 
    20101 TGCGGTGAAT CAAGACGGTG CGTCGAATGG TTTGACGGCG CCGAATGGTC CGTCGCAGCA 
    20161 GCGGGTGATC CGTCAGGCGT TGGCGAATGC GGGTCTTGTG GCGTCGGATG TGGATGCGGT 
    20221 GGAGGCGCAC GGTACGGGTA CGACGCTGGG TGATCCGATC GAGGCGCAGG CGTTGTTGGC 
    20281 CACGTACGGT CAGGGTCGGG ATGCGGGTCG GCCGTTGTGG TTGGGGTCGG TGAAGTCGAA 
    20341 CATCGGTCAT ACGCAGGCGG CTGCGGGTGT GGCTGGTGTG ATCAAGATGG TGATGGCCAT 
    20401 GCGGCATGGG GTGTTGCCGC GGACGTTGCA TGTGGATGAG CCGTCGCCGC ATGTGGATTG 
    20461 GTCTGCTGGT GCGGTGGAGT TGTTGACGGG GCAGGTGGCG TGGCCGGAGG TGGATCGGCC 
    20521 GCGTCGGGCG GGTGTGTCGG CGTTCGGGGT GAGTGGGACG AATGCGCATG TGATTGTGGA 
    20581 GCAGGCGCCT GAAGTGGTGG AGCCTGAGGC TGAAGGTGTG GTGTTGCCTG CTGTGCCGTG 
    20641 GGTGGTGTCG GGTGTGGGTG AGGTGGCGGT GCGGGCGCAG GTGGAGCGGT TGCGGGCCTT 
    20701 CGCGGACCGG AATCCGGGTC TGGATCCGGT GGATGTGGGG TGGTCTTTGG TGGCCACCCG 
    20761 GTCTGGGTTG TCGCATCGTG CGGTGGTGGT GGTTGCGGAT GGTGAGGAGT TGTTGGGGGC 
    20821 TTTGGAGGGT GTTCCGGTGG TGGGTGGGTT GGGTGTGTTG TTTGCGGGTC AGGGGTCGCA 
    20881 GCGGTTGGGG ATGGGTCGTG GGTTGTATGA GGGGTATCCG GTGTTCGCTG CGGCGTGGGA 
    20941 TGAGGTGTGC GCCCAGCTGG ACCAGCATCT GGATAGGCCG GTGGGTGAGG TGGTGTGGGG 
    21001 TGATGATGCC GAGCTAATTG GCGAGACGGT GTATGCGCAG GCGGGGTTGT TCGCGCTTGA 
    21061 GGTGGCGCTG TATCGGCTGG TCGCCTCGTG GGGTGTGAGG GCGGATTACC TGCTGGGTCA 
    21121 TTCGATTGGT GAGTTGGCTG CGGCGTATGT GGCGGGTGTG TGGTCGTTGG AGGATGCGGC 
    21181 GAGGGTGGTG GCGGCGCGGG GACGTTTGAT GCAGGCGTTG CCGTCGGGTG GCGCGATGGT 
    21241 CGCGGTGGCG GCGTCGGAGG GTGAGGTGCG GCCGCTGCTG GGCGAGGGTG TGGTGGTTGC 
    21301 GGCGGTGAAC GGTCCCGAGT CGGTAGTGGT CTCGGGTGAT GAGGATGCGG TGCATGCCAT 
    21361 CGAGGAGACG TTCGCCATGG GTGGGGTGCG GACGCGGCGG TTGCGGGTGA GTCATGCGTT 
    21421 CCATTCGGCT CGTATGGACG GGATGCTCGC GGAGTTCGGT GAGGTGCTTC GGGGCGTGGA 
    21481 GTTCCGTGCC CCGAGCGTGC CTGTCGTGTC GAACGTGTCC GGTGCGGTGG CCGGTGAGGA 
    21541 GCTCTGCTCG CCGGAGTATT GGGTGCGGCA TGTGCGGGAA ACGGTCCGGT TCGCCGATGG 
    21601 GCTGGATACT CTCCGTGAGC TGGGTGTGGG TTCGTTCCTG GAGTTGGGGC CGGACGGGAC 
    21661 GTTGACCGCC TTGGCGGATG GCGATGGTGT GCCTGTCTTG CGTCGGGATC GTCCGGAGCC 
    21721 CCTGACCGCT ATGGCGGCTC TGGGCGGGCT GTACGTCCGG GGTGTGGAGG TGGACTGGGA 
    21781 CGCGGTGTTC CCCGGCGGTC GGCGGGTCGA TCTCCCCACC TACGCGTTCC AACGGCAGCG 
    21841 GTTCTGGTTG GAGTCGGCCT CGGACCAGCC TGCGACCAGC GCGGTGGACG CGGCGTTCTG 
    21901 GGACGCGGTC GAGCGCGGGG ATGCGCGGGC GCTGGGCATT GACGAGGAAC AGCCGTTGAG 
    21961 TGCCGTACTG CCCGCCCTCT CGTCGTGGCG GAGGGCGCGG CAGGAGCAGT CGGTGATTGA 
    22021 TGGCTGGCGT TATCGGCTCG GTTGGATGCC GATTCCGGCG GTGTTGGGGG AGGTGGGCCT 
    22081 CATCGGTACC TGGCTGGTTG TGGTCGAGCC GGGTGTGGAC GGTACTGATG TGGCCGCAGT 
    22141 GTTGCGGTCG GCCGGGGCTG GTGTCGAGGT TGTGACGTCG GCGGAGCTGA GCGCTGGTCC 
    22201 GGTTGCGGGT GTGGTGTCGT TGGTGTCGGT CGAGGCGACG GTGTCGTTGC TGCAAGTCCT 
    22261 TGTGGCGGCC GGGGTCGATG CGCCGTTGTG GTGTGTGACT CGTGGTGCGG TCTCGGTGGT 
    22321 CGACGGTGAC CTGGTGGATC CTGGCCAGGC GGGAATCTGG GGTCTGGGCC GTGTGATCGG 
    22381 TCTGGAGTGT CCGGACCGTT GGGGCGGGCT GATCGACTTG CCTGGCGAAC TGGACGATCG 
    22441 CGCGGGGAAT GCGCTGGTAG GCATCCTTGC CGGGGGCACC GGTGAGGATC AGGTGGCCAT 
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    22501 CCGTGTCACC GGCATATGGG GTGCCCGGCT GGTGCGGGCG ACGCCGGTCC CGATCGGTGA 
    22561 CGCGGGTGGT GAGGCTGCGG CCGCGTGGCG TGGGCGTGGT ACCGCGCTGG TCACCGGTGG 
    22621 TACGGGGGCG TTGGGGCGTC AGGTGGCGCG GTGGCTGGTG GGCAGTGGTC TGGAGCGGGT 
    22681 CGTGCTGACG AGCCGTCGGG GGGTTGAGGC GCCCGGTGCC GTCGAGCTGG TGGCTGAGTT 
    22741 GGGGAGCCGA GTGCGTGTCG TGGCCTGTGA TGTCGGCGAT CGTGAGGAGC TTGCGGCTCT 
    22801 TTTGGTGACG CTTCCGGATG TGCGGACCAT CGTGCATGCG GCGGGTGTCC TCGACGACGG 
    22861 GGTGCTCGAA TCGCTGACGC CCGAGCGGAT CCGTGAGGTG ATGCGGGCCA AGGCCGACGG 
    22921 CGCGCGGCAT CTCCACGAGT TGACCCGTGA CATCGACCTC GACGCCTTTG TGTTGTTCTC 
    22981 CTCGGCTGCC GGGACCGTGG GTAATGCGGG TCAGGGGAGC TATGCGGCGG CCAACGCCGT 
    23041 CCTGGACGGG CTGGCGTGGC GTCGCCGGGC CGAGGGCTTG GTGGCCACAT CGGTGGCCTG 
    23101 GGGAGCCTGG GCCGAATCCG GTATGGCCGC GGAGATGGCG CGGTCGCAGG GCATGGATCC 
    23161 GAGGTCGGCG CTCGCCGCCC TGGGGCTGGT GCTGGCCGCT GACGAGACCA CGGTGATGGT 
    23221 GGCCGACATC GACTGGGCGA CCTTCGGGGC CCGGTTCACC GCCTCACGGC CGAGCCCGCT 
    23281 GCTCAGCGAG TTGCTCGGCG ACGGATCCGT GTCGACCGAG GCAGCCGACG GCGAACCGGC 
    23341 CGACGCGTTC GCCACCCGCC TGGAGGCCAT GGCCGAGCGG GAACGGGCGG CCACCGTGCT 
    23401 GGACCTCGTC CGTACGCATG TGGCCGCTGT CCTGGGACAC ACGGCATCCG AGGCGATCGA 
    23461 CCCGGCCCGG CCCTTCCAGG AGATCGGTTT CGACTCGCTC ACCGCGGTGG AGCTGCGGAA 
    23521 CCGGCTCACC GCGGCCACCG GGGTACGGTT CCCGGCTTCC GTGATCTACG ACTACCCGAC 
    23581 CCCGGCCGCG CTCGCCGAGC ACGTGTGCCG GGAGGCGCTG GGTCCGGGCG GACGGACACC 
    23641 GGCTCCGGTG GTGCCACGCC CGGTGGACGA CGAACCGATC GCCATCATCG GGATGAGCTG 
    23701 CCGTTTCCCC GGCGGGGTGA GCTCGCCGGA GGACCTGTGG GGGCTGCTGG CCGAGGGCCG 
    23761 TGACGCCGTG TCGGACTTCC CGGCGGACCG TGGCTGGAAC CTGGCCGAGC TGTACGACCC 
    23821 GGATCCCGAC CACCCCGGCT CCTCGTACGT CCGGGCGGGC GGATTCCTTG ATGACGCGGC 
    23881 CGCGTTCGAC CCCGGCTTCT TCGGGATATC GCCGCGCGAG GCGCTCGCGA TGGACCCGCA 
    23941 GCAGCGGCTA TTGCTGGAGG TCGCCTGGGA GGCGTTCGAG CGCGCCCATA TGTCCCCCGC 
    24001 CACCCTCAAG GGCAGCCGGA CCGGGGTGTT CGTCGGGACC AACGGCCAGG ATTACGCCGC 
    24061 TCTGGCGAGC GGGGCCCCGC GGAGCGCGGA AGGGTATCTG GGCACGGGCA GCGCCGCCAG 
    24121 TGTCGCCTCG GGCCGGCTGG CGTACACCTT CGGCCTCGAG GGCCCGGCGG TCACCGTGGA 
    24181 CACCGCCTGC TCGTCGTCGC TGGTCGCGCT GCACCTCGCC GCACAGGCCC TGCGCTCCGG 
    24241 TGAATGCTCC TTGGCCTTGG CCGGTGGTGC GACCGTCATG GCCACTCCGG CGGCCTTCCT 
    24301 GGAATTCTCC CGCCAGCGTG CGTTGGCGGC CGATGGGCGC TGCAAGGCGT TCGCGGCGGC 
    24361 GGCGGACGGC ACCGGCTGGG GCGAGGGCGT CGGCATGCTC CTGGTGGAGC GGCTCTCCGA 
    24421 CGCGGAGCGC AACGGCCACC GGGTGCTGGC GGTGATGCGT GGCTCCGCCG TCAATCAGGA 
    24481 CGGCGCGTCC AACGGGCTCA CGGCGCCGAA CGGCCCGTCG CAGCAGCGAG TGATCCGTCA 
    24541 GGCCCTGGCG AACGCCCGGC TGTCCGCCAC GGACATCGAC GTGGTGGAGG CGCACGGCAC 
    24601 CGGCACCAGT CTCGGCGACC CGATCGAGGC GCAGGCACTG CTCGCCACGT ACGGTCAGGG 
    24661 CCGGTCCCAG AACAAGCCAC TGTGGCTCGG CTCGGTGAAG TCCAACATCG GGCACACCCA 
    24721 GGCGGCCGCC GGCGTGGCCG GTGTGATCAA GATGGTCATG GCCATGCGAC ACGGTGTACT 
    24781 GCCGCGGACC CTGCATGTCG ACTCGCCCTC GCCCCATGTG GACTGGGCGG CGGCCCGGGT 
    24841 CGAGTTGCTC GTCGAAGCGA GGGAGTGGCC GCGGACCGGC GCTCCTCGCC GGGCGGGTGT 
    24901 GTCCTCGTTC GGGGTCAGTG GCACCAACGC CCATGTCATC GTCGAGCAGG GGCCGGTGGT 
    24961 GGCCCGGCCC GATCGGGAGT CGGCGCGCGA GCCGTCACCC TCCGTGCCGT GGGTGCTGTC 
    25021 AGGTGCGGGG GAGGCCGGGC TGAGGGCCCA GGTCGAGCGC CTGGCGTCCT TCATCGACGC 
    25081 CCATCCGGGC CTGGATCCCG CCGATGTCGG GTGGACGCTG GTGGCCGGCC GTTCGTGTCA 
    25141 GTCGCACCGC GCCGTAGTGG TGGGTGCAGA CCTCGCGGAG CTTCGACGTG GACTGGACGC 
    25201 AGTCTCGACC GGTGGCGCCG CCCGGTCCGG CCGCAAGGTG GTGTTCGTCT TCCCCGGCCA 
    25261 GGGGTCGCAG TGGGCCGGAA TGGCGTTGGA ACTGTTGGAG CATTCGCCGG TGTTCGCGGA 
    25321 GCGGATGCGT GCATGCGCCG ATGCGCTCAC CCCGTTCGCC GAGTGGTCGC TGTTCGATGT 
    25381 GCTGGGTGAT GAGGTGGCGC TCGGTCGGGT TGATGTGGTG CAGCCGGTGT TGTGGGCGGT 
    25441 GATGGTGTCG CTGGCCGAGT TGTGGCGTTC GTTTGGTGTG GTGCCGTCGG CGGTGGTGGG 
    25501 GCATTCGCAG GGTGAGATCG CGGCGGCGTG TGTGGCCGGG GGTCTGTCGC TGGAGGACGG 
    25561 TGCCCGTGTG GTGGCCTTGC GGAGCAGGGC GTTGCTGGCT CTGTCGGGTC GGGGTGGGAT 
    25621 GGTGTCCGTA CCGGTGTCCG CCGATCGGCT CCGTGACCGT GCGGGGTTGT CGGTGGCGGC 
    25681 GGTGAACGGT CCGGCGTCGA CGGTGGTGTC GGGGGCTGTT GAGGTGCTGG ATGGGGTGCT 
    25741 GGCGGAGTTT CCGGAGGCCA AACGGATTCC GGTGGATTAC GCCTCACACT CCCCGCAGGT 
    25801 GGCCGAGATC CAGCGGGAGC TGGCGGACGT GCTGGCGCCG GTCCGGCCGC GCGGTGGACA 
    25861 GATCGCGTTC CACTCGACGG TGACCGGACG GCTCACCGAC ACCTCCGAAC TCGACGCCGA 
313 
 
    25921 CTACTGGTAC CGCAACCTCC GGCACACCGT GGAATTCCAG AGCACCGTCG AAGCCCTGAT 
    25981 GAACCAGGGC CACACCGTGT TCGTCGAGGT GAGCCCGCAC CCCGTGCTGA CCATCGGCAT 
    26041 CCAGGACACC GCCGAGACCC CAGGCACCCC CGACACCCCA GGCACCCCCG ACACCGCGGA 
    26101 CGCCACCGAC GCTCACGAGG CCACCGGCGC CCCCGACGTC GCCAACACCG CCGACGTCAC 
    26161 CGGCGCTCCC GACGTCACCG GCGCCGACAT CGTCATCACC GGATCGCTGC GCCGCGACGA 
    26221 CGGTGGCCCC GCCCGCTTCC TCACCGCCCT CGGCGACCTC CACACCCGGG GCGTGGACGT 
    26281 GGACTGGAGC CCGGTCTTCA CCGGAGCCCG GACGGTGGAC CTTCCCACCT ACGCCTTCCA 
    26341 ACGGGAACGC TTCTGGCTGA AGCCCGCGCG GGCGGTGACC CAGGCGTCCG GGCTGGGCCT 
    26401 CGGCGATATC GAGCACCCCC TGCTGGGCGC GGTACTGCCC CTGCCCGGGG ACGAGGGCGG 
    26461 TGTGCTGACC GGACTGCTCT CCCTGGACGG ACAGCCCTGG CTGGCCCACC ACATGGTGCG 
    26521 GGACACGGTT GTCTTCCCCG GCACGGGATT CGTCGAACTC GCCCTGCAGG CCGGTCAGCA 
    26581 CTTCGGCCAC TCGGTGATCG AGGAGCTGAC CCTGCATGCC CCGCTGGTGG TGCCGGACCA 
    26641 GGGCGGGGTC CAGGTACAGG TGGCCGTATC GGCGGCGGAC GAACGGGGCC GGAGGCCGGT 
    26701 CACGGTGCAC TCGTGCCGTG CCGGGGAGTG GCTGCTGCAC GCCTCGGGCA CTCTCGGCGC 
    26761 CACCGGAGGC CTCGACGTCA CCGAGCCGCG CCCCGCCGAC GTGGCCCGGC CCCTGGAGGT 
    26821 CTGGCCGCCC GAGGGCGCGC GGAGCCTCGA TGTCTCGGGG ATGTACGAGG CGATGGCGGA 
    26881 GCGCGGCTAC GGGTACGGTC CCGCTTTCCA AGGGCTGCGC GCCGCGTGGA CACGGGACGA 
    26941 TGAGATCTAC GCCGAAGTGG CTCTGGAGCC GGAGGCACAG GACGTGGCGG CGCGGTGCGG 
    27001 TGCGCATCCG GCCCTGCTCG ACGCCGCGCT CCACGGAGTG GGGCTCGGCC GCTTCCTCAC 
    27061 CGACCCCGGC CAGGCGTATC TGCCGTTCTC CTGGAGCGGG GTCGCGCTGC ACGCGGTAGG 
    27121 CGCCTCCGCC ATCCGCGTGG TGCTCTCCCC GGCCGGTACG GACGCGGTGT CGCTGGAGGT 
    27181 GACGGACCCG ACGGGAGCGC CGGTGCTGTC GGTGGCGTCG CTCTCGTTGC GTCCGCTGTC 
    27241 CAGCGGGCGG ATCGCGGACA CCCGAGGGGT GGACCAGGAC TCGCTGTACC GCGTGGACTG 
    27301 GGTCGAGATG CCGCTGCCGA CTGCCCCGGC AGGCTCGGCC CCGGCCGAGT ACGACGCGCC 
    27361 GGCGATGTTC GACGCCCTGG TATTCGACGC CCCGGTCGAG TACGACGTTC TCGCCTCCGA 
    27421 CGCCTCCGAC GCCTCCGACG CCTCCGACGC CCCCGGCACC CCCGACGCCT CCAGTGCCCC 
    27481 GGTGCCCGAC ATGCCCGACA TGGTGGTGCT GCCGTGTGAG TCGGCCGGTG ACGCGGTGTC 
    27541 CACCGTCGTG TGCCGGGCGC TGGCGGCGGT ACGGCGATGG CTCGCCGACG AGCGCTGTGC 
    27601 CCGGTCGCGG CTGGCCGTGC TGACGCGCGG CGCGATGGCC ACCGCTCCCG GCGAGAGCGT 
    27661 CGAAGACCTC GGCGCGGCAG CGGTCTGGGG CCTGCTCCGC AGCGCCCAGG CCGAGCACCC 
    27721 GGACCGCTTC GTCCTCGTCG ACCACGACGG CCACCAGGAT TCCCGTGCGG TGCTCGCCGC 
    27781 CGCGCTGGCC GCCGCGGTCG ACGGTGGCCA TGCGCATCTC GCGCTGCGCC GTGGCCGTGT 
    27841 CCTGACGCCT CAGCTCGCTC CGCTCACCCC GTCCGCGACC GCCCTGTCCA CCACCGCACC 
    27901 GCCCGCCGCC ACCCCAACCC CGGAGGCCGG GGCACCGTGG CGGATGGACG TCACCAGTCA 
    27961 GGGCACGCTG GAGAACCTGG CCGCCGTCCC CTGCCCGGAG GCCGCCGGTG TCCTCGGCGC 
    28021 CGGACAGGTG CGGGTGGCGA TGCACGCGGC CGGGGTGAAC TTCCGGGACG TCGTCGTCGC 
    28081 CCTCGGCATG ATCCCCGGTC AGGACGTCAT CGGCAGCGAG GGTGCCGGAG TGGTGCTCGA 
    28141 CATCGGCCCC GGTGTGTCCG GCCTGGCGCC CGGTGACCGG GTGATGGGTC TGTTCTCCGG 
    28201 GGCGTTCGGC CCCGTGGCGG TGACCGATCA CCGACTGTTG GCGCGGCTGC CGGAAGGCTG 
    28261 GTCGTTCGCC GACGCCGCGG CCACGCCGGT GGTGTTCCTG ACCGCCATGT ACGGGCTGAT 
    28321 GGACCTGGCC GGTCTGCGAC CCGGTGAATC GGTGCTGCTG CACTCGGCCG CCGGCGGGGT 
    28381 GGGCATGGCC GCGACACAGG TGGCCCGCTG GCTCGGCGCT GAGGTGTACG CCACCGCGAG 
    28441 CCCAGGGAAG TGGGACGCGC TGCGCGCCGG AGGAGTGGCG GACGACCGGA TCGCCTCGTC 
    28501 CCGCTCCTTG GAGTTCGCCG ACCGCTTCGG CCGGGTGGAC GTGGTGCTGA ACTCGCTGGC 
    28561 GGGCGAGTAC GTGGACGCCT CGCTCGGCCT GCTCGCCGAC GGTGGCCGTT TCCTGGAGAT 
    28621 GGGCAAGACC GACATCCGCG ACGGTGAGCG CGTGGCCGCG GAGCACGGGG TGCGGTACCA 
    28681 GGCGTTCGAC CTCATGGACG CGGGGCCCGA CCGGGTCGGG GAACTGCTCA GGCTGCTGGT 
    28741 GTCGCTCTTC GAGCGAGGGA TCTTCACGGC ACTGCCGACC CGCGTCTGGG ACGTCCGGCA 
    28801 GGCGGGTGAC GCGCTGCGCT TCCTCTCGCA GGCACGCCAC ATCGGCAAGC TGGTGCTGTC 
    28861 CATTCCGCAG CCGCTGCGGG AGGGGGACAC CGTGCTCATC ACCGGCGGCA CCGGCACACT 
    28921 GGGCGGGCTG GTCGCCCGTC ACCTGGTCGA ACGGCACGGA GTACGGGATG TCGTCCTGGC 
    28981 CGGCCGGCGG GGGCCGGACG CCCCGGACGC GGCCGAACTC GCCGCCGCCC TGCGCGAATA 
    29041 CGGCGCCCGG GTGCGGGTGG TGGCCTGTGA CGTGGCCGAC CGGGACCAGC TGGCACGGCT 
    29101 GCTGGACACC GTCTCCGGCC TGCGGATGGT GGTGCACACC GCGGGTGTGC TCGACGACGG 
    29161 GGTGATCGAG TCGCTCACCC CGGAGCGGGT GCGCGAGGTC CTGAGGCCGA AAGTGGACGC 
    29221 CGCCTGGTAT CTGCACGAGC TGACGGCCGG TCGTGAGCTG GCGGAATTCG TGGTGTTCTC 
    29281 CTCGGCCGCG GGTGTTCTGG GAAGCCCCGG GCAGGGCGCC TACGCGGCGG CGAACGCCTG 
314 
 
    29341 GCTGGACGCG CTGATGGCGC ATCGCCGGGC CGCCGGGCTG CCGGGTCTCT CCGTGGCCTG 
    29401 GGGGCTGTGG GCCGAGCGCA GCGGGATGAC CGGCCATCTG TCGGACCGGG ATCTCGCCCG 
    29461 GATGGCCAGG GCCGGTGCCA CGCCTCTCGC CACCGATCAG GGGCTCCGGC TCCTGGACAG 
    29521 TGCCAGGGCG GCCACCGAGG CGCTCGTGCT GGCCACACCG CTGGACGCCG CGGCGCTGCG 
    29581 GGCACAAGCC GACGCCGGGG CGCTGCCCGC GCTCTTCCGC GGTCTGGTCC GTGCGCCGAT 
    29641 CCGCCGCGCG ACCGGCGCGG GCCCGGTGGA GGACGAGTCG TCGCTGCGGG GCCGGATGGC 
    29701 CGCGATGCCG GTCGCCGAGC GCGAACAGCT GGTGCTGGAC CTGGTCCGTA CGCAGGTGGC 
    29761 GACCGTGCTG GGGCACGGCA CCGCCACCGC GGTCGACCCG GCGCGTACGT TCGCGGAGAC 
    29821 CGGCTTCGAC TCGCTCACGG CCGTCGAGCT GCGCAACCGG CTGCGCACCG CCACCGGGGT 
    29881 CAGGCTGTCG GCCACCGCGA TCTTCGACTA TCCGACACCC GCGGTCCTGG CCGGTCATCT 
    29941 CCTCCGGGAG CTGGACGGCA CCGTCGGCGA GGCCGTGACA CGGCCCGCCG CCCCGGCCGC 
    30001 CGCCACCGAC CGGGACCCGA TCGTGATCGT CGGAATGGCC TGCCGCTATC CGGGCGGAGT 
    30061 GGCGTCGCCC GAGGAGTTGT GGGAGCTGCT CGCCACCGGG CGCGACGCGG TCGCGGATCT 
    30121 GCCGGACGAC CGGGGCTGGG ACCTGGACGG CCTGTACAGC GCCGATCCGG ACAGCTCGGG 
    30181 CACCTCGTAC GTCCGCTCCG GTGGCTTCGT GTACGACGCG GGCGAGTTCG ACGCCGACTT 
    30241 CTTCGGCATC TCGCCGCGCG AGGCGCTCGC GATGGATCCG CAGCAGCGGT TGCTGCTGGA 
    30301 AGTGGCCTGG GAGACGGTGG AGCGGGCCGG TGTCCCGGCG GCGTCGCTGA AGGGGAGCCA 
    30361 GACCGGGGTG TTCGTCGGTG CCGCGGCACA GGGCTACGGC ACGGGGGCCG GGCAGGCGGC 
    30421 GGAGGGATCC GAGGGCTACT TCCTGACCGG TGGCGCGGGC AGCGTGGTCT CCGGCCGGCT 
    30481 CTCGTACACC TTCGGCCTGG AGGGGCCGGC GGTCACCGTG GACACCGCCT GCTCGTCGTC 
    30541 GCTGGTCGCG CTGCACCTGG CGGCGCAGGC CCTGCGGTCC GGCGAGTGCT CGCTGGCACT 
    30601 GGCCGGCGGG GTGACGGTGA TGGCCACCCC GGGCATCTTC GTGGAGTTCT CCCGACAGCG 
    30661 CGGACTGGCC GCCGACGGCC GCTGCAAGGC GTTCGCCGAC GCGGCGGACG GCACCGGCTG 
    30721 GGGCGAGGGC GTCGGCATGC TGCTGCTGGA GCGGCTGTCC GACGCCCGCC GCAACGGCCA 
    30781 CCGGGTCCTG GCGGTCGTAC GGGGCTCCGC CGTCAACCAG GACGGCGCCT CGAACGGCCT 
    30841 GACGGCGCCG AACGGGCCCT CGCAGCAGCG GGTGATCCGG GCCGCGCTGG CGAACGCCGG 
    30901 GCTGGCCGCG TCGGACGTGG ACGCGGTGGA GGCACACGGC ACCGGCACCA GCCTGGGCGA 
    30961 CCCGATCGAG GCACAGGCGC TGCTGGCCAC CTACGGGCAG CAACGCGAAC GGCCGCTGCT 
    31021 GCTGGGCTCG ATCAAGTCGA ACATCGGGCA CACCCAGTCG GCCGCGGGAG TGGCCGGTGT 
    31081 GATCAAGATG GTGCTGGCGA TGCGGCACGG GGCGCTGCCC CGCACCCTGC ACGTGGACCA 
    31141 GCCGTCGACC CATGTGGACT GGTCGGCCGG TGCGGTGGAG CTGCTGACCG AGCCCGCCGA 
    31201 GTGGCCGGGG ACCTCCCGCC CCCGCCGGGC CGGGGTGTCC TCGTTCGGGG TGAGCGGGAC 
    31261 CAACGCCCAT GTGATCCTCG AACAGCCACC CGCGGAGGCG GAGTCCGGGC CCGCTCCGGA 
    31321 GTCGGCACCC GGGCCCGTCC CGGCGGTGGT GCCCGGGCCC GTCCCGGCGG TGGTGCCATG 
    31381 GGTGCTCTCC GGCCAGGGCG AGCGCGGACT GCGGGCGCAG GCCGCCCGGT TGCGGTCCTT 
    31441 CCTGGCCGCG CGCCCCGAGT CCGGCCCGGC CGACGTGGGC TGGTCGCTGG CCGCCACCCG 
    31501 TTCGGCGCTC TCCCACCGGG CCGCGGTGGT CGGGGCGGAC CGGGCGGAAC TGCTGGACGG 
    31561 ACTGGCCGCG CTTGCGGCCG GCGAGCCCGC CCCGGGCGTG GTCTTGGGCA CCGCGGACCC 
    31621 GGGCCGGGTG GGCGTGCTGT TCGCGGGCCA GGGTACGCAA CGGCCCGGTA TGGGGCGTGA 
    31681 GTTGTACCAG TCGTTCCCGG TTTTCGCGGC GGCGTGGGAC GAGGTGTGCG CCGCGCTCGA 
    31741 CCCGCATCTG GACCGTCCGC TCGGCGAGGT GGTGACCGAT GCCACCGGCG CGCTGGACGC 
    31801 CACCACGTAC ACGCAGGCGG GCCTGTTCGC CCTCGAAGTG TCGCTGTTCC GGCTGGTGTC 
    31861 CTCCTGGGGC GTGCGGCCGG ACTATCTGCT GGGCCACTCC ATCGGCGAGC TGGCGGCCGC 
    31921 GCAGGTGGCC GGTCTGTGGT CGCTGGAGGA CGCCGCCAAG GTGGTGGCGG CCCGGGGCCG 
    31981 GCTCATGGGC GCGCTGCCGC CGGGCGGGGC GATGGTGGCC CTGGCCGCGC CGGAGGACCA 
    32041 GGTACGGCCG TTCCTGACCG ACCGGGTCGC CCTCGCGGCC GTGAACGGGC CGTCGTCGGT 
    32101 CGTGGTGTCC GGGGACGAGG ACGCGGTGTG CGGTGTGGCC GAGGCGTTCG CCGCCCGTGG 
    32161 GGTGAAGACG CGGCGGCTGC GGGTCGGCCA CGCCTTCCAC TCGCCGCTGA TGGACGAGAT 
    32221 GCTCATCGCG TTCGCCGAGG TACTCGACAC GGTGGACTTC CGCACCCCGC GGATACCGGT 
    32281 GGTGTCGAAC CTCTCCGGTG CGGTGGCGGG GGAGGAGCTG TGCTCCCCCG CTTACTGGGT 
    32341 GCGGCAGGTG CGGGAGACGG TGCGGTTCGC CGCCGGGCTT GAGCGTCTGC GGGAGCTCGG 
    32401 CACGGGCACC TTCCTCGAAC TCGGGCCGGA CGGCACCCTC ACCGCCTTGG CCCAGGCCCA 
    32461 GATCACCGGG GCGGACGCCG AGTTCATCCC CACTCTGCGC GCCGACCGGC CCGAGCCGGT 
    32521 CACGGTCACC ACCGCCCTCG CCCAGTTGCA CACACACGGT GTGGAGCCGG ACTGGTCCGC 
    32581 GGTCTTCCCC GGCGCCCACC GGGCCGAGCT GCCGACCTAC GCCTTCCAGC GCTCCCGCTT 
    32641 CTGGCTGGAG CCCTCCCGTA CACCCGGTGA CGCGGGCGAC TTCGGGCTCG GCGCGCTGGA 
    32701 CCATCCGCTG GTCGGCGCGA GGGTGCCGCT GCCCGACGCG GACGGCGTTC TGCTCACCGG 
315 
 
    32761 CCGCATCTCC GCCGAGGCCC ACTCGTGGCT GATCGGTCAG CGGGCGCTGG GCGTGCCCCT 
    32821 GTTCCCGGCG ACCGGCTTCC TGGAACTGGT GCTCCAGGCG GGGCTCCAGT GCGACAGCCG 
    32881 GACGGTGGAC GAACTCACCA TCCATGAACC ACTCGTCCTC CCCGAGCGGG GCGGGGTCGA 
    32941 GGTGCAGGTG TCCGTCCGTG GCGCCGACGA GTCCGGCCGC CGCCCGGCCA CCGTGTACTG 
    33001 CCGCCGCGAC CAGCGGTGGG TCCGGCATGC CACGGCCGTC CTCGGCGCGG ACCGGCCGCC 
    33061 CGCGCCGGAG CCGCGCCCCG AGCCCTGGCC GCCCACCGGC GCCCGGCCGC TGGAGTCCGG 
    33121 CGGGACACCG GCGTGGCGCC GTGACGACGA GGTCTTCCTG GACATCGAGC TGCCCGAGGT 
    33181 GGCCGGGGCC GAGGCCGAAC GCTGGACGCT GCATCCCGCC CTGCTCGAAC AGGCGTTGCG 
    33241 CGGGGAGGCG CTGGCAGGGC TGGTCACGGC GGCCGAGGGG ACCCATCTGC CGTTCTCCTG 
    33301 GACGGGGATC ACCCTGCACA CGACGGGTGC CACGAGACTG CGAGCCACCC TCGCGCCCGT 
    33361 CGGCCCGGAC ACGGTCTCGC TCCACGTGGC CGACGCCGCC GGAACACCCG TGCTGTCGGT 
    33421 GGACTCGCTG GCGCTCCGCC CGGTGTCCGG ACAGCGGCTG CGCCAGGCCA ACGCGGCGCT 
    33481 GTTCCGGCCG GTGTGGGCGG CTTGCCGCAC GCGGGCCGAA CCGGACACCG GCTCTGTCCG 
    33541 ATGGGGGCTC GTCGGCGACC CGGACGCCTG GAAACCGGAC ACGCTCGGCG CGCCGGTCGC 
    33601 GCTGTACCCG GACCTGTCGG CCATCGAGGA CGTACCGGAC GTCATCCTCC TCCCGTGCGT 
    33661 ATCCGAGGGC GGAACGGCGT CCGAGGTGGC CGTCCGCGTA TCCGAGACCG TGCGGACGTG 
    33721 GTTGGCCGGG GAGCGGTTCG CCGCCTCGCG TCTGGTGCTG GTGACCCGGG GCGCGCTCGC 
    33781 CACGGCGGCC GGTGAGGAGC TCGAGGACCT GGCCGCGGCC GCGGTGTGGT CGCTGGTCGA 
    33841 GCCCCTCCAG GCGGCCGTGG CGGGACGGCT GACACTCGTC GACACCGATA CGTCCGATCT 
    33901 GCGCATGCTG CCCGCCGCGG TGGCCGTGGG GGAGGACCGG GTCGCGGTCC GGGCGGGAGC 
    33961 GGTGCTGGTA CCGGACCTGG TCACGCCGCC GGCCACCGAG CAGGATCCGC CCGCCTGGGG 
    34021 CCCGGGGACG GTGCTGGTCA CCGGTGGGTC GGCCATGGCT GTCTCCCGGC ATCTGGTCGC 
    34081 CGAACGCGGT GTGCGTGACC TGGTCCTGGC CGGGGACGGC GACATGGCCG AACTGGCGGC 
    34141 CCTCGGAGCC ACGGTTCGGC TCGCCCCGTG TGATCCGGCG GACGGTCAGG CGCTGGCGGC 
    34201 GCTGGTGGCG GAGATTCCCG GGCTGCGGAG CGTGGTGCAC ACCGCGGCCG ACGCCCCGGA 
    34261 GCGGACCCGG TCCCTCTTGC CGGAATCCCT GCGGCCACAG CTGCGGTCGG GAGTGGCGGC 
    34321 GGCCTGGAAC CTGCACCTGG CCACGCGGGG CCTGGAACTG GACCGCTTTG TGCTGTTCAC 
    34381 CTCCGCCGAC GGGACACTGG GCCCCGCGTA CGCCGACGCG CTGGCCGCAC ACCGGCGGGC 
    34441 TCGCGGACTG CCCGCGGTGT CCGTCTCCAC CGATCTGGGT CTCGCCCTGT TCGACGAGGC 
    34501 ATGCGCCGGG CCCGGGGAGG CGATCCGGGT CACCACCGCC ACGCCGGCCC CCGCACCCAC 
    34561 CGAGGCGGAC CGGCAGCCGG TGGAACAACC CCCGGCGGCC GAGGCCTCCG CGACCACGTT 
    34621 GCTGGAGCGG CTGGCCGGGC GGACGGAGGA CGAGCAGGAC GAGATCCTGC TGGAGCTGGT 
    34681 CCGTGGCCAG GTCGCCATGG TGCTCGGCCA TCCCGACGCC ACCATGGTCG ACCCGGACCG 
    34741 AGGCTTCGTG GAACTGGGCT TCGACTCGGT GGCGGCCGTG AAGCTCCGCA ACCAACTGGC 
    34801 CGGAGCCACC CGGCTCGACC TGCCCGCCAG CCTCACCTTC GACCACCCCA CGGCTGTCGA 
    34861 TCTCGCCCGC CATCTGCGCG CCGAAATGCT GCCCGACGAC GCGGCGGCCG CCATTCTCGT 
    34921 GCTCGAAGAG CTCAACAAGC TCGACGATTC GATCCTCGTG CTCGACCCGG CAAGCGCGGC 
    34981 ACGGGTGCGG ATCTCGACCC TGCTCCAGGA CCTGGCCGCG AAATGGGTCG AGCGGACGGA 
    35041 TCGGCCATGA gctagcGTGG CACTTTTCGG GCAGAATAAA TGATCATATC GTCAATTATT 
    35101 ACCTCCACGG GGAGAGCCTG AGCAAACTGG CCTCAGGCAT TTGAGAAGCA CACGGTCACA 
    35161 CTGCTTCCGG TAGTCAATAA ACCGGTAAGT AGCGTATGCG CTCACGCAAC TGGTCCAGAA 
    35221 CCTTGACCGA ACGCAGCGGT GGTAACGGCG CAGTGGCGGT TTTCATGGCT TGTTATGACT 
    35281 GTTTTTTTGG GGTACAGTCT ATGCCTCGGG CATCCAAGCA GCAAGCGCGT TACGCCGTGG 
    35341 GTCGATGTTT GATGTTATGG AGCAGCAACG ATGTTACGCA GCAGGGCAGT CGCCCTAAAA 
    35401 CAAAGTTAAA CATCATGAGG GAAGCGGTGA TCGCCGAAGT ATCGACTCAA CTATCAGAGG 
    35461 TAGTTGGCGT CATCGAGCGC CATCTCGAAC CGACGTTGCT GGCCGTACAT TTGTACGGCT 
    35521 CCGCAGTGGA TGGCGGCCTG AAGCCACACA GTGATATTGA TTTGCTGGTT ACGGTGACCG 
    35581 TAAGGCTTGA TGAAACAACG CGGCGAGCTT TGATCAACGA CCTTTTGGAA ACTTCGGCTT 
    35641 CCCCTGGAGA GAGCGAGATT CTCCGCGCTG TAGAAGTCAC CATTGTTGTG CACGACGACA 
    35701 TCATTCCGTG GCGTTATCCA GCTAAGCGCG AACTGCAATT TGGAGAATGG CAGCGCAATG 
    35761 ACATTCTTGC AGGTATCTTC GAGCCAGCCA CGATCGACAT TGATCTGGCT ATCTTGCTGA 
    35821 CAAAAGCAAG AGAACATAGC GTTGCCTTGG TAGGTCCAGC GGCGGAGGAA CTCTTTGATC 
    35881 CGGTTCCTGA ACAGGATCTA TTTGAGGCGC TAAATGAAAC CTTAACGCTA TGGAACTCGC 
    35941 CGCCCGACTG GGCTGGCGAT GAGCGAAATG TAGTGCTTAC GTTGTCCCGC ATTTGGTACA 
    36001 GCGCAGTAAC CGGCAAAATC GCGCCGAAGG ATGTCGCTGC CGACTGGGCA ATGGAGCGCC 
    36061 TGCCGGCCCA GTATCAGCCC GTCATACTTG AAGCTAGACA GGCTTATCTT GGACAAGAAG 
    36121 AAGATCGCTT GGCCTCGCGC GCAGATCAGT TGGAAGAATT TGTCCACTAC GTGAAAGGCG 
316 
 
    36181 AGATCACCAA GGTAGTCGGC AAATAATAAT ACTAGCAGAA ATCATCCTTA GCGAAAGCTA 
    36241 AGGATTTTTT TTATCTGATT ACCGCCTTTG AGTGAGCGAA GTTCCTATTC CGAAGTTCCT 
    36301 ATTCTCATAT AAGTATAGGA ACTTCTTTCA GCTTTCCGCA ACAGTATAAc tgtgcggtat 
    36361 ttcacaccgc atagatccgt cgagttcaag agaaaaaaaa agaaaaagca aaaagaaaaa 
    36421 aggaaagcgc gcctcgttca gaatgacacg tatagaatga tgcattacct tgtcatcttc 
    36481 agtatcatac tgttcgtata catacttact gacattcata ggtatacata tatacacatg 
    36541 tatatatatc gtatgctgca gctttaaata atcggtgtca ctacataaga acacctttgg 
    36601 tggagggaac atcgttggta ccattgggcg aggtggcttc tcttatggca accgcaagag 
    36661 ccttgaacgc actctcacta cggtgatgat cattcttgcc tcgcagacaa tcaacgtgga 
    36721 gggtaattct gctagcctct gcaaagcttt caagaaaatg cgggatcatc tcgcaagaga 
    36781 gatctcctac tttctccctt tgcaaaccaa gttcgacaac tgcgtacggc ctgttcgaaa 
    36841 gatctaccac cgctctggaa agtgcctcat ccaaaggcgc aaatcctgat ccaaaccttt 
    36901 ttactccacg cactgctcct agggcctctt taaaagcttg accgagagca atcccgcagt 
    36961 cttcagtggt gtgatggtcg tctatgtgta agtcaccaat gcactcaacg attagcgacc 
    37021 agccggaatg cttggccaga gcatgtatca tatggtccag aaaccctata cctgtgtgga 
    37081 cgttaatcac ttgcgattgt gtggcctgtt ctgctactgc ttctgcctct ttttctggga 
    37141 agatcgagtg ctctatcgct aggggaccac cctttaaaga gatcgcaatc tgaatcttgg 
    37201 tttcatttgt aatacgcttt actagggctt tctgctctgt accagaacca ccagaaccTT 
    37261 TGTACAATTC ATCCATACCA TGGGTAATAC CAGCAGCAGT AACAAATTCT AACAAGACCA 
    37321 TGTGGTCTCT CTTTTCGTTT GGATCTTTGG ATAAGGCAGA TTGAGTGGAT AAGTAATGGT 
    37381 TGTCTGGTAA CAAGACTGGA CCATCACCAA TTGGAGTATT TTGTTGATAA TGGTCAGCTA 
    37441 ATTGAACAGA ACCATCTTCA ATGTTGTGTC TAATTTTGAA GTTAACTTTG ATACCATTCT 
    37501 TTTGTTTGTC AGCCATGATG TAAACATTGT GAGAGTTATA GTTGTATTCC AATTTGTGAC 
    37561 CTAAAATGTT ACCATCTTCT TTAAAATCAA TACCTTTTAA TTCGATTCTA TTAACTAAGG 
    37621 TATCACCTTC AAACTTGACT TCAGCTCTGG TCTTGTAGTT ACCGTCATCT TTGAAAAAAA 
    37681 TAGTTCTTTC TTGAACATAA CCTTCTGGCA TGGCAGACTT GAAAAAGTCA TGTTGTTTCA 
    37741 TATGATCTGG GTATCTcGCA AAACATTGAA CACCATAACC GAAAGTAGTG ACTAAGGTTG 
    37801 GCCATGGAAC TGGCAATTTA CCAGTAGTAC AAATAAATTT TAAGGTCAAT TTACCGTAAG 
    37861 TAGCATCACC TTCACCTTCA CCGGAGACAG AAAATTTGTG ACCATTAACA TCACCATCTA 
    37921 ATTCAACCAA AATTGGGACA ACACCAGTGA ATAATTCTTC ACCTTTAGAC ATTGTGATGA 
    37981 TGTTTTATTT GTTTTGATTG GTGTCTTGTA AATAGAAACA AGAGAGAATA ATAAACAAGT 
    38041 TAAGAATAAA AAACCAAAGG ATGAAAAAGA ATGAATATGA AAAAGAGTAG AGAATAACTT 
    38101 TGAAAGGGGA CCATGATATA ACTGGAAAAA AGAGGTTCTT GGAAATGAAA AGTTACCAAA 
    38161 GAGTATTTAT AATTCAGAAA AAAAAGCCAA CGAATATCGT TTTGATGGCG AGCCTTTTTT 
    38221 TTTTTTTAGG AAGACACTAA AGGTACCTAG CATCATATGG GAAGGAAAGG AAATCACTTG 
    38281 GAAGACATCA CAAGCATTCA TTTACCAAGA GAAAAAATAT GCATTTTAGC TAAGATCCAT 
    38341 TGAACAAAGC ACTCACTCAA CTCAACTGAA TGAACGAAAG AAGAAAGAAC AGTAGAAAAC 
    38401 ACTTTGTGAC GGTGCGGAAC ACATTTACGT AGCTATCATG CTGAATTCTA CTATGAAAAT 
    38461 CTCCCAATCT GTCGATGGCA AAACGACCCA CGTGGCAGAG TTGGGTCAAG TGCCAGTTTC 
    38521 TGGATTAAGT AACAGATACA GACATCACAC GCCATAGAGG AATCCCGCCG TTGCGAGAGA 
    38581 TGGAAAACAA TAGAGCCGAA ATTGTGGAAG CCCGATGTCT GGGTGTACAT TTTTTTTTTT 
    38641 TttCTTTCTT TCTCTTTCAA TAATCTTTCC TTTTTCCATT TAGCTTGCCG GAAAAACTTT 
    38701 CGGGTAGCGA AAATCTTTCT GCCGGAAAAA TTAGCTATTT TTTTCTTCCT TATTATTTTT 
    38761 TTAGTTCTGA AGTTTGACCA GGGCGCTACC CTGACCGTAT CACAACCGAC GATCCGGGGT 






A.6 Sequence of Fragment 4 yeast assembly. 
Sequence of Fragment 2 shown schematically in Fig. 2-1. To show the context of the sequence in 
the chromosome, the last 30 bp of the HO(L) region on the 5’ end, and the pPYK promoter of the 
acceptor module on the 3’ end are included. The sequence is in Genbank format: 
LOCUS       mer-fragment-4-031016     22270 bp    DNA     linear   UNA 07-
Apr-2012 
DEFINITION   
FEATURES             Location/Qualifiers 
     Misc._recombina 1..30 
                     /label=R1-homology-AN38 
     Misc._recombina 31..78 
                     /label=FRT-WT 
     ORF             79..879 
                     /label=URA3 
     Primer_binding_ 463..482 
                     /label=AN184 
     Primer          complement(688..710) 
                     /label=AN299 
     Primer_binding_ complement(857..885) 
                     /label=AN106 
     Terminator      892..1057 
                     /label=tADH 
     Primer          998..1023 
                     /label=AN324 
     Misc.           1008..1170 
                     /label=cr7-repair 
     Primer          1008..1067 
                     /label=AN489 
     Primer          1046..1105 
                     /label=AN490 
     Restriction_sit 1058..1063 
                     /label=XbaI 
     Cleavage_site   1058..1063 
                     /label=assembly1 
     Misc._recombina 1064..1111 
                     /label=FRT13 
     Primer          complement(1071..1130) 
                     /label=AN491 
     Primer          complement(1111..1170) 
                     /label=AN492 
     Amplification   1112..1385 
                     /label="from pSE34" 
     Primer          1201..1220 
                     /label=AN580 
     Promoter        1207..1383 
                     /label=ermE 
     Primer          complement(1359..1379) 
                     /label=AN579 
     Primer          complement(1367..1385) 
                     /label=AN20 
     Primer          complement(1367..1407) 
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                     /label=AN221 
     Primer          1367..1403 
                     /label=DD1 
     RBS             1386..1415 
                     /label=merE 
     ORF             1416..2609 
                     /label=merE 
     Primer          complement(1553..1572) 
                     /label=LK2 
     Primer_binding_ 1652..1673 
                     /label=DAN1 
     Primer_binding_ complement(1654..1675) 
                     /label=DAN2 
     Primer          complement(1654..1675) 
                     /label=LK13 
     Primer          1848..1868 
                     /label=DD14 
     Primer_binding_ 2279..2301 
                     /label=DAN3 
     Primer_binding_ complement(2283..2305) 
                     /label=DAN4 
     Primer          2560..2580 
                     /label=DD59 
     Primer          complement(2560..2580) 
                     /label=DD63 
     Primer          complement(2675..2693) 
                     /label=DD13 
     ORF             complement(2759..3415) 
                     /label=merF-1 
     Primer          2900..2920 
                     /label=DD7 
     Primer          complement(2991..3009) 
                     /label=DD4 
     Primer          3198..3217 
                     /label=DD5 
     ORF             complement(3301..3837) 
                     /label=merF-2 
     Primer_binding_ complement(3348..3367) 
                     /label=DD3 
     Primer          complement(3348..3367) 
                     /label=DD3 
     Primer          complement(3471..3493) 
                     /label=DD64 
     Primer_binding_ 3477..3499 
                     /label=DAN5 
     Primer          complement(3902..3921) 
                     /label=DD2 
     Primer_binding_ 3991..4010 
                     /label=DAN6 
     ORF             complement(4237..5721) 
                     /label=merG 
     Primer          4319..4337 
                     /label=DD11 
     Primer          complement(4539..4558) 
                     /label=DD8 
     Primer          5047..5067 
                     /label=DD9 
319 
 
     Primer          complement(5191..5211) 
                     /label=DD6 
     Primer_binding_ 5620..5641 
                     /label=DAN7 
     Primer_binding_ complement(5758..5780) 
                     /label=DAN8 
     Primer          5779..5803 
                     /label=DD29 
     ORF             complement(5840..6319) 
                     /label=merH 
     Primer          6110..6131 
                     /label=DD23 
     Primer          6189..6209 
                     /label=DD24 
     Primer          complement(6323..6343) 
                     /label=DD12 
     Primer_binding_ 6352..6374 
                     /label=DAN9 
     ORF             complement(6401..7345) 
                     /label=merI 
     Primer_binding_ complement(6534..6554) 
                     /label=DAN10 
     Primer          complement(6876..6895) 
                     /label=DD60 
     Primer          7105..7123 
                     /label=DD16 
     Primer          7105..7123 
                     /label=DD18 
     Primer          complement(7265..7286) 
                     /label=DD15 
     Primer          complement(7270..7292) 
                     /label=DD10 
     ORF             7300..8295 
                     /label=merJ 
     Primer_binding_ 7691..7713 
                     /label=DAN11 
     Primer_binding_ complement(7701..7720) 
                     /label=DAN12 
     Primer          8103..8123 
                     /label=DD26 
     Primer          complement(8143..8161) 
                     /label=DD25 
     Primer          complement(8317..8337) 
                     /label=DD28 
     ORF             complement(8405..9229) 
                     /label=merK 
     Primer_binding_ 8771..8792 
                     /label=DAN13 
     Primer_binding_ complement(8798..8818) 
                     /label=DAN14 
     Primer          9005..9023 
                     /label=DD21 
     Primer          complement(9119..9136) 
                     /label=DD20 
     Primer          complement(9119..9136) 
                     /label=DD19 
     Primer          complement(9136..9155) 
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                     /label=DD17 
     ORF             complement(9342..10391) 
                     /label=merL 
     Primer_binding_ complement(9381..9401) 
                     /label=DAN16 
     Primer_binding_ 9414..9433 
                     /label=DAN15 
     Primer          9856..9876 
                     /label=DD44 
     Primer          9904..9923 
                     /label=DD34 
     Primer          complement(10041..10059) 
                     /label=DD27 
     ORF             complement(10461..10868) 
                     /label=merM 
     Primer_binding_ 10582..10601 
                     /label=DAN17 
     Primer_binding_ complement(10614..10633) 
                     /label=DAN18 
     Primer          10820..10839 
                     /label=DD30 
     Primer          complement(10922..10942) 
                     /label=DD22 
     ORF             complement(10953..12446) 
                     /label=merN 
     Primer_binding_ complement(11301..11319) 
                     /label=DAN20 
     Primer_binding_ 11306..11324 
                     /label=DAN19 
     Primer          11746..11764 
                     /label=DD36 
     Primer          11906..11925 
                     /label=DD55 
     Primer          complement(11907..11925) 
                     /label=DD35 
     Primer          complement(12007..12026) 
                     /label=DD45 
     ORF             complement(12443..13084) 
                     /label=merO 
     Primer          12478..12499 
                     /label=DD56 
     Primer_binding_ complement(12491..12511) 
                     /label=DAN21 
     Primer          12894..12912 
                     /label=DD32 
     Primer          complement(13073..13093) 
                     /label=DD31 
     Primer_binding_ 13137..13156 
                     /label=DAN22 
     Primer_binding_ complement(13159..13178) 
                     /label=DAN23 
     ORF             complement(13174..14220) 
                     /label=merQ 
     Primer          13367..13426 
                     /label=AN374 
     Misc._signal    13407..13426 
                     /label="cr6-2 target" 
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     Primer          complement(13407..13466) 
                     /label=AN375 
     Misc._signal    complement(13415..13434) 
                     /label=cr6-target 
     Mutation        13416 
                     /label="C to T" 
     Primer          13722..13740 
                     /label=DD46 
     Primer          complement(13912..13929) 
                     /label=DD37 
     ORF             14085..14741 
                     /label=merR 
     Primer_binding_ 14347..14366 
                     /label=DAN24 
     Primer_binding_ complement(14394..14414) 
                     /label=DAN25 
     Primer          14769..14788 
                     /label=DD38 
     Primer          14769..14788 
                     /label=DD51 
     ORF             14870..16249 
                     /label=merS 
     Primer          complement(14955..14972) 
                     /label=DD33 
     Primer          complement(15074..15094) 
                     /label=DD61 
     Primer          15535..15553 
                     /label=DD48 
     Primer          complement(15706..15724) 
                     /label=DD47 
     Primer          16036..16054 
                     /label=DD62 
     Primer_binding_ complement(16246..16266) 
                     /label=DAN27 
     Primer_binding_ 16291..16309 
                     /label=DAN26 
     ORF             complement(16299..16706) 
                     /label=merT 
     Primer          16730..16751 
                     /label=DD40 
     Primer          complement(16850..16869) 
                     /label=DD39 
     Primer          16850..16869 
                     /label=DD52 
     ORF             complement(16939..18628) 
                     /label=merU 
     Primer_binding_ complement(17031..17052) 
                     /label=DAN28 
     Primer_binding_ 17035..17056 
                     /label=DAN29 
     Primer          17696..17713 
                     /label=DD50 
     Primer          complement(17809..17828) 
                     /label=DD49 
     Primer          complement(18234..18255) 
                     /label=DD57 
     Primer          18310..18330 
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                     /label=DD58 
     Primer_binding_ complement(18383..18403) 
                     /label=DAN30 
     RBS             complement(18599..18628) 
                     /label=merT 
     Primer          18607..18666 
                     /label=DD42 
     Primer          complement(18608..18667) 
                     /label=DD41 
     Promoter        18664..18692 
                     /label=ampR 
     ORF             18734..19594 
                     /label=Ampicillin 
     Primer          19077..19101 
                     /label=AN380 
     Primer          complement(19123..19143) 
                     /label=AN381 
     Primer          complement(19646..19681) 
                     /label=DD43 
     Primer          complement(19646..19675) 
                     /label=AN347 
     Primer          complement(19646..19681) 
                     /label=DD54 
     Misc._recombina 19741..19788 
                     /label=FRT3 
     Primer          complement(19866..19881) 
                     /label=AN112 
     Terminator      complement(19867..19924) 
                     /label=tHIS3 
     Terminator      complement(19994..22270) 
                     /label=HIS3-part 
     ORF             complement(19994..20697) 
                     /label=HIS3 
     Primer          complement(20076..20097) 
                     /label=AN272 
     ORF             complement(20698..21411) 
                     /label=GFP 
     Promoter        complement(21412..22270) 
                     /label=pPYK 
ORIGIN 
        1 aaaattgtgc ctttggactt aaaatggcgt GAAGTTCCTA TTCCGAAGTT CCTATTCTCT 
       61 AGAAAGTATA GGAACTTCTC GAAAGCTACA TATAAGGAAC GTGCTGCTAC TCATCCTAGT 
      121 CCTGTTGCTG CCAAGCTATT TAATATCATG CACGAAAAGC AAACAAACTT GTGTGCTTCA 
      181 TTGGATGTTC GTACCACCAA GGAATTACTG GAGTTAGTTG AAGCATTAGG TCCCAAAATT 
      241 TGTTTACTAA AAACACATGT GGATATCTTG ACTGATTTTT CCATGGAGGG CACAGTTAAG 
      301 CCGCTAAAGG CATTATCCGC CAAGTACAAT TTTTTACTCT TCGAAGACAG AAAATTTGCT 
      361 GACATTGGTA ATACAGTCAA ATTGCAGTAC TCTGCGGGTG TATACAGAAT AGCAGAATGG 
      421 GCAGACATTA CGAATGCACA CGGTGTGGTG GGCCCAGGTA TTGTTAGCGG TTTGAAGCAG 
      481 GCGGCAGAAG AAGTAACAAA GGAACCTAGA GGCCTTTTGA TGTTAGCAGA ATTGTCATGC 
      541 AAGGGCTCCC TATCTACTGG AGAATATACT AAGGGTACTG TTGACATTGC GAAGAGCGAC 
      601 AAAGATTTTG TTATCGGCTT TATTGCTCAA AGAGACATGG GTGGAAGAGA TGAAGGTTAC 
      661 GATTGGTTGA TTATGACACC CGGTGTGGGT TTAGATGACA AGGGAGACGC ATTGGGTCAA 
      721 CAGTATAGAA CCGTGGATGA TGTGGTCTCT ACAGGATCTG ACATTATTAT TGTTGGAAGA 
      781 GGACTATTTG CAAAGGGAAG GGATGCTAAG GTAGAGGGTG AACGTTACAG AAAAGCAGGC 
      841 TGGGAAGCAT ATTTGAGAAG ATGCGGCCAG CAAAACTAAG TCGACCTCGA Ggcgaatttc 
      901 ttatgattta tgatttttat tattaaataa gttataaaaa aaataagtgt atacaaattt 
      961 taaagtgact cttaggtttt aaaacgaaaa ttcttattct tgagtaactc tttcctgtag 
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     1021 gtcaggttgc tttctcaggt atagcatgag gtcgctctct agaGAAGTTC CTATTCCGAA 
     1081 GTTCCTATTC TCATATAAGT ATAGGAACTT CtaccAGCCC GACCCGAGCA CGCGCCGGCA 
     1141 CGCCTGGTCG ATGTCGGACC GGAGTTCGAG GTACGCGGCT TGCAGGTCCA GGAAGGGGAC 
     1201 GTCCATGCGA GTGTCCGTTC GAGTGGCGGC TTGCGCCCGA TGCTAGTCGC GGTTGATCGG 
     1261 CGATCGCAGG TGCACGCGGT CGATCTTGAC GGCTGGCGAG AGGTGCGGGG AGGATCTGAC 
     1321 CGACGCGGTC CACACGTGGC ACCGCGATGC TGTTGTGGGC ACAATCGTGC CGGTTGGTAg 
     1381 gatccTCAGT TGATGCGCGA ACGAGGGAGT CAACAGTGAG CGAGACCTTG TCCCTTCCCG 
     1441 GGACCGTGAA GGCCGAACGG CGTTGTCCGT ACGACCCGCC GGAGGCGCAC CGCCGACTGC 
     1501 GGGACAAGGG CGAACTGGGC AAACTGGAGC TGCCCGGCGG TCTGGTGATG TGGTTCCTGA 
     1561 CCAAGCACGA CGACATCAGG GCCATGCTGG CCGACTCCCG GTTCAGCGGT GCGAGGGTGC 
     1621 CGTTTCCGGC GATGAACCCG GAGATACCCG CGGGCTTCTT CTTCTCCATG GACCCGCCGG 
     1681 ACCACACCCG CTACCGCCGC ACACTCACCG CCGAGTTCTC GGTGCGCGGC GCACGCGAAC 
     1741 TGACCGGCCG GATCGAGCGG CTGGCCGACC GGCACCTCGA TGCGATGGAG GCGGCGGGCA 
     1801 CGAGCGCGGA CCTCGTGGCG GCCTACGCCA GTCCGGTGCC CGCGATGGTG ATCTCCGAAA 
     1861 TCCTCGGCGT GCCGTACACC TACCACCAGA AGTTCGACCA CGAGGTACGC ACGCTCCGGG 
     1921 AGACCGGCGG CGACGATCAG GCCGTCGGCG CGATGGCGAC CGCGTGGTGG GACGAGATGC 
     1981 GCGGATTCGT GCGTGCCAAA CGGGCCGAGC CCGGGGACGA CATGATCAGC AGGCTGCTGC 
     2041 ATGATGAGGT CGAGGGCGGT GCGCTGACCG ACGAGGAGGT GGTCGGCATT GCGATGACCA 
     2101 TCATTTTCGC CGGTCATGAA CCCGTGGAGA ACCTGATCGG CCTCGGCATG CTGGCGCTGT 
     2161 TCCAGGACGG TGAGCAGCTG ACCCGGTTGC GGGAGAACCC CGACCTCATT GACAGCGCCG 
     2221 TGGAGGAGTT CCTTCGCTAC TTCCCCGTCA ACAACTTCGG CACCGTGCGC ACCGCCACCG 
     2281 AGGATGCAGT GATCAATGGT CACCCCATCG CGAAGGGCGA GATCGTGGCC GGTCTGGTGT 
     2341 CCACCGCCAA CCGGGACCCC GAGCGGTTCG CCGATCCCGA CCGCCTTGTC CTCGACCGGT 
     2401 CGCACACCTC CCACCTCGCG TTCGGGCACG GTGTGCACCA GTGTCTGGGC CAGCAGCTGG 
     2461 CGAGGGTGGA ACTGAAGGTG CTCCTACAGC GGCTGCTCGT CAGGTTCCCC GCTCTGCGGC 
     2521 TGGCGGTGGC CCCGGAGGAG ATCAGGTACC GGGAGAACAC CTCGTTCTAC GGTGTCCACG 
     2581 AGCTCCCGGT GACCTGGGCG GCCGAGTAGC CGCAGCCGGG GCCGGAAGAC ACGGCGCGGG 
     2641 CGGTGGCCGC GGGGTCCGGC GCGAGCGGTG GCCGGATACC CGGCCACCGG CTCAGCCGGC 
     2701 CCGGGTGACG CCCACTGCCG CCCTGAGATC CGCCCAGAAC TCCGGCCGAC CGCGGATCTC 
     2761 AAGAGCCGAG CCGGCCGCCG GTCAGGCGTG CCAGCGGGCG GCGGCGACGA GCCGCGCGCC 
     2821 TGCGCAGGAC GACCGCGGCG GTGGCGCCCG CCGCGGCGGC ACCCGCACCG GCGACGGCTG 
     2881 CCAGGACCTT CCGGGCCTTG ATCATCATCC AGGCCGAACC CGCCGCCGCG GCAGCCTTCT 
     2941 TGGGCGCCTC AGCGGCCACG GTACGACCGG TGGTCACGGC CTTCCCGGCG GCCACTTGAG 
     3001 CCTTGTCGGC GGCGACATGA GCGGTGTGCG CCGCGGTCGT CGCCGCGCCG GCCGCGGCGG 
     3061 TCTTCGCCGT GGTCTCCGCC TTGCCCGCGG TGTCCTTGGC CCTTTCCGCG GTCTCCTTGG 
     3121 CCTTGGTGGC GGTGGCCTTC GCGTTCACGT TGGTGCTCCG GGTAGTGTGT GCGTTCTTCT 
     3181 TCTCGGTCAT GTTCACCGCG TTACCACTCG ACCCGACAAC AAACCCGCGT CCTCGGGGCC 
     3241 GGCCGCCACG GCGTGACGAT CCGAGGGGGC GGCACACCGG GAGGCGCGCC GCCCATCGGC 
     3301 TCATTCGATG TCTGAGCCGC CCGAACCACC CGAGCCGCGC CGCTGCTGGA ACAGCACAAA 
     3361 CCCTCCGGCC AGGGCGAACA GACAGACGCC GATGATGATG CCCACGGCGG GCCAAGCGGA 
     3421 TCCGCCGTCG GATGTCGCGG CCTTCGAAGG CTCCAGCGAT GTGGCATCGG GCAACTGTCT 
     3481 TACGACGAAA CTGTGTTCGG CGTTCTCGCC GGGTGCGAGC GCCGGGCCGC CGACCGAGTA 
     3541 GCCGTCATCG GTGGGCTTCA GCTTCCAGCC CTTCGGGGCC TGCTTCAGCC TCACATCGCC 
     3601 GGGGTCGATG CCCGTGGGCA ACACGGTCCG GATCTCGGTG AAACCGGCCC TCCCGTCCTC 
     3661 CGCCTCCGAC TCGAACGTCA GCGTGACGTC CTTCGCCAGG GCGCGGGAGT CGGAGGCGCT 
     3721 CACCTCGGTG TGGGCCAGGG CGGGGGTCGC CGTGGCGAGG ACGAGCGCCG AGGTGGCGAC 
     3781 GGCCAGGGCG CCGATCCGTC GCGGCCGCGG GTGGGACGGC GGACGATGTG CTTTCACGGT 
     3841 ATCTCTCCTC GTCCATGGGG TGGTCACCCG AGCCCTCCTC ACCGGTCACC CGGCGCGCTC 
     3901 ACCAGGTGCG TTCACATTCC CCGGTACGTA CGGCCCGGGC GCGATGTTCA TCCTCGCCCA 
     3961 GACCGGAAGC CCGCTTGCCA CGCGGGGGAG CAAGGAGTTC CGGCGTCTTC GTGGCCCGCG 
     4021 CAAGGCGGAC CGAGGGGGTC GCCGCGTCCC AGTGCGGTGA TGTGCCCGGT GGTCAGGTGG 
     4081 TCCGCTGGTC CCGCAGGGTC CGGGACAGCT CCTCCTCGGT GAGCACCCGG GGCGCGGGTC 
     4141 CGGCACCGGG CTTCGTCTCG GCGCCGTTCG CCGGGCTCTT GTTCTCGGTC GTCGTCATGA 
     4201 GGGTGCACCT TTCGCTGGTG GTGGCGGAGG ACGGGATCAG GCGGTGGCGA CCGGTGTGGC 
     4261 GGGCGGATTG GCGTTCCGCG GCACAGCGGG GGGCTTGCGC GCAGGTCCTC GCAGTACGGT 
     4321 GAACGCCACC GCGAAGGCCG CCACGATGAG CCCCGTTCCG ACGGCGAAGG CCAGGTGGTA 
     4381 GCCGCCGGTC AGCGCCTCGG CCCGACCCTT GCCCCGGGAG AGCAGGGCAT CCGTGCGGGA 
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     4441 GGCGGCCAGG GTGGACAGCA CCGCGACGCC CAGCGCCATG CCGATCTGCT GGGTGGTGTT 
     4501 GAACAGCCCG GAGACGAGCC CGGCCTCGTC CTCCTTCGCA CCGGACATTC CCAGGCTGGT 
     4561 CAGCGCAGGG AGCGCCAGCC CGAAACCGGC GGCGAGCAGC ATCACCGGGA GGAGGTCGGG 
     4621 GAGGTACCGG GCGTGCACGG GGACGCGGAC GAGCAGGCCG AGAACGCCGG TCAGGAGGGC 
     4681 CAGCCCGGTC AGCAGCACCG CGCGGTCGCC GAAGCGTGCG CTGAGCCGTG CGGAGACGCC 
     4741 GAGGGACACC GCGCCGATGG CGATGGCGGC CGGGAGCATG GCCAGACCGG TTCCGGTGGC 
     4801 GTCGTACCCC AGCACATTGC GCAGATAGAG GGCGACCAGG ATCTGGAACG AGAAGAGCGC 
     4861 GGCCACCATC AGGAGCTGGA CCAGATTGGC CCCCGCCACC CCGCGCGACC GCAGGATCCG 
     4921 CAGGGGCATC AGCGGGGTGC GGGCGGTGGT CTGGCGGACC AGGAACAGGG CGATCAGGAG 
     4981 GATCGAGACG GCGCCGAGGC CGAGTGTGCG CGCCGCCGTC CAGCCGTAGT CCGCCACCTT 
     5041 GACCACGGTG TAGATGCCCA GCATCAGCCC GGTCGTGACC AGCAGGGCGC CGAGGACATC 
     5101 GGCGCCGGCC GCGAGGCCCG GCCCGCGGTC GGCGGGCAGG ACGGGTATGG CGACCGCGAG 
     5161 CGTCAGCAGC CCGATCGGCA GATTGATCAG GAAGATCCAG TGCCAGCTGA GCGCGTCGGT 
     5221 GAGGAGGCCG CCGAGCACCT GGCCGATCGA CGCTCCGGCG GCGCCGGTGA AGCTGAACAC 
     5281 GGCGATCGCC TTCGACCGTT CGGCGCGTTC GGTGAAGAGC GTGACGAGGA TGCCCAGGCT 
     5341 GACCGCCGAG GCCATCGCGC TGCCGACCCC CTGGAGGAAC CGTGCGGCGA TCAGCACAGC 
     5401 GGGGGAGGTG GCCACGGCCG CGAGCAACGA GGCCGCGGTG AACACCGCGG TACCGGTCAG 
     5461 GAACACCCGC TTGCGGCCGA TGAGATCGCC GATACGGCCG CCGAGCAGCA GCAGACCGCC 
     5521 GAACGCGATC AGGTAGGCGT TGACGACCCA GCTGAGCCCG GCGGGGGAGA ACCGCAGATC 
     5581 GCTCTGGATG GCGGGCATGG CCACGGTCAC GATGCTGCCG TCGAGGATCA CCATCAGCAT 
     5641 GCCGGTGGCG ATGACCCCGA GGGCCAGTCG ACGTGTCGGG GGGACACGGG GAGACGTCGG 
     5701 GTCGGAAGAG GCGGCGGACA TGCGGACACT CCTGTCAGTA GGCGCGACAG GAGTGACCGT 
     5761 AGCAGATGGT TTTGTTGCAG ACTATTTGTT TCGGCTCTAC TTGTGGCGCA TGACGGGCGG 
     5821 CCGCGCGGAT GTCTCCGCTC TACTTCTCGC GCTGCCGCGC CCTCCGCGCC GGGCGGGGGC 
     5881 TCTCGGCGGG CGTGGCCAGA TGCCCCTCGG ACAGCCGGGT CAACGCCTTT AGCAGCGCGG 
     5941 CGCGTTGGGT CTCGGGGAGT GTCGCCAACG CCTCGCGATG GACGCGGTCC ACGATCTCCT 
     6001 GGCTCCGTTC GGCGATCCGC GCGCCCTCCT CGGTGACCGC GATGATCCGG GCCCGGCGAT 
     6061 CGTGGGTCGA GGCGCGCCGC TCCGCGAGGC CCGCCTTCTC CAGGGCGTCC ACCGTCACCA 
     6121 CCATCGTGGT CTTGTCCATG TCGCCGATCT CGGCGAGCTG GGCCTGGGTG CGCTCTTCCT 
     6181 CCAGGGCGTG GACCAGTACG CAGTGCATCC GCGCCGTCAG CCCGATTTCG GCGAGCGCGG 
     6241 CCGACATCTG GGTGCGGAGG ACGTGGCTGG TGTGGTCGAG GAGGAACGAC AGGTCGGGTT 
     6301 CGGTCTTGGT GGGCGCCATG GCGGTCATGC GGCCCAGGGT AACAATTCGA TCCGTACTGG 
     6361 ATTATCCGGA ACAGTCCATA GGGAGGGGTG GGGTCAGGGG TCAGCCGTTG CGGTAGAGGG 
     6421 CGGTGAGCAG CTCGACCGCG GTCTGGGTGG CGGGGTGCGG GTCGTCCCGC CACCAGGCGA 
     6481 GGCGTACCGC GATGGGCTCG GCGTCGCGGA CCGGCCGGTA GGCGATTCCG GGCCTCGGAT 
     6541 ACTGGTTGGC CGTGGACTCC GCCGTCATGC CGACGCAGCG GCCCGCGGAG ATCACGGTGA 
     6601 GCCAGTCCTC CACGTCGTGG GTCTCCTCCG TGGCCGGCCG GGAGTCGGGC GGCCACAGCT 
     6661 CCGTGGTGGT GGTACCGGTC CTGCGGTCGA CCAGCAGGGT GCGCCCGCTG AGGTCGGCCA 
     6721 GCCGGACCGA GCGGCGCCTG GCGAGCGGGT CGTCGGCGGC CACGGCGCAC AGCCGCCGCT 
     6781 CCAGTCCGAC GATGGCGGAG TCGAAGCGGC GCTCGTCGAG CGGTCTGCGC ACCACGGCCA 
     6841 GGTCGCAGGC GCCCTCCGTC AGCCCCGCGG TGGCGGAATT GACGCGGACG AGGTGCAGCT 
     6901 CCGTCTCGGG ATACGCCTGC GCCCAGCGGC GCTGGAAGGC GGGGGTGTGA CGGCCCAGCG 
     6961 CGGACCAGGC GTAGCCGATC CGCAGATGGG CGTGGCCCGA TACGGCCTCC CGGATCAGCC 
     7021 CGTCCACCTC GGCCAGCACC CGCCGGGCGT GTGCCACCAC CCGCAGCCCG GTGCCCGTCG 
     7081 GGGTCACCTC GCGGGAGGTC CGCCGCAACA GCCTTGTCCC CAGGGCGCGT TCGAGCGCTG 
     7141 CCAGGGTGCG GGACACGGCC GCCTGGGAGA CGCCGAGCGC GATGGCGGCG TCGGTGAAGG 
     7201 TGCCCTCGTC GACGATCGCG ACGAGGCAGC GCAGTTGCCG TAGCTCCACA TCCATACGTC 
     7261 CAGCGTATAG ATAGAACCCC GAACGCATTT TGCGCATGCA TGAGCCGGGC GCACGATCGA 
     7321 CGCATGCGAC TCGCCCCCGC GTCACGCACC CCGTCCCCAC GAGCGATGGA CACCGCACAC 
     7381 CGGACCGCGC CGACCCCTGC CGACTACGAC CTGGGACAGG GCCTGGAGCG GGGCCTGGCC 
     7441 CCTGACCCTG ATCAGCGGCC GACCGGACGG CGGTTCGCCG GTGTGGCCAC GATGATCGGC 
     7501 AGTGGGCTGT CCAACCAGAC CGGCGCCGCG ATCGGATCCC AGGCCTTCCC CGTCATCGGC 
     7561 CCGGTCGGGG TCGTCGCCGT CCGCCAGTAC GTGGCCGCGA TCGTCCTGCT GGCCGTCGGC 
     7621 AGGCCCCGGT TGCGGAGCTT CACCTGGTGG CAGTGGCGGC CGGTGGTGGG GCTCGCCGTG 
     7681 GTGTTCGGCA CCATGAATCT GTCCCTGTAC AGCGCCATCG ACCGCATCGG CCTCGGGCTG 
     7741 GCGGTGACCC TGGAGTTCCT CGGCCCGCTG TGCATCGCGC TCGCCGGCTC ACGGCGCCGC 
     7801 GTGGACGCCT GCTGTGCGCT GGTCGCGGCG GCCGCCGTGG TGACCCTCAT GCGCCCGCGC 
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     7861 CCCTCGGCCG ACTATCTGGG TATGGGGCTG GGGTTGCTGG CCGCCGTGTG CTGGGCGTCG 
     7921 TACATCCTGC TCAACCGCAC CGTGGGGCGG CGGGTCCCCG GCGCCCAGGG GTCGGCGGCG 
     7981 GCCGCGGGGA TCTCCGCGCT GATGTTCCTG CCGGTCGGGA TCGCCGTCGC CGTCCACCAG 
     8041 CCGCCGACCG TGAGCGCCGC GGCGTACGCC ATCATCGCGG GCGTCCTCTC CTCGGCCGTG 
     8101 CCGTACCTCG CGGACCTGTT CACGCTGCGC CGCGTGCCCG CCCAGGCGTT CGGGCTCTTC 
     8161 ATGAGCGTCA ACCCCGTCCT CGCCGCACTG GTCGGCTGGG TCGGCCTGGG GCAGAGCCTG 
     8221 GGGTGGACGG AGTGGATCAG CGTGGGCGCC ATCGTCGCGG CCAACGCGCT GAGCATCCTC 
     8281 ACCCGGCGCG GCTGAAGGAC CAGCGGGGGT GGCCCGGTGA CTTGGCTGAC CTGGACCCGG 
     8341 GGGTGGACCC GGGGACGGAG GGCCGCGCCG CCCCCAGGCC ACCGCTCCGC CCCCGGGCCA 
     8401 CCGCTCAGCC CGCGGCCTCG AACAGCGCCT CCGCGGCGGC GATCGCCTCG GCCAGGGCGG 
     8461 TGGGCTCCGG CCGCAGCCCC GCCACGATCG TGTCGATGGC GCGCAGGTCC GCCCGCTGGA 
     8521 GGAGCCGCTT CTCGTTGGTG ACCCACTCAC CGCGCGCCGC CAGCACCGCG TGCGCCGTCT 
     8581 GGAGGGCGGC GGTCGCCACC GCCCCCGCGA CCTCGGTGGC CTGGCCACGT CCCACGTACG 
     8641 CGGCCGAGGC GTACCGCAGG GTCAAGGCCG CCCGCCCGCG CCACGCCGGG GGTGCCGCCT 
     8701 CACGCAGCGC CGCCGGGTAC TCGGGGCGGG GCAGGGTGCC CCGCAGCACC TGGTTCAGGG 
     8761 CGAGTTCGGC CACCACCAGA TAGCTGGGGA TGCCCGCGAG GTGGAACATC AGCGGCTCCC 
     8821 AGTGGAAGCG GCCCCGTCGC GACTCGGCGA GTTCGTGTTC CACCACCTCG AGGTCGCGGT 
     8881 AGTGGACGTC CACGCGCCGT CCGTCGATCG TCAGCCAGGC GCCCCCGTTG AAGACACCAC 
     8941 CGCCCCACTC GCCGAGCTCG GAGACCTCGC CCTCCCAGCC CACGGCCCGC AGCGCGGCCG 
     9001 GGTCGAAGCC GCCTCGGTAG TACAGGGCCA GGTCCCAGTC GCTCTCCGGG GTGTGGGTCC 
     9061 CCTGCGCACG CGAGCCCCCG AGGGCGACGG CGTGCACGGC GGGCAGGGCG GCGAGTCGCT 
     9121 CTGCGACATC GTCGAGGAAC GTGTCGTCGG TCATGAGGAA CATGTCGTCG GTCATACGGA 
     9181 TCCGATCGTG TGAAGTGGAT GACGGGTGCC GCGGGCACAC CGAACGCACG CCGGAGCACA 
     9241 GGCTCGAACG GCGGCGTCCA TACGGATCGG TGTGCCGGGT CATCACTCCA TGACGCCGAC 
     9301 CTTACCGCCC CCGTCAGAGG GCGGCAGCGG CCAGCGGCGG ATCAGTCCTT CACCAGGCCC 
     9361 AGGCGGAACA GGCTCTCCGC GGTGTCGAGG ATGGTCGTCA CCGGGTCGCG CGGGGTCCAG 
     9421 CCGAACACGG AACGCGCCTT CTCGGTGCGC AGGATCGGCA CCCGCTCCGT CACGCCGACC 
     9481 GCTTCCCGCG CTCGTTCGTC GTCGAACTCC CGCGTGGGCA CCCGGGCGGC GCGCTCGCCG 
     9541 AGGTGCTCGG CCAGCACCTG GGCGATCCAC AGGAAGCTGA CGGTCCGGTC GCCGCTGGCG 
     9601 AGGAAGCGCT CTCCGGCCGC GGCGGGGTGT GCCATGGCCC GGAGGTGGAG CTCGGCGACA 
     9661 TCGCGCACGT CCACCATGCC GAAGTGTGCG CGGGGGACGG CCGACATCGC CCCCTCCAGC 
     9721 ATCGCCCGGA CGTGTTCCGT CGAGGCGGAC AGCCGGGGGC CGAGTGCCGG ACCGAAGATC 
     9781 CCGGTCGGGT TGATCACCGT CAGTTCGAGG CCGTCCCCCT CCTTCGCCAC GAAGTCCCAG 
     9841 GCGGCCAGCT CCGCGATGGT CTTCGAGCGG ATGTAGGGCG GGTTGTCGTC CTCGGGGTCG 
     9901 GTCCAGTCGC TCTCGTCGTA CTCGTCACCG TCCTTGTGGC TGTATCCCAC CGCGGCGAAC 
     9961 GAGGACGTCA TCACGACCCG TTTCACACCC TGGTCCCGTG CGGCCCTCAG CACACGAAGG 
    10021 GTGCCGTCCC GCGCGGGGAC GATCAGCTCG TCGGCGTTGT CCGGCTGGAC GGCGGGGAAC 
    10081 GGTGACGCGA CGTGGTGGAC GCGGGTGCAC CCCGCCATCG CGTCGTCCCA GCCGTCGTCC 
    10141 GTGGTCAGGT CGGCGCTGAC GATATCGAGC CGCCCGCCGG GATCGACACC GGAGGCCGCG 
    10201 ATGGCCGACC GGACACTCGC GGCGGCGCCG GTGGCCGGGC CGTGTGAACG GACCGTGGTG 
    10261 CGGACCCGAT GGCCGCTCCG CAGCAGGCCG CTGATCACAT GGGTGCCGAG ATAGCCGCTG 
    10321 CCTCCTGTCA CCAGGACGAG TTCGCCACTA ACGGTGTCGC CACGGGCGTC GGCGCCGGCA 
    10381 TCAGCGGACA CGGGGGTTGC CTTGCTTTCC ATGGGGTACT TCGGATCCCT TCCCAAGTGT 
    10441 GTTTCTCGCA GCTGTGTCTC TCACGGCCGC AGCGCGTCGA TGACGTCCGT CAGTTCGTCG 
    10501 ATCGCCCGGC GCTCCGCATC GGCGTCGGCG CGCTCCCGCG CGTCCCACAT GTCCGCCTTG 
    10561 AGCCGCAGAT AGCGCAGCCG GACCTCCATG AGCGCGATCT CCCGCTCCAG GCGGTCCGCG 
    10621 TTGCGTTGGA AGAGGTCACG CAGGGGAGCC GCACCCTGAT CGCCTTCGTC GAGGTGGCCG 
    10681 AGGTAGGCGC GCATGTCCTG CATGCTCATG CCGGTGGATC TCAGGCACCC CAGCGACCTG 
    10741 ATCGTCTCCA CCACGGAGGG GGGATAGCGC CGGTGGCCAC TGTCCCGGTC GCGGTCCACG 
    10801 GCGGGGATCA AGCCGATCTT CTCGTAGTAG CGCAGTGTCG GCTCCGAGAG GCCACTCAGC 
    10861 CTCGACACCT GCTGGATGGT CATCGGGGAG CCCCGGACCT CTGTCCTCGT CGTTGTCATA 
    10921 GGACGAGCAT CCGATACTTG AAGCGCTTGA GGTCAAGCGA GCCGATCGGC CTTTGCGGGG 
    10981 ACGGCGGTCC CGGAAGTGGG CGCGCCCGGG CGCTTCCCGG CCGTGGCGAT GGAGATGTCC 
    11041 CGCATGAGGA GCAGCGCCCC GAGGGCGAGG AGCCCGGCGG CGCCGCCGCT CCAGGAGACG 
    11101 GTGGAGCCGA TGGCCGTGGC GGTGGGCGCG GCCGCGCCGG AGTGGCCGAT CAGGGACTGG 
    11161 GCGCTGGCCA GGCCGACCGC GCCACCGAGC TGCTTGGTGA GCGCGGAACC CGCGGTGGCG 
    11221 GTGCCCATGT CCGCACGCGG GACGGCGCTC TGGGTGGCGA TGGTGAGCCC GCCCATGGCC 
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    11281 GGTCCCGCGC CGAGCCCGAC GAGCAGCAGC AGAACGGACG TCAGCGCGAG AGGGGTCGTG 
    11341 GCCCGCAGGG CGACGAAGGC GGCGGTACCG GCGGTGAGCA GCCCCGCGCC GATCAGCAGG 
    11401 ACCGGCTTGA CGTGCCCGCT GCGCAGCACG GTGGCGGCGG TGAGCCGGTT GCCCAGGGTC 
    11461 ATGCCGATGA GCAGGGGGAG CAGCAGCAGA CCGGAGGCGG TGGCCGAATG GCCGCGGATG 
    11521 TGCTGGAAGT ACAGCGGCAG GAAGATTCCC ACCGGCGCCG CGGCGACCTG GAAGAAGAAA 
    11581 CCGGCGGTCA GCAGGGCGGT GTAGGTGCGG TGCCGGAACA GCCGCAGGGG CAGGACGGGG 
    11641 ACGGCGGCCC GCCGCTCGAC CGGTATGAGC GTGGTGAGCA GCGCCAGACC GCCGAGCAGA 
    11701 CAGCCCAGCA CGGCCGGGTC CGTCCAGGAG GGCGCGTGTC CGGCGGTCGC GTTCCCCTTG 
    11761 AGGCTGAGGC CGGTCAGCGC GAGGGCGAGC CCCGCGGCGA GCAGGAGGAT CCCCGCCACG 
    11821 TCGAGCCGGC CGGACGGCGG GGTGGCGGGA CGGCGGTCGG GCAGGGCCAG GACGATGACG 
    11881 GCGCCCGCGG CCAGCCCGAG CGGGAGGTTG AGCCAGAACG CCCAGCGCCA GCCGATGTGA 
    11941 TCGGCGAGTA ACCCGCCGAG GAGCGGGCCG CCCACCATGC CCAGGATCAT CATGGCGGCC 
    12001 ATCGCCGTCT GCATCCGGAT GAGGCCCTGG GGGCGGGACG GCGGGTGGAG GTCGCGGACC 
    12061 AGTGCCATGC CGAGGGTCAG CAGGGATCCG GCACCCAGGC CCTGGAGCGC GCGGGAGAGG 
    12121 ATCAGGGCGG GCATCGAGGC GGACAGGCCG CAGGCGATGG AGCCGATCAG GAAGACGCCG 
    12181 AGCCCGCCGA TCAGCAGCCG GCGGCGGCCG TGGAGGTCGG AGAAGCGGCC GTAGACCGGC 
    12241 ACGCTGACCG AGGAGGTCAG CAGATAGGCG GTGACGAGCC AGACGTACCA GGAGTCCCCT 
    12301 CCGCCGATCT GCTCGACGAT GCGGGGCAGC GCGGTGCCGA CCACGGTGCC GTCCAGCATG 
    12361 GCCAGGAAGG CGCAGCCCAG CAGGGCGATG GTGACCAGGG CCCGGCGGCG GTGCGGGAGC 
    12421 GCTTCGTACC CGTCGGGTCC GGTCACCGGG CCTCCCCGGG CGCCACGAGC GCGCCGTGCA 
    12481 GGAAGAGGTC CACGACTTCC TCGGTGGTCA GCGGCTCGGG GGCGCCCAGG CGCCCGGCCG 
    12541 ACATCAGCGT CAGCTGGAAG GCGTCGGCGA GCCGTTCCGG GGCGAGTCGC AGGCGGTCCC 
    12601 GGTCGGGCTC GAACAGCGCG GCCAGCGCGG CGCGCGGCCG GACCAGGCTC GCCTCGCGGT 
    12661 CCGGGAGGCG CCCGTCCTTG CCGGGCTTGG GCGCCATGCG CTCCAGCCGC CCGGCCGCCG 
    12721 CGAGCGCCCC GGCGACCGCG CCGATGCGCG CCATGTGTCC GCGCACCACA TCGGCCGCCT 
    12781 CGGCGAGCCG GTCCGCAAGC GGCTGGTCAA GGGCGATCGA CTCCAGATGG GCCACGGTGT 
    12841 CATCGGGCCG CACGGCCTCC GCCATACAGG CCGCGAGCAG GGCGTCCTTG TCCTCGAAGA 
    12901 CGCGGAAGAT AGTGCCTTCC CCGATGCCCG CGGCCCGGGC GATCTTCGCG GTCGTCACGG 
    12961 TGGCGCCGTA TTCGACGACG AGGGGGAGCG CGGCGGCGAC GATCATCGCG CGGCGCTGGT 
    13021 CGGGATCCAT GGCCGGAGCG CGGCGGCGGG TCGGAGTGGA GGGGTTCTCT GCCTTCTCTG 
    13081 TCATGCGGGA TACGGTACGG AGTGAGTACT CACTCCGTCA ATGCACGGTG CGCGGCCACA 
    13141 AGGCGAGTGG CGGTTCGGCT TCGACGTTGT CGGTCAGCGC GCGGCGAGCA GGGCCCGGCG 
    13201 CAGGGCGCGG CCCGCCTCGG ACGGGGGATG GTTGCGCGAG GCGGCGAGGC CGAGACCGTG 
    13261 CAGCGGCGGT GGATCGGCGA GATCGACCTG GGTCAGGCCG GGCCGCGAGG CGATGGTCTC 
    13321 CTCGGCCACG AAGGCGAGCC CGAGACGCCG CCGGACCATG GTCAGGGCGG TCGTGGTGTC 
    13381 GACGACCTCC AGTGCCACGG TGCGCTGAAC TCCGGCGGTG CCGAAGAGGC TGTCGACGAT 
    13441 GGTGCGGTCG CCCCACCCCG TGGGGAAGTC GATGAAGCGG CGGTCGGCGA GGTCGGCGTA 
    13501 GGTCACGCCG TGCGCCTCGG CGAGGGGGTC GTCGGTGCGG CAGGCCAGCC CGAGGCGTAT 
    13561 CCGCGACACA TCATCGATGA TCAGATCCGG GCCGAGGACG GCGGGGCCGT GCGGGGGCAC 
    13621 CGGCAGCAGC ATCAGGTCGA ACCTGCCCTC GCGCAGGGCG GTGGCGTGTC CGGCCAGCGG 
    13681 ACCGGTCGAG TGGCGCAGCC GCACCACGAC ATCGGGGTGC TCGGCCTGAA ACGTGCTCAG 
    13741 CGCCCCGATC AGGTCGAACG AGCCGGTGGA CAGGACCGTC CCGAGGGTGA CCGTACCGCT 
    13801 GAGCCCCCCG GTGAGACGGC CCATGTCATC GCGCGCCCGC TGCGCCTCCG CGAGCAGGAT 
    13861 CCGGGCCCGG GCCAGCAGGG TGCGCCCCGC GGTGGTCAGC TCCAGGGTGC GGTGCGAGCG 
    13921 GTCGAAGAGC GCGGTCTGGA ACTCCTGCTC CAGCCGGGCC ACGGCGGCGG AGGCCGCCGA 
    13981 CTGGACGACG TGTTCCCGCT GGGCGCCGCG GGTGAAGCTG CGCTCCTCGG CCACCGCGAC 
    14041 GAAGTACGCC AGCTGCCGGA GCTCCACCAT CATCTCCATT CGCGATGCCA CACAGCACAC 
    14101 ATCATCGTTG GACACGATAC CTATGGGACC GCCACCGTGG AGGGGAAGCG GAACGCCCCG 
    14161 GCCGGACGGC CCGGTTCGGC GCCACGCCCC CCAACTTCCC CGTGTGCCAG CACACTTCAC 
    14221 CACGGAAGGC ATCCATCGTC ATGAGCGTCT CAGCCATCCA GATCGGGCTC CACCCCGATG 
    14281 CCATCGACTA CGAGGCGCCG GAGTTCGCCG CCTTCGCCGG TCTGAGCCGG GAGACGTTGC 
    14341 GCGCCGCCAA CGACGACAAC CTCGCCCTGC TGCTCGACGC CGGATACGAG GCGGACGGCT 
    14401 GTCAGATCGA CTTCGGGGAG ACCGCCCTCG ACACCATCCG CGCCATGCTC GGCCGCAAGC 
    14461 GCTACGACGC GGTCCTCATC GGCGCCGGGG TACGGCTCAC CGCGGGCAAT ACACTGCTCT 
    14521 TCGAATCCAT CGTCAACCTC GTCCACACCG CGTTGCCCCA CGCGCGGTTC ATCTTCAACC 
    14581 ACTCCGCCGC GGCCACCCCC GACGACATCC GCCGCCACTA CCCCGACCCG GCCTCCACCG 
    14641 TTCCCCTCGA CGTCCCCCGC GACCTCGAGG AGGCCGCGCT GAAGAACCCC GGCAACGCCG 
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    14701 CCCGCCCCGA AGCCGCCCAC GGCCCGCGGG AGACGCGGTG ACCGCCCCGG CCCGGCCCCA 
    14761 CGGTGAGGCG AACCCGGACC TTCACACCAC GGATGTGCTC GTCGTCGGCG GCGGGCCGAC 
    14821 CGGAATGACC CTGGCCGGGG ATCTGGCACG GGCCGGACGC GCGGTCACCG TGCTGGAACG 
    14881 CCGGCCGGCG ATCCATCCGT CCAGCCGTGC CTTCGTCACC ATGCCCCGCA CCCTGGAAGT 
    14941 CCTCGACAGC CGTGGTCTGG CCGACGACCT CCTGGCCGGG GCGAACACCA CCGAAGCGGT 
    15001 CCACCTGTTC GCGGGCGCCA CGCTCGATCT GACACATCTG CCCTCCCGCC ACCGATACGG 
    15061 GATGATCACC CCGCAGACCA ATGTGGACCA GGCGCTCGAA CGCTACGCCC GCGACCAGGG 
    15121 CGCCCGGGTG CTGCGCGGCA CCGAGGTCAC CGGCCTCGCC CAGGACGCCG ACGCGGTCAC 
    15181 CGTCACCGCC CGCGCCGACG GCGGCGGACC CGCTTCCACG TGGCGAGCCC GGTACGTCGT 
    15241 GGGGGCGGAC GGGGCGCACA GCACCGTCCG CGGCCTCCTC GGCGCCGACT TCCCCGGAAG 
    15301 GACGGTTCTG ACCTCCGTGG TGCTGGCCGA TGTCCGCCTC GCCGACGGCC CCACCGGGAA 
    15361 CGGGCTCACC CTGGGCAACA CCCCTGAGGT CTTCGGCTTC CTCGTGCCGT ACGGGAAGGC 
    15421 GCGCCCCGGC TGGTACCGGT CGATGACCTG GGACCGCCGC CACCAACTGC CCGACAAGGC 
    15481 CGCCGTGGAG GAGGCGGAGG TCACCCGCGT ACTGGCCGAG GCCATGGGAC GTGACGTCGG 
    15541 GGTCCGTGAG ATCGGCTGGC ACTCCCGGTT CCACTGCGAT GAACGCCAGG TCCGCTCCTA 
    15601 CCGGCACGGC CGGGTCTTCC TCGCCGGGGA CGCCGCCCAC GTGCACTCCC CGATGGGCGG 
    15661 CCAGGGCATG AACACCGGCG TCCAGGACGC GGCCAACCTC GCCTGGAAGC TCGACCTCGC 
    15721 CCTCGGCGGC GCCGACCCGG CCATCCTGGA CACCTACCAC CGGGAGCGCC ACCCCGTCGG 
    15781 CCGCCGTGTC CTGCTCCAGA GCGGTGCCAT GATGCGCGCC GTCACCCTCG GGCCGCGCCC 
    15841 GGCGCGGTGG CTGCGCGACC ATCTGGCCCC GGCCCTGCTG GGCGTCGGCC GGGTGCGCGA 
    15901 CACCATCGCC GGAAGCTTCA CCGGCGTCAC CCCGCGCTAT CCGCGCGGAC GGCGACAGCA 
    15961 CGCACTGGTG GGCACCCGCG CCACCGAAGT CCCGCTCGCC GAGGGCCGGT TGACCGAACT 
    16021 GCAGCGGGCC GGTGGCTTTC TGCTGATCCG CGAGCGGGGC GCGGCGCGCG TCGACACCAC 
    16081 GGTGGCCCAG GCCGAGCGCA CCGACTCCGG CCCCGCCCTG CTGGTCCGCC CCGACGGCTA 
    16141 TATCGCCTGG GCCGGACCCG GTGTCCGTAC GGACGGCCCC GACGGCTGGC ACACCACATG 
    16201 GCGGGCCTGG ACCGGCCCGG CCACCGATGC GGTGCGCGCC GGGCGCTGAA CAGGAGACGG 
    16261 GGAGACGGCG CCGGGCGGGC GGCCCGGCGC CGACGCCCTC ATCCGTTCCC CGTCGCCTGC 
    16321 CCGGCGGACA GGGAGTCGGG GAGGGCAGCG GCGGCCGGTT CCTCGGGTCG TCCCTTGCGG 
    16381 AAGAACCGGA GCAGCGACGG GCCGCCCCGG AAACACCACA GCGCGATGAC CGGATCGCAG 
    16441 ATCGCACAGC CCAGCGACGA GCCATGCGCG AACGGGACGA TGGGGTTGCC CTTGATGTGA 
    16501 TGCACGATGT CCCACGCGGT GTGCAGCAGC CAGCCGATGC CGATGAAGGT CCACGACTCC 
    16561 AGGCCACGGT AGGCCACATA GGTGGCGACC ACGGTGAAGG CGAACTCCCA GCCGTCCAGG 
    16621 CCGCCGCCGC TGAGGTAGGC CGCACCCGCT CCGCCGACCA TGATCGCGTT GAAGCGCCGG 
    16681 CGGTGCGGTT CGCGAATCAG GGACATCAGG AGCGCGTAGA GGACACCGAT GAAGACCGGA 
    16741 GCGATGTATT GGATCATGCG GAAGAACTTC CTGCGGGTGA CGGAACGTTG GCCGCCCGGC 
    16801 GGGGCGACGG TTCATCACGC TAGATCCGCC CCCGGCCGCC CCACAGGGCC ATTCCCGACA 
    16861 CGCTCCAACG GATAATCGCC GGGGCCGGAT CATCGCCGTG GCCACGGCCT CCACCCGGCC 
    16921 ACCACGCTCA GGGCCCGATC ACAGCAGCCG CCACAGGTGG TCATCGGTTC CGTTGTCGTC 
    16981 GTACTGCACC ACCTGGGCGC TGTTGGCGGT GGACATGCCG TCGACACCCA GCACCTTCTG 
    17041 GCTGTTCTTG TTGAGGACGC GGAACCAGCC GTCGCCGTTG TCCACCTTCC GCCAGAGGTG 
    17101 ATCGGCCGTG CCGTTGTCCT CGTACTGGAC GACGATGGCG CTGTTCGCGG TGGACATCCG 
    17161 GTCGACGCCC AGGACCTTGC CGCTGTGGCC GTTGCGGATC AGGAACCAGC CGTCGCCCCG 
    17221 GTCGATCCAC TGCCAGGCGT GGTCGCCCGT CGGTGTGTTG TCGTACTGCA CCACGCGGGC 
    17281 GCTGTTGGCC GTGGACATCT CGTCGACGGC GAGCACCTTG CCGCTGTGCT TGTTGAGCAG 
    17341 TCGGCGGAAG GGCGGCTCCG GGGTCCACGC CCGGCCGTCC GGCGCGGCCG TGGGAAAGCA 
    17401 GGTGATACGC AGCCGGGCGG CGCCCATGGG GATGAGGGTG ACCGTCTCCG CCGGTGCGTC 
    17461 GGCCCGGGCC GGGCTCTGCT GAAGCGGGGT GACCACATGC TCGTCGTCCG AGACCCACTC 
    17521 GGCGATACGG CGCGCCTGGG CGGTCATGCG GACCGGGGTG GTCTCGTGGG TGAAGGGATT 
    17581 GGCGGCGAGC GGACCGTCGT CGCGGGTGAG CACGGGGAGG GCTCCGGGGG CGAGGCCGTA 
    17641 GTTCCACGGA GTGGTGGCGT GCACTTCGTA CTCGGGGAAG GTGTCGGTGC CGGCGTAGCG 
    17701 CACGAAGTCC TCGCCGATGC GCAGGGAGta cgtcagcggg ccgtggtcga cgctgaccgc 
    17761 gccgtgctgc gccgaccagg tccgcagggc ggtgcgctgc ggcaggcgga tcgtcaccac 
    17821 atcgccgtcc gtccagctcc ggtcgacctt gacgaaggcc ggaccgccgc gcgtggccac 
    17881 cgcccggccg ttgacctcga tccgggggtt cttgcaccag ccggggaccc gcagatggag 
    17941 cgggaaggcc accttctcgg gggtggacag cgtgagtgtg atggtctcgt cgaacggata 
    18001 gtcggtgtcc tcggtgacgg tgaccgtcgt accgcccgcc accttcgcgg acacctggct 
    18061 tgcggcgtac agggaggcgg cgagcccctt gtcgggcgtg gccagccaca gctcctcgct 
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    18121 gaagtacggc cagcccatgc cgtagttgtg cggacagcag cggtactggt cgacgcccgg 
    18181 ctggtacgac tgcatcgcga agccgttctg gaactgcccc tgcgacttca ccgcgttgtt 
    18241 cagatcgatg ctgttcgcgc tggtgatgta gtgggtgccg gtgccctggg ggtcgagggc 
    18301 ggcgggcagc atgttgaacg ccaggtcctc gcaccggtcg gcccacaccg gatcgccggt 
    18361 gatccgggtc agcagctcat ggctggccat gaattcgacg atgccgcagg tctcgaagcc 
    18421 ctgccggggg tctccgaaac ccgggcggta gttctcgtcc ccggcgaagc caccgcccgg 
    18481 gaactggccg tatgcgccga gcaccgacgt atagccgcgg taggtcgcct gcctgagctc 
    18541 ggcggagccg gtcagctggg cgtactgggc gggctcgcgg aagccctggg cgatattgac 
    18601 gttgtgcggg gtcgggatgt tgtcgaccgc tagcACCCCT ATTTGTTTAT TTTTCTAAAT 
    18661 ACATTCAAAT ATGTATCCGC TCATGAGACA ATAACCCTGA TAAATGCTTC AATAATATTG 
    18721 AAAAAGGAAG AGTATGAGTA TTCAACATTT CCGTGTCGCC CTTATTCCCT TTTTTGCGGC 
    18781 ATTTTGCCTT CCTGTTTTTG CTCACCCAGA AACGCTGGTG AAAGTAAAAG ATGCTGAAGA 
    18841 TCAGTTGGGT GCACGAGTGG GTTACATCGA ACTGGATCTC AACAGCGGTA AGATCCTTGA 
    18901 GAGTTTTCGC CCCGAAGAAC GTTTTCCAAT GATGAGCACT TTTAAAGTTC TGCTATGTGG 
    18961 CGCGGTATTA TCCCGTATTG ACGCCGGGCA AGAGCAACTC GGTCGCCGCA TACACTATTC 
    19021 TCAGAATGAC TTGGTTGAGT ACTCACCAGT CACAGAAAAG CATCTTACGG ATGGCATGAC 
    19081 AGTAAGAGAA TTATGCAGTG CTGCCATAAC CATGAGTGAT AACACTGCGG CCAACTTACT 
    19141 TCTGACAACG ATCGGAGGAC CGAAGGAGCT AACCGCTTTT TTGCACAACA TGGGGGATCA 
    19201 TGTAACTCGC CTTGATCGTT GGGAACCGGA GCTGAATGAA GCCATACCAA ACGACGAGCG 
    19261 TGACACCACG ATGCCTGTAG CAATGGCAAC AACGTTGCGC AAACTATTAA CTGGCGAACT 
    19321 ACTTACTCTA GCTTCCCGGC AACAATTAAT AGACTGGATG GAGGCGGATA AAGTTGCAGG 
    19381 ACCACTTCTG CGCTCGGCCC TTCCGGCTGG CTGGTTTATT GCTGATAAAT CTGGAGCCGG 
    19441 TGAGCGTGGG TCTCGCGGTA TCATTGCAGC ACTGGGGCCA GATGGTAAGC CCTCCCGTAT 
    19501 CGTAGTTATC TACACGACGG GGAGTCAGGC AACTATGGAT GAACGAAATA GACAGATCGC 
    19561 TGAGATAGGT GCCTCACTGA TTAAGCATTG GTAACTGTCA GACCAAGTTT ACTCATATAT 
    19621 ACTTTAGATT GATTTAAAAC TTCATTTTTA ATTTAAAAGG ATCTAGGTGA AGATCcaatt 
    19681 gTTTCAGCTT TCCGCAACAG TATAActgtg cTTAATTCGA GCTCGGTACC CGGGGATCTT 
    19741 GAAGTTCCTA TTCCGAAGTT CCTATTCTTC AAATAGTATA GGAACTTCAG AGCGCTTTTG 
    19801 AAGCTAGCga gctctccgtc gagttcaaga gaaaaaaaaa gaaaaagcaa aaagaaaaaa 
    19861 ggaaagcgcg cctcgttcag aatgacacgt atagaatgat gcattacctt gtcatcttca 
    19921 gtatcatact gttcgtatac atacttactg acattcatag gtatacatat atacacatgt 
    19981 atatatatcg tatgctgcag ctttaaataa tcggtgtcac tacataagaa cacctttggt 
    20041 ggagggaaca tcgttggtac cattgggcga ggtggcttct cttatggcaa ccgcaagagc 
    20101 cttgaacgca ctctcactac ggtgatgatc attcttgcct cgcagacaat caacgtggag 
    20161 ggtaattctg ctagcctctg caaagctttc aagaaaatgc gggatcatct cgcaagagag 
    20221 atctcctact ttctcccttt gcaaaccaag ttcgacaact gcgtacggcc tgttcgaaag 
    20281 atctaccacc gctctggaaa gtgcctcatc caaaggcgca aatcctgatc caaacctttt 
    20341 tactccacgc actgctccta gggcctcttt aaaagcttga ccgagagcaa tcccgcagtc 
    20401 ttcagtggtg tgatggtcgt ctatgtgtaa gtcaccaatg cactcaacga ttagcgacca 
    20461 gccggaatgc ttggccagag catgtatcat atggtccaga aaccctatac ctgtgtggac 
    20521 gttaatcact tgcgattgtg tggcctgttc tgctactgct tctgcctctt tttctgggaa 
    20581 gatcgagtgc tctatcgcta ggggaccacc ctttaaagag atcgcaatct gaatcttggt 
    20641 ttcatttgta atacgcttta ctagggcttt ctgctctgta ccagaaccac cagaaccTTT 
    20701 GTACAATTCA TCCATACCAT GGGTAATACC AGCAGCAGTA ACAAATTCTA ACAAGACCAT 
    20761 GTGGTCTCTC TTTTCGTTTG GATCTTTGGA TAAGGCAGAT TGAGTGGATA AGTAATGGTT 
    20821 GTCTGGTAAC AAGACTGGAC CATCACCAAT TGGAGTATTT TGTTGATAAT GGTCAGCTAA 
    20881 TTGAACAGAA CCATCTTCAA TGTTGTGTCT AATTTTGAAG TTAACTTTGA TACCATTCTT 
    20941 TTGTTTGTCA GCCATGATGT AAACATTGTG AGAGTTATAG TTGTATTCCA ATTTGTGACC 
    21001 TAAAATGTTA CCATCTTCTT TAAAATCAAT ACCTTTTAAT TCGATTCTAT TAACTAAGGT 
    21061 ATCACCTTCA AACTTGACTT CAGCTCTGGT CTTGTAGTTA CCGTCATCTT TGAAAAAAAT 
    21121 AGTTCTTTCT TGAACATAAC CTTCTGGCAT GGCAGACTTG AAAAAGTCAT GTTGTTTCAT 
    21181 ATGATCTGGG TATCTcGCAA AACATTGAAC ACCATAACCG AAAGTAGTGA CTAAGGTTGG 
    21241 CCATGGAACT GGCAATTTAC CAGTAGTACA AATAAATTTT AAGGTCAATT TACCGTAAGT 
    21301 AGCATCACCT TCACCTTCAC CGGAGACAGA AAATTTGTGA CCATTAACAT CACCATCTAA 
    21361 TTCAACCAAA ATTGGGACAA CACCAGTGAA TAATTCTTCA CCTTTAGACA TTGTGATGAT 
    21421 GTTTTATTTG TTTTGATTGG TGTCTTGTAA ATAGAAACAA GAGAGAATAA TAAACAAGTT 
    21481 AAGAATAAAA AACCAAAGGA TGAAAAAGAA TGAATATGAA AAAGAGTAGA GAATAACTTT 
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    21541 GAAAGGGGAC CATGATATAA CTGGAAAAAA GAGGTTCTTG GAAATGAAAA GTTACCAAAG 
    21601 AGTATTTATA ATTCAGAAAA AAAAGCCAAC GAATATCGTT TTGATGGCGA GCCTTTTTTT 
    21661 TTTTTTAGGA AGACACTAAA GGTACCTAGC ATCATATGGG AAGGAAAGGA AATCACTTGG 
    21721 AAGACATCAC AAGCATTCAT TTACCAAGAG AAAAAATATG CATTTTAGCT AAGATCCATT 
    21781 GAACAAAGCA CTCACTCAAC TCAACTGAAT GAACGAAAGA AGAAAGAACA GTAGAAAACA 
    21841 CTTTGTGACG GTGCGGAACA CATTTACGTA GCTATCATGC TGAATTCTAC TATGAAAATC 
    21901 TCCCAATCTG TCGATGGCAA AACGACCCAC GTGGCAGAGT TGGGTCAAGT GCCAGTTTCT 
    21961 GGATTAAGTA ACAGATACAG ACATCACACG CCATAGAGGA ATCCCGCCGT TGCGAGAGAT 
    22021 GGAAAACAAT AGAGCCGAAA TTGTGGAAGC CCGATGTCTG GGTGTACATT TTTTTTTTTT 
    22081 ttCTTTCTTT CTCTTTCAAT AATCTTTCCT TTTTCCATTT AGCTTGCCGG AAAAACTTTC 
    22141 GGGTAGCGAA AATCTTTCTG CCGGAAAAAT TAGCTATTTT TTTCTTCCTT ATTATTTTTT 
    22201 TAGTTCTGAA GTTTGACCAG GGCGCTACCC TGACCGTATC ACAACCGACG ATCCGGGGTC 






A.7 Sequence of pAN84. 
LOCUS       pAN84-pSBAC-acceptor     12032 bp    DNA     circular UNA 31-MAR-
2011 
COMMENT     This file is created by Vector NTI 
            http://www.invitrogen.com/ 
FEATURES             Location/Qualifiers 
     Primer          749..772 
                     /label=AN509 
     Primer          870..889 
                     /label=AN512 
     Misc._signal    876..948 
                     /label="attP site" 
     Primer          976..995 
                     /label=AN14 
     CDS             992..2617 
                     /vntifkey="4" 
                     /gene="int" 
     Primer          complement(1094..1138) 
                     /label=AN841 
     Mutation        1114 
                     /label="A to G (NheI delete)" 
     Primer          1444..1465 
                     /label=AN813 
     Primer          1514..1534 
                     /label=AN511 
     Primer          complement(1560..1582) 
                     /label=AN812 
     Primer          complement(2052..2073) 
                     /label=AN510 
     Primer          2336..2356 
                     /label=AN814 
     Mutation        2570 
                     /label="Insertion G" 
     Primer          complement(2604..2621) 
                     /label=AN13 
     Mutation        2648 
                     /label="Insertion G" 
     Primer          complement(2848..2871) 
                     /label=AN513 
     Primer          2888..2912 
                     /label=AN815 
     Primer          complement(2960..2981) 
                     /label=AN508 
     CDS             complement(3339..3710) 
                     /vntifkey="4" 
                     /gene="TraJ" 
     Primer          4364..4384 
                     /label=AN358 
     Primer          4456..4479 
                     /label=M13F(-47) 
     Primer          4456..4472 
                     /label=VM129 
     Primer          4458..4515 
                     /label=AN363 
     Primer          4462..4479 
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                     /label=M13F(-41) 
     Primer          4482..4499 
                     /label=M13F(-21) 
     Primer          4494..4553 
                     /label=AN344 
     Restriction_sit 4527..4532 
                     /label=NheI 
     Primer          complement(4532..4591) 
                     /label=AN343 
     Restriction_sit 4569..4574 
                     /label=MfeI 
     Primer          complement(4573..4630) 
                     /label=AN362 
     Primer          complement(4628..4644) 
                     /label=M13R 
     Primer          complement(4629..4647) 
                     /label=VM130 
     Primer          complement(4738..4758) 
                     /label=AN357 
     Primer          5344..5363 
                     /label=AN43 
     CDS             complement(5463..6266) 
                     /vntifkey="4" 
                     /gene="aacIII(IV)" 
     Primer          5464..5484 
                     /label=AN2 
     Primer          complement(6236..6257) 
                     /label=AN1 
     Primer          6236..6255 
                     /label=AN369 
     Primer          complement(6573..6592) 
                     /label=AN42 
     Primer          6844..6866 
                     /label=AN370 
     Primer          7550..7571 
                     /label=AN371 
     Primer          8071..8091 
                     /label=AN816 
     CDS             8442..9197 
                     /vntifkey="4" 
                     /gene="repE" 
     Primer          complement(8508..8527) 
                     /label=AN368 
     Primer          8677..8699 
                     /label=AN817 
     CDS             9795..10952 
                     /vntifkey="4" 
                     /gene="parA" 
     Primer          10010..10064 
                     /label=AN840 
     Primer          10014..10050 
                     /label=AN22 
     Primer          complement(10023..10059) 
                     /label=AN21 
     Mutation        complement(10034) 
                     /label="T-G (MfeI delete)" 
     Primer          10227..10249 
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                     /label=AN818 
     Primer          complement(10375..10395) 
                     /label=AN24 
     CDS             10952..11710 
                     /vntifkey="4" 
                     /gene="parB" 
     Primer          11249..11269 
                     /label=AN820 
     Primer          complement(11388..11411) 
                     /label=AN819 
     Primer          11779..11799 
                     /label=AN839 
     Primer          complement(11920..11941) 
                     /label=AN838 
ORIGIN 
        1 ATTATTAGTC TGGGACCACG GTCCCACTCG TATCGTCGGT CTGATTATTA GTCTGGAACC 
       61 ACGGTCCCAC TCGTATCGTC GGTCTGATTA TTAGTCTGGG ACCACGGTCC CACTCGTATC 
      121 GTCGGTCTGA TTATTAGTCT GGGACCACGA TCCCACTCGT GTTGTCGGTC TGATTATCGG 
      181 TCTGGGACCA CGGTCCCACT TGTATTGTCG ATCAGACTAT CAGCGTGAGA CTACGATTCC 
      241 ATCAATGCCT GTCAAGGGCA AGTATTGACA TGTCGTCGTA ACCTGTAGAA CGGAGTAACC 
      301 ATAGGCCTCA GTGAGGCACC TATCTCAGCG ATCTGTCTAT TTCGTTCATC CATAGTTGCC 
      361 TGACTCCCCG TCGTGTAGAT AACTACGATA CGGGAGGGCT TACCATCTGG CCCCAGTGCT 
      421 GCAATGATAC CGCGAGACCC ACGCTCACCG GCTCCAGATT TATCAGCAAT AAACCAGCCA 
      481 GCCGGAAGGG CCGAGCGCAG AAGTGGTCCT GCAACTTTAT CCGCCTCCAT CCAGTCTATT 
      541 AATTGTTGCC GGGAAGCTAG AGTAAGTAGT TCGCCAGTTA ATAGTTTGCG CAACGTTGTT 
      601 GCCATTGCTA CAGGCATCGT GGTGTCACGC TCGTCGTTTG GTATGGCTTC ATTCAGCTCC 
      661 GGTTCCCAAC GATCAAGGCG AGTTACATGA TCCCCCATGT TGTGCAAAAA AGCGGTTAGC 
      721 TCCTTCGGTC CTCCGATCGT TGTCAGAAGT AAGTTGGCCG CAGTGTTATC ACTCATGGTT 
      781 ATGGCAGCAC TGCATAATTC TCTTACTGTC ATGCCATCCG TAAGATGCTT TTCTGTGACT 
      841 GGTGAGTATC CCTAGGTGGC GCCGGACGGG GCTTCAGACG TTTCGGGTGC TGGGTTGTTG 
      901 TCTCTGGACA GTGATCCATG GGAAACTACT CAGCACCACC AATGTTCCCA AAAGAAAGCG 
      961 CAGGTCAGCG CCCATGAGCC AAGATCTAGG CATGTCGCCC TTCATCGCTC CCGACGTCCC 
     1021 TGAGCACCTT CTAGACACTG TTCGCGTCTT CCTGTACGCG CGTCAGTCTA AGGGCCGGTC 
     1081 CGACGGCTCA GACGTGTCGA CCGAAGCACA GCTGGCGGCC GGTCGTGCGT TGGTCGCGTC 
     1141 TCGCAACGCC CAGGGGGGTG CGCGCTGGGT CGTGGCAGGT GAGTTCGTGG ACGTCGGGCG 
     1201 CTCCGGCTGG GACCCGAACG TGACCCGTGC CGACTTCGAG CGCATGATGG GCGAAGTCCG 
     1261 CGCCGGCGAA GGTGACGTTG TCGTTGTGAA TGAGCTTTCC CGGCTCACTC GCAAGGGCGC 
     1321 CCATGACGCG CTCGAAATCG ACAACGAATT GAAGAAGCAC GGCGTGCGCT TCATGTCGGT 
     1381 TCTTGAGCCG TTCCTTGACA CGTCTACCCC TATCGGCGTC GCCATTTTCG CGCTGATCGC 
     1441 TGCCCTTGCG AAACAGGACA GTGACCTGAA GGCGGAGCGC CTGAAGGGTG CGAAAGACGA 
     1501 GATTGCCGCG CTGGGTGGCG TTCACTCGTC TTCCGCCCCG TTCGGAATGC GCGCCGTGCG 
     1561 CAAGAAGGTC GATAATCTCG TGATCTCCGT TCTTGAGCCG GACGAAGACA ACCCGGATCA 
     1621 CGTCGAGCTA GTTGAGCGCA TGGCGAAAAT GTCGTTCGAA GGCGTGTCCG ACAACGCCAT 
     1681 TGCAACGACC TTCGAGAAGG AAAAGATCCC GTCGCCCGGA ATGGCTGAGA GACGCGCCAC 
     1741 GGAAAAGCGT CTTGCGTCCG TCAAGGCACG TCGCCTGAAC GGCGCTGAAA AGCCGATCAT 
     1801 GTGGCGCGCT CAAACGGTCC GATGGATTCT CAACCATCCC GCAATCGGCG GTTTCGCATT 
     1861 CGAGCGTGTG AAGCACGGTA AGGCGCACAT CAACGTCATA CGGCGCGACC CCGGCGGCAA 
     1921 GCCGCTAACG CCCCACACGG GCATTCTCAG CGGCTCGAAG TGGCTTGAGC TTCAAGAGAA 
     1981 GCGTTCCGGG AAGAATCTCA GCGACCGGAA GCCTGGGGCC GAAGTCGAAC CGACGCTTCT 
     2041 GAGCGGGTGG CGTTTCCTGG GGTGCCGAAT CTGCGGCGGC TCAATGGGTC AGTCCCAGGG 
     2101 TGGCCGTAAG CGCAACGGCG ACCTTGCCGA AGGCAATTAC ATGTGCGCCA ACCCGAAGGG 
     2161 GCACGGCGGC TTGTCGGTCA AGCGCAGCGA ACTGGACGAG TTCGTTGCTT CGAAGGTGTG 
     2221 GGCACGGCTC CGCACAGCCG ACATGGAAGA TGAACACGAT CAGGCATGGA TTGCCGCCGC 
     2281 TGCGGAGCGC TTCGCCCTTC AGCACGACCT AGCGGGGGTG GCCGATGAGC GGCGCGAACA 
     2341 ACAGGCGCAC CTAGACAACG TGCGGCGCTC CATCAAGGAC CTTCAGGCGG ACCGTAAGCC 
     2401 CGGTCTGTAC GTCGGGCGTG AAGAGCTGGA AACGTGGCGC TCAACGGTGC TGCAATACCG 
     2461 GTCCTACGAA GCGGAGTGCA CGACCCGACT CGCTGAGCTT GACGAGAAGA TGAACGGCAG 
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     2521 CACCCGCGTT CCGTCTGAGT GGTTCAGCGG CGAAGACCCG ACGGCCGAAG GGGCATCTGG 
     2581 GCAAGCTGGG ACGTGTACGA GCGTCGGGAG TTCCTGAGCT TCTTCCTTGA CTCCGTCATG 
     2641 GTCGACCGGG GCGCCACCCT GAGACGAAGA AATACATCCC CCTGAAGGAC CGTGTGACGC 
     2701 TCAAGTGGGC GGAGCTGCTG AAGGAGGAAG ACGAAGCGAG CGAAGCCACT GAGCGGGAGC 
     2761 TTGCGGCGCT GTAGCGCACA GCGGGAGGGG TCGAGCCGGC GGACGGTTCG GCCCCTTTTT 
     2821 TGGCCTTGAA ATCGTTAGTT AGGCTAACTA GTAGTTCCTT CGTCACCACA GCGGGCAGGG 
     2881 AGCGCCTAGG GATACTCAAC CAAGTCATTC TGAGAATAGT GTATGCGGCG ACCGAGTTGC 
     2941 TCTTGCCCGG CGTCAATACG GGATAATACC GCGCCACATA GCAGAACTTT AAAAGTGCTC 
     3001 ATCATTGGAA AACGTTCTTC GGGGCGAAAA CTCTCAAGGA TCTTACCGCT GTTGAGATCC 
     3061 AGTTCGATGT AACCCACTCG TGCACCCAAC TGATCTTCAG CATCTTTTAC TTTCACCAGC 
     3121 GTTTCTGGGT GAGCAAAAAC AGGAAGGCAA AATGCCGCAA AAAAAGGGAA TAAGGGCGAC 
     3181 ACGGAAATGT TGAATACTCA TACTCTTCCT TTTTCAATTT GCCTTGCTCG TCGGTGATGT 
     3241 ACTTCACCAG CTCCGCGTAG TCGCTCTTCT TGATGGAGCG CATGGGGACG TGCTTGGCAA 
     3301 TCACGCGCAC CCCCCGGCCG TTTTAGCGGC TAAAAAAGTC ATGGCTCTGC CCTCGGGCGG 
     3361 ACCACGCCCA TCATGACCTT GCCAAGCTCG TCCTGCTTCT CTTCGATCTT CGCCAGCAGG 
     3421 GCGAGGATCG TGGCATCACC GAACCGCGCC GTGCGCGGGT CGTCGGTGAG CCAGAGTTTC 
     3481 AGCAGGCCGC CCAGGCGGCC CAGGTCGCCA TTGATGCGGG CCAGCTCGCG GACGTGCTCA 
     3541 TAGTCCACGA CGCCCGTGAT TTTGTAGCCC TGGCCGACGG CCAGCAGGTA GGCCGACAGG 
     3601 CTCATGCCGG CCGCCGCCGC CTTTTCCTCA ATCGCTCTTC GTTCGTCTGG AAGGCAGTAC 
     3661 ACCTTGATAG GTGGGCTGCC CTTCCTGGTT GGCTTGGTTT CATCAGCCAT CCGCTTGCCC 
     3721 TCATCTGTTA CGCCGGCGGT AGCCGGCCAG CCTCGCAGAG CAGGATTCCC GTTGAGCACC 
     3781 GCCAGGTGCG AATAAGGGAC AGTGAAGAAG GAACACCCGC TCGCGGGTGG GCCTACTTCA 
     3841 CCTATCCTGC CCGGCTGACG CCGTTGGATA CACCAAGGAA AGTCTACACG AACCCTTTGG 
     3901 CAAAATCCTG TATATCGTGC GATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG 
     3961 GATACATATT TGAATGTATT TAGAAAAATA AACAAATAGG GGTTCCGCGC ACATTTCCCC 
     4021 GAAAAGTGCC ACCTGACGTC TAAGAAACCA TTATTATCAT GACATTAACC TATAAAAATA 
     4081 GGCGTATCAC GAGGCCCTTT CGTCTCGCGC GTTTCGGTGA TGACGGTGAA AACCTCTGAC 
     4141 ACATGCAGCT CCCGGAGACG GTCACAGCTT GTCTGTAAGC GGATGCCGGG AGCAGACAAG 
     4201 CCCGTCAGGG CGCGTCAGCG GGTGTTGGCG GGTGTCGGGG CTGGCTTAAC TATGCGGCAT 
     4261 CAGAGCAGAT TGTACTGAGA GTGCACCATA TGCGGTGTGA AATACCGCAC AGATGCGTAA 
     4321 GGAGAAAATA CCGCATCAGG CGCCATTCGC CATTCAGGCT GCGCAACTGT TGGGAAGGGC 
     4381 GATCGGTGCG GGCCTCTTCG CTATTACGCC AGCTGGCGAA AGGGGGATGT GCTGCAAGGC 
     4441 GATTAAGTTG GGTAACGCCA GGGTTTTCCC AGTCACGACG TTGTAAAACG ACGGCCAGTG 
     4501 AATTCTCTAG Accggcacga ttgtgcGCTA GCTTCATCAG GGCTTCGACG GTGCTCTGGA 
     4561 GCTCGGTACA ATTGCCCGGG GATCCTCTAG AGTCGACCTG CAGGCATGCA AGCTTGGCGT 
     4621 AATCATGGTC ATAGCTGTTT CCTGTGTGAA ATTGTTATCC GCTCACAATT CCACACAACA 
     4681 TACGAGCCGG AAGCATAAAG TGTAAAGCCT GGGGTGCCTA ATGAGTGAGC TAACTCACAT 
     4741 TAATTGCGTT GCGCTCACTG CCCGCTTTCC AGTCGGGAAA CCTGTCGTGC CAGCTGCATT 
     4801 AATGAATCGG CCAACGCGCG GGGAGAGGCG GTTTGCGTAT TGGGCGCTCT TCCGCTTCCT 
     4861 CGCTCACTGA CTCGCTGCGC TCGGTCGTTC GGCTGCGGCG AGCGGTATCA GCTCACTCAA 
     4921 AGGCGGTAAT ACGGTTATCC ACAGAATCAG GGGATAACGC AGGAAAGAAC ATGCATGGAG 
     4981 ATCCCCAATT CCCCAATGTC AAGCACTTCC GGAATCGGGA GCGCGGCCGA TGCAAAGTGC 
     5041 CGATAAACAT AACGATCTTT GTAGAAACCA TCGGCGCAGC TATTTACCCG CAGGACATAT 
     5101 CCACGCCCTC CTACATCGAA GCTGAAAGCA CGAGATTCTT CGCCCTCCGA GAGCTGCATC 
     5161 AGGTCGGAGA CGCTGTCGAA CTTTTCGATC AGAAACTTCT CGACAGACGT CGCGGTGAGT 
     5221 TCAGGCTTTT TCATATCTCA TTGCCCCCGG ACGAGCGTCT GCTCCGCCAT TCGCCGTCCG 
     5281 CCGTGCCAAT CGGATCAGCC GTCCAAATGC GGGATTTTCG TTAGTCGGAG GCCAAACGGC 
     5341 ATTGAGCGTC AGCATATCAT CAGCGAGCTG AAGAAAGACA ATCCCCGATC CGCTCCACGT 
     5401 GTTGCCCCAG CAATCAGCGC GACCTTGCCC CTCCAACGTC ATCTCGTTCT CCGCTCATGA 
     5461 GCTCAGCCAA TCGACTGGCG AGCGGCATCG CATTCTTCGC ATCCCGCCTC TGGCGGATGC 
     5521 AGGAAGATCA ACGGATCTCG GCCCAGTTGA CCCAGGGCTG TCGCCACAAT GTCGCGGGAG 
     5581 CGGATCAACC GAGCAAAGGC ATGACCGACT GGACCTTCCT TCTGAAGGCT CTTCTCCTTG 
     5641 AGCCACCTGT CCGCCAAGGC AAAGCGCTCA CAGCAGTGGT CATTCTCGAG ATAATCGACG 
     5701 CGTACCAACT TGCCATCCTG AAGAATGGTG CAGTGTCTCG GCACCCCATA GGGAACCTTT 
     5761 GCCATCAACT CGGCAAGATG CAGCGTCGTG TTGGCATCGT GTCCCACGCC GAGGAGAAGT 
     5821 ACCTGCCCAT CGAGTTCATG GACACGGGCG ACCGGGCTTG CAGGCGAGTG AGGTGGCAGG 
     5881 GGCAATGGAT CAGAGATGAT CTGCTCTGCC TGTGGCCCCG CTGCCGCAAA GGCAAATGGA 
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     5941 TGGGCGCTGC GCTTTACATT TGGCAGGCGC CAGAATGTGT CAGAGACAAC TCCAAGGTCC 
     6001 GGTGTAACGG GCGACGTGGC AGGATCGAAC GGCTCGTCGT CCAGACCTGA CCACGAGGGC 
     6061 ATGACGAGCG TCCCTCCCGG ACCCAGCGCA GCACGCAGGG CCTCGATCAG TCCAAGTGGC 
     6121 CCATCTTCGA GGGGCCGGAC GCTACGGAAG GAGCTGTGGA CCAGCAGCAC ACCGCCGGGG 
     6181 GTAACCCCAA GGTTGAGAAG CTGACCGATG AGCTCGGCTT TTCGCCATTC GTATTGCACG 
     6241 ACATTGCACT CCACCGCTGA TGACATCAGT CGATCATAGC ACGATCAACG GCACTGTTGC 
     6301 AAATAGTCGG TGGTGATAAA CTTATCATCC CCTTTTGCTG ATGGAGCTGC ACATGAACCC 
     6361 ATTCAAAGGC CGGCATTTTC AGCGTGACAT CATTCTGTGG GCCGTACGCT GGTACTGCAA 
     6421 ATACGGCATC AGTTACCGTG AGCGGGTACC GAGCTCGAAT TAATTCGTAA TCATGGCCAT 
     6481 GCATGTGAGC AAAAGGCCAG CAAAAGGCCA GGAACCGTAA AAAGGCCGCG TTGCTGGCGT 
     6541 TTTTCCATAG GCTCCGCCCC CCTGACGAGC ATCACAAAAA TCGACGCTCA AGTCAGAGGT 
     6601 GGCGAAGGCC TGAAGGGCTT CCCGGTATCA ACAGGGACAC CAGGATTTAT TTATTCTGCG 
     6661 AAGTGATCTT CCGTCACAGG TATTTATTCG CGATAAGCTC ATGGAGCGGC GTAACCGTCG 
     6721 CACAGGAAGG ACAGAGAAAG CGCGGATCTG GGAAGTGACG GACAGAACGG TCAGGACCTG 
     6781 GATTGGGGAG GCGGTTGCCG CCGCTGCTGC TGACGGTGTG ACGTTCTCTG TTCCGGTCAC 
     6841 ACCACATACG TTCCGCCATT CCTATGCGAT GCACATGCTG TATGCCGGTA TACCGCTGAA 
     6901 AGTTCTGCAA AGCCTGATGG GACATAAGTC CATCAGTTCA ACGGAAGTCT ACACGAAGGT 
     6961 TTTTGCGCTG GATGTGGCTG CCCGGCACCG GGTGCAGTTT GCGATGCCGG AGTCTGATGC 
     7021 GGTTGCGATG CTGAAACAAT TATCCTGAGA ATAAATGCCT TGGCCTTTAT ATGGAAATGT 
     7081 GGAACTGAGT GGATATGCTG TTTTTGTCTG TTAAACAGAG AAGCTGGCTG TTATCCACTG 
     7141 AGAAGCGAAC GAAACAGTCG GGAAAATCTC CCATTATCGT AGAGATCCGC ATTATTAATC 
     7201 TCAGGAGCCT GTGTAGCGTT TATAGGAAGT AGTGTTCTGT CATGATGCCT GCAAGCGGTA 
     7261 ACGAAAACGA TTTGAATATG CCTTCAGGAA CAATAGAAAT CTTCGTGCGG TGTTACGTTG 
     7321 AAGTGGAGCG GATTATGTCA GCAATGGACA GAACAACCTA ATGAACACAG AACCATGATG 
     7381 TGGTCTGTCC TTTTACAGCC AGTAGTGCTC GCCGCAGTCG AGCGACAGGG CGAAGCCCTC 
     7441 GAGCTGGTTG CCCTCGCCGC TGGGCTGGCG GCCGTCTATG GCCCTGCAAA CGCGCCAGAA 
     7501 ACGCCGTCGA AGCCGTGTGC GAGACACCGC GGCCGGCCGC CGGCGTTGTG GATACCTCGC 
     7561 GGAAAACTTG GCCCTCACTG ACAGATGAGG GGCGGACGTT GACACTTGAG GGGCCGACTC 
     7621 ACCCGGCGCG GCGTTGACAG ATGAGGGGCA GGCTCGATTT CGGCCGGCGA CGTGGAGCTG 
     7681 GCCAGCCTCG CAAATCGGCG AAAACGCCTG ATTTTACGCG AGTTTCCCAC AGATGATGTG 
     7741 GACAAGCCTG GGGATAAGTG CCCTGCGGTA TTGACACTTG AGGGGCGCGA CTACTGACAG 
     7801 ATGAGGGGCG CGATCCTTGA CACTTGAGGG GCAGAGTGCT GACAGATGAG GGGCGCACCT 
     7861 ATTGACATTT GAGGGGCTGT CCACAGGCAG AAAATCCAGC ATTTGCAAGG GTTTCCGCCC 
     7921 GTTTTTCGGC CACCGCTAAC CTGTCTTTTA ACCTGCTTTT AAACCAATAT TTATAAACCT 
     7981 TGTTTTTAAC CAGGGCTGCG CCCTGTGCGC GTGACCGCGC ACGCCGAAGG GGGTGCCCCC 
     8041 CTTCTCGAAC CCTCCCGGTC GAGTGAGCGA GGAAGCACCA GGGAACAGCA CTTATATATT 
     8101 CTGCTTACAC ACGATGCCTG AAAAAACTTC CCTTGGGGTT ATCCACTTAT CCACGGGGAT 
     8161 ATTTTTATAA TTATTTTTTT ATTAGTTTTT AGATCTTCTT TTTTAGAGCG CCTTGTAGGC 
     8221 CTTTATCCAT GCTGGTTCTA GAGAAGGTGT TGTGACAAAT TGCCCTTTCA GTGTGACAAA 
     8281 TCACCCTCAA ATGACAGTCC TGTCTGTGAC AAATTGCCCT TAACCCTGTG ACAAATTGCC 
     8341 CTCAGAAGAA GCTGTTTTTT CACAAAGTTA TCCCTGCTTA TTGACTCTTT TTTATTTAGT 
     8401 GTGACAATCT AAAAACTTGT CACACTTCAC ATGGATCTGT CATGGCGGAA ACAGCGGTTA 
     8461 TCAATCACAA GAAACGTAAA AATAGCCCGC GAATCGTCCA GTCAAACGAC CTCACTGAGG 
     8521 CGGCATATAG TCTCTCCCGG GATCAAAAAC GTATGCTGTA TCTGTTCGTT GACCAGATCA 
     8581 GAAAATCTGA TGGCACCCTA CAGGAACATG ACGGTATCTG CGAGATCCAT GTTGCTAAAT 
     8641 ATGCTGAAAT ATTCGGATTG ACCTCTGCGG AAGCCAGTAA GGATATACGG CAGGCATTGA 
     8701 AGAGTTTCGC GGGGAAGGAA GTGGTTTTTT ATCGCCCTGA AGAGGATGCC GGCGATGAAA 
     8761 AAGGCTATGA ATCTTTTCCT TGGTTTATCA AACGTGCGCA CAGTCCATCC AGAGGGCTTT 
     8821 ACAGTGTACA TATCAACCCA TATCTCATTC CCTTCTTTAT CGGGTTACAG AACCGGTTTA 
     8881 CGCAGTTTCG GCTTAGTGAA ACAAAAGAAA TCACCAATCC GTATGCCATG CGTTTATACG 
     8941 AATCCCTGTG TCAGTATCGT AAGCCGGATG GCTCAGGCAT CGTCTCTCTG AAAATCGACT 
     9001 GGATCATAGA GCGTTACCAG CTGCCTCAAA GTTACCAGCG TATGCCTGAC TTCCGCCGCC 
     9061 GCTTCCTGCA GGTCTGTGTT AATGAGATCA ACAGCAGAAC TCCAATGCGC CTCTCATACA 
     9121 TTGAGAAAAA GAAAGGCCGC CAGACGACTC ATATCGTATT TTCCTTCCGC GATATCACTT 
     9181 CCATGACGAC AGGATAGTCT GAGGGTTATC TGTCACAGAT TTGAGGGTGG TTCGTCACAT 
     9241 TTGTTCTGAC CTACTGAGGG TAATTTGTCA CAGTTTTGCT GTTTCCTTCA GCCTGCATGG 
     9301 ATTTTCTCAT ACTTTTTGAA CTGTAATTTT TAAGGAAGCC AAATTTGAGG GCAGTTTGTC 
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     9361 ACAGTTGATT TCCTTCTCTT TCCCTTCGTC ATGTGACCTG ATATCGGGGG TTAGTTCGTC 
     9421 ATCATTGATG AGGGTTGATT ATCACAGTTT ATTACTCTGA ATTGGCTATC CGCGTGTGTA 
     9481 CCTCTACCTG GAGTTTTTCC CACGGTGGAT ATTTCTTCTT GCGCTGAGCG TAAGAGCTAT 
     9541 CTGACAGAAC AGTTCTTCTT TGCTTCCTCG CCAGTTCGCT CGCTATGCTC GGTTACACGG 
     9601 CTGCGGCGAG CGCTAGTGAT AATAAGTGAC TGAGGTATGT GCTCTTCTTA TCTCCTTTTG 
     9661 TAGTGTTGCT CTTATTTTAA ACAACTTTGC GGTTTTTTGA TGACTTTGCG ATTTTGTTGT 
     9721 TGCTTTGCAG TAAATTGCAA GATTTAATAA AAAAAACGCA AAGCAATGAT TAAAGGATGT 
     9781 TCAGAATGAA ACTCATGGAA ACACTTAACC AGTGCATAAA CGCTGGTCAT GAAATGACGA 
     9841 AGGCTATCGC CATTGCACAG TTTAATGATG ACAGCCCGGA AGCGAGGAAA ATAACCCGGC 
     9901 GCTGGAGAAT AGGTGAAGCA GCGGATTTAG TTGGGGTTTC TTCTCAGGCT ATCAGAGATG 
     9961 CCGAGAAAGC AGGGCGACTA CCGCACCCGG ATATGGAAAT TCGAGGACGG GTTGAGCAAC 
    10021 GTGTTGGTTA TACCATTGAA CAAATTAATC ATATGCGTGA TGTGTTTGGT ACGCGATTGC 
    10081 GACGTGCTGA AGACGTATTT CCACCGGTGA TCGGGGTTGC TGCCCATAAA GGTGGCGTTT 
    10141 ACAAAACCTC AGTTTCTGTT CATCTTGCTC AGGATCTGGC TCTGAAGGGG CTACGTGTTT 
    10201 TGCTCGTGGA AGGTAACGAC CCCCAGGGAA CAGCCTCAAT GTATCACGGA TGGGTACCAG 
    10261 ATCTTCATAT TCATGCAGAA GACACTCTCC TGCCTTTCTA TCTTGGGGAA AAGGACGATG 
    10321 TCACTTATGC AATAAAGCCC ACTTGCTGGC CGGGGCTTGA CATTATTCCT TCCTGTCTGG 
    10381 CTCTGCACCG TATTGAAACT GAGTTAATGG GCAAATTTGA TGAAGGTAAA CTGCCCACCG 
    10441 ATCCACACCT GATGCTCCGA CTGGCCATTG AAACTGTTGC TCATGACTAT GATGTCATAG 
    10501 TTATTGACAG CGCGCCTAAC CTGGGTATCG GCACGATTAA TGTCGTATGT GCTGCTGATG 
    10561 TGCTGATTGT TCCCACGCCT GCTGAGTTGT TTGACTACAC CTCCGCACTG CAGTTTTTCG 
    10621 ATATGCTTCG TGATCTGCTC AAGAACGTTG ATCTTAAAGG GTTCGAGCCT GATGTACGTA 
    10681 TTTTGCTTAC CAAATACAGC AATAGCAATG GCTCTCAGTC CCCGTGGATG GAGGAGCAAA 
    10741 TTCGGGATGC CTGGGGAAGC ATGGTTCTAA AAAATGTTGT ACGTGAAACG GATGAAGTTG 
    10801 GTAAAGGTCA GATCCGGATG AGAACTGTTT TTGAACAGGC CATTGATCAA CGCTCTTCAA 
    10861 CTGGTGCCTG GAGAAATGCT CTTTCTATTT GGGAACCTGT CTGCAATGAA ATTTTCGATC 
    10921 GTCTGATTAA ACCACGCTGG GAGATTAGAT AATGAAGCGT GCGCCTGTTA TTCCAAAACA 
    10981 TACGCTCAAT ACTCAACCGG TTGAAGATAC TTCGTTATCG ACACCAGCTG CCCCGATGGT 
    11041 GGATTCGTTA ATTGCGCGCG TAGGAGTAAT GGCTCGCGGT AATGCCATTA CTTTGCCTGT 
    11101 ATGTGGTCGG GATGTGAAGT TTACTCTTGA AGTGCTCCGG GGTGATAGTG TTGAGAAGAC 
    11161 CTCTCGGGTA TGGTCAGGTA ATGAACGTGA CCAGGAGCTG CTTACTGAGG ACGCACTGGA 
    11221 TGATCTCATC CCTTCTTTTC TACTGACTGG TCAACAGACA CCGGCGTTCG GTCGAAGAGT 
    11281 ATCTGGTGTC ATAGAAATTG CCGATGGGAG TCGCCGTCGT AAAGCTGCTG CACTTACCGA 
    11341 AAGTGATTAT CGTGTTCTGG TTGGCGAGCT GGATGATGAG CAGATGGCTG CATTATCCAG 
    11401 ATTGGGTAAC GATTATCGCC CAACAAGTGC TTATGAACGT GGTCAGCGTT ATGCAAGCCG 
    11461 ATTGCAGAAT GAATTTGCTG GAAATATTTC TGCGCTGGCT GATGCGGAAA ATATTTCACG 
    11521 TAAGATTATT ACCCGCTGTA TCAACACCGC CAAATTGCCT AAATCAGTTG TTGCTCTTTT 
    11581 TTCTCACCCC GGTGAACTAT CTGCCCGGTC AGGTGATGCA CTTCAAAAAG CCTTTACAGA 
    11641 TAAAGAGGAA TTACTTAAGC AGCAGGCATC TAACCTTCAT GAGCAGAAAA AAAGCTGGGG 
    11701 TGATATTTGA AGCTGAAGAA GTTATCACTC TTTTAACTTC TGTGCTTAAA ACGTCATCTG 
    11761 CATCAAGAAC TAGTTTAAGC TCACGACATC AGTTTGCTCC TGGAGCGACA GTATTGTATA 
    11821 AGGGCGATAA AATGGTGCTT AACCTGGACA GGTCTCGTGT TCCAACTGAG TGTATAGAGA 
    11881 AAATTGAGGC CATTCTTAAG GAACTTGAAA AGCCAGCACC CTGATGCGAC CTCGTTTTAG 
    11941 TCTACGTTTA TCTGTCTTTA CTTAATGTCC TTTGTTACAG GCCAGAAAGC ATAACTGGCC 






A.8 Sequence of pAN146. 
LOCUS       pSBAC-Flp-acceptor-pGAL-Flp     19162 bp    DNA     circular UNA 
31-MAR-2011 
COMMENT     This file is created by Vector NTI 
            http://www.invitrogen.com/ 
FEATURES             Location/Qualifiers 
     CDS             complement(323..1081) 
                     /vntifkey="4" 
                     /gene="parB" 
     CDS             complement(1081..2238) 
                     /vntifkey="4" 
                     /gene="parA" 
     Primer          1638..1658 
                     /label=AN24 
     Primer          1974..2010 
                     /label=AN21 
     Primer          complement(1983..2019) 
                     /label=AN22 
     Mutation        1999 
                     /label="T-G (MfeI delete)" 
     CDS             complement(2836..3591) 
                     /vntifkey="4" 
                     /gene="repE" 
     Primer          3506..3525 
                     /label=AN368 
     Primer          complement(4462..4483) 
                     /label=AN371 
     Primer          complement(5167..5189) 
                     /label=AN370 
     Primer          5420..5447 
                     /label=pB1 
     Primer          5441..5460 
                     /label=AN42 
     CDS             5767..6570 
                     /vntifkey="4" 
                     /gene="aacIII(IV)" 
     Primer          5776..5797 
                     /label=AN1 
     Primer          complement(5778..5797) 
                     /label=AN369 
     Primer          complement(6549..6569) 
                     /label=AN2 
     Primer          complement(6670..6689) 
                     /label=AN43 
     Primer          7275..7295 
                     /label=AN357 
     Mutation        7358 
                     /label="T to A" 
     Primer          7386..7404 
                     /label=VM130 
     Primer          7389..7405 
                     /label=M13R 
     Primer          7389..7438 
                     /label=AN619 
     Restriction_sit 7418 
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                     /label="destroyed HindIII" 
     Promoter        7419..7875 
                     /label=pGAL 
     Primer          7876..7921 
                     /label=AN5 
     ORF             7876..9147 
                     /label=Flp 
     Primer          7879..7921 
                     /label=AN47 
     Primer          complement(8132..8151) 
                     /label=AN87 
     Primer          8333..8352 
                     /label=AN243 
     Primer          complement(8647..8665) 
                     /label=AN86 
     Primer          8937..8955 
                     /label=AN170 
     Primer          complement(9118..9159) 
                     /label=AN620 
     Primer          complement(9122..9147) 
                     /label=AN48 
     Primer          9129..9165 
                     /label=AN621 
     Terminator      9148..9402 
                     /label=tACT 
     Primer          complement(9371..9430) 
                     /label=AN622 
     Restriction_sit 9403 
                     /label="destroyed HindIII" 
     Primer          9415..9466 
                     /label=AN415 
     Replication_ori complement(9445..9963) 
                     /label=CEN/ARS 
     Primer          10425..10442 
                     /label=AN61 
     ORF             complement(10690..11784) 
                     /label=LEU2-f1 
     ORF             complement(10690..11796) 
                     /label=LEU2-f2 
     Primer          10944..10961 
                     /label=AN62 
     Primer          11438..11456 
                     /label=AN63 
     Primer          complement(11777..11826) 
                     /label=AN447 
     Primer          11782..11832 
                     /label=AN448 
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                     /label="F1 ori" 
     Primer          12851..12868 
                     /label=AN50 
     Primer          12982..13002 
                     /label=AN358 
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                     /label=AN154 
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                     /label=FRT3 
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     Terminator      complement(13244..13495) 
                     /label=tCYC 
     Primer          13508..13537 
                     /label=AN108 
     ORF             complement(13508..14179) 
                     /label=TRP1 
     Primer          complement(13729..13750) 
                     /label=AN183 
     Primer          14059..14081 
                     /label=AN285 
     Misc._recombina complement(14180..14227) 
                     /label=FRT(WT) 
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                     /label=pMET25 
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                     /label=AN416 
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                     /label=M13F(-21) 
     Primer          complement(14684..14707) 
                     /label=M13F(-47) 
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                     /label=M13F(-41) 
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                     /label=VM129 
     Primer          complement(14779..14799) 
                     /label=AN358 
     Replication_ori complement(15275..15373) 
                     /label="oriT (RP4)" 
     CDS             15453..15824 
                     /vntifkey="4" 
                     /gene="TraJ" 
     Primer          16182..16203 
                     /label=AN508 
     Source          16277..18307 
                     /label=Phi-BT1 
     Primer          16542..16559 
                     /label=AN13 
     CDS             complement(16546..18171) 
                     /vntifkey="4" 
                     /gene="int" 
     Primer          17090..17111 
                     /label=AN510 
     Primer          complement(17629..17649) 
                     /label=AN511 
     Mutation        18049 
                     /label="T-C (NheI delete)" 
     Primer          complement(18168..18187) 
                     /label=AN14 
     Misc._recombina complement(18215..18287) 
                     /label=attP 
     Primer          complement(18391..18414) 
                     /label=AN509 
     Primer          complement(18835..18862) 
                     /label=pB2 
ORIGIN 
        1 AAGTGGAACA GTGGGCCCAG AGAGAATATT CAGGCCAGTT ATGCTTTCTG GCCTGTAACA 
       61 AAGGACATTA AGTAAAGACA GATAAACGTA GACTAAAACG AGGTCGCATC AGGGTGCTGG 
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      121 CTTTTCAAGT TCCTTAAGAA TGGCCTCAAT TTTCTCTATA CACTCAGTTG GAACACGAGA 
      181 CCTGTCCAGG TTAAGCACCA TTTTATCGCC CTTATACAAT ACTGTCGCTC CAGGAGCAAA 
      241 CTGATGTCGT GAGCTTAAAC TAGTTCTTGA TGCAGATGAC GTTTTAAGCA CAGAAGTTAA 
      301 AAGAGTGATA ACTTCTTCAG CTTCAAATAT CACCCCAGCT TTTTTTCTGC TCATGAAGGT 
      361 TAGATGCCTG CTGCTTAAGT AATTCCTCTT TATCTGTAAA GGCTTTTTGA AGTGCATCAC 
      421 CTGACCGGGC AGATAGTTCA CCGGGGTGAG AAAAAAGAGC AACAACTGAT TTAGGCAATT 
      481 TGGCGGTGTT GATACAGCGG GTAATAATCT TACGTGAAAT ATTTTCCGCA TCAGCCAGCG 
      541 CAGAAATATT TCCAGCAAAT TCATTCTGCA ATCGGCTTGC ATAACGCTGA CCACGTTCAT 
      601 AAGCACTTGT TGGGCGATAA TCGTTACCCA ATCTGGATAA TGCAGCCATC TGCTCATCAT 
      661 CCAGCTCGCC AACCAGAACA CGATAATCAC TTTCGGTAAG TGCAGCAGCT TTACGACGGC 
      721 GACTCCCATC GGCAATTTCT ATGACACCAG ATACTCTTCG ACCGAACGCC GGTGTCTGTT 
      781 GACCAGTCAG TAGAAAAGAA GGGATGAGAT CATCCAGTGC GTCCTCAGTA AGCAGCTCCT 
      841 GGTCACGTTC ATTACCTGAC CATACCCGAG AGGTCTTCTC AACACTATCA CCCCGGAGCA 
      901 CTTCAAGAGT AAACTTCACA TCCCGACCAC ATACAGGCAA AGTAATGGCA TTACCGCGAG 
      961 CCATTACTCC TACGCGCGCA ATTAACGAAT CCACCATCGG GGCAGCTGGT GTCGATAACG 
     1021 AAGTATCTTC AACCGGTTGA GTATTGAGCG TATGTTTTGG AATAACAGGC GCACGCTTCA 
     1081 TTATCTAATC TCCCAGCGTG GTTTAATCAG ACGATCGAAA ATTTCATTGC AGACAGGTTC 
     1141 CCAAATAGAA AGAGCATTTC TCCAGGCACC AGTTGAAGAG CGTTGATCAA TGGCCTGTTC 
     1201 AAAAACAGTT CTCATCCGGA TCTGACCTTT ACCAACTTCA TCCGTTTCAC GTACAACATT 
     1261 TTTTAGAACC ATGCTTCCCC AGGCATCCCG AATTTGCTCC TCCATCCACG GGGACTGAGA 
     1321 GCCATTGCTA TTGCTGTATT TGGTAAGCAA AATACGTACA TCAGGCTCGA ACCCTTTAAG 
     1381 ATCAACGTTC TTGAGCAGAT CACGAAGCAT ATCGAAAAAC TGCAGTGCGG AGGTGTAGTC 
     1441 AAACAACTCA GCAGGCGTGG GAACAATCAG CACATCAGCA GCACATACGA CATTAATCGT 
     1501 GCCGATACCC AGGTTAGGCG CGCTGTCAAT AACTATGACA TCATAGTCAT GAGCAACAGT 
     1561 TTCAATGGCC AGTCGGAGCA TCAGGTGTGG ATCGGTGGGC AGTTTACCTT CATCAAATTT 
     1621 GCCCATTAAC TCAGTTTCAA TACGGTGCAG AGCCAGACAG GAAGGAATAA TGTCAAGCCC 
     1681 CGGCCAGCAA GTGGGCTTTA TTGCATAAGT GACATCGTCC TTTTCCCCAA GATAGAAAGG 
     1741 CAGGAGAGTG TCTTCTGCAT GAATATGAAG ATCTGGTACC CATCCGTGAT ACATTGAGGC 
     1801 TGTTCCCTGG GGGTCGTTAC CTTCCACGAG CAAAACACGT AGCCCCTTCA GAGCCAGATC 
     1861 CTGAGCAAGA TGAACAGAAA CTGAGGTTTT GTAAACGCCA CCTTTATGGG CAGCAACCCC 
     1921 GATCACCGGT GGAAATACGT CTTCAGCACG TCGCAATCGC GTACCAAACA CATCACGCAT 
     1981 ATGATTAATT TGTTCAATGG TATAACCAAC ACGTTGCTCA ACCCGTCCTC GAATTTCCAT 
     2041 ATCCGGGTGC GGTAGTCGCC CTGCTTTCTC GGCATCTCTG ATAGCCTGAG AAGAAACCCC 
     2101 AACTAAATCC GCTGCTTCAC CTATTCTCCA GCGCCGGGTT ATTTTCCTCG CTTCCGGGCT 
     2161 GTCATCATTA AACTGTGCAA TGGCGATAGC CTTCGTCATT TCATGACCAG CGTTTATGCA 
     2221 CTGGTTAAGT GTTTCCATGA GTTTCATTCT GAACATCCTT TAATCATTGC TTTGCGTTTT 
     2281 TTTTATTAAA TCTTGCAATT TACTGCAAAG CAACAACAAA ATCGCAAAGT CATCAAAAAA 
     2341 CCGCAAAGTT GTTTAAAATA AGAGCAACAC TACAAAAGGA GATAAGAAGA GCACATACCT 
     2401 CAGTCACTTA TTATCACTAG CGCTCGCCGC AGCCGTGTAA CCGAGCATAG CGAGCGAACT 
     2461 GGCGAGGAAG CAAAGAAGAA CTGTTCTGTC AGATAGCTCT TACGCTCAGC GCAAGAAGAA 
     2521 ATATCCACCG TGGGAAAAAC TCCAGGTAGA GGTACACACG CGGATAGCCA ATTCAGAGTA 
     2581 ATAAACTGTG ATAATCAACC CTCATCAATG ATGACGAACT AACCCCCGAT ATCAGGTCAC 
     2641 ATGACGAAGG GAAAGAGAAG GAAATCAACT GTGACAAACT GCCCTCAAAT TTGGCTTCCT 
     2701 TAAAAATTAC AGTTCAAAAA GTATGAGAAA ATCCATGCAG GCTGAAGGAA ACAGCAAAAC 
     2761 TGTGACAAAT TACCCTCAGT AGGTCAGAAC AAATGTGACG AACCACCCTC AAATCTGTGA 
     2821 CAGATAACCC TCAGACTATC CTGTCGTCAT GGAAGTGATA TCGCGGAAGG AAAATACGAT 
     2881 ATGAGTCGTC TGGCGGCCTT TCTTTTTCTC AATGTATGAG AGGCGCATTG GAGTTCTGCT 
     2941 GTTGATCTCA TTAACACAGA CCTGCAGGAA GCGGCGGCGG AAGTCAGGCA TACGCTGGTA 
     3001 ACTTTGAGGC AGCTGGTAAC GCTCTATGAT CCAGTCGATT TTCAGAGAGA CGATGCCTGA 
     3061 GCCATCCGGC TTACGATACT GACACAGGGA TTCGTATAAA CGCATGGCAT ACGGATTGGT 
     3121 GATTTCTTTT GTTTCACTAA GCCGAAACTG CGTAAACCGG TTCTGTAACC CGATAAAGAA 
     3181 GGGAATGAGA TATGGGTTGA TATGTACACT GTAAAGCCCT CTGGATGGAC TGTGCGCACG 
     3241 TTTGATAAAC CAAGGAAAAG ATTCATAGCC TTTTTCATCG CCGGCATCCT CTTCAGGGCG 
     3301 ATAAAAAACC ACTTCCTTCC CCGCGAAACT CTTCAATGCC TGCCGTATAT CCTTACTGGC 
     3361 TTCCGCAGAG GTCAATCCGA ATATTTCAGC ATATTTAGCA ACATGGATCT CGCAGATACC 
     3421 GTCATGTTCC TGTAGGGTGC CATCAGATTT TCTGATCTGG TCAACGAACA GATACAGCAT 
     3481 ACGTTTTTGA TCCCGGGAGA GACTATATGC CGCCTCAGTG AGGTCGTTTG ACTGGACGAT 
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     3541 TCGCGGGCTA TTTTTACGTT TCTTGTGATT GATAACCGCT GTTTCCGCCA TGACAGATCC 
     3601 ATGTGAAGTG TGACAAGTTT TTAGATTGTC ACACTAAATA AAAAAGAGTC AATAAGCAGG 
     3661 GATAACTTTG TGAAAAAACA GCTTCTTCTG AGGGCAATTT GTCACAGGGT TAAGGGCAAT 
     3721 TTGTCACAGA CAGGACTGTC ATTTGAGGGT GATTTGTCAC ACTGAAAGGG CAATTTGTCA 
     3781 CAACACCTTC TCTAGAACCA GCATGGATAA AGGCCTACAA GGCGCTCTAA AAAAGAAGAT 
     3841 CTAAAAACTA ATAAAAAAAT AATTATAAAA ATATCCCCGT GGATAAGTGG ATAACCCCAA 
     3901 GGGAAGTTTT TTCAGGCATC GTGTGTAAGC AGAATATATA AGTGCTGTTC CCTGGTGCTT 
     3961 CCTCGCTCAC TCGACCGGGA GGGTTCGAGA AGGGGGGCAC CCCCTTCGGC GTGCGCGGTC 
     4021 ACGCGCACAG GGCGCAGCCC TGGTTAAAAA CAAGGTTTAT AAATATTGGT TTAAAAGCAG 
     4081 GTTAAAAGAC AGGTTAGCGG TGGCCGAAAA ACGGGCGGAA ACCCTTGCAA ATGCTGGATT 
     4141 TTCTGCCTGT GGACAGCCCC TCAAATGTCA ATAGGTGCGC CCCTCATCTG TCAGCACTCT 
     4201 GCCCCTCAAG TGTCAAGGAT CGCGCCCCTC ATCTGTCAGT AGTCGCGCCC CTCAAGTGTC 
     4261 AATACCGCAG GGCACTTATC CCCAGGCTTG TCCACATCAT CTGTGGGAAA CTCGCGTAAA 
     4321 ATCAGGCGTT TTCGCCGATT TGCGAGGCTG GCCAGCTCCA CGTCGCCGGC CGAAATCGAG 
     4381 CCTGCCCCTC ATCTGTCAAC GCCGCGCCGG GTGAGTCGGC CCCTCAAGTG TCAACGTCCG 
     4441 CCCCTCATCT GTCAGTGAGG GCCAAGTTTT CCGCGAGGTA TCCACAACGC CGGCGGCCGG 
     4501 CCGCGGTGTC TCGCACACGG CTTCGACGGC GTTTCTGGCG CGTTTGCAGG GCCATAGACG 
     4561 GCCGCCAGCC CAGCGGCGAG GGCAACCAGC TCGAGGGCTT CGCCCTGTCG CTCGACTGCG 
     4621 GCGAGCACTA CTGGCTGTAA AAGGACAGAC CACATCATGG TTCTGTGTTC ATTAGGTTGT 
     4681 TCTGTCCATT GCTGACATAA TCCGCTCCAC TTCAACGTAA CACCGCACGA AGATTTCTAT 
     4741 TGTTCCTGAA GGCATATTCA AATCGTTTTC GTTACCGCTT GCAGGCATCA TGACAGAACA 
     4801 CTACTTCCTA TAAACGCTAC ACAGGCTCCT GAGATTAATA ATGCGGATCT CTACGATAAT 
     4861 GGGAGATTTT CCCGACTGTT TCGTTCGCTT CTCAGTGGAT AACAGCCAGC TTCTCTGTTT 
     4921 AACAGACAAA AACAGCATAT CCACTCAGTT CCACATTTCC ATATAAAGGC CAAGGCATTT 
     4981 ATTCTCAGGA TAATTGTTTC AGCATCGCAA CCGCATCAGA CTCCGGCATC GCAAACTGCA 
     5041 CCCGGTGCCG GGCAGCCACA TCCAGCGCAA AAACCTTCGT GTAGACTTCC GTTGAACTGA 
     5101 TGGACTTATG TCCCATCAGG CTTTGCAGAA CTTTCAGCGG TATACCGGCA TACAGCATGT 
     5161 GCATCGCATA GGAATGGCGG AACGTATGTG GTGTGACCGG AACAGAGAAC GTCACACCGT 
     5221 CAGCAGCAGC GGCGGCAACC GCCTCCCCAA TCCAGGTCCT GACCGTTCTG TCCGTCACTT 
     5281 CCCAGATCCG CGCTTTCTCT GTCCTTCCTG TGCGACGGTT ACGCCGCTCC ATGAGCTTAT 
     5341 CGCGAATAAA TACCTGTGAC GGAAGATCAC TTCGCAGAAT AAATAAATCC TGGTGTCCCT 
     5401 GTTGATACCG GGAAGCCCTT CAGGCCTTCG CCACCTCTGA CTTGAGCGTC GATTTTTGTG 
     5461 ATGCTCGTCA GGGGGGCGGA GCCTATGGAA AAACGCCAGC AACGCGGCCT TTTTACGGTT 
     5521 CCTGGCCTTT TGCTGGCCTT TTGCTCACAT GCATGGCCAT GATTACGAAT TAATTCGAGC 
     5581 TCGGTACCCG CTCACGGTAA CTGATGCCGT ATTTGCAGTA CCAGCGTACG GCCCACAGAA 
     5641 TGATGTCACG CTGAAAATGC CGGCCTTTGA ATGGGTTCAT GTGCAGCTCC ATCAGCAAAA 
     5701 GGGGATGATA AGTTTATCAC CACCGACTAT TTGCAACAGT GCCGTTGATC GTGCTATGAT 
     5761 CGACTGATGT CATCAGCGGT GGAGTGCAAT GTCGTGCAAT ACGAATGGCG AAAAGCCGAG 
     5821 CTCATCGGTC AGCTTCTCAA CCTTGGGGTT ACCCCCGGCG GTGTGCTGCT GGTCCACAGC 
     5881 TCCTTCCGTA GCGTCCGGCC CCTCGAAGAT GGGCCACTTG GACTGATCGA GGCCCTGCGT 
     5941 GCTGCGCTGG GTCCGGGAGG GACGCTCGTC ATGCCCTCGT GGTCAGGTCT GGACGACGAG 
     6001 CCGTTCGATC CTGCCACGTC GCCCGTTACA CCGGACCTTG GAGTTGTCTC TGACACATTC 
     6061 TGGCGCCTGC CAAATGTAAA GCGCAGCGCC CATCCATTTG CCTTTGCGGC AGCGGGGCCA 
     6121 CAGGCAGAGC AGATCATCTC TGATCCATTG CCCCTGCCAC CTCACTCGCC TGCAAGCCCG 
     6181 GTCGCCCGTG TCCATGAACT CGATGGGCAG GTACTTCTCC TCGGCGTGGG ACACGATGCC 
     6241 AACACGACGC TGCATCTTGC CGAGTTGATG GCAAAGGTTC CCTATGGGGT GCCGAGACAC 
     6301 TGCACCATTC TTCAGGATGG CAAGTTGGTA CGCGTCGATT ATCTCGAGAA TGACCACTGC 
     6361 TGTGAGCGCT TTGCCTTGGC GGACAGGTGG CTCAAGGAGA AGAGCCTTCA GAAGGAAGGT 
     6421 CCAGTCGGTC ATGCCTTTGC TCGGTTGATC CGCTCCCGCG ACATTGTGGC GACAGCCCTG 
     6481 GGTCAACTGG GCCGAGATCC GTTGATCTTC CTGCATCCGC CAGAGGCGGG ATGCGAAGAA 
     6541 TGCGATGCCG CTCGCCAGTC GATTGGCTGA GCTCATGAGC GGAGAACGAG ATGACGTTGG 
     6601 AGGGGCAAGG TCGCGCTGAT TGCTGGGGCA ACACGTGGAG CGGATCGGGG ATTGTCTTTC 
     6661 TTCAGCTCGC TGATGATATG CTGACGCTCA ATGCCGTTTG GCCTCCGACT AACGAAAATC 
     6721 CCGCATTTGG ACGGCTGATC CGATTGGCAC GGCGGACGGC GAATGGCGGA GCAGACGCTC 
     6781 GTCCGGGGGC AATGAGATAT GAAAAAGCCT GAACTCACCG CGACGTCTGT CGAGAAGTTT 
     6841 CTGATCGAAA AGTTCGACAG CGTCTCCGAC CTGATGCAGC TCTCGGAGGG CGAAGAATCT 
     6901 CGTGCTTTCA GCTTCGATGT AGGAGGGCGT GGATATGTCC TGCGGGTAAA TAGCTGCGCC 
341 
 
     6961 GATGGTTTCT ACAAAGATCG TTATGTTTAT CGGCACTTTG CATCGGCCGC GCTCCCGATT 
     7021 CCGGAAGTGC TTGACATTGG GGAATTGGGG ATCTCCATGC ATGTTCTTTC CTGCGTTATC 
     7081 CCCTGATTCT GTGGATAACC GTATTACCGC CTTTGAGTGA GCTGATACCG CTCGCCGCAG 
     7141 CCGAACGACC GAGCGCAGCG AGTCAGTGAG CGAGGAAGCG GAAGAGCGCC CAATACGCAA 
     7201 ACCGCCTCTC CCCGCGCGTT GGCCGATTCA TTAATGCAGC TGGCACGACA GGTTTCCCGA 
     7261 CTGGAAAGCG GGCAGTGAGC GCAACGCAAT TAATGTGAGT TAGCTCACTC ATTAGGCACC 
     7321 CCAGGCTTTA CACTTTATGC TTCCGGCTCG TATGTTGTGT GGAATTGTGA GCGGATAACA 
     7381 ATTTCACACA GGAAACAGCT ATGACCATGA TTACGCCAac ggattagaag ccgccgagcg 
     7441 ggtgacagcc ctccgaagga agactctcct ccgtgcgtcc tcgtcttcac cggtcgcgtt 
     7501 cctgaaacgc agatgtgcct cgcgccgcac tgctccgaac aataaagatt ctacaatact 
     7561 agcttttatg gttatgaaga ggaaaaattg gcagtaacct ggccccacaa accttcaaat 
     7621 gaacgaatca aattaacaac cataggatga taatgcgatt agttttttag ccttatttct 
     7681 ggggtaatta atcagcgaag cgatgatttt tgatctatta acagatatat aaatgcaaaa 
     7741 actgcataac cactttaact aatactttca acattttcgg tttgtattac ttcttattca 
     7801 aatgtaataa aagtatcaac aaaaaattgt taatatacct ctatacttta acgtcaagga 
     7861 gaaaaaaccc cggatatgcc acaatttggt atattatgta AAACACCACC TAAGGTGCTT 
     7921 GTTCGTCAGT TTGTGGAAAG GTTTGAAAGA CCTTCAGGTG AGAAAATAGC ATTATGTGCT 
     7981 GCTGAACTAA CCTATTTATG TTGGATGATT ACACATAACG GAACAGCAAT CAAGAGAGCC 
     8041 ACATTCATGA GCTATAATAC TATCATAAGC AATTCGCTGA GTTTCGATAT TGTCAATAAA 
     8101 TCACTCCAGT TTAAATACAA GACGCAAAAA GCAACAATTC TGGAAGCCTC ATTAAAGAAA 
     8161 TTGATTCCTG CTTGGGAATT TACAATTATT CCTTACTATG GACAAAAACA TCAATCTGAT 
     8221 ATCACTGATA TTGTAAGTAG TTTGCAATTA CAGTTCGAAT CATCGGAAGA AGCAGATAAG 
     8281 GGAAATAGCC ACAGTAAAAA AATGCTTAAA GCACTTCTAA GTGAGGGTGA AAGCATCTGG 
     8341 GAGATCACTG AGAAAATACT AAATTCGTTT GAGTATACTT CGAGATTTAC AAAAACAAAA 
     8401 ACTTTATACC AATTCCTCTT CCTAGCTACT TTCATCAATT GTGGAAGATT CAGCGATATT 
     8461 AAGAACGTTG ATCCGAAATC ATTTAAATTA GTCCAAAATA AGTATCTGGG AGTAATAATC 
     8521 CAGTGTTTAG TGACAGAGAC AAAGACAAGC GTTAGTAGGC ACATATACTT CTTTAGCGCA 
     8581 AGGGGTAGGA TCGATCCACT TGTATATTTG GATGAATTTT TGAGGAATTC TGAACCAGTC 
     8641 CTAAAACGAG TAAATAGGAC CGGCAATTCT TCAAGCAATA AACAGGAATA CCAATTATTA 
     8701 AAAGATAACT TAGTCAGATC GTACAATAAA GCTTTGAAGA AAAATGCGCC TTATTCAATC 
     8761 TTTGCTATAA AAAATGGCCC AAAATCTCAC ATTGGAAGAC ATTTGATGAC CTCATTTCTT 
     8821 TCAATGAAGG GCCTAACGGA GTTGACTAAT GTTGTGGGAA ATTGGAGCGA TAAGCGTGCT 
     8881 TCTGCCGTGG CCAGGACAAC GTATACTCAT CAGATAACAG CAATACCTGA TCACTACTTC 
     8941 GCACTAGTTT CTCGGTACTA TGCATATGAT CCAATATCAA AGGAAATGAT AGCATTGAAG 
     9001 GATGAGACTA ATCCAATTGA GGAGTGGCAG CATATAGAAC AGCTAAAGGG TAGTGCTGAA 
     9061 GGAAGCATAC GATACCCCGC ATGGAATGGG ATAATATCAC AGGAGGTACT AGACTACCTT 
     9121 TCATCCTACA TAAATAGACG CATATAATCT CTGCTTTTGT GCGCGTATGT TTATGTATGT 
     9181 ACCTCTCTCT CTATTTCTAT TTTTAAACCA CCCTCTCAAT AAAATAAAAA TAATAAAGTA 
     9241 TTTTTAAGGA AAAGACGTGT TTAAGCACTG ACTTTATCTA CTTTTTGTAC GTTTTCATTG 
     9301 ATATAATGTG TTTTGTCTCT CCCTTTTCTA CGAAAATTTC AAAAATTGAC CAAAAAAAGG 
     9361 AATATATATA CGAAAAACTA TTATATTTAT ATATCATAGT GTTGCATGCC TGCAGGTCGA 
     9421 CTCTAGAGGA TCCCCGGGCA ATTGGGTCCT TTTCATCACG TGCTATAAAA ATAATTATAA 
     9481 TTTAAATTTT TTAATATAAA TATATAAATT AAAAATAGAA AGTAAAAAAA GAAATTAAAG 
     9541 AAAAAATAGT TTTTGTTTTC CGAAGATGTA AAAGACTCTA GGGGGATCGC CAACAAATAC 
     9601 TACCTTTTAT CTTGCTCTTC CTGCTCTCAG GTATTAATGC CGAATTGTTT CATCTTGTCT 
     9661 GTGTAGAAGA CCACACACGA AAATCCTGTG ATTTTACATT TTACTTATCG TTAATCGAAT 
     9721 GTATATCTAT TTAATCTGCT TTTCTTGTCT AATAAATATA TATGTAAAGT ACGCTTTTTG 
     9781 TTGAAATTTT TTAAACCTTT GTTTATTTTT TTTTCTTCAT TCCGTAACTC TTCTACCTTC 
     9841 TTTATTTACT TTCTAAAATC CAAATACAAA ACATAAAAAT AAATAAACAC AGAGTAAATT 
     9901 CCCAAATTAT TCCATCATTA AAAGATACGA GGCGCGTGTA AGTTACAGGC AAGCGATCCG 
     9961 TCCTAAGAAA CCATTATTAT CATGACATTA ACCTATAAAA ATAGGCGTAT CACGAGGCCC 
    10021 TTTCGTCTCG CGCGTTTCGG TGATGACGGT GAAAACCTCT GACACATGCA GCTCCCGGAG 
    10081 ACGGTCACAG CTTGTCTGTA AGCGGATGCC GGGAGCAGAC AAGCCCGTCA GGGCGCGTCA 
    10141 GCGGGTGTTG GCGGGTGTCG GGGCTGGCTT AACTATGCGG CATCAGAGCA GATTGTACTG 
    10201 AGAGTGCACC ATATCGACTA CGTCGTAAGG CCGTTTCTGA CAGAGTAAAA TTCTTGAGGG 
    10261 AACTTTCACC ATTATGGGAA ATGGTTCAAG AAGGTATTGA CTTAAACTCC ATCAAATGGT 
    10321 CAGGTCATTG AGTGTTTTTT ATTTGTTGTA TTTTTTTTTT TTTAGAGAAA ATCCTCCAAT 
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    10381 ATCAAATTAG GAATCGTAGT TTCATGATTT TCTGTTACAC CTAACTTTTT GTGTGGTGCC 
    10441 CTCCTCCTTG TCAATATTAA TGTTAAAGTG CAATTCTTTT TCCTTATCAC GTTGAGCCAT 
    10501 TAGTATCAAT TTGCTTACCT GTATTCCTTT ACTATCCTCC TTTTTCTCCT TCTTGATAAA 
    10561 TGTATGTAGA TTGCGTATAT AGTTTCGTCT ACCCTATGAA CATATTCCAT TTTGTAATTT 
    10621 CGTGTCGTTT CTATTATGAA TTTCATTTAT AAAGTTTATG TACAAATATC ATAAAAAAAG 
    10681 AGAATCTTTT TAAGCAAGGA TTTTCTTAAC TTCTTCGGCG ACAGCATCAC CGACTTCGGT 
    10741 GGTACTGTTG GAACCACCTA AATCACCAGT TCTGATACCT GCATCCAAAA CCTTTTTAAC 
    10801 TGCATCTTCA ATGGCCTTAC CTTCTTCAGG CAAGTTCAAT GACAATTTCA ACATCATTGC 
    10861 AGCAGACAAG ATAGTGGCGA TAGGGTCAAC CTTATTCTTT GGCAAATCTG GAGCAGAACC 
    10921 GTGGCATGGT TCGTACAAAC CAAATGCGGT GTTCTTGTCT GGCAAAGAGG CCAAGGACGC 
    10981 AGATGGCAAC AAACCCAAGG AACCTGGGAT AACGGAGGCT TCATCGGAGA TGATATCACC 
    11041 AAACATGTTG CTGGTGATTA TAATACCATT TAGGTGGGTT GGGTTCTTAA CTAGGATCAT 
    11101 GGCGGCAGAA TCAATCAATT GATGTTGAAC CTTCAATGTA GGGAATTCGT TCTTGATGGT 
    11161 TTCCTCCACA GTTTTTCTCC ATAATCTTGA AGAGGCCAAA ACATTAGCTT TATCCAAGGA 
    11221 CCAAATAGGC AATGGTGGCT CATGTTGTAG GGCCATGAAA GCGGCCATTC TTGTGATTCT 
    11281 TTGCACTTCT GGAACGGTGT ATTGTTCACT ATCCCAAGCG ACACCATCAC CATCGTCTTC 
    11341 CTTTCTCTTA CCAAAGTAAA TACCTCCCAC TAATTCTCTG ACAACAACGA AGTCAGTACC 
    11401 TTTAGCAAAT TGTGGCTTGA TTGGAGATAA GTCTAAAAGA GAGTCGGATG CAAAGTTACA 
    11461 TGGTCTTAAG TTGGCGTACA ATTGAAGTTC TTTACGGATT TTTAGTAAAC CTTGTTCAGG 
    11521 TCTAACACTA CCGGTACCCC ATTTAGGACC ACCCACAGCA CCTAACAAAA CGGCATCAAC 
    11581 CTTCTTGGAG GCTTCCAGCG CCTCATCTGG AAGTGGGACA CCTGTAGCAT CGATAGCAGC 
    11641 ACCACCAATT AAATGATTTT CGAAATCGAA CTTGACATTG GAACGAACAT CAGAAATAGC 
    11701 TTTAAGAACC TTAATGGCTT CGGCTGTGAT TTCTTGACCA ACGTGGTCAC CTGGCAAAAC 
    11761 GACGATCTTC TTAGGGGCAG ACATAGGGGC AGACATTAGA ATGGTATATC CTTGAAATAT 
    11821 ATATATATAT TGCTGAAATG TAAAAGGTAA GAAAAGTTAG AAAGTAAGAC GATTGCTAAC 
    11881 CACCTATTGG AAAAAACAAT AGGTCCTTAA ATAATATTGT CAACTTCAAG TATTGTGATG 
    11941 CAAGCATTTA GTCATGAACG CTTCTCTATT CTATATGAAA AGCCGGTTCC GGCCTCTCAC 
    12001 CTTTCCTTTT TCTCCCAATT TTTCAGTTGA AAAAGGTATA TGCGTCAGGC GACCTCTGAA 
    12061 ATTAACAAAA AATTTCCAGT CATCGAATTT GATTCTGTGC GATAGCGCCC CTGTGTGTTC 
    12121 TCGTTATGTT GAGGAAAAAA ATAATGGTTG CTAAGAGATT CGAACTCTTG CATCTTACGA 
    12181 TACCTGAGTA TTCCCACAGT TAACTGCGGT CAAGATATTT CTTGAATCAG GCGCCTTAGA 
    12241 CCGCTCGGCC AAACAACCAA TTACTTGTTG AGAAATAGAG TATAATTATC CTATAAATAT 
    12301 AACGTTTTTG AACACACATG AACAAGGAAG TACAGGACAA TTGATTTTGA AGAGAATGTG 
    12361 GATTTTGATG TAATTGTTGG GATTCCATTT TTAATAAGGC AATAATATTA GGTATGTGGA 
    12421 TATACTAGAA GTTCTCCTCG ACCGTCGATA TGCGGTGTGA AATACCGCAC AGATGCGTAA 
    12481 GGAGAAAATA CCGCATCAGG AAATTGTAAA CGTTAATATT TTGTTAAAAT TCGCGTTAAA 
    12541 TTTTTGTTAA ATCAGCTCAT TTTTTAACCA ATAGGCCGAA ATCGGCAAAA TCCCTTATAA 
    12601 ATCAAAAGAA TAGACCGAGA TAGGGTTGAG TGTTGTTCCA GTTTGGAACA AGAGTCCACT 
    12661 ATTAAAGAAC GTGGACTCCA ACGTCAAAGG GCGAAAAACC GTCTATCAGG GCGATGGCCC 
    12721 ACTACGTGAA CCATCACCCT AATCAAGTTT TTTGGGGTCG AGGTGCCGTA AAGCACTAAA 
    12781 TCGGAACCCT AAAGGGAGCC CCCGATTTAG AGCTTGACGG GGAAAGCCGG CGAACGTGGC 
    12841 GAGAAAGGAA GGGAAGAAAG CGAAAGGAGC GGGCGCTAGG GCGCTGGCAA GTGTAGCGGT 
    12901 CACGCTGCGC GTAACCACCA CACCCGCCGC GCTTAATGCG CCGCTACAGG GCGCGTCGCG 
    12961 CCATTCGCCA TTCAGGCTGC GCAACTGTTG GGAAGGGCGA TCGGTGCGGG CCTCTTCGCT 
    13021 ATTACGCCAG CTGGCGAAAG GGGGATGTGC TGCAAGGCGA TTAAGTTGGG TAACGCCAGG 
    13081 GTTTTCCCAG TCACGACGTT GTAAAACGAC GGCCAGTGAG CGCGCGTAAT ACGACTCACT 
    13141 ATAGGGCGAA TTGGGTACCG CTAGCTTCAA AAGCGCTCTG AAGTTCCTAT ACTATTTGAA 
    13201 GAATAGGAAC TTCGGAATAG GAACTTCAAG ATCCCCGGGT ACCGGCCGCA AATTAAAGCC 
    13261 TTCGAGCGTC CCAAAACCTT CTCAAGCAAG GTTTTCAGTA TAATGTTACA TGCGTACACG 
    13321 CGTCTGTACA GAAAAAAAAG AAAAATTTGA AATATAAATA ACGTTCTTAA TACTAACATA 
    13381 ACTATAAAAA AATAAATAGG GACCTAGACT TCAGGTTGTC TAACTCCTTC CTTTTCGGTT 
    13441 AGAGCGGATG TGGGGGGAGG GCGTGAATGT AAGCGTGACA TAACTAATTA CATGACTCGA 
    13501 GGTCGACCTA TTTCTTAGCA TTTTTGACGA AATTTGCTAT TTTGTTAGAG TCTTTTACAC 
    13561 CATTTGTCTC CACACCTCCG CTTACATCAA CACCAATAAC GCCATTTAAT CTAAGCGCAT 
    13621 CACCAACATT TTCTGGCGTC AGTCCACCAG CTAACATAAA ATGTAAGCTC TCGGGGCTCT 
    13681 CTTGCCTTCC AACCCAGTCA GAAATCGAGT TCCAATCCAA AAGTTCACCT GTCCCACCTG 
    13741 CTTCTGAATC AAACAAGGGA ATAAACGAAT GAGGTTTCTG TGAAGCTGCA CTGAGTAGTA 
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    13801 TGTTGCAGTC TTTTGGAAAT ACGAGTCTTT TAATAACTGG CAAACCGAGG AACTCTTGGT 
    13861 ATTCTTGCCA CGACTCATCT CCATGCAGTT GGACGATATC AATGCCGTAA TCATTGACCA 
    13921 GAGCCAAAAC ATCCTCCTTA GGTTGATTAC GAAACACGCC AACCAAGTAT TTCGGAGTGC 
    13981 CTGAACTATT TTTATATGCT TTTACAAGAC TTGAAATTTT CCTTGCAATA ACCGGGTCAA 
    14041 TTGTTCTCTT TCTATTGGGC ACACATATAA TACCCAGCAA GTCAGCATCG GAATCTAGTG 
    14101 CACATTCTGC GGCCTCTGTG CTCTGCAAGC CGCAAACTTT CACCAATGGA CCAGAACTAC 
    14161 CTGTGAAATT AATAACAGAG AAGTTCCTAT ACTTTCTAGA GAATAGGAAC TTCGGAATAG 
    14221 GAACTTCCAT GGATCCACTA GTTCTAGAGT ATGGATGGGG GTAATAGAAT TGTATCTATG 
    14281 TATCTGACGA CCCTGTATTA CACGAAGGAA ATAGTAGATG AAAAGACAAG AGAGCAAGAA 
    14341 AAAGGAAAAA CTTCCTTTCT AACAGACGCT TTACTTAACC TTATATATAT CTTATTTTTT 
    14401 TCATCGAGCG TGTTCAATTG GACAAGGTGC CACCTTTTCG ACACTTCGGT TATTATGTTA 
    14461 CACAGTTTTC ATGAGGATGG CGCCTTGACT AACTTAATTA GTCATTTGCC AACCACCACA 
    14521 GTTCCCCAAT ATCGACAGCT TCACGTGCCA TTTGCCATTT TGCGATCATG TGACCTCAAG 
    14581 AGAAAAAGCA AAAAATAATG AGAGCTAAGG GATTCGAACC CTTGCATCCG GCTAGCgcac 
    14641 aatcgtgccg gTCTAGAGAA TTCACTGGCC GTCGTTTTAC AACGTCGTGA CTGGGAAAAC 
    14701 CCTGGCGTTA CCCAACTTAA TCGCCTTGCA GCACATCCCC CTTTCGCCAG CTGGCGTAAT 
    14761 AGCGAAGAGG CCCGCACCGA TCGCCCTTCC CAACAGTTGC GCAGCCTGAA TGGCGAATGG 
    14821 CGCCTGATGC GGTATTTTCT CCTTACGCAT CTGTGCGGTA TTTCACACCG CATATGGTGC 
    14881 ACTCTCAGTA CAATCTGCTC TGATGCCGCA TAGTTAAGCC AGCCCCGACA CCCGCCAACA 
    14941 CCCGCTGACG CGCCCTGACG GGCTTGTCTG CTCCCGGCAT CCGCTTACAG ACAAGCTGTG 
    15001 ACCGTCTCCG GGAGCTGCAT GTGTCAGAGG TTTTCACCGT CATCACCGAA ACGCGCGAGA 
    15061 CGAAAGGGCC TCGTGATACG CCTATTTTTA TAGGTTAATG TCATGATAAT AATGGTTTCT 
    15121 TAGACGTCAG GTGGCACTTT TCGGGGAAAT GTGCGCGGAA CCCCTATTTG TTTATTTTTC 
    15181 TAAATACATT CAAATATGTA TCCGCTCATG AGACAATAAC CCTGATAAAT GCTTCAATAA 
    15241 TCGCACGATA TACAGGATTT TGCCAAAGGG TTCGTGTAGA CTTTCCTTGG TGTATCCAAC 
    15301 GGCGTCAGCC GGGCAGGATA GGTGAAGTAG GCCCACCCGC GAGCGGGTGT TCCTTCTTCA 
    15361 CTGTCCCTTA TTCGCACCTG GCGGTGCTCA ACGGGAATCC TGCTCTGCGA GGCTGGCCGG 
    15421 CTACCGCCGG CGTAACAGAT GAGGGCAAGC GGATGGCTGA TGAAACCAAG CCAACCAGGA 
    15481 AGGGCAGCCC ACCTATCAAG GTGTACTGCC TTCCAGACGA ACGAAGAGCG ATTGAGGAAA 
    15541 AGGCGGCGGC GGCCGGCATG AGCCTGTCGG CCTACCTGCT GGCCGTCGGC CAGGGCTACA 
    15601 AAATCACGGG CGTCGTGGAC TATGAGCACG TCCGCGAGCT GGCCCGCATC AATGGCGACC 
    15661 TGGGCCGCCT GGGCGGCCTG CTGAAACTCT GGCTCACCGA CGACCCGCGC ACGGCGCGGT 
    15721 TCGGTGATGC CACGATCCTC GCCCTGCTGG CGAAGATCGA AGAGAAGCAG GACGAGCTTG 
    15781 GCAAGGTCAT GATGGGCGTG GTCCGCCCGA GGGCAGAGCC ATGACTTTTT TAGCCGCTAA 
    15841 AACGGCCGGG GGGTGCGCGT GATTGCCAAG CACGTCCCCA TGCGCTCCAT CAAGAAGAGC 
    15901 GACTACGCGG AGCTGGTGAA GTACATCACC GACGAGCAAG GCAAATTGAA AAAGGAAGAG 
    15961 TATGAGTATT CAACATTTCC GTGTCGCCCT TATTCCCTTT TTTTGCGGCA TTTTGCCTTC 
    16021 CTGTTTTTGC TCACCCAGAA ACGCTGGTGA AAGTAAAAGA TGCTGAAGAT CAGTTGGGTG 
    16081 CACGAGTGGG TTACATCGAA CTGGATCTCA ACAGCGGTAA GATCCTTGAG AGTTTTCGCC 
    16141 CCGAAGAACG TTTTCCAATG ATGAGCACTT TTAAAGTTCT GCTATGTGGC GCGGTATTAT 
    16201 CCCGTATTGA CGCCGGGCAA GAGCAACTCG GTCGCCGCAT ACACTATTCT CAGAATGACT 
    16261 TGGTTGAGTA TCCCTAGGCG CTCCCTGCCC GCTGTGGTGA CGAAGGAACT ACTAGTTAGC 
    16321 CTAACTAACG ATTTCAAGGC CAAAAAAGGG GCCGAACCGT CCGCCGGCTC GACCCCTCCC 
    16381 GCTGTGCGCT ACAGCGCCGC AAGCTCCCGC TCAGTGGCTT CGCTCGCTTC GTCTTCCTCC 
    16441 TTCAGCAGCT CCGCCCACTT GAGCGTCACA CGGTCCTTCA GGGGGATGTA TTTCTTCGTC 
    16501 TCAGGGTGGC GCCCCGGTCG ACCATGACGG AGTCAAGGAA GAAGCTCAGG AACTCCCGAC 
    16561 GCTCGTACAC GTCCCAGCTT GCCCAGATGC CCCTTCGGCC GTCGGGTCTT CGCCGCTGAA 
    16621 CCACTCAGAC GGAACGCGGG TGCTGCCGTT CATCTTCTCG TCAAGCTCAG CGAGTCGGGT 
    16681 CGTGCACTCC GCTTCGTAGG ACCGGTATTG CAGCACCGTT GAGCGCCACG TTTCCAGCTC 
    16741 TTCACGCCCG ACGTACAGAC CGGGCTTACG GTCCGCCTGA AGGTCCTTGA TGGAGCGCCG 
    16801 CACGTTGTCT AGGTGCGCCT GTTGTTCGCG CCGCTCATCG GCCACCCCCG CTAGGTCGTG 
    16861 CTGAAGGGCG AAGCGCTCCG CAGCGGCGGC AATCCATGCC TGATCGTGTT CATCTTCCAT 
    16921 GTCGGCTGTG CGGAGCCGTG CCCACACCTT CGAAGCAACG AACTCGTCCA GTTCGCTGCG 
    16981 CTTGACCGAC AAGCCGCCGT GCCCCTTCGG GTTGGCGCAC ATGTAATTGC CTTCGGCAAG 
    17041 GTCGCCGTTG CGCTTACGGC CACCCTGGGA CTGACCCATT GAGCCGCCGC AGATTCGGCA 
    17101 CCCCAGGAAA CGCCACCCGC TCAGAAGCGT CGGTTCGACT TCGGCCCCAG GCTTCCGGTC 
    17161 GCTGAGATTC TTCCCGGAAC GCTTCTCTTG AAGCTCAAGC CACTTCGAGC CGCTGAGAAT 
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    17221 GCCCGTGTGG GGCGTTAGCG GCTTGCCGCC GGGGTCGCGC CGTATGACGT TGATGTGCGC 
    17281 CTTACCGTGC TTCACACGCT CGAATGCGAA ACCGCCGATT GCGGGATGGT TGAGAATCCA 
    17341 TCGGACCGTT TGAGCGCGCC ACATGATCGG CTTTTCAGCG CCGTTCAGGC GACGTGCCTT 
    17401 GACGGACGCA AGACGCTTTT CCGTGGCGCG TCTCTCAGCC ATTCCGGGCG ACGGGATCTT 
    17461 TTCCTTCTCG AAGGTCGTTG CAATGGCGTT GTCGGACACG CCTTCGAACG ACATTTTCGC 
    17521 CATGCGCTCA ACTAGCTCGA CGTGATCCGG GTTGTCTTCG TCCGGCTCAA GAACGGAGAT 
    17581 CACGAGATTA TCGACCTTCT TGCGCACGGC GCGCATTCCG AACGGGGCGG AAGACGAGTG 
    17641 AACGCCACCC AGCGCGGCAA TCTCGTCTTT CGCACCCTTC AGGCGCTCCG CCTTCAGGTC 
    17701 ACTGTCCTGT TTCGCAAGGG CAGCGATCAG CGCGAAAATG GCGACGCCGA TAGGGGTAGA 
    17761 CGTGTCAAGG AACGGCTCAA GAACCGACAT GAAGCGCACG CCGTGCTTCT TCAATTCGTT 
    17821 GTCGATTTCG AGCGCGTCAT GGGCGCCCTT GCGAGTGAGC CGGGAAAGCT CATTCACAAC 
    17881 GACAACGTCA CCTTCGCCGG CGCGGACTTC GCCCATCATG CGCTCGAAGT CGGCACGGGT 
    17941 CACGTTCGGG TCCCAGCCGG AGCGCCCGAC GTCCACGAAC TCACCTGCCA CGACCCAGCG 
    18001 CGCACCCCCC TGGGCGTTGC GAGACGCGAC CAACGCACGA CCGGCCGCCA GCTGTGCTTC 
    18061 GGTCGACACG TCTGAGCCGT CGGACCGGCC CTTAGACTGA CGCGCGTACA GGAAGACGCG 
    18121 AACAGTGTCT AGAAGGTGCT CAGGGACGTC GGGAGCGATG AAGGGCGACA TGCCTAGATC 
    18181 TTGGCTCATG GGCGCTGACC TGCGCTTTCT TTTGGGAACA TTGGTGGTGC TGAGTAGTTT 
    18241 CCCATGGATC ACTGTCCAGA GACAACAACC CAGCACCCGA AACGTCTGAA GCCCCGTCCG 
    18301 GCGCCACCTA GGGATACTCA CCAGTCACAG AAAAGCATCT TACGGATGGC ATGACAGTAA 
    18361 GAGAATTATG CAGTGCTGCC ATAACCATGA GTGATAACAC TGCGGCCAAC TTACTTCTGA 
    18421 CAACGATCGG AGGACCGAAG GAGCTAACCG CTTTTTTGCA CAACATGGGG GATCATGTAA 
    18481 CTCGCCTTGA TCGTTGGGAA CCGGAGCTGA ATGAAGCCAT ACCAAACGAC GAGCGTGACA 
    18541 CCACGATGCC TGTAGCAATG GCAACAACGT TGCGCAAACT ATTAACTGGC GAACTACTTA 
    18601 CTCTAGCTTC CCGGCAACAA TTAATAGACT GGATGGAGGC GGATAAAGTT GCAGGACCAC 
    18661 TTCTGCGCTC GGCCCTTCCG GCTGGCTGGT TTATTGCTGA TAAATCTGGA GCCGGTGAGC 
    18721 GTGGGTCTCG CGGTATCATT GCAGCACTGG GGCCAGATGG TAAGCCCTCC CGTATCGTAG 
    18781 TTATCTACAC GACGGGGAGT CAGGCAACTA TGGATGAACG AAATAGACAG ATCGCTGAGA 
    18841 TAGGTGCCTC ACTGAGGCCT ATGGTTACTC CGTTCTACAG GTTACGACGA CATGTCAATA 
    18901 CTTGCCCTTG ACAGGCATTG ATGGAATCGT AGTCTCACGC TGATAGTCTG ATCGACAATA 
    18961 CAAGTGGGAC CGTGGTCCCA GACCGATAAT CAGACCGACA ACACGAGTGG GATCGTGGTC 
    19021 CCAGACTAAT AATCAGACCG ACGATACGAG TGGGACCGTG GTCCCAGACT AATAATCAGA 
    19081 CCGACGATAC GAGTGGGACC GTGGTTCCAG ACTAATAATC AGACCGACGA TACGAGTGGG 
    19141 ACCGTGGTCC CAGACTAATA AT 
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